0001493152-17-013526.txt : 20171120 0001493152-17-013526.hdr.sgml : 20171120 20171120070139 ACCESSION NUMBER: 0001493152-17-013526 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171120 DATE AS OF CHANGE: 20171120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marathon Patent Group, Inc. CENTRAL INDEX KEY: 0001507605 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 010949984 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36555 FILM NUMBER: 171212589 BUSINESS ADDRESS: STREET 1: 11100 SANTA MONICA BLVD., STE. 380 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: (800) 804-1690 MAIL ADDRESS: STREET 1: 11100 SANTA MONICA BLVD., STE. 380 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: American Strategic Minerals Corp DATE OF NAME CHANGE: 20111213 FORMER COMPANY: FORMER CONFORMED NAME: VERVE VENTURES INC DATE OF NAME CHANGE: 20101210 10-Q 1 form10q.htm

 

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2017

 

or

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from _______to______

 

MARATHON PATENT GROUP, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   001-36555   01-0949984
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

11100 Santa Monica Blvd., Ste. 380
Los Angeles, CA
  90025
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 703-232-1701

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [x] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. [X]

 

Large accelerated filer [  ] Accelerated filer [  ]
       

Non-accelerated filer

 

(Do not check if smaller reporting company)

[  ]

Smaller reporting company

 

Emerging growth company

[X]

 

[  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes [  ] No [x]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 8,747,931 shares of common stock are issued and outstanding as of November 14, 2017.

 

 

 

 

 

TABLE OF CONTENTS

 

    Page No.
PART I. - FINANCIAL INFORMATION
Item 1. Financial Statements 3
  Consolidated Condensed Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016 3
  Consolidated Condensed Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2017 and 2016 (unaudited) 4
  Consolidated Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (unaudited) 5
  Notes to Unaudited Consolidated Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 29
Item 3. Quantitative and Qualitative Disclosures About Market Risk 39
Item 4. Controls and Procedures 39
     
PART II – OTHER INFORMATION
Item 1. Legal Proceedings 40
Item 1A Risk Factors 40
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41
Item 3. Defaults upon Senior Securities 41
Item 4. Mine Safety Disclosures 41
Item 5. Other Information 41
Item 6. Exhibits 41

 

OTHER PERTINENT INFORMATION

 

Unless specifically set forth to the contrary, “Marathon Patent Group, Inc.,” “we,” “us,” “our” and similar terms refer to Marathon Patent Group, Inc., a Nevada corporation, and its subsidiaries. Unless otherwise indicated, the per share information has been adjusted to reflect the four for one reverse stock split that went into effect on October 30, 2017 (the “Reverse Split”).

 

2

 

Item 1. Financial Statements

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS

(Unaudited)

 

   September 30, 2017   December 31, 2016 
           
ASSETS          
Current assets:          
Cash  $122,172   $4,998,314 
Restricted Cash   3,919,718    - 
Total cash   4,041,890    4,998,314 
Accounts receivable - net of allowance for bad debt of $387,976 and $387,976 for September 30, 2017 and December 31, 2016   123,630    95,069 
Note receivable   588,864    225,982 
Prepaid expenses and other current assets, net of discounts of $2,659 for September 30, 2017 and $3,724 for December 31, 2016   108,878    202,067 
Total current assets   4,863,262    5,521,432 
           
Other assets:          
Property and equipment, net of accumulated depreciation of $133,224 and $108,407 for September 30, 2017 and December 31, 2016   9,803    28,329 
Intangible assets, net of accumulated amortization of $12,813,915 and $11,323,185 for September 30, 2017 and December 31, 2016   7,590,213    12,314,628 
Other non current assets, net of discounts of $797 for December 31, 2016   -    201,203 
Goodwill   228,401    222,843 
Total other assets   7,828,417    12,767,003 
           
Total Assets  $12,691,679   $18,288,435 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable and accrued expenses  $1,954,836   $7,217,078 
Clouding IP earn out - current portion   32,637    81,930 
Revenue share liability   1,225,000    - 
Warrant liability   2,411,750    - 
Notes payable, net of discounts of $5,837,363 and $852,404 for September 30, 2017 and December 31, 2016   15,582,156    13,162,007 
    21,206,379    20,461,015 
           
Long-term liabilities          
Notes Payable, net of discount of $57,763 for December 31, 2016   -    4,670,502 
Clouding IP earn out   681,175    1,400,082 
Revenue share liability   -    1,000,000 
Other long term liability   37,236    43,978 
Total long-term liabilities   718,411    7,114,562 
           
Total liabilities   21,924,790    27,575,577 
           
Stockholders' Deficit:          
Preferred stock Series B, $.0001 par value, 50,000,000 shares  authorized: 195,501 issued and outstanding at September 30, 2017 and December 31, 2016   78    78 
Common stock, $.0001 par value; 200,000,000 shares authorized; 7,776,016 and 4,638,118 at September 30, 2017 and December 31, 2016   3,111    1,856 
Additional paid-in capital   61,833,077    49,877,710 
Accumulated other comprehensive income (loss)   (450,623)   (1,060,390)
Accumulated deficit   (70,427,472)   (57,942,548)
           
Total Marathon Patent Group stockholders' equity   (9,041,829)   (9,123,294)
           
Noncontrolling interests   (191,282)   (163,848)
           
Total deficit   (9,233,111)   (9,287,142)
           
Total liabilities and stockholders' deficit  $12,691,679   $18,288,435 

 

The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

 

3

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

 

   For the Three
Months Ended
30-Sep-17
   For the Three
Months Ended
30-Sep-16
   For the Nine
Months Ended
30-Sep-17
   For the Nine
Months Ended
30-Sep-16
 
                 
Revenues  $162,713   $43,113   $609,650   $36,452,551 
                     
Expenses                    
Cost of revenues   64,836    1,094,378    1,544,322    19,202,118 
Amortization of patents and website   457,419    2,030,886    1,803,264    6,018,196 
Compensation and related taxes   1,871,946    1,252,571    3,718,034    3,406,841 
Consulting fees   133,018    257,420    189,819    903,032 
Professional fees   616,125    432,496    1,686,955    1,336,201 
General and administrative   213,130    183,771    599,416    612,284 
Goodwill impairment   -    -    -    83,000 
Patent impairment   723,218    5,531,383    723,218    6,525,273 
Total operating expenses   4,079,692    10,782,905    10,265,028    38,086,945 
                     
Operating loss from continuing operations   (3,916,979)   (10,739,792)   (9,655,378)   (1,634,394)
                     
Other income (expenses)                    
Other income (expense)   2,252,886    (37,116)   3,151,418    (68,647)
Foreign exchange (loss)   (480,240)   (175,850)   (463,191)   (238,073)
Loss on debt extinguishment   (283,237)   -    (283,237)   - 
Loss on sale of company   (1,519,875)   -    (1,519,875)   - 
Change in fair value adjustment of Clouding IP earn out   754,321    1,954,378    768,200    2,122,208 
Warrant income (expense)   (1,909,879)   -    (1,914,786)   - 
Interest income   931    931    2,793    2,793 
Interest expense   (1,283,223)   (649,065)   (2,416,722)   (2,500,321)
Total other income (expenses)   (2,468,316)   1,093,278    (2,675,400)   (682,040)
                     
Loss from continuing operations before benefit for income taxes   (6,385,295)   (9,646,514)   (12,330,778)   (2,316,434)
                     
Income tax benefit (expense)   (12,191)   3,347,909    (29,433)   26,974 
                     
Net Income (loss)   (6,397,486)   (6,298,605)   (12,360,211)   (2,289,460)
                     
Net income (loss) attributable to Noncontrolling interests   (280,000)   24,195    (124,714)   27,918 
                     
Net (loss) attributable to common shareholders  $(6,677,486)  $(6,274,410)  $(12,484,925)  $(2,261,542)
                     
Income (loss) per common share:                    
Basic  $(1.06)  $(1.67)  $(2.24)  $(0.61)
Diluted                    
                     
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:                    
Basic   6,270,299    3,761,786    5,564,465    3,736,213 
                     
Net loss  $(6,677,486)  $(6,274,410)  $(12,484,925)  $(2,261,542)
Other comprehensive loss:                    
Unrealized gain on foreign currency translation   482,622    209,159    609,768    306,411 
Comprehensive loss   (6,194,864)   (6,065,251)   (11,875,157)   (1,955,131)
Less: comprehensive income (loss) related to non-controlling interest   (280,000)   24,195    (124,714)   27,918 
Comprehensive loss attributable to Marathon Patent Group, Inc.  $(6,474,864)  $(6,041,056)  $(11,999,871)  $(1,927,213)

 

The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

 

4

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For The
Nine Months Ended
September 30, 2017
   For The
Nine Months Ended
September 30, 2016
 
Cash flows from operating activities:          
Net loss  $(12,484,924)  $(2,261,542)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation   1,248    3,780 
Amortization of patents and website   1,803,264    6,018,196 
Deferred tax asset   -    531,757 
Deferred tax liability   -    (638,268)
Loss on sale of companies   -    - 
Warrant liability   -    - 
Impairment of intangible assets   704,678    6,525,273 
Impairment of goodwill   -    83,000 
Stock based compensation   1,523,187    1,541,615 
Stock issued for services   -    136,000 
Non-cash interest, discount, and financing costs   (4,397,381)   952,231 
Change in fair value of Clouding earnout   (768,200)   (2,122,198)
Allowance for doubtful accounts   -    12,226 
Beneficial conversion feature   4,017,729    - 
Noncontrolling interest   (27,435)   (27,918)
Other non-cash adjustments   182,024    96,996 
Changes in operating assets and liabilities          
Accounts receivable   (28,561)   43,763 
Bonds posted with courts   -    883,695 
Prepaid expenses and other assets   (269,693)   (6,652)
Other non current assets   201,203    - 
Accounts payable and accrued expenses   (5,262,242)   (557,832)
           
Net cash and restricted cash provided by (used in) operating activities   (14,805,103)   11,214,122 
           
Cash flows from investing activities:          
Acquisition of patents   -    (3,552,656)
Disposal of patents   2,771,757    - 
Purchase of property, equipment, and other intangible assets   (6,291)   (8,387)
Net cash provided by (used in) investing activities   2,765,466    (3,561,043)
           
Cash flows from financing activities:          
Payment on note payable in connection with the acquisition of Medtech and Orthophoenix   -    (2,953,779)
Payment on Fortress note payable   (63,286)   (5,379,105)
Payment on 3D Nano license note payable   (100,000)   - 
Cash received upon issuance of equity (net of issuance costs)   5,158,906    - 
Issuance of warrants   2,549,084    - 
Issuance of convertible  notes payable   5,500,000      
Medtronic note payable   600,000    - 
Payment of Medtronic note payable   (600,000)     
Payments on Seimens notes payable   (1,750,000)   - 
Payments on notes payable to vendors   (125,000)   - 
Payments on notes payable, net   (103,000)   (578,804)
Net cash provided (used in) by financing activities   11,066,704    (8,911,688)
           
Effect of exchange rate changes on cash   16,509    (1,592)
           
Net decrease in cash   (956,424)   (1,260,201)
           
Cash at beginning of period   4,998,314    2,555,151 
           
Cash and restricted cash at end of period  $4,041,890   $1,294,950 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW  INFORMATION:          
Cash paid for:          
Interest expense  $368,923   $1,187,074 
Taxes paid  $29,433   $27,682 
Cash invested in 3D Nano  $-   $115,000 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Revenue share liability incurred in conjunction with note payable  $225,000   $- 
Warrant issued in conjunction with common stock issuance  $257,957   $- 
Note payable issued in conjunction with the acquisition of Munitech patents  $-   $1,755,635 
Note payable issued in conjunction with the acquisition of GE patent   -    1,000,000 
Note payable issued in conjunction with the acquisition of 3D Nano license   -    200,000 

 

The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

 

5

 

Notes to Unaudited Consolidated Condensed Financial Statements

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

 

Marathon Patent Group, Inc.’s (the “Company”) business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company. We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies. Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets. Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances. Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.

 

The Company was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in the business of exploration and potential development of uranium and vanadium minerals business. In June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October 2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company’s name was changed to Marathon Patent Group, Inc.

 

On October 1, 2012, the shareholders holding a majority of the Company’s voting capital had voted and authorized the Company to change the name of the Company to Marathon Patent Group, Inc. (the “Name Change”). The Board of Directors approved the Name Change on October 1, 2012. The Board of Directors determined the name “Marathon Patent Group, Inc.” better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change.

 

On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.

 

On September 6, 2017, the Board of Directors approved and adopted, subject to shareholder approval on or prior to September 6, 2018, the Company’s 2017 Equity Incentive Plan. The Company’s 2017 Equity Incentive Plan was approved by the shareholders of the Company at a special meeting held on September 29, 2017.

 

All share and per share values for all periods presented in the accompanying consolidated financial statements have been retroactively adjusted to reflect the Reverse Split.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position, the results of operations and cash flows of the Company for the periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.

 

6

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

Cash

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation and restricted cash, held in escrow pursuant to the terms of the Unit Purchase Agreement entered into on August 14, 2017, with another financial institution that is also insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2017, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

 

Accounts Receivable

 

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At each of September 30, 2017 and December 31, 2016, the Company had recorded an allowance for bad debts in the amount of $387,976 and $387,976, respectively. Accounts receivable, net at September 30, 2017 and December 31, 2016, amounted to $123,630 and $95,069, respectively.

 

Concentration of Revenue and Geographic Area

 

Revenue from the Company’s patent enforcement activities is considered United States revenue as any payments for licenses included in that revenue are for United States operations irrespective of the location of the licensee’s or licensee’s parent home domicile.

 

The Company had $0 in revenues from newly issued patent licenses for both the three months ended September 30, 2017 and the three months ended September 30, 2016. The revenue for the three months ended September 30, 2017 is attributable to a non-enforcement technology access license for one of the Company’s subsidiaries and running royalties from the Company’s Medtech portfolio and for the three months ended September 30, 2016, the revenue is attributable to running royalties from the Company’s Medtech portfolio.

 

At the current time, we define customers as firms that obtain licenses to the Company’s patents, either prior to or during enforcement litigation. These firms generally enter into non-recurring, non-exclusive, non-assignable license agreements with the Company, and these customers do not generally engage in ongoing, recurring business activity with the Company. The Company has historically had a small number of customers enter into such agreements, resulting in higher levels of revenue concentration.

 

7

 

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.

 

These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.

 

The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.

 

The Company also considers the revenue generated from its settlement and licensing agreements as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, since the settlement element and license element for past and future use are the Company’s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. There was no revenue from newly issued patent licenses for the three months ended September 30, 2017 and September 30, 2016, respectively.

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets of $108,878 and $202,067 at September 30, 2017 and December 31, 2016, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

 

Bonds Posted with Courts

 

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of September 30, 2017 and December 31, 2016, the Company had no outstanding bonds posted with the German courts.

 

Related Party Transactions

 

Parties are considered related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.

 

On May 13, 2013, we entered into a nine-year advisory services agreement (the “Advisory Services Agreement”) with IP Navigation Group, LLC (“IP Nav”), of which Erich Spangenberg is founder and former Chief Executive Officer. Mr. Spangenberg is an affiliate of the Company. The terms of the Advisory Services Agreement provide that, in consideration for its services as intellectual property licensing agent, the Company will pay to IP Navigation Group, LLC between 10% and 20% of the gross proceeds of certain licensing campaigns in which IP Navigation Group, LLC acts as intellectual property licensing agent.

 

8

 

On November 18, 2013, we entered into a consulting agreement with Jeff Feinberg (“Feinberg Agreement”), pursuant to which we agreed to grant Mr. Feinberg 25,000 shares of our restricted Common Stock, 50% of which shall vest on the one-year anniversary of the Feinberg Agreement and the remaining 50% of which shall vest on the second-year anniversary of the Feinberg Agreement. Mr. Feinberg is the trustee of The Feinberg Family Trust and holds voting and dispositive power over shares held by The Feinberg Family Trust, which is a 10% beneficial owner of our Common Stock.

 

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company. TechDev, SFF and Granicus are owned or controlled by Erich Spangenberg or family members or associates.

 

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. The remaining cash payment was made on February 24, 2015 and is fully paid. Under the terms of the Sarif Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement. Under the terms of the Pay Proceeds Agreement, as amended in 2016, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $13,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the cumulative gross proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the cumulative gross proceeds of such recoveries to the sellers. Pursuant to the amendment to the Pay Proceeds Agreement, the Company paid TechDev, Granicus and SFF $2.4 million. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

 

9

 

On May 2, 2014, we entered into an opportunity agreement (the “Marathon Opportunity Agreement”) with Erich Spangenberg, who is an affiliate of the Company. The terms of the Marathon Opportunity Agreement provide that we have ten business days after receiving notice from Mr. Spangenberg to provide up to 50% of the funding for certain opportunities relating to the licensing, intellectual property acquisitions and/or intellectual property enforcement actions in which Mr. Spangenberg, IP Nav or any entity controlled by Mr. Spangenberg, other than: (i) IP Nav or any of its affiliates, and (ii) Medtech Development, LLC or any of its affiliates.

 

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly-owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”). Selene owned a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav provided patent monetization and support services under an existing agreement with Selene prior to the return of the patents to Stanford Research Institute (“SRI”), the original owners of the patents.

 

On August 29, 2014, the Company entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP, LLC for an aggregate purchase price of $2.4 million, of which $1.4 million was paid in cash and $1.0 million was paid in the form of a promissory note issued by the Company that matured on October 31, 2014 and was fully paid prior to the maturation date. The Company also issued 6,250 shares of its restricted common stock in connection with the acquisition. Clouding IP, LLC is also entitled to certain possible future cash payments. Clouding IP LLC is owned or controlled by Erich Spangenberg or family members or associates.

 

On October 10, 2014, the Company entered into an interest sale agreement with MedTech Development, LLC (“MedTech”) to acquire from MedTech 100% of the limited liability membership interests of OrthoPhoenix and TLIF as well as 100% of the shares of MedTech GmbH. In connection with the transaction, the Company is obligated to pay to MedTech $1 million at closing and $1 million on each of the following nine (9) month anniversary dates of the closing. On July 16, 2015, the Company entered into a forbearance agreement (the “Agreement”) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company agreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 500,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment during the year ended September 30, 2015. On October 23, 2015, the Company entered into Amendment No. 1 to the Forbearance Agreement (the “Amendment”) entered into with MedTech Development on July 16, 2015. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. The acquired subsidiaries are also obligated to make certain additional payments to MedTech from recoveries following the receipt by the acquired subsidiaries of 200% of the purchase payments, plus recovery of out of pocket expenses in connection with patent claims. The participation payments may be paid, at the election of the Company, in common stock of Marathon at the market price on the date of issuance. In connection with the transaction, the Company entered into a promissory note, common interest agreement and in the event of issuance of common stock to MedTech, will enter into a lockup and registration rights agreement. Approximately forty-five percent (45%) of MedTech is owned or controlled by Erich Spangenberg or family members or associates.

 

On October 1, 2016, one of the Company’s subsidiaries, PG Technologies S.a.r.l. entered into an advisory services agreement with Granicus IP, LLC, an entity owned or controlled by one of the Company’s employees, whereby Granicus receives a percentage of pre-tax return from PG Technologies after certain revenue thresholds have been met.

 

During 2016, certain officers and directors of the Company received restricted common stock in the Company’s 3D Nanocolor Corp. (“3D Nano”) subsidiary.

 

At December 31, 2016, ‘‘Other noncurrent assets’’ in the Balance Sheets consists of a note receivable from an entity controlled by one of the Company’s employees that is uncollateralized. The note receivable does not carry interest and is repayable to the Company at the earlier of March 31, 2022 or based on certain milestones. The note receivable balance has been classified as current assets because the Company believes that it will be collected within one year from the Balance Sheet dates.

 

10

 

On September 29, 2017, the Company entered into an Irrevocable Stock Power whereby the Company sold the shares it owns in the Company’s subsidiary, 3D Nano to Doug Croxall, the Company’s Chief Executive Officer with such assignment including the assumption of all of 3D Nano’s liabilities. The Company engaged a third party to value the assignment, the results of which were that the valuation and assignment were deemed to be at fair value.

 

Fair Value of Financial Instruments

 

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

 

  Level 1:   Observable inputs such as quoted market prices in active markets for identical assets or liabilities
  Level 2:   Observable market-based inputs or unobservable inputs that are corroborated by market data
  Level 3:   Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated condensed balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

Clouding IP earn out liability was determined as a Level 3 liability, which requires an assessment of fair value at each period end by using discounted cash flow as a valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2017, the Company determined that there was a reduction in the Clouding IP earn out liability during the three and nine months ended September 30, 2017 in the amounts of $754,321and $754,321, respectively and a reduction in the carrying value of the Clouding IP intangible assets during the three and nine months ended September 30, 2017 in the amounts of $723,218 and $723,218, respectively.

 

The Company determined that the Warrants issued pursuant to the Unit Purchase Agreement should be treated as a Level 2 liability, which determine the value based on observable market-based inputs. in this instance, the Warrants were valued using a Monte-Carlo simulation utilizing market-based inputs for volatility and risk-free rate of interest, which resulted in the Warrants issued pursuant to the August 31, 2017 close being fair valued at $0.0364 per share and the Warrants issued pursuant to the September 29, 2017 close being fair valued at $0.0877 per share.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

11

 

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2016 tax returns. After review of the prior year financial statements and the results of operations through December 31, 2016, the Company has recorded a full valuation allowance on its deferred tax asset.

 

Basic and Diluted Net Loss per Share

 

Net loss per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 613,195 shares of Common Stock, warrants to purchase 7,487,894 shares of Common Stock, Convertible Notes convertible into up to 13,750,000 shares of Common Stock and shares of Series B Convertible Preferred Stock convertible into 195,501 shares of Common Stock outstanding at September 30, 2017, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

 

The following table sets forth the computation of basic and diluted loss per share:

 

  

For the Three Months Ended

September 30, 2017

  

For the Three Months Ended

September 30, 2016

  

For the Nine Months
Ended

September 30, 2017

  

For the Nine Months
Ended

September 30, 2016

 
Net income (loss) attributable to Common shareholders  $(6,677,485)  $(6,274,410)  $(12,484,924)  $(2,261,542)
                     
Denominator                    
Weighted average common shares – Basic and Diluted   6,270,299    3,761,786    5,564,465    3,736,213 
                     
Earnings (loss) per common share:                    
Earnings (loss) – Basic and Diluted  $(1.06)  $(1.67)  $(2.24)  $(0.60)

 

Intangible Assets - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.

 

12

 

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.

 

When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three and nine months ended September 30, 2017 the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment charge to its goodwill in the amount of $0 and $83,000, respectively.

 

Other Intangible Assets

 

In accordance with ASC 350-30, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.

 

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

13

 

For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company’s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

 

Liquidity and Capital Resources

 

At September 30, 2017, we had approximately $0.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of approximately $20.3 million.

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months from the issuance date of the financial statements, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

  raise additional funds to support the Company’s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
     
   review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlements of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern

 

Recent Accounting Pronouncements

 

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted.

 

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This ASU provides clarity about which changes to the terms or conditions of a share-based payment award require the application of modification accounting. Specifically, ASU 2017-09 clarifies that changes to the terms or conditions of an award should be accounted for as a modification unless all of the following are met: 1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted. The Company does not expect the adoption of ASU 2017-09 to significantly impact its accounting for share-based payment awards, as changes to awards’ terms and conditions subsequent to the grant date are unusual and infrequent in nature.

 

14

 

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04 Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for interim and annual period beginning after December 15, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which clarifies the definition of a business and assists entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under this guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or group of similar assets), the assets acquired would not represent a business. In addition, in order to be considered a business, an acquisition would have to include at a minimum an input and a substantive process that together significantly contribute to the ability to create an output. The amended guidance also narrows the definition of outputs by more closely aligning it with how outputs are described in FASB guidance for revenue recognition. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted.

 

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity’s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period.

 

In October 2016, the FASB issued ASU 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which eliminates the exception in existing guidance which defers the recognition of the tax effects of intra-entity asset transfers other than inventory until the transferred asset is sold to a third party. Rather, the amended guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated condensed financial statements.

 

In August 2016, the FASB issued ASU 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated condensed financial statements.

 

In May 2014, the FASB Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, as a new Topic, (ASC) Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. This ASU must be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are considering the alternatives of adoption of this ASU and we are conducting our review of the likely impact to the existing portfolio of customer contracts entered into prior to adoption. After completing our review, we will continue to evaluate the effect of adopting this guidance upon our results of operations, cash flows and financial position.

 

15

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated condensed financial statements.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

 

NOTE 3 — ACQUISITIONS

 

Clouding Corp.

 

On August 29, 2014, the Company entered into a patent purchase agreement (the “Clouding Agreement”) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Clouding”) and Clouding IP, LLC, a Delaware limited liability company (“Clouding IP”), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. The Clouding Agreement included an earn out payable to Clouding IP, which was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value.

 

The Clouding IP earn out liability was determined to be a Level 3 liability, which requires assessment of fair value at each period end by using a discounted cash flow model as the valuation methodology, using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rates. Based on the reassessment of fair value as of September 30, 2017, the Company determined the Clouding IP earn out liability to be $32,637 (current portion) and $681,175 (long-term portion) and as of December 31, 2016, the Company determined the Clouding IP earn out liability to be $81,930 (current portion) and $1,400,082 (long-term portion).

 

Munitech IP S.a.r.l. (“Munitech”)

 

On June 27, 2016, Munitech S.a.r.l. (“Munitech”), a Luxembourg limited liability company and newly formed wholly-owned subsidiary of the Company, entered into two Patent Purchase Agreements (the “PPA” or together, the “PPAs”) to purchase 221 patents from Siemens Aktiengesellschaft. The patents purchased by Munitech relate to W-CDMA and GSM cellular technology and cover all the major global economies including China, France, Germany, the United Kingdom and the United States. Significantly, many of the patent families have been declared to be Standard Essential Patents (“SEPs”) with the European Telecommunications Standard Institute (“ETSI”) and/or the Association of Radio Industries and Businesses (“ARIB”) related to Long Term Evolution (“LTE”), Universal Mobile Telecommunications System (“UMTS”), and/or General Packet Radio Service (“GPRS”).

 

Pursuant to the terms of the PPAs, Munitech (i) paid Siemens Aktiengesellschaft $1,150,000 in cash upon closing and (ii) agreed to two future payments, one in the amount of $1,000,000 payable on December 31, 2016 and the second in the amount of $750,000 payable on September 30, 2017.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On September 1, 2017, the Company entered into a Share Purchase Agreement with GPat Technologies, LLC (“GPat”) whereby the Company sold its 100% interest in Munitech to GPat.

 

16

 

Magnus IP GmbH (“Magnus”)

 

On July 5, 2016, Marathon IP GmbH (“Marathon IP”), a German corporate entity and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreements (the “PPA”) to purchase 86 patents from Siemens Switzerland Ltd and Siemens Industry Inc., (together, “Siemens”). On September 15, 2016, the patents were assigned by Marathon IP to Magnus, both of which are wholly-owned subsidiaries of the Company. The patents purchased by Marathon IP relate to Internet-of-Things (IOT) technology. Generally, the portfolio’s subject matter is directed toward self-healing control networks for automation systems. The patents are relevant to wireless mesh or home area networks for use in IOT, or connected home devices and enable simple commissioning, application level security, simplified bridging, and end-to-end IP security. The technology can support a wide variety of IOT enabled devices including lighting, sensors, appliances, security, and more. Pursuant to the terms of the PPA, Marathon IP paid Siemens $250,000 in cash upon closing.

 

Pursuant to the terms of the PPAs, Munitech (i) paid Siemens $250,000 in cash upon closing and (ii) will pay a percentage of gross proceeds in excess of a reserve threshold on behalf of Marathon IP.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 20, 2017, the Company assigned the patents held by Magnus to DBD, pursuant to the First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the “First Amendment and Restructuring Agreement”) entered into with DBD. In exchange for the assignment of three of the Company’s portfolios, of which Magnus was one, DBD cancelled all indebtedness owed by the Company to DBD.

 

Traverse Technologies Corp. (“Traverse”)

 

On August 3, 2016, Traverse Technologies Corp. (“Traverse”), a United States corporation and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreement (the “PPA”) to purchase 12 patents from CPT IP Holdings (“CPT”). The patents purchased by Traverse relate to batteries and principally cover various Asian and the United States markets.

 

Pursuant to the terms of the PPAs, Traverse (i) paid CPT $1,300,000 in cash upon closing and (ii) will pay a percentage of net recoveries in excess of a reserve threshold on behalf of Traverse.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 20, 2017, the Company assigned the patents held by Traverse to DBD, pursuant to the First Amendment and Restructuring Agreement entered into with DBD. In exchange for the assignment of three of the Company’s portfolios, of which Traverse was one, DBD cancelled all indebtedness owed by the Company to DBD.

 

PG Technologies S.a.r.l. (“PG Tech”)

 

On August 11, 2016, PG Technologies S.a.r.l. (“PG Tech”), a Luxembourg limited liability company jointly owned with a large litigation financing fund, entered into a Patent Funding and Exclusive License Agreement (the “ELA”) to manage the monetization of greater than 10,000 patents in a single industry vertical with a Fortune 50 company. The patents cover all the major global economies including China, France, Germany, the United Kingdom and the United States. The Company determined that its ownership in PG Tech constitutes a VIE and that the Company is the primary beneficiary, as a result of which, the Company consolidated PG Tech in its financial statements.

 

Pursuant to the terms of the ELA, PG Tech agreed with the Fortune 50 company to pay (i) $1,000,000 in cash upon closing, (ii) a future payment in the amount of $1,000,000 payable on or before December 31, 2016, (iii) minimum quarterly payments of $250,000 starting on April 1, 2017 and (iv) split 50% of the net licensing revenues.

 

17

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 27, 2017, the Company entered into an Assignment and Confirmation Agreement (the “Assignment”) with Luxone Ventures S.a.r.l. (“Luxone”) whereby the Company assigned all of its ownership interest in PG Technologies, S.a.r.l. (“PG Tech”) to Luxone. Pursuant to the Assignment, Luxone assumed the Company’s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio.

 

NOTE 4 – INTANGIBLE ASSETS

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. Patents purchased are recorded based at their acquisition cost and patents acquired in lieu of cash are recorded at their fair market value. Intangible assets consisted of the following:

 

   September 30, 2017   December 31, 2016 
         
Intangible Assets  $20,403,408   $23,637,813 
Accumulated Amortization & Impairment   (12,813,195)   (11,323,185)
           
Intangible assets, net  $7,590,213   $12,314,628 

 

Intangible assets are comprised of patents with estimated useful lives between approximately 1 to 16 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis. During the three and nine months ended September 30, 2017, respectively, the Company capitalized a total of $0 and $0 in patent acquisition costs and during the three and nine months ended September 30, 2016, respectively, the Company capitalized a total of $3,550,000 and $6,450,000 in patent acquisition costs. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included as an operating expense as reflected in the accompanying consolidated condensed statements of operations. The Company assesses fair market value for any impairment to the carrying values. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.

 

Patent amortization expense for the three and nine months ended September 30, 2017 was $457,419 and $1,803,264, respectively, and for the three and nine months ended September 30, 2016, patent amortization expense was $2,030,886 and $6,018,196, respectively. All patent amortization expense figures are net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:

 

2017  $401,804 
2018   1,517,219 
2019   1,447,660 
2020   1,154,767 
2021   1,004,600 
2022 and thereafter   2,064,163 
Total  $7,590,213 

 

As of September 30, 2017, our operating subsidiaries owned 170 patents, as set forth below, and had economic rights to over 10,000 additional patents, both of which include U.S. patents and certain foreign counterparts. In the aggregate, the earliest date for expiration of a patent in the Company’s patent portfolio has passed (the patent is expired, but patent rules allow for nine-year look-back for royalties), the median expiration date for patents in the Company’s portfolio is September 13, 2021, and the latest expiration date for a patent in any of the Company’s patent portfolios is February 27, 2033. A summary of the Company’s patent portfolios is as follows:

 

18

 

Subsidiary  Number of
Patents
   Earliest
Expiration Date
   Median
Expiration Date
   Latest
Expiration Date
   Subject Matter
Clouding Corp.   25    2/3/18    9/10/21    5/29/29   Network and data management
CRFD Research, Inc.   5    5/25/21    9/17/21    8/19/23   Web page content translator and device-to-device transfer system
Dynamic Advances, LLC   2    11/6/21    9/7/23    7/9/25   Natural language interface
Magnus IP   55    1/28/22    9/27/25    12/9/31   Network Management/Connected Home Devices
Medtech Group Acquisition Corp.   45    Expired    12/8/18    8/9/29   Medical technology
Signal IP, Inc.   2    8/28/20    8/17/21    8/6/22   Automotive
Traverse Technologies   20    2/27/22    2/25/29    2/27/33   Li-Ion Battery/High Capacity Electrodes
Soems Acquisition   16    11/11/17    4/6/19    7/18/24   N/A
         Median    09/13/21         

 

On October 20, 2017, the Company assigned the patent held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) to DBD.

 

On October 27, 2017, the Company assigned the economic rights to its more than 10,000 patents to Luxone.

 

NOTE 5 - STOCKHOLDERS’ EQUITY

 

The Company has authorized capital to 200,000,000 shares of Common Stock with par value to $0.0001 per share, and has authorized capital of 50,000,000 shares of preferred stock, par value $0.0001 per share.

 

On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.

 

Series B Convertible Preferred Stock

 

The terms of the Series B Convertible Preferred Stock are summarized below:

 

Dividend. The holders of Series B Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series B Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.

 

Liquidation Preference. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Common Stock and the holders of Series B Convertible Preferred Stock as if the Series B Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company.

 

Voting Rights. The Series B Convertible Preferred Stock have no voting rights except with regard to certain customary protective provisions set forth in the Series B Convertible Preferred Stock Certificate of Designations and as otherwise provided by applicable law.

 

Conversion. Each share of Series B Convertible Preferred Stock may be converted at the holder’s option at any time after issuance into one share of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days’ notice.

 

19

 

Series D Convertible Preferred Stock

 

The Company issued Series D Convertible Preferred Stock in exchange for the outstanding convertible note issued in October 2014 and prior to September 30, 2017, all of the Series D Convertible Preferred Stock was converted to the Company’s Common Stock and no shares of the Series D Convertible Preferred Stock remain outstanding. The terms of the Series D Convertible Preferred Stock are summarized below:

 

Dividend. The holders of Series D Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series D Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.

 

Liquidation Preference. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Series B Convertible Preferred Stock and Series D Convertible Preferred Stock as if the Series B Convertible Preferred Stock and Series D Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company, prior to any distributions to Junior Stock, which includes the Company’s Common Stock.

 

Voting Rights. Except as otherwise expressly required by law, each holder of Preferred Shares shall be entitled to vote on all matters submitted to shareholders of the Company and shall be entitled to the number of votes for each Preferred Share owned at the record date for the determination of shareholders entitled to vote on such matter or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited, equal to the number of shares of Common Stock such Preferred Shares are convertible into (voting as a class with Common Stock),

 

Conversion. Each share of Series D Convertible Preferred Stock may be converted at the holder’s option at any time after issuance into five shares of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days’ notice.

 

Common Stock

 

On May 11, 2016, the Company entered into a consulting agreement with the Cooper Law Firm, LLC (“Cooper”), pursuant to which the Company agreed to issue 20,000 shares of the Company’s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $6.80 per share or $136,000.

 

On December 9, 2016, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the sale of an aggregate of 870,500 shares of the Company’s common stock, at a purchase price of $6.00 per share, and warrants to purchase 435,249 shares of common stock for a purchase price of $0.01 per warrant, or $17,019.95 in total. None of the warrants were purchased prior to December 31, 2016, and all were subsequently purchased prior to the date of this report.

 

On February 1, 2017, the Company issued 187,500 shares of common stock pursuant to an At-The-Market (“ATM”) securities offering with certain institutional investors at an average price of $6.96 per share, yielding gross proceeds of $1,301,923.

 

On April 12, 2017, pursuant to an amendment entered into on March 6, 2017 to the settlement agreement entered into on October 29, 2015 between the Company and Dominion Harbor, the Company issued 31,250 shares of common stock to Dominion Harbor. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $0.83 per share or $103,750.

 

On April 18, 2017, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with certain institutional investors for the sale of an aggregate of 950,000 shares of the Company’s common stock at a purchase price of $2.80per share and warrants to purchase 570,000 shares of common stock at a purchase price of $3.32 per share.

 

20

 

On April 24, 2017, the Company issued one of its vendors 7,500 shares of Common Stock in exchange for cancellation of the vendor’s outstanding invoices. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $3.32 per share or $24,897.

 

On August 9, 2017, the Company issued 250,000 shares of the Company’s Common Stock pursuant to the conversion of 200,000 shares of Series D Convertible Preferred Stock.

 

On August 29, 2017, the Company issued 200,000 shares in total of the Company’s Common Stock to four different vendors in partial or total payment of outstanding invoices.

 

On September 5, 2017, the Company issued 62,500 shares of the Company’s Common Stock pursuant to the conversion of 50,000 shares of Series D Convertible Preferred Stock.

 

On September 6, 2017, the Company issued 534,710 shares of the Company’s Common Stock pursuant to the conversion of $427,768 in principal amount invested in the Convertible Note.

 

On September 13, 2017, the Company issued 315,925 shares of the Company’s Common Stock pursuant to the conversion of 252,750 shares of Series D Convertible Preferred Stock.

 

On September 29, 2017, the Company issued 598,500 shares of the Company’s Common Stock to holders of the warrants issued pursuant to the April Purchase Agreement following approval by the Company’s shareholders of the warrant exchange at a special meeting held on September 29, 2017.

 

Common Stock Warrants

 

Pursuant to the sales of securities underlying the Purchase Agreement entered into on December 9, 2016, the Company issued a warrant to the underwriter (“Underwriter’s Warrant”) to purchase 43,525 shares of Common Stock on December 9, 2016. The Underwriter’s Warrant has an exercise price of $6.92 per share. In addition, in a series of issuances in January 2017, the Company issued warrants to the investors (“Investor Warrants”) pursuant to the Purchase Agreement to purchase 435,249 shares of the Company’s Common Stock. The Investor Warrants have an exercise price of $6.80 per share. The warrants were issued in a series of transaction during January 2017 and were valued based on the Black-Scholes model, using the strike price of $6.80 per share, market prices ranging from $7.00 to $8.52 per share, an expected term of 3.25 years, volatility ranging from 38% to 39%, based on the average volatility of comparable companies over the comparable prior period, and a discount rate as published by the Federal Reserve ranging from 1.50% to 1.56%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as a liability and marked to market every reporting period. Following acceptance by the SEC of the Company’s registration statement registering these warrants, the warrants were reclassified from a liability to equity.

 

On January 10, 2017, pursuant to the amendment to the Fortress debt, the Company issued a five-year warrant to DBD to purchase 46,875 shares of the Company’s Common Stock, exercisable at $6.80 per share, subject to adjustment. The warrant was valued based on the Black-Scholes model, using the strike and market prices of $6.80 and $7.60 per share, respectively, an expected term of 3.00 years, volatility of 39% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.52%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.

 

Pursuant to the sales of securities underlying the April Purchase Agreement entered into on April 18, 2017, the Company issued a warrant to the underwriter (“Underwriter’s Warrant”) to purchase 14,250 shares of Common Stock. The Underwriter’s Warrant has an exercise price of $3.08 per share. In addition, also associated with the April Purchase Agreement, the Company issued warrants to the investors (“April Investor Warrants”) pursuant to the Purchase Agreement to purchase 570,000 shares of the Company’s Common Stock. The Investor Warrants have an exercise price of $3.32 per share. The Investor Warrants were valued based on the Black-Scholes model, using the strike price of $3.08 per share, an expected term of 2.5 years, volatility of 39%, based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.60%. The Underwriter’s Warrant was valued based on the Black-Scholes model, using the strike price of $3.32 per share, an expected term of 3.25 years, volatility of 38%, based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as equity.

 

21

 

Pursuant to the Unit Purchase Agreement entered into on August 14, 2017, the Company, in two closings, issued warrants to the investors (“Note Investor Warrants”) to purchase 6,875,000 shares of the Company’s Common Stock. The Note Investor Warrants have an exercise price of $1.20 per share. The Note Investor Warrants from the first close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the terms of the Unit Purchase Agreement which set the volatility at the greater 100% or the 100-day volatility immediately following certain events and a discount rate as published by the Federal Reserve of 1.76%. The Note Investor Warrants from the second close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the methodology set forth above and a discount rate as published by the Federal Reserve of 1.98%. The Company reviewed the issuance of the Note Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Note Investor Warrants should be classified as a liability.

 

At September 30, 2017, the Company had warrants outstanding to purchase 7,487,894 shares of Common Stock with a weighted average remaining life of 5.35 years. A summary of the status of the Company’s outstanding stock warrants and changes during the period then ended is as follows:

 

   Number of
Warrants
   Weighted
Average Exercise
Price
  

Weighted
Average
Remaining

Life

 
Balance at December 31, 2016   116,520   $15.17    3.25 
Granted   7,941,374    1.70    5.01 
Cancelled   -    -    - 
Forfeited   -    -    - 
Exercised   570,000    3.32    - 
Balance at September 30, 2017  7,487,894   $1.86    5.35 
                
Warrants exercisable at September 30, 2017   612,894           
Weighted average fair value of warrants granted during the period       $ 0.09      

 

Warrant Amendment Letter

 

On March 11, 2016, the Company entered into an agreement with the remaining investor in the Company’s convertible debt issued on October 9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 5,834 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $16.50 to the lower of 1) $8.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company’s Common Stock.

 

Common Stock Options

 

On May 10, 2016, the Company entered into an executive employment agreement with Erich Spangenberg (“Spangenberg Agreement”) pursuant to which Mr. Spangenberg would serve as the Company’s Director of Acquisitions, Licensing and Strategy. As part of the consideration, the Company agreed to grant Mr. Spangenberg a ten-year stock option to purchase an aggregate of 125,000 shares of Common Stock, with a strike price of $7.48 per share, vesting in twenty-four (24) equal installments on each monthly anniversary of the date of the Spangenberg Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.48 per share, an expected term of 5.75 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.32%.

 

22

 

On May 20, 2016, the Company entered into an employment agreement with Kathy Grubbs (“Grubbs Agreement”) pursuant to which Ms. Grubbs would serve as an analyst. As part of the consideration, the Company agreed to grant Ms. Grubbs a ten-year stock option to purchase an aggregate of 12,500 shares of Common Stock, with a strike price of $9.00 per share, vesting in thirty-nine (36) equal installments on each monthly anniversary of the date of the Grubbs Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.00 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.88%.

 

On July 1, 2016, in conjunction with an executive employment agreement with David Liu (“Liu Agreement”) pursuant to which Mr. Liu would serve as the Company’s CTO, entered into on June 29, 2016, the Company granted Mr. Liu a ten-year stock option to purchase an aggregate of 37,500 shares of Common Stock, with a strike price of $11.16 per share, vesting in thirty-nine (36) equal installments on each monthly anniversary of the date of the Liu Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $11.16 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.20%.

 

On October 13, 2016, the Company issued its independent board members ten-year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $9.64 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.64 per share, an expected term of 5.5 years, volatility of 46% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.21%. As there were not sufficient shares in the Company’s equity incentive plans to accommodate these grants, Mr. Croxall forfeited a portion of one of his options to purchase 20,000 shares.

 

At September 30, 2017, there was a total of $7,072 of unrecognized compensation expenses related to non-rested option-based compensation arrangements entered into during the year. A summary of the stock options as of September 30, 2017 and changes during the period are presented below:

 

   Number of
Options
   Weighted
Average Exercise
Price
  

Weighted
Average
Remaining

Life

 
Balance at December 31, 2016   879,034   $17.84    6.80 
Granted   -    -    - 
Cancelled   48,542    -    - 
Forfeited   217,298    16.71    - 
Exercised   -    -    - 
Balance at September 30, 2017  613,194   $17.04    3.06 
                
Options Exercisable at September 30, 2017   591,841   $13.83    2.91 
Options expected to vest   21,354   $20.33    7.23 
Weighted average fair value of options granted during the period       $-      

 

 

23

 

NOTE 6 – DEBT, COMMITMENTS AND CONTINGENCIES

 

Debt consists of the following:

 

   Maturity  Interest   September 30,   December 31, 
   Date  Rate   2017   2016 
                
Senior secured term notes  9-Jul-20   LIBOR + 9.75%  $15,881,493   $15,620,759 
Less: debt discount           (1,686,090)   (1,425,167)
Total senior-term notes, net of discount          $14,195,403   $14,195,592 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
                   
Convertible Note  10-Oct-18   11%  $0   $500,000 

 

   Maturity   Late    September 30,    December 31, 
   Date   Fee    2017    2016 
iRunway trade payable  On Demand   1.5% per month   $0   $191,697 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Note payable  31-Jan-17   NA   $-   $103,000 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Siemens  30-Sep-17   NA   $-   $1,672,924 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Dominion Harbor  15-Oct-17   NA   $-   $125,000 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Oil & Gas  On Demand   NA   $1,000,000   $944,296 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Convertible Note  10-May-18   0   $1,876,300   $- 
Less: debt discount           (1,851,171)   - 
Total Convertible notes, net of discount          $25,129   $- 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Convertible Note  31-May-18   5%  $3,195,932   $- 
Less: debt discount           (2,834,308)   - 
Total Convertible notes, net of discount          $361,624   $- 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
Medtech Note  1-May-18   NA   $-   $- 

 

   Maturity   Interest    September 30,    December 31, 
   Date   Rate    2017    2016 
3D Nano license Fee  31-Jan-17   NA   $-   $100,000 

 

   September 30, 2017   December 31, 2016 
Total  $15,582,156   $17,832,509 
Less: current portion   (15,582,156)   (13,162,007)
Total, net of current portion  $-   $4,670,502 

 

24
Table of Contents 

 

Senior Secured Term Notes

 

On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement with DBD Credit Funding LLC, (“DBD”) an affiliate of Fortress Credit Corp., under which the terms of the notes were:

 

  (i) $15,000,000 original principal amount of Fortress Notes (the “Initial Note”);
  (ii) a right to receive a portion of certain proceeds from monetization net revenues received by the Company (the “Revenue Stream”, after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes);
  (iii)  a five-year Fortress Warrant to purchase 25,000 shares of the Company’s Common Stock exercisable at $29.76 per share, subject to adjustment; and
  (iv) 33,603 shares of the Issuer’s Common Stock (the “Fortress Shares”).

 

On February 12, 2015, the Company issued an additional $5,000,000 of Notes (which increase proportionately the Revenue Stream).

 

The Initial Note matures on July 29, 2018. Additional Notes issued pursuant to the Fortress Purchase Agreement mature 42 months after issuance. The unpaid principal amount of the Initial Note plus the additional $5,000,000 note (including any PIK Interest, as defined below) bear cash interest at a rate equal to LIBOR plus 9.75% per annum payable on the last business day of each month. Interest is paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest. Monthly principal payments are due commencing one year after the anniversary dates of the loans.

 

The terms of the Fortress Warrant provide that until January 29, 2020, the Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company’s Common Stock. The exercise price of the warrant is $29.76 and the warrant fair value was determined to be $318,679 utilizing the Black-Scholes model, with the fair value of the warrants recorded as additional paid-in capital and reducing the carrying value of the Notes. As of September 30, 2017 and December 31, 2016, the unamortized discount on the Notes was $1,686,090 and $1,425,167, respectively.

 

Senior Secured Term Note Amendment

 

On January 10, 2017 the Company and certain of its subsidiaries entered into the Amended and Restated Revenue Sharing and Securities Purchase Agreement (“ARRSSPA”) with DBD Credit Funding LLC, under which the Company and DBD amended and restated the Revenue Sharing and Securities Purchase Agreement dated January 29, 2015 (the “Original Agreement”) pursuant to which (i) Fortress purchased $20,000,000 in promissory notes, of which $15,881,493 is outstanding as of September 30, 2017, (ii) an interest in the Company’s revenues from certain activities and warrants to purchase 25,000 shares of the Company’s common stock. The ARRSSPA amends and restates the Original Agreement to provide for (i) the sale by the Company of a $4,500,000 promissory note (the “New Note”) and (ii) the insurance of additional warrants to purchase 46,875 shares of common stock (the “New Warrant”). Pursuant to the ARRSSPA, Fortress acquired an increased revenue stream right to certain revenues generated by the Company through monetization of our patent portfolio (“Monetization Revenues”). The ARRSSPA increases the revenue stream basis to $1,225,000. The ARRSSPA provides for the potential issuance of up to $7,500,000 of additional notes (the “Additional Notes”), of which not more than $3,750,000 shall be made prior to June 30, 2017 and of which not more than $3,750,000 shall be made available during the period following June 30, 2017 and on or prior to December 31, 2017 and not more than two such issuances shall occur under the ARRSSPA.

 

The unpaid principal amount of the New Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Initial Note), the interest rate shall increase by an additional 2% per annum.

 

Interest on the Initial Note shall be paid on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2017. Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest, effective as of the applicable Interest Payment Date (“PIK Interest”). PIK Interest shall be treated as added principal of the New Note for all purposes, including interest accrual and the calculation of any prepayment premium. The Company paid a structuring fee of 2.0% of the New Note and would pay a 2.0% fee upon the issuance of any Additional Notes. The proceeds of the New Note and any Additional Notes may be used for working capital purposes, portfolio acquisitions, growth capital and other general corporate purposes.

 

25

 

The ARRSSPA contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,250,000 in unrestricted cash and cash equivalents.

 

The terms of the New Warrants provide that from July 10, 2017 until January 10, 2022, the Warrant may be exercised for cash or on a cashless basis. Exercisability of the Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Issuer’s Common Stock.

 

Pursuant to the ARSSPA, as security for the payment and performance in full of the Secured Obligations (as defined in the Security Agreement entered in favor of the Note purchasers (the “Security Agreement”) the Company and certain subsidiaries executed and delivered in favor of the purchasers a Security Agreement and a Patent Security Agreement, including a pledge of the Company’s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations (as defined in the Notes) is secured by a first priority lien and security interest in all the assets of the Company, subject to certain permitted liens. Certain subsidiaries of the Company also executed guarantees in favor of the purchasers (each, a “Guaranty”), guaranteeing the Note Obligations.

 

Amendment to Senior Secured Term Note Amendment

 

On August 3, 2017, the Company and certain of its operating subsidiaries entered into a First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the “First Amendment and Restructuring Agreement”) with DBD to cancel the indebtedness and other obligations of the Company under that certain ARRSSPA, dated January 10, 2017, which was originally entered into by the Company and DBD on January 29, 2015.

 

Pursuant to the First Amendment and Restructuring Agreement, certain intellectual property owned by the Company (the “Designated IP”) is to be assigned to one or more newly created special purpose entities (the “SPE”) as elected by DBD, which to be formed SPE shall be under the management and control of an affiliate of DBD (the “IP Monetization Manager”). All intellectual property owned by the Company that will not be assigned to one or more newly created special purpose entities shall be referred to as “Non- Designated IP.” The patents that are part of the Designated IP are referred to as the “Designated Patents”. Until shareholder approval and the close of the First Amendment and Restructuring Agreement (the “Restructuring”), all Monetization Revenues arising from the Designated IP and Non-Designated IP shall be paid to an account that is under the sole and exclusive control of the Collateral Agent as the IP Monetization Manager. In addition, until the Restructuring, the Company shall be responsible for the expenses associated with the maintenance, prosecution and enforcement of all of the Company’s intellectual property including the Designated IP and the other IP owned by the Company which is not to be transferred to the SPE, and for any expenses associated with the pursuit of monetization activities relating to both the Designated IP and the Non-Designated IP. From and after the Restructuring, the SPE shall have sole responsibility for the expenses associated with the Designated IP and the Company shall have sole responsibility for the expenses associated with the Non-Designated IP.

 

On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.

 

As of September 30, 2017 and December 31, 2016, the outstanding balances were $15,881,493 and $15,620,759, respectively.

 

Convertible Note

 

In two transactions, on October 9, 2014 and October 16, 2014, the Company sold an aggregate $5,550,000 of principal amount of convertible notes (“Convertible Notes”) along with two-year warrants to purchase 32,375 shares of the Company’s Common Stock. The Convertible Notes are convertible into shares of the Company’s Common Stock at $30.00 per share and the Warrants have an exercise price of $33.00 per share. The Notes mature on October 10, 2018 and bear interest at the rate of 11% per annum, payable quarterly in cash on each of the three, nine, nine and twelve-month anniversaries of the issuance date and on each conversion date. The Notes may become secured by a security interest granted to the holder in certain future assets under certain circumstances. In the event the Company’s Common Stock trades at a price of at least $108.00 per share for four out of eight trading days, the Notes will be mandatorily converted into Common Stock of the Company at the then applicable conversion price per share. The Company repaid the Convertible Notes for all but one holder in early 2015, and exchanged the remaining balance for Series D Convertible Preferred Stock on August 7, 2017, with the Series D Convertible Preferred Stock converted in its entirety prior to September 30, 2017. The balance was $0 and $500,000 as of September 30, 2017 and December 31, 2016, respectively.

 

26

 

iRunway

 

The Company converted a set of outstanding invoices related to work performed by one of the Company’s vendors to a short-term payable whereby the Company agreed to pay iRunway over time for the open invoices, subject to a payment schedule as defined. To the extent that the Company does not make payments according to that schedule, the remaining balance accrues interest at 1.5% per month. On August 20, 2017, the Company entered into a release agreement with iRunway pursuant to which the Company made an immediate cash payment to iRunway in return for a release of the remaining amount outstanding. As of September 30, 2017 and December 31, 2016, the principal balance was $0 and $191,697, respectively.

 

Note Payable

 

The Company entered into a short-term advance with an officer related to funds the Company was transferring from its European subsidiaries. The advance carried no interest and as of September 30, 2017 and December 31, 2016, the outstanding balance was $0 and $103,000, respectively.

 

Siemens Purchase Payment

 

The Company entered into a purchase agreement to acquire ownership of certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest. On September 1, 2017, the Company entered into Share Purchase Agreement with GPat whereby the Company sold its 100% interest in Munitech, the wholly-owned subsidiary holding these patents, to GPat. As of September 30, 2017 and December 31, 2016, the outstanding balances were $0 and $1,672,924, respectively.

 

Dominion Harbor Settlement Note

 

The Company entered into a settlement agreement with Dominion Harbor, a former licensing agent for some of the Company’s subsidiaries, on October 29, 2015 whereby the Company agreed to issue 75,000 shares of the Company’s Common Stock to Dominion Harbor and make eight (8) payments of $25,000 each ending on October 15, 2017. The shares issued to Dominion Harbor were valued at the quoted market price on the date of the grant of $6.84 per share or $513,000. As of September 30, 2017 and December 31, 2016, $0 and $125,000, respectively, remained outstanding, following an agreement between the Company and Dominion wherein the Company paid $25,000 and issued 31,250 shares of Common Stock to Dominion in full resolution of the outstanding obligation.

 

Oil & Gas Purchase Payment

 

The Company entered into a purchase agreement to acquire monetization rights to certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest and as of September 30, 2017 and December 31, 2016, the Company had an outstanding obligation for purchase of certain Siemens patents in the amount of $1,000,000 and $944,296, respectively, with such payments expected to be made by December 31, 2017.

 

Convertible Note

 

On August 14, 2017, the Company entered into a unit purchase agreement (the “Unit Purchase Agreement”) with certain accredited investors providing for the sale of up to $5,500,000 of 5% secured convertible promissory notes (the “Convertible Notes”), which are convertible into shares of the Corporation’s common stock, and the issuance of warrants to purchase 6,875,000 shares of the Company’s Common Stock (the “Warrants”). The Convertible Notes are convertible into shares of the Company’s Common Stock at the lesser of (i) $0.80 per share or (ii) the closing bid price of the Company’s common stock on the day prior to conversion of the Convertible Note; provided that such conversion price may not be less than $0.40 per share. The Warrants have an exercise price of $1.20 per share. The Convertible Notes mature on May 31, 2018 and bear interest at the rate of 5% per annum. In two closings of the Unit Purchase Agreement, the Company issued all $5,500,000 in Convertible Notes to the investors. As of September 30, 2017, the Company had an outstanding obligation pursuant to the Convertible Notes in the amount of $5,072,232.

 

27

 

3D Nano Purchase Payment

 

3D Nano entered into a license and purchase agreement with HP Inc. (“HP”) to acquire the rights to use if 3D Nano chooses, the right to exercise an option to acquire, ownership of certain patents, trade secrets and other intellectual property (the “Technology”). As part of the purchase agreement, the Company agreed to license the Technology for two payments of $100,000 each, with the first payment made in April 2016 and the second payment due by January 31, 2017. Under the original agreement, the payment obligations bear no interest and as of September 30, 2017 and December 31, 2016, 3D Nano had an outstanding obligation in the amount of $0 and $100,000, respectively. On May 1, 2017, 3D Nano entered into an amendment with HP whereby the agreement was extended for two years. While 3D Nano does not have the obligation under the amendment to make additional payments, should 3D Nano desire to do so, payments in the amount of $100,000 in each of 2018 and 2019 would be due to HP for the agreement to remain in effect.

 

Medtech Note

 

On May 31, 2017, the Company entered into a note payable with Medtronic, Inc. (“Medtronic”), the original owner of the patents in the Company’s Medtech portfolio, whereby the Company agreed to pay Medtronic a total of $750,000 in ten equal monthly installments for patent enforcement related expenses incurred by Medtronic. Following two payments of $75,000 each in May and June 2017, the Company entered into an agreement on August 29, 2017 to pay a discounted amount in return for a full release from the remaining obligations. The note payable carries no interest and since the note payable arose after December 31, 2016 and was repaid in full prior to September 30, 2016, as of September 30, 2017 and December 31, 2016, the outstanding balance, was $0 and $0, respectively.

 

Total Future Minimum Principal Payments

 

Future minimum principal payments for all items set forth above are as follows:

 

2017  $16,881,493 
2018   5,072,232 
Total  $21,953,725 

 

Office Lease

 

In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California. The lease will commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease. In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes. Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit. In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease. Minimum future lease payments under this lease at September 30, 2017, for the next five years are as follows:

 

2017 (Three Months)  $18,081 
2018   74,540 
2019   77,872 
2020   81,336 
2021   27,504 
Total  $297,333 

 

28

 

NOTE 7 – SUBSEQUENT EVENTS

 

On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.

 

On October 27, 2017, the Company entered into the Assignment with Luxone whereby the Company assigned all of its ownership interest in PG Tech to Luxone. Pursuant to the Assignment, Luxone assumed the Company’s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio. Luxone is owner or controlled by a former affiliate of the Company.

 

On November 1, 2017, the Company entered into an agreement to acquire, through its wholly-owned subsidiary, Global Bit Ventures Acquisition Corp., a Nevada corporation (“GBVAC”), 100% of the Capital Stock of Global Bit Ventures, Inc., a Nevada corporation (“GBV”), which currently secures and powers digital asset blockchains by running specialized servers. Under the terms of the Agreement and Plan of Merger (the “Merger Agreement”), the Company will issue 126,674,557 shares of the Company’s Common Stock in exchange for one-hundred (100%) percent of the shares of GBV’s capital stock. At the closing of the merger, GBVAC shall be merged with and into GBV pursuant to the Merger Agreement and the separate existence of GBVAC shall cease and GBV shall be the surviving company. The closing of the acquisition is subject to certain closing conditions including approval of the Merger Agreement by the Company’s Shareholders.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This report on Form 10-Q (“Report”) and other written and oral statements made from time to time by us may contain so-called “forward-looking statements,” all of which are subject to risks and uncertainties. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “forecasts,” “projects,” “intends,” “estimates,” and other words of similar meaning. One can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address our growth strategy, financial results and product and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ from our forward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

 

Information regarding market and industry statistics contained in this Report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from all sources, and cannot assure investors of the accuracy or completeness of the data included in this Report. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not assume any obligation to update any forward-looking statement. As a result, investors should not place undue reliance on these forward-looking statements.

 

Overview

 

The Company has acquired patents and patent rights from owners or other ventures and seeks to monetize the value of the patents through litigation and licensing strategies, alone or with others. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into comprehensive settlement and license agreements that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms. As of September 30, 2017, we owned 170 patents and had economic rights to over 10,000 additional patents, both of which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries. The greater than 10,000 patents to which the Company has economic rights were assigned to Luxone in an agreement entered into in October 2017; the Company retained an earn-out associated with future income from this portfolio, but no longer manages or is responsible for costs associated with licensing the portfolio.

 

The Company previously announced that it intended to review alternative business directions with the goal of enhancing shareholder value, and on November 1, 2017, the Company announced that it will be entering into the cryptocurrency mining market pursuant to the agreement to acquire 100% ownership of GBV, a digital asset technology company that mines cryptocurrencies. GBV is a technology company that powers and secures Blockchains by operating custom hardware and software, which verify Blockchain transactions. Blockchains are decentralized digital ledgers that record and enable secure peer-to-peer transactions without third party intermediaries. With the acquisition of GBV, the Company will be supplementing its existing business with this new business opportunity. GBV currently owns 250GH/s of GPU mining servers and plans to add 14PH/s of ASIC hashing servers, with significant capability for expansion.

 

29

 

Our principal office is located at 11100 Santa Monica Blvd., Suite 380, Los Angeles, CA 90025. Our telephone number is (703) 232-1701.

 

We were incorporated in the State of Nevada on February 23, 2010 under the name “Verve Ventures, Inc.” On December 7, 2011, we changed our name to “American Strategic Minerals Corporation” and were engaged in exploration and potential development of uranium and vanadium minerals business. During June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In November 2012, we discontinued our real estate business.

 

On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.

 

All share and per share values for all periods presented in the accompanying condensed consolidated financial statements are retroactively adjusted as of September 30, 2017 to reflect the Reverse Split.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with US GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Management believes the following critical accounting policies affect the significant judgments and estimates used in the preparation of the financial statements.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position, the results of operations and cash flows of the Company for the periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated condensed financial statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

30

 

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.

 

These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.

 

The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.

 

The Company also considers the revenue generated from its settlement and licensing agreements as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, due to the fact that the settlement element and license element for past and future use are the Company’s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis. The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

Intangible Asset - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to an impairment charge associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.

 

31

 

Goodwill

 

When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three and nine months ended September 30, 2017, the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment to its Goodwill in the amount of $0 and $83,000, respectively.

 

Other Intangible Assets

 

In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.

 

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

32

 

For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company’s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

 

Liquidity and Capital Resources

 

At September 30, 2017, we had approximately $.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of $20.3 million.

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

  raise additional funds to support the Company’s operations; however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
     
  review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets.

 

Results of Operations

 

For the Three and Nine Months Ended September 30, 2017 and 2016

 

We generated revenues of $162,713 and $609,650 during the three and nine months ended September 30, 2017 as compared to $43,113 and $36,452,551 during the three and nine months ended September 30, 2016. For the three and nine months ended September 30, 2017, this represented an increase of $119,600 or 277% and a decrease of $35,842,901 or 98%, respectively. On an absolute basis, revenue for the three and nine months ended September 30, 2017 was derived from the issuance of a one-time technology license outside of litigation and recurring royalties from the Company’s Medtech portfolio and for the three and nine months ended September 30, 2016 revenue was primarily derived from the issuance of one-time patent licenses with the remainder of the revenue derived from recurring royalties.

 

The Company had no revenues from the issuance of one-time patent licenses to certain of the Company’s patent portfolios for the three months and nine ended September 30, 2017 and 0% and 99% for the three and nine months ended September 30, 2016, respectively. For the three months ended September 30, 2017, there were no patent settlement and license agreements, whereas revenues from the five largest settlement and license agreements accounted for 99% of the Company’s revenue for the comparable period ending September 30, 2016.

 

Direct cost of revenues during the three and nine months ended September 30, 2017 amounted to $64,836 and $1,544,322, respectively and for the three and nine months ended September 30, 2016, the direct cost of revenues amounted to $1,094,378 and $19,202,118, respectively. For the three and nine months ended September 30, 2017, this represented a decrease of $1,479,486 or 94% and $18,107,740 or 92%, respectively. Direct costs of revenue include contingent payments to patent enforcement legal costs, patent enforcement advisors and inventors as well as various non-contingent costs associated with enforcing the Company’s patent rights and otherwise in developing and entering into settlement and licensing agreements that generate the Company’s revenue. For the three and nine months ended September 30, 2017, the Company had lower contingent fee costs associated with lower levels of revenue and fewer number of active infringement cases. Direct cost of revenues were 40% and 253%, respectively, for the three and nine months ended September 30, 2017 and direct costs of revenues were 2,538% and 53%, respectively, for the comparable periods in 2016.

 

33

 

We incurred other operating expenses of $4,014,856 and $8,720,754 for the three and nine months September 30, 2017, respectively and $9,688,527 and $18,884,827 for the three and nine months ended September 30, 2016, respectively. For the three and nine months ended September 30, 2017, this represented a decrease in other operating expenses of $5,669,671 or 59% and $10,164,073 or 54%, respectively. These expenses primarily consisted of amortization of patents, general expenses, compensation to our officers, directors and employees, professional and consulting fees incurred in connection with the day-to-day operation of our business and patent and goodwill impairment charges. The year over year decline in other operating expenses for the three and nine months ended September 30, 2017 resulted from declines in patent amortization and impairment costs and consulting fees, offset by increases in compensation, professional fees and other general and administrative costs, compared to 2016. The increase in compensation expenses is related to costs associated with the cancellation of existing employment agreements between the Company and the Company’s CEO, CFO and COO, as well as other termination provisions for non-executive employees.

 

Other operating expenses consisted of the following:

 

   Total Other Operating Expenses   Total Other Operating Expenses 
   For the Three Months Ended
September 30, 2017
   For the Three Months Ended
September 30, 2016
   For the Nine Months Ended
September 30, 2017
   For the Nine Months Ended
September 30, 2016
 
                     
Amortization of patents(1)  $457,419   $2,030,886   $1,803,264   $6,018,196 
Compensation and related taxes (2)   1,871,946    1,252,571    3,718,034    3,406,841 
Consulting fees (3)   133,018    257,420    189,819    903,032 
Professional fees (4)   616,125    432,496    1,686,955    1,336,201 
Other general and administrative (5)   213,130    183,771    599,464    612,284 
Goodwill impairment (6)   -    -    -    83,000 
Patent Impairment (7)   723,218    5,531,383    723,218    6,525,273 
Total  $4,014,856   $9,688,527   $8,720,754   $18,884,827 

 

Operating expenses for the three and nine months ended September 30, 2017 include non-cash operating expenses totaling $2,541,798 and $4,069,413, respectively, and for the three and nine month ended September 30, 2016, the Company incurred non-cash operating expenses of $8,053,556 and $14,332,533, respectively. Non-cash operating expenses consisted of the following:

 

   Non-Cash Operating Expenses   Non-Cash Operating Expenses 
   For the Three Months Ended
September 30, 2017
   For the Three Months Ended
September 30, 2016
   For the Nine Months Ended
September 30, 2017
   For the Nine Months Ended
September 30, 2016
 
                 
Amortization of patents (1)  $457,419   $2,030,886   $1,803,264   $6,018,196 
Compensation and related taxes (2)   1,319,629    440,161    1,636,906    1,306,399 
Consulting fees (3)   42,910    30,038    (91,228)   345,510 
Professional fees (4)   108    8,620    325    25,707 
Other general and administrative (5)   (1,486)   12,468    (3,072)   28,448 
Goodwill impairment (6)   -    -    -    83,000 
Patent Impairment (7)   723,218    5,531,383    723,218    6,525,273 
Total  $2,541,798   $8,053,556   $4,069,413   $14,332,533 

 

34

 

  (1) Amortization of intangibles and depreciation: Amortization expenses associated with patents and the Company’s website were $457,419 and $1,803,264 during the three and nine months ended September 30, 2017, respectively, a decrease of $1,573,467 or 77% and $4,214,932 or 70% relative to the three and nine months ended September 30, 2016. The decrease results from the partial or full impairment of numerous of the Company’s portfolios reducing the carrying fair value and the related amortization expenses. When the Company acquires patents and patent rights, the Company capitalizes the cost of those assets and amortizes those costs over the remaining useful lives of the assets. All patent amortization expenses are non-cash expenses.
     
  (2) Compensation expense and related taxes: Compensation expense includes cash compensation and related payroll taxes and benefits, and non-cash equity compensation expenses. For the three and nine months ended September 30, 2017, respectively, compensation expense and related payroll taxes were $1,871,946 and $3,718,034, an increase of $619,375 or 49% and 311,193 or 9% relative to the three and nine months ended September 30, 2016. The increase in compensation expenses is related to costs associated with the cancellation of existing employment agreements between the Company and the Company’s CEO, CFO and COO, as well as other termination provisions for non-executive employees. We recognized non-cash employee and board equity based compensation of $1,319,629 and $1,636,906, respectively, for the three and nine months ended September 30, 2017 and $440,161 and $1,306,399, respectively, for the three and nine months ended September 30, 2016.
     
  (3) Consulting fees: For the three and nine months ended September 30, 2017, respectively, we incurred consulting fees of $133,018 and $189,819. This represented decreases in the amount of $124,402 or 48% and $713,213 or 79% compared to the three and nine months ended September 30, 2016. Consulting fees include both cash and non-cash related consulting fees primarily for investor relations, public relations and general consulting services. The decrease in consulting fees for the three and nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 reflects a reduction in activity related to the acquisition of new portfolios as well as a credit recognized during the three months ended March 31, 2017 associated with the mark to market of an option grant issued to a consultant who no longer derives a majority of his compensation from the Company. As a result, the Company must mark to market his option grant on a quarterly basis. The credit for the three months ended March 31, 2017 was partially offset by a mark to market expense of the same option during the three months ended September 30, 2017. During the three ended September 30, 2017, we recognized non-cash equity based consulting expenses of $42,910 and during the nine months ended September 30, 2017, we recognized a non-cash equity based consulting credit of $91,228. During the three and nine months ended September 30, 2016, we recognized non-cash equity-based consulting expenses of $30,038 and $345,510, respectively.
     
  (4) Professional fees: For the three and nine months ended September 30, 2017, we incurred professional fees of $616,125 and $1,686,955, respectively, an increase of $183,629 or 42% and $350,754 or 26% over the comparable periods in 2016. Professional fees primarily reflect the costs of professional outside accounting fees, legal fees and audit fees. The increase in professional fees for the three and nine months ended September 30, 2017 over the three and nine months ended September 30, 2016 relate to higher professional outside legal, accounting and audit fees resulting from the costs associated with closing the Fortress restructuring in January 2017, the equity issuance in April 2017, the Convertible Note issuance in August, the restructuring of other indebtedness and the entrance into the merger agreement with GBV. During the three and nine months ended September 30, 2017, we recognized non-cash equity-based professional expenses of $108 and $325, respectively, compared to non-cash equity-based professional expenses of $8,620 and $25,707, respectively, during the same periods in 2016.
     
  (5) Other general and administrative expenses: For the three and nine months ended September 30, 2017, we incurred other general and administrative expenses of $213,130 and $599,464, respectively, an increase of $29,359 or 16% for the three months ended September 30, 2017 and a decrease of $12,820 or 2% over the comparable periods in 2016. General and administrative expenses reflect the other non-categorized operating costs of the Company and include expenses related to being a public company, rent, insurance, technology and other expenses incurred to support the operations of the Company. During the three and nine months ended September 30, 2017, we recognized non-cash equity based other G&A credits of $1,486 and $3,072, respectively, compared to non-cash equity-based other G&A expenses of $12,468 and $28,448, respectively, during the same periods in 2016.

 

35

 

  (6) Goodwill impairment: For the three and nine months ended September 30, 2017, there was no impairment of goodwill. Based on the Company’s decision to end of life one of its portfolios, the Company took an impairment charge during the three and nine months ended September 30, 2016 in the carrying value of the related goodwill in the amount of $83,000.
     
  (7) Patent impairment: For the three and nine months ended September 30, 2017, the Company took an impairment charge of the carrying value of the Company’s Clouding portfolio patents in the amount of $723,218 and $723,218, respectively. Based on changes in the expected timing of proceeds from the Clouding portfolio, as well as the impairment of one portfolio during the three months ended September 30, 2016 and two portfolios during the three months ended March 31, 2016, the Company took impairment charges for three and nine months September 30, 2016 in the carrying value of the Company’s patents assets in the amount of $5,531,383 and $6,525,273, respectively.

 

We reported operating income (loss) of $(3,916,979) and $(9,655,378) for the three and nine months ended September 30, 2017 and operating income (loss) of $(10,739,792) and $(1,634,394) for the three and nine months ended September 30, 2016. For the three and nine months ended September 30, 2017, this represented an increase in operating income of $6,822,813 for the three months ended September 30, 2017 and a decrease in operating income of $8,020,984 for the three months ended September 30, 2017. The increase in operating income for the three months ended September 30, 2017 results from markedly lower expenses and the decreased income from operations in 2017 relative to 2016 was primarily attributable to lower revenue and higher direct cost of revenues as a percentage of revenue, only partially offset by lower cash and non-cash operating expenses.

 

Other Income (Expenses)

 

Total other income (expenses) was $(2,468,316) and $(2,675,400) for the three and nine months ended September 30, 2017, respectively, and $1,093,278 and $(682,040) for the three and nine months ended September 30, 2016, respectively. For the three and nine months ended September 30, 2016, this represented an increase in other expense of $3,561,594 and $1,993,360, respectively.

 

Income Tax Benefit (Expense)

 

For the three and nine months ended September 30, 2016, the Company recognized no income tax benefit as a result of the Company’s profit. We recognized an income tax expense for the three and nine months ended September 30, 2017 in the amounts of $(12,191) and $(29,433), respectively and an income tax benefit in the amount of $3,347,909 and $26,974 for the three and nine months ended September 30, 2016, respectively.

 

Net Income (Loss)

 

We reported net income (loss) of $(6,677,486) and $(12,484,925) for the three and nine months ended September 30, 2017, respectively, and net income (loss) of $(6,274,410) and $(2,261,542) for the three and nine months ended September 30, 2016, respectively. For the three and nine months ended September 30, 2017, this represented a decrease in the net income of $98,881 and $10,070,751, respectively.

 

Non-GAAP Reconciliation

 

Non-GAAP earnings as presented in this Annual Report is a supplemental measure of our performance that is neither required by, nor presented in accordance with, U.S. generally accepted accounting principles (“US GAAP”). Non-GAAP earnings is not a measurement of our financial performance under US GAAP and should not be considered as alternative to net income, operating income, or any other performance measures derived in accordance with US GAAP, or as alternative to cash flow from operating activities as a measure of our liquidity. In addition, in evaluating Non-GAAP earnings, you should be aware that in the future we will incur expenses or charges such as those added back to calculate Non-GAAP earnings. Our presentation of Non-GAAP earnings should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

 

Non-GAAP earnings has limitations as an analytical tool, and you should not consider it in isolation, or as substitutes for analysis of our results as reported under US GAAP. Some of these limitations are (i) it does not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments, (ii) they do not reflect changes in, or cash requirements for, our working capital needs, (iii) it does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debt, (iv) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Non-GAAP earnings does not reflect any cash requirements for such replacements, (v) it does not adjust for all non-cash income or expense items that are reflected in our statements of cash flows, and (vi) other companies in our industry may calculate this measure differently than we do, limiting its usefulness as comparative measures.

 

36

 

We compensate for these limitations by providing specific information regarding the US GAAP amounts excluded from such non-GAAP financial measures. We further compensate for the limitations in our use of Non-GAAP financial measures by presenting comparable US GAAP measures more prominently.

 

We believe that Non-GAAP earnings facilitates operating performance comparisons from period to period by isolating the effects of some items that vary from period to period without any correlation to core operating performance or that vary widely among similar companies. These potential differences may be caused by variations in capital structures (affecting interest expense), tax positions (such as the impact on periods or companies of changes in effective tax rates or net operating losses) and the age and book depreciation of facilities and equipment (affecting relative depreciation expense). We also present Non-GAAP earnings because (i) we believe that this measure is frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry, (ii) we believe that investors will find these measures useful in assessing our ability to service or incur indebtedness, and (iii) we use Non-GAAP earnings internally as benchmark to compare our performance to that of our competitors.

 

The Company uses a Non-GAAP reconciliation of net income (loss) and earnings (EPS reconciliation loss) per share in the presentation of financial results here. Management believes that this presentation may be more meaningful in analyzing our income generation.

 

On a Non-GAAP basis, the Company’s recorded a Non-GAAP loss of $(1,448,278) and $(6,187,993) for the three and nine months ended September 30, 2017, respectively, compared to Non-GAAP loss in the amount of $(3,235,092) and non-GAAP income of $10,874,080 for the three and nine months ended September 30, 2016, respectively. The details of those expenses and non-GAAP reconciliation of these non-cash items are set forth below:

 

   Non-GAAP Reconciliation   Non-GAAP Reconciliation 
   For the Quarter Ended
September 30, 2017
   For the Quarter Ended
September 30, 2016
   For the Nine Months Ended
September 30, 2017
   For the Nine Months Ended
September 30, 2016
 
Net income (loss) attributable to Common Shareholders  $(6,677,486)  $(6,274,410)  $(12,484,925)  $(2,261,542)
Non-GAAP                    
Amortization of intangible assets & depreciation   457,719    2,030,886    1,804,512    6,018,196 
Equity-based compensation   1,371,480    478,819    1,554,835    1,677,616 
Impairment of intangible assets   723,218    5,531,383    723,218    6,608,273 
Change in the fair value of the clouding IP liability   (754,320)   (1,954,378)   (768,199)   (2,122,208)
Loss on debt extinguishment   283,237    -    283,237    - 
Loss on sale of companies   1,519,875    -    1,519,875    - 
Warrant (Income) Expense, net   1,909,879    -    1,914,786    - 
Non-cash Other (Income) expense, net   (1,323,407)   -    (2,221,939)   - 
Non-cash interest expense   1,043,012    288,049    1,489,678    952,231 
Deferred tax benefit   -    (3,347,909)   -    (26,974)
Other   (1,486)   12,468    (3,072)   28,488 
Non-GAAP earnings (loss)  $(1,448,278)  $(3,235,092)  $(6,187,993)  $10,874,080 

 

37

 

The following table sets forth the computation of basic and diluted loss per share on a Non-GAAP basis:

 

   Non-GAAP Reconciliation   Non-GAAP Reconciliation 
   For the Quarter Ended
September 30, 2017
   For the Quarter Ended
September 30, 2016
   For the Nine Months Ended
September 30, 2017
   For the Nine Months Ended
September 30, 2016
 
Non-GAAP net income (loss)  $(1,448,278)  $(3,235,092)  $(6,187,993)  $10,874,080 
                     
Denominator                    
Weighted average common shares - Basic   6,270,299    3,761,785    5,564,465    3,736,213 
Weighted average common shares - Diluted   6,270,299    3,761,785    5,564,465    3,996,067 
                     
Non-GAAP earnings (loss) per common share:                    
Non-GAAP earnings (loss) - Basic  $(0.23)  $(0.86)  $(1.11)  $2.91 
Non-GAAP earnings (loss) - Diluted   NA     NA     NA     2.72 

 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. At September 30, 2017, the Company’s unrestricted cash balances totaled $122,172 compared to $4,998,314 at December 31, 2016 and the Company’s restricted cash balances totaled $3,919,718 at September 30, 2017 and $0 at December 31, 2016. The decrease in the cash balances of $4,876,142 resulted primarily from net cash used in operations, offset by cash received upon the issuance of the Convertible Note and equity.

 

The unrestricted net working capital deficit declined by $5,323,251 to $(20,262,835) at September 30, 2017 from $(14,939,583) at December 31, 2016. The decrease in net working capital resulted primarily from a reduction in the Company’s cash as well as the reclassification of all Fortress indebtedness into short-term liabilities in anticipation of the Restructuring.

 

Cash provided in operating activities was $(14,805,103) during the nine months ended September 30, 2017 and cash provided in operating activities of was $11,214,122 during the nine months ended September 30, 2016. The difference between the nine months ended September 30, 2016, during which the Company generated cash from operating activities, and the nine months ended September 30, 2017, during which the Company used cash in operating activities, is largely tied to the much lower level of revenues during the nine months ended September 30, 2017 as compared to the comparable period in 2016.

 

Cash provided in investing activities was $2,765,466 for the nine months ended September 30, 2017 compared to $(3,561,043) cash used in investing activities for the nine months ended September 30, 2016. The generation of cash in investing activities during the nine months ended September 30, 2017 was primarily related to the disposition of certain patent portfolios, offset slights by the purchases of property, equipment and other non-patent intangible assets and cash used during the nine months ended September 30, 2016 was primarily the acquisition of new patent portfolios.

 

Cash provided in financing activities was $11,066,704 during the nine months ended September 30, 2017 compared to cash provided in financing activities in the amount of $(8,911,688) during the nine months ended September 30, 2016. Cash generated by financing activities for the nine months ended September 30, 2017 resulted from the issuance of equity, issuance of Convertible Notes, offset by the repayment of some outstanding debt. Cash used in financing activities for the nine months ended September 30, 2016 resulted from the repayment of notes payable related to the acquisition of the Medtech portfolios, the repayment of principal on the Fortress debt and the repayment of other minor debt obligations.

 

Management is uncertain that the balance of cash and cash equivalents of $122,172 in unrestricted cash at September 30, 2017 is sufficient to continue to fund the Company’s operations through at least the next twelve months and there is no certainty that the Company will achieve the milestones to have the restricted cash released from escrow. The Company’s operations are subject to various risks and there is no assurance that changes in the operations of the Company will not require the Company to raise additional cash sooner than planned in order to continue uninterrupted operations. In that event, the Company would seek to raise additional capital from the sale of the Company’s securities, from borrowing or from other sources. Should the Company seek to raise capital from the issuances of its securities, such transactions would be subject to the risks of the market for the Company’s securities at the time.

 

38

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

  raise additional funds to support the Company’s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
     
  review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets.

 

Off-balance Sheet Arrangements

 

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholder’s equity or that are not reflected in our consolidated condensed financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management is also required to assess and report on the effectiveness of our internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States. Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2016. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework in the 2013 COSO framework.

 

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, we will implement procedures to assure that the initiation of transactions, the custody of assets and the recording of transactions will be performed by separate individuals.

 

We believe that the foregoing steps if implemented, will help remediate the material weakness identified above, and we will continue to monitor the effectiveness of these steps and make any changes that our management deems appropriate. Due to the nature of this material weakness in our internal control over financial reporting, there is more than a remote likelihood that misstatements which could be material to our annual or interim financial statements could occur that would not be prevented or detected.

 

39

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company’s financial reporting.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

 

Changes in Internal Controls.

 

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

In the normal course of our business of patent monetization, it is generally necessary for us to initiate litigation in order to commence the process of protecting our patent rights. Such litigation is expected to lead to a monetization event. Accordingly, we are, and in the future, expect to become, a party to ongoing patent enforcement related litigation alleging infringement by various third parties of certain patented technologies owned and/or controlled by us. Litigation is commenced by and managed through the subsidiary that owns the related portfolio of patents or patent rights. In connection with our enforcement activities, we are currently involved in multiple patent infringement cases. As of September 30, 2017, the Company is involved into a total of 5 lawsuits against defendants in the following jurisdictions:

 

United States     
District of Delaware   5 

 

Marathon Patent Group, Inc. and Clouding Corp. are currently defendants in a lawsuit captioned as Symantec Corporation v. IP Navigation Group, LLC; Clouding IP, LLC, et al., Los Angeles County Superior Court, Case No.: BC640931. Symantec alleges the following causes of action against Marathon and Clouding in the First Amended Complaint: fraudulent misrepresentation; interference with contractual relations; violation of Business and Professions Code section 17200, et seq.; and accounting. A Post Mediation Status Conference is scheduled for January 24, 2018 (although the parties have not discussed mediation or any other form of alternative dispute resolution). A Final Status Conference is scheduled for March 16, 2018. Trial of the matter is scheduled to commence on March 26, 2018.

 

Marathon Patent Group, Inc., Doug Croxall and Francis Knuettel II are currently defendants in a lawsuit captioned as Jeffrey Feinberg v. Marathon Patent Group, Inc., Doug Croxall, Francis Knuettel II and Does 1-10, inclusive, Los Angeles County Superior Court, Case No.: BC673128. Mr. Feinberg alleges the following causes of action against Marathon, Doug Croxall and Francis Knuettel II: violation of Section 11 of the Securities Act; violation of Section 12(a)(2) of the Securities Act; violation of Section 15 of the Securities Act; fraud and fraudulent concealment; constructive fraud; and negligent misrepresentation. On November 9, 2017, Mr. Feinberg filed a request for dismissal.

 

Other than as disclosed herein, we know of no other material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation other than in the normal course of business.

 

Item 1A. Risk Factors.

 

Not required for smaller reporting companies.

 

40

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

On August 9, 2017, the Company issued 250,000 shares of the Company’s Common Stock pursuant to the conversion of 200,000 shares of Series D Convertible Preferred Stock.

 

On August 29, 2017, the Company issued 200,000 shares in total of the Company’s Common Stock to four different vendors in partial or total payment of outstanding invoices.

 

On September 5, 2017, the Company issued 62,500 shares of the Company’s Common Stock pursuant to the conversion of 50,000 shares of Series D Convertible Preferred Stock.

 

On September 6, 2017, the Company issued 534,710 shares of the Company’s Common Stock pursuant to the conversion of $427,768 in principal amount invested in the Convertible Note.

 

On September 13, 2017, the Company issued 315,925 shares of the Company’s Common Stock pursuant to the conversion of 252,750 shares of Series D Convertible Preferred Stock.

 

On September 29, 2017, the Company issued 598,500 shares of the Company’s Common Stock to holders of the warrants issued pursuant to the April Purchase Agreement following approval by the Company’s shareholders of the warrant exchange at a special meeting held on September 29, 2017.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Certain officers of the Company have received stock grants and / or options in 3D Nanocolor Corp. (“3D Nano”), a wholly-owned subsidiary of the Company, pursuant to 3D Nano’s 2016 Equity Incentive Plan.

 

Item 6. Exhibits.

 

31.1   Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.ins   XBRL Instance Document**
101.sch   XBRL Taxonomy Schema Document**
101.cal   XBRL Taxonomy Calculation Document**
101.def   XBRL Taxonomy Linkbase Document**
101.lab   XBRL Taxonomy Label Linkbase Document**
101.pre   XBRL Taxonomy Presentation Linkbase Document**

 

* Furnished herewith

** Filed herein

 

41

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 20, 2017

 

  MARATHON PATENT GROUP, INC.
     
  By: /s/ Doug Croxall
    Name: Doug Croxall
    Title: Chief Executive Officer and Chairman
    (Principal Executive Officer)
     
  By: /s/ Francis Knuettel II
    Name: Francis Knuettel II
    Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

42
 

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Doug Croxall, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Marathon Patent Group, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Dated: November 20, 2017 By: /s/ Doug Croxall
    Doug Croxall
    Chief Executive Officer and Chairman (Principal Executive Officer)

 

 
 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Francis Knuettel II, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Marathon Patent Group, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Dated: November 20, 2017 By: /s/ Francis Knuettel II
    Francis Knuettel II
    Chief Financial Officer (Principal Financial and Accounting Officer)

 

 
 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

About the Quarterly Report of Marathon Patent Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Doug Croxall, Chief Executive Officer and Chairman (Principal Executive Officer) of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 20, 2017   By: /s/ Doug Croxall
      Doug Croxall
      Chief Executive Officer and Chairman (Principal
Executive Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Marathon Patent Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Francis Knuettel II, Chief Financial Officer, Secretary and Director (Principal Financial Officer) of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 20, 2017   By: /s/ Francis Knuettel II
      Francis Knuettel II
      Chief Financial Officer (Principal Financial and
Accounting Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
 

EX-101.INS 6 mara-20170930.xml XBRL INSTANCE FILE 0001507605 2017-01-01 2017-09-30 0001507605 2017-09-30 0001507605 2016-12-31 0001507605 us-gaap:SeriesBPreferredStockMember 2017-09-30 0001507605 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001507605 2017-07-01 2017-09-30 0001507605 2016-07-01 2016-09-30 0001507605 2016-01-01 2016-09-30 0001507605 2015-12-31 0001507605 2016-09-30 0001507605 MARA:MedtechAndOrthophoenixMember 2017-01-01 2017-09-30 0001507605 MARA:FortressNotePayableMember 2017-01-01 2017-09-30 0001507605 MARA:ThreeDnanoLicenseNotePayableMember 2017-01-01 2017-09-30 0001507605 MARA:MedtronicNotePayableMember 2017-01-01 2017-09-30 0001507605 MARA:MedtechAndOrthophoenixMember 2016-01-01 2016-09-30 0001507605 MARA:FortressNotePayableMember 2016-01-01 2016-09-30 0001507605 MARA:ThreeDnanoLicenseNotePayableMember 2016-01-01 2016-09-30 0001507605 MARA:MedtronicNotePayableMember 2016-01-01 2016-09-30 0001507605 MARA:SiemensNotesPayableMember 2016-01-01 2016-09-30 0001507605 MARA:SiemensNotesPayableMember 2017-01-01 2017-09-30 0001507605 MARA:VendorsNotesPayableMember 2017-01-01 2017-09-30 0001507605 MARA:VendorsNotesPayableMember 2016-01-01 2016-09-30 0001507605 us-gaap:MaximumMember 2017-09-30 0001507605 us-gaap:SalesRevenueNetMember MARA:LicenseAgreementsMember 2017-07-01 2017-09-30 0001507605 us-gaap:SalesRevenueNetMember MARA:LicenseAgreementsMember 2016-07-01 2016-09-30 0001507605 MARA:AdvisoryServicesAgreementMember MARA:NavigationGroupLLCMember MARA:FounderAndFormerChiefExecutiveOfficerMember 2013-05-12 2013-05-13 0001507605 MARA:AdvisoryServicesAgreementMember MARA:NavigationGroupLLCMember MARA:FounderAndFormerChiefExecutiveOfficerMember us-gaap:MaximumMember 2013-05-12 2013-05-13 0001507605 MARA:AdvisoryServicesAgreementMember MARA:NavigationGroupLLCMember MARA:FounderAndFormerChiefExecutiveOfficerMember us-gaap:MinimumMember 2013-05-12 2013-05-13 0001507605 MARA:FeinbergAgreementMember us-gaap:RestrictedStockMember MARA:TrusteeMember us-gaap:BeneficialOwnerMember 2013-11-17 2013-11-18 0001507605 MARA:FeinbergAgreementMember MARA:RestrictedCommonStockMember MARA:TrusteeMember us-gaap:BeneficialOwnerMember 2013-11-18 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesLLCMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesLLCMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-02 0001507605 MARA:IPLiquidityVenturesLLCMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-02 0001507605 MARA:IPLiquidityVenturesLLCMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-01 2014-05-02 0001507605 MARA:SarifBiomedicalLLCMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-02 0001507605 MARA:SarifBiomedicalLLCMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:RangeOneMember MARA:PayProceedsAgreementMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:RangeTwoMember MARA:PayProceedsAgreementMember us-gaap:MinimumMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:RangeTwoMember MARA:PayProceedsAgreementMember us-gaap:MaximumMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:RangeTwoMember MARA:PayProceedsAgreementMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:RangeThreeMember MARA:PayProceedsAgreementMember us-gaap:MaximumMember 2014-05-01 2014-05-02 0001507605 MARA:MarathonOpportunityAgreementMember us-gaap:AffiliatedEntityMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:RangeThreeMember MARA:PayProceedsAgreementMember 2014-05-01 2014-05-02 0001507605 MARA:DynamicAdvancesIPLiquidityAndSarifBiomedicalMember MARA:AcquiredIntellectualPropertyMember us-gaap:AffiliatedEntityMember MARA:PayProceedsAgreementMember 2014-05-01 2014-05-02 0001507605 MARA:PatentPurchaseAgreementMember MARA:CloudingIPLLCMember us-gaap:AffiliatedEntityMember 2014-08-28 2014-08-29 0001507605 MARA:PatentPurchaseAgreementMember MARA:CloudingIPLLCMember us-gaap:AffiliatedEntityMember MARA:PromissoryNoteMember 2014-08-28 2014-08-29 0001507605 MARA:PatentPurchaseAgreementMember MARA:CloudingIPLLCMember us-gaap:AffiliatedEntityMember MARA:RestrictedCommonStockMember 2014-08-28 2014-08-29 0001507605 MARA:InterestSaleAgreementMember MARA:MedTechDevelopmentLLCMember MARA:MedTechGmbHMember us-gaap:AffiliatedEntityMember 2014-10-10 0001507605 MARA:InterestSaleAgreementMember MARA:MedTechDevelopmentLLCMember MARA:OrthoPhoenixAndTLIFMember us-gaap:AffiliatedEntityMember 2014-10-10 0001507605 MARA:InterestSaleAgreementMember MARA:MedTechDevelopmentLLCMember us-gaap:AffiliatedEntityMember 2014-10-08 2014-10-10 0001507605 MARA:InterestSaleAgreementMember MARA:MedTechDevelopmentLLCMember us-gaap:AffiliatedEntityMember 2015-10-22 2015-10-23 0001507605 MARA:InterestSaleAgreementMember MARA:MedTechDevelopmentLLCMember us-gaap:AffiliatedEntityMember 2014-10-10 0001507605 MARA:OptionsMember 2017-01-01 2017-09-30 0001507605 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001507605 MARA:SeriesBConvertiblePreferredStockMember 2017-01-01 2017-09-30 0001507605 MARA:CloudingCorpMember 2017-09-30 0001507605 MARA:CloudingCorpMember 2016-12-31 0001507605 MARA:MunitechSarlMember MARA:PatentPurchaseAgreementMember 2016-07-26 2016-07-27 0001507605 MARA:MunitechSarlMember MARA:PatentPurchaseAgreementMember MARA:FuturePaymentOneMember 2016-01-01 2016-12-31 0001507605 MARA:MunitechSarlMember MARA:PatentPurchaseAgreementMember MARA:FuturePaymentTwoMember 2017-01-01 2017-09-30 0001507605 MARA:MagnusIPGmbHMember MARA:PatentPurchaseAgreementMember 2016-07-04 2016-07-05 0001507605 MARA:TraverseTechnologiesCorpMember MARA:PatentPurchaseAgreementMember MARA:CPTIPHoldingsMember 2016-08-02 2016-08-03 0001507605 MARA:PGTechnologiesSarlMember MARA:PatentFundingAndExclusiveLicenseAgreementMember 2016-08-10 2016-08-11 0001507605 MARA:PGTechnologiesSarlMember MARA:PatentFundingAndExclusiveLicenseAgreementMember us-gaap:MinimumMember 2016-08-10 2016-08-11 0001507605 MARA:PGTechnologiesSarlMember MARA:PatentFundingAndExclusiveLicenseAgreementMember MARA:FuturePaymentOneMember 2016-08-10 2016-08-11 0001507605 MARA:PGTechnologiesSarlMember MARA:PatentFundingAndExclusiveLicenseAgreementMember MARA:FuturePaymentTwoMember 2016-08-10 2016-08-11 0001507605 us-gaap:MinimumMember 2017-01-01 2017-09-30 0001507605 us-gaap:MaximumMember 2017-01-01 2017-09-30 0001507605 us-gaap:PatentsMember 2017-01-01 2017-09-30 0001507605 MARA:CloudingCorpMember MARA:NetworkAndDataManagementMember 2017-01-01 2017-09-30 0001507605 MARA:CRFDResearchIncMember MARA:WebPageContentTranslatorAndDeviceToDeviceTransferSystemMember 2017-01-01 2017-09-30 0001507605 MARA:DynamicAdvancesLLCMember MARA:NaturalLanguageInterfaceMember 2017-01-01 2017-09-30 0001507605 MARA:MagnusIPMember MARA:NetworkManagementConnectedHomeDevicesMember 2017-01-01 2017-09-30 0001507605 MARA:MedtechGroupAcquisitionCorpMember MARA:MedicalTechnologyMember 2017-01-01 2017-09-30 0001507605 MARA:SignalIPIncMember MARA:AutomotiveMember 2017-01-01 2017-09-30 0001507605 MARA:TraverseTechnologiesMember MARA:LiIonBatteryHighCapacityElectrodesMember 2017-01-01 2017-09-30 0001507605 us-gaap:CommonStockMember MARA:ConsultingAgreementMember MARA:CooperLawFirmLLCMember 2016-05-09 2016-05-11 0001507605 us-gaap:CommonStockMember MARA:ConsultingAgreementMember MARA:CooperLawFirmLLCMember 2016-05-11 0001507605 us-gaap:CommonStockMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2016-12-08 2016-12-09 0001507605 us-gaap:CommonStockMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2016-12-09 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2016-12-09 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2016-12-08 2016-12-09 0001507605 us-gaap:CommonStockMember MARA:AtTheMarketOfferingMember 2017-02-01 2017-02-02 0001507605 us-gaap:CommonStockMember MARA:AtTheMarketOfferingMember 2017-02-02 0001507605 us-gaap:CommonStockMember MARA:SettlementAgreementMember MARA:DominionHarborGroupMember 2017-04-11 2017-04-12 0001507605 us-gaap:CommonStockMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2017-04-17 2017-04-18 0001507605 us-gaap:CommonStockMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2017-04-18 0001507605 us-gaap:CommonStockMember MARA:VendorsMember MARA:CancellationOfInvoicesMember 2017-04-23 2017-04-24 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:UnderwriterMember 2016-12-09 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2017-01-31 0001507605 us-gaap:CommonStockMember MARA:SettlementAgreementMember MARA:DominionHarborGroupMember 2017-04-12 0001507605 us-gaap:CommonStockMember MARA:VendorsMember MARA:CancellationOfInvoicesMember 2017-04-24 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember us-gaap:MinimumMember 2017-01-31 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember us-gaap:MaximumMember 2017-01-31 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember us-gaap:MinimumMember 2017-01-01 2017-01-31 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember us-gaap:MaximumMember 2017-01-01 2017-01-31 0001507605 MARA:CommonStockWarrantsMember MARA:SecuritiesPurchaseAgreementMember MARA:InstitutionalInvestorsMember 2017-01-01 2017-01-31 0001507605 MARA:CommonStockWarrantsMember MARA:DBDCreditFundingLLCMember MARA:FortressPurchaseAgreementAmendedAndRestatedMember 2017-01-10 0001507605 MARA:CommonStockWarrantsMember MARA:DBDCreditFundingLLCMember MARA:FortressPurchaseAgreementAmendedAndRestatedMember 2017-01-09 2017-01-10 0001507605 MARA:CommonStockWarrantsMember MARA:AprilPurchaseAgreementMember MARA:UnderwriterMember 2017-04-18 0001507605 MARA:CommonStockWarrantsMember MARA:AprilPurchaseAgreementMember MARA:InvestorsMember 2017-04-18 0001507605 MARA:CommonStockWarrantsMember MARA:AprilPurchaseAgreementMember MARA:InvestorsMember 2017-04-17 2017-04-18 0001507605 MARA:CommonStockWarrantsMember MARA:AprilPurchaseAgreementMember MARA:UnderwriterMember 2017-04-17 2017-04-18 0001507605 MARA:CommonStockWarrantsMember 2017-09-30 0001507605 MARA:CommonStockWarrantsMember 2017-01-01 2017-09-30 0001507605 MARA:CommonStockWarrantsMember MARA:InvestorsMember 2016-03-11 0001507605 MARA:CommonStockWarrantsMember MARA:InvestorsMember us-gaap:MinimumMember 2016-03-11 0001507605 MARA:CommonStockWarrantsMember MARA:InvestorsMember us-gaap:MaximumMember 2016-03-11 0001507605 us-gaap:EmployeeStockOptionMember MARA:SpangenbergAgreementMember MARA:DirectorOfAcquisitionsLicensingAndStrategyMember 2016-05-09 2016-05-10 0001507605 us-gaap:EmployeeStockOptionMember MARA:SpangenbergAgreementMember MARA:DirectorOfAcquisitionsLicensingAndStrategyMember 2016-05-10 0001507605 us-gaap:EmployeeStockOptionMember MARA:GrubbsAgreementMember MARA:AnalystMember 2016-05-19 2016-05-20 0001507605 us-gaap:EmployeeStockOptionMember MARA:GrubbsAgreementMember MARA:AnalystMember 2016-05-20 0001507605 us-gaap:EmployeeStockOptionMember MARA:LiuAgreementMember MARA:ChiefTechnologyOfficerMember 2016-07-01 2016-07-02 0001507605 us-gaap:EmployeeStockOptionMember MARA:LiuAgreementMember MARA:ChiefTechnologyOfficerMember 2016-07-02 0001507605 us-gaap:EmployeeStockOptionMember MARA:IndependentBoardMemberMember 2016-10-12 2016-10-13 0001507605 MARA:WarrantsMember 2017-01-01 2017-09-30 0001507605 MARA:WarrantsMember 2017-09-30 0001507605 MARA:WarrantsMember 2016-12-31 0001507605 MARA:StockOptionsMember 2017-01-01 2017-09-30 0001507605 MARA:StockOptionsMember 2016-12-31 0001507605 MARA:StockOptionsMember 2017-09-30 0001507605 MARA:SeniorSecuredTermNotesMember MARA:SecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:InitialNoteMember 2015-01-29 0001507605 MARA:SeniorSecuredTermNotesMember MARA:SecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember 2015-01-28 2015-01-29 0001507605 MARA:SecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:WarrantsMember 2015-01-29 0001507605 MARA:SeniorSecuredTermNotesMember MARA:FortressPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:AdditionalNotesMember 2015-02-12 0001507605 MARA:SeniorSecuredTermNotesMember MARA:SecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:InitialNoteMember 2015-01-28 2015-01-29 0001507605 MARA:SeniorSecuredTermNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-01-01 2016-09-30 0001507605 MARA:SeniorSecuredTermNotesMember 2017-09-30 0001507605 MARA:SeniorSecuredTermNotesMember 2016-12-31 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember 2017-01-10 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember 2017-01-09 2017-01-10 0001507605 MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:NewWarrantMember 2017-01-10 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:AdditionalNotesMember 2017-01-10 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:AdditionalNotesOneMember 2017-01-10 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:AdditionalNotesTwoMember 2017-01-10 0001507605 MARA:SeniorSecuredTermNotesMember MARA:FortressPurchaseAgreementMember MARA:DBDCreditFundingLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-01-28 2015-01-29 0001507605 MARA:SeniorSecuredTermNotesMember MARA:FortressPurchaseAgreementMember MARA:DBDCreditFundingLLCMember 2015-01-28 2015-01-29 0001507605 MARA:SeniorSecuredTermNotesMember 2016-01-01 2016-09-30 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:NewNoteMember 2017-01-01 2017-09-30 0001507605 MARA:SeniorSecuredTermNotesMember MARA:AmendedAndRestatedRevenueSharingAndSecuritiesPurchaseAgreementMember MARA:DBDCreditFundingLLCMember MARA:AdditionalNotesMember 2017-01-01 2017-09-30 0001507605 MARA:ConvertibleNoteMember 2014-10-09 0001507605 MARA:ConvertibleNoteMember 2014-10-16 0001507605 MARA:ConvertibleNoteMember 2014-10-08 2014-10-09 0001507605 MARA:ConvertibleNoteMember 2014-10-15 2014-10-16 0001507605 MARA:IRunwayMember 2017-09-30 0001507605 MARA:IRunwayMember 2016-12-31 0001507605 us-gaap:OfficerMember 2017-09-30 0001507605 us-gaap:OfficerMember 2016-12-31 0001507605 MARA:SettlementAgreementMember MARA:DominionHarborSettlementNoteMember 2015-10-28 2015-10-29 0001507605 MARA:SettlementAgreementMember MARA:DominionHarborSettlementNoteMember 2015-10-29 0001507605 MARA:SettlementAgreementMember MARA:DominionHarborSettlementNoteMember 2017-09-30 0001507605 MARA:SettlementAgreementMember MARA:DominionHarborSettlementNoteMember 2016-12-31 0001507605 MARA:SettlementAgreementMember MARA:DominionHarborSettlementNoteMember 2017-01-01 2017-09-30 0001507605 MARA:OilAndGasPurchasePaymentArrangementMember 2016-12-31 0001507605 MARA:OilAndGasPurchasePaymentArrangementMember 2017-09-30 0001507605 MARA:SiemensPurchasePaymentArrangementMember 2017-09-30 0001507605 MARA:SiemensPurchasePaymentArrangementMember 2016-12-31 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:LicenseAndPurchaseAgreementMember MARA:HPIncMember 2016-04-01 2016-04-30 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:LicenseAndPurchaseAgreementMember MARA:HPIncMember 2017-01-01 2017-01-31 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:LicenseAndPurchaseAgreementMember MARA:HPIncMember 2017-09-30 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:LicenseAndPurchaseAgreementMember MARA:HPIncMember 2016-12-31 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:HPIncMember 2017-05-01 2017-05-02 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:HPIncMember MARA:TwoThousandAndEighteenMember 2017-05-01 2017-05-02 0001507605 MARA:ThreeDNanoPurchasePaymentMember MARA:HPIncMember MARA:TwoThousandAndNineteenMember 2017-05-01 2017-05-02 0001507605 MARA:MedtechNoteMember MARA:MedtronicIncMember 2017-05-31 0001507605 2014-05-01 2014-05-02 0001507605 2014-05-02 0001507605 MARA:SeniorSecuredTermNotesMember 2017-01-01 2017-09-30 0001507605 MARA:SeniorSecuredTermNotesMember 2016-01-01 2016-12-31 0001507605 MARA:SeniorSecuredTermNotesMember 2017-09-30 0001507605 MARA:SeniorSecuredTermNotesMember 2016-12-31 0001507605 MARA:ConvertibleNoteMember 2017-09-30 0001507605 MARA:ConvertibleNoteMember 2016-12-31 0001507605 MARA:ConvertibleNoteMember 2017-01-01 2017-09-30 0001507605 MARA:ConvertibleNoteMember 2016-01-01 2016-12-31 0001507605 MARA:IRunwayTradePayableMember 2017-01-01 2017-09-30 0001507605 MARA:IRunwayTradePayableMember 2016-01-01 2016-12-31 0001507605 MARA:IRunwayTradePayableMember 2017-09-30 0001507605 MARA:IRunwayTradePayableMember 2016-12-31 0001507605 MARA:NotePayableMember 2017-01-01 2017-09-30 0001507605 MARA:NotePayableMember 2016-01-01 2016-12-31 0001507605 MARA:NotePayableMember 2017-09-30 0001507605 MARA:NotePayableMember 2016-12-31 0001507605 MARA:SeniorSecuredTermNotesMember MARA:LIBORMember 2017-01-01 2017-09-30 0001507605 MARA:SeniorSecuredTermNotesMember MARA:LIBORMember 2016-01-01 2016-12-31 0001507605 MARA:SiemensPurchasePaymentArrangementMember 2017-01-01 2017-09-30 0001507605 MARA:SiemensPurchasePaymentArrangementMember 2016-01-01 2016-12-31 0001507605 MARA:DominionHarborSettlementAgreementMember 2017-01-01 2017-09-30 0001507605 MARA:DominionHarborSettlementAgreementMember 2016-01-01 2016-12-31 0001507605 MARA:DominionHarborSettlementAgreementMember 2017-09-30 0001507605 MARA:DominionHarborSettlementAgreementMember 2016-12-31 0001507605 MARA:OilAndGasPurchasePaymentArrangementMember 2017-01-01 2017-09-30 0001507605 MARA:OilAndGasPurchasePaymentArrangementMember 2016-01-01 2016-12-31 0001507605 MARA:MedtechNoteMember 2017-01-01 2017-09-30 0001507605 MARA:MedtechNoteMember 2016-01-01 2016-12-31 0001507605 MARA:MedtechNoteMember 2017-09-30 0001507605 MARA:MedtechNoteMember 2016-12-31 0001507605 MARA:ThreeDnanoLicenseAndPurchaseAgreementMember 2017-01-01 2017-09-30 0001507605 MARA:ThreeDnanoLicenseAndPurchaseAgreementMember 2017-09-30 0001507605 MARA:ThreeDnanoLicenseAndPurchaseAgreementMember 2016-01-01 2016-12-31 0001507605 MARA:ThreeDnanoLicenseAndPurchaseAgreementMember 2016-12-31 0001507605 MARA:SeniorAndJuniorDebtMember 2017-09-30 0001507605 2017-11-14 0001507605 MARA:OctoberTweentyFiveTwoThousandSeventeenMember 2017-07-16 2017-07-18 0001507605 MARA:OctoberThirtyTwoThousandSeventeenMember 2017-07-16 2017-07-18 0001507605 2017-07-18 0001507605 MARA:SeleneCommunicationTechnologiesLLCMember MARA:MergerAgreementMember 2014-06-16 2014-06-17 0001507605 MARA:SoemsAcquistionMember MARA:NAMember 2017-01-01 2017-09-30 0001507605 MARA:SeriesBConvertiblePreferredStockMember 2017-01-01 2017-09-30 0001507605 MARA:SeriesDConvertiblePreferredStockMember 2017-01-01 2017-09-30 0001507605 MARA:SeriesDConvertiblePreferredStockMember 2017-08-08 2017-08-09 0001507605 2017-08-28 2017-08-29 0001507605 MARA:SeriesDConvertiblePreferredStockMember 2017-09-04 2017-09-05 0001507605 MARA:SeriesDConvertiblePreferredStockMember 2017-09-12 2017-09-13 0001507605 2017-09-28 2017-09-29 0001507605 MARA:WarrantFirstCloseMember 2017-09-30 0001507605 MARA:WarrantSecondCloseMember 2017-09-30 0001507605 MARA:WarrantFirstCloseMember 2017-01-01 2017-09-30 0001507605 MARA:WarrantSecondCloseMember 2017-01-01 2017-09-30 0001507605 MARA:ConvertibleNoteMember 2017-09-30 0001507605 MARA:ConvertibleNoteMember 2017-12-31 0001507605 MARA:SiemensPurchasePaymentArrangementMember 2017-09-01 0001507605 MARA:ConvertibleNoteOneMember MARA:UnitPurchaseAgreementMember 2017-08-14 0001507605 MARA:ConvertibleNoteOneMember MARA:UnitPurchaseAgreementMember 2017-08-13 2017-08-14 0001507605 MARA:MedtechNoteMember MARA:MedtronicIncMember 2017-05-30 2017-05-31 0001507605 MARA:MedtechNoteMember MARA:MedtronicIncMember 2017-06-29 2017-06-30 0001507605 MARA:MedtechNoteMember MARA:MedtronicIncMember 2016-12-30 2016-12-31 0001507605 MARA:ConvertibleNoteOneMember 2017-01-01 2017-09-30 0001507605 MARA:ConvertibleNoteOneMember 2017-09-30 0001507605 MARA:ConvertibleNoteOneMember 2016-01-01 2016-12-31 0001507605 MARA:ConvertibleNoteOneMember 2016-12-31 0001507605 MARA:ConvertibleNoteTwoMember 2017-01-01 2017-09-30 0001507605 MARA:ConvertibleNoteTwoMember 2017-09-30 0001507605 MARA:ConvertibleNoteTwoMember 2016-01-01 2016-12-31 0001507605 MARA:ConvertibleNoteTwoMember 2016-12-31 0001507605 us-gaap:SubsequentEventMember MARA:MergerAgreementMember 2017-10-30 2017-11-01 0001507605 us-gaap:SubsequentEventMember MARA:GlobalBitVenturesAcquisitionCorpMember 2017-11-01 0001507605 MARA:MedtechNoteMember MARA:MedtronicIncMember 2017-09-27 2017-09-30 0001507605 2017-09-02 2017-09-06 0001507605 2017-07-16 2017-07-18 0001507605 MARA:MunitechSarlMember MARA:PatentPurchaseAgreementMember 2017-08-30 2017-09-01 0001507605 2017-08-31 0001507605 2017-09-29 0001507605 MARA:ConvertibleNoteOneMember MARA:UnitPurchaseAgreementMember 2017-09-30 0001507605 MARA:MunitechPatentsMember 2017-01-01 2017-09-30 0001507605 MARA:MunitechPatentsMember 2016-01-01 2016-09-30 0001507605 MARA:ThreeDNanoLicenseMember 2016-01-01 2016-09-30 0001507605 MARA:ThreeDNanoLicenseMember 2017-01-01 2017-09-30 0001507605 MARA:SEPatentMember 2017-01-01 2017-09-30 0001507605 MARA:SEPatentMember 2016-01-01 2016-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares MARA:Installments MARA:Patents xbrli:pure MARA:Institutions MARA:Payments MARA:Integer Marathon Patent Group, Inc. 0001507605 10-Q 2017-09-30 false --12-31 Smaller Reporting Company 2017 8747931 228401 222843 32637 81930 32637 81930 681175 1400082 681175 1400082 387976 387976 2659 3724 133224 108407 797 5837363 852404 57763 0.0001 .0001 .0001 195501 195501 97750 97750 195501 195501 0.0001 0.0001 0.0001 200000000 200000000 7776016 4638118 7776016 4638118 5158906 2549084 103000 578804 63286 100000 600000 2953779 5379105 1750000 125000 600000 Q3 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Marathon Patent Group, Inc.&#8217;s (the &#8220;Company&#8221;) business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company. We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies. Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets. Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances. Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in the business of exploration and potential development of uranium and vanadium minerals business. In June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October 2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company&#8217;s name was changed to Marathon Patent Group, Inc.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2012, the shareholders holding a majority of the Company&#8217;s voting capital had voted and authorized the Company to change the name of the Company to Marathon Patent Group, Inc. (the &#8220;Name Change&#8221;). The Board of Directors approved the Name Change on October 1, 2012. The Board of Directors determined the name &#8220;Marathon Patent Group, Inc.&#8221; better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company&#8217;s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company&#8217;s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 6, 2017, the Board of Directors approved and adopted, subject to shareholder approval on or prior to September 6, 2018, the Company&#8217;s 2017 Equity Incentive Plan. The Company&#8217;s 2017 Equity Incentive Plan was approved by the shareholders of the Company at a special meeting held on September 29, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All share and per share values for all periods presented in the accompanying consolidated financial statements have been retroactively adjusted to reflect the Reverse Split.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation and Principles of Consolidation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position, the results of operations and cash flows of the Company for the periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation and restricted cash, held in escrow pursuant to the terms of the Unit Purchase Agreement entered into on August 14, 2017, with another financial institution that is also insured by the Federal Deposit Insurance Corporation. The Company&#8217;s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). As of September 30, 2017, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At each of September 30, 2017 and December 31, 2016, the Company had recorded an allowance for bad debts in the amount of $387,976 and $387,976, respectively. Accounts receivable, net at September 30, 2017 and December 31, 2016, amounted to $123,630 and $95,069, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentration of Revenue and Geographic Area</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue from the Company&#8217;s patent enforcement activities is considered United States revenue as any payments for licenses included in that revenue are for United States operations irrespective of the location of the licensee&#8217;s or licensee&#8217;s parent home domicile.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had $0 in revenues from newly issued patent licenses for both the three months ended September 30, 2017 and the three months ended September 30, 2016. The revenue for the three months ended September 30, 2017 is attributable to a non-enforcement technology access license for one of the Company&#8217;s subsidiaries and running royalties from the Company&#8217;s Medtech portfolio and for the three months ended September 30, 2016, the revenue is attributable to running royalties from the Company&#8217;s Medtech portfolio.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At the current time, we define customers as firms that obtain licenses to the Company&#8217;s patents, either prior to or during enforcement litigation. These firms generally enter into non-recurring, non-exclusive, non-assignable license agreements with the Company, and these customers do not generally engage in ongoing, recurring business activity with the Company. The Company has historically had a small number of customers enter into such agreements, resulting in higher levels of revenue concentration.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 605, &#8220;Revenue Recognition&#8221;. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company&#8217;s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also considers the revenue generated from its settlement and licensing agreements as one unit of accounting under ASC 605-25, &#8220;Multiple-Element Arrangements&#8221; as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Also, since the settlement element and license element for past and future use are the Company&#8217;s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. There was no revenue from newly issued patent licenses for the three months ended September 30, 2017 and September 30, 2016, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets of $108,878 and $202,067 at September 30, 2017 and December 31, 2016, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Bonds Posted with Courts</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of September 30, 2017 and December 31, 2016, the Company had no outstanding bonds posted with the German courts.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related Party Transactions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties are considered related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 13, 2013, we entered into a nine-year advisory services agreement (the &#8220;Advisory Services Agreement&#8221;) with IP Navigation Group, LLC (&#8220;IP Nav&#8221;), of which Erich Spangenberg is founder and former Chief Executive Officer. Mr. Spangenberg is an affiliate of the Company. The terms of the Advisory Services Agreement provide that, in consideration for its services as intellectual property licensing agent, the Company will pay to IP Navigation Group, LLC between 10% and 20% of the gross proceeds of certain licensing campaigns in which IP Navigation Group, LLC acts as intellectual property licensing agent.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 18, 2013, we entered into a consulting agreement with Jeff Feinberg (&#8220;Feinberg Agreement&#8221;), pursuant to which we agreed to grant Mr. Feinberg 25,000 shares of our restricted Common Stock, 50% of which shall vest on the one-year anniversary of the Feinberg Agreement and the remaining 50% of which shall vest on the second-year anniversary of the Feinberg Agreement. Mr. Feinberg is the trustee of The Feinberg Family Trust and holds voting and dispositive power over shares held by The Feinberg Family Trust, which is a 10% beneficial owner of our Common Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 2, 2014, the Company completed the acquisition of certain ownership rights (the &#8220;Acquired Intellectual Property&#8221;) from TechDev, Granicus and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company. TechDev, SFF and Granicus are owned or controlled by Erich Spangenberg or family members or associates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company&#8217;s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company&#8217;s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. The remaining cash payment was made on February 24, 2015 and is fully paid. Under the terms of the Sarif Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement. Under the terms of the Pay Proceeds Agreement, as amended in 2016, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $13,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the cumulative gross proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the cumulative gross proceeds of such recoveries to the sellers. Pursuant to the amendment to the Pay Proceeds Agreement, the Company paid TechDev, Granicus and SFF $2.4 million. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 2, 2014, we entered into an opportunity agreement (the &#8220;Marathon Opportunity Agreement&#8221;) with Erich Spangenberg, who is an affiliate of the Company. The terms of the Marathon Opportunity Agreement provide that we have ten business days after receiving notice from Mr. Spangenberg to provide up to 50% of the funding for certain opportunities relating to the licensing, intellectual property acquisitions and/or intellectual property enforcement actions in which Mr. Spangenberg, IP Nav or any entity controlled by Mr. Spangenberg, other than: (i) IP Nav or any of its affiliates, and (ii) Medtech Development, LLC or any of its affiliates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 17, 2014, Selene Communication Technologies Acquisition LLC (&#8220;Acquisition LLC&#8221;), a Delaware limited liability company and newly formed wholly-owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (&#8220;Selene&#8221;). Selene owned a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav provided patent monetization and support services under an existing agreement with Selene prior to the return of the patents to Stanford Research Institute (&#8220;SRI&#8221;), the original owners of the patents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 29, 2014, the Company entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP, LLC for an aggregate purchase price of $2.4 million, of which $1.4 million was paid in cash and $1.0 million was paid in the form of a promissory note issued by the Company that matured on October 31, 2014 and was fully paid prior to the maturation date. The Company also issued 6,250 shares of its restricted common stock in connection with the acquisition. Clouding IP, LLC is also entitled to certain possible future cash payments. Clouding IP LLC is owned or controlled by Erich Spangenberg or family members or associates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 10, 2014, the Company entered into an interest sale agreement with MedTech Development, LLC (&#8220;MedTech&#8221;) to acquire from MedTech 100% of the limited liability membership interests of OrthoPhoenix and TLIF as well as 100% of the shares of MedTech GmbH. In connection with the transaction, the Company is obligated to pay to MedTech $1 million at closing and $1 million on each of the following nine (9) month anniversary dates of the closing. On July 16, 2015, the Company entered into a forbearance agreement (the &#8220;Agreement&#8221;) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company agreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 500,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment during the year ended September 30, 2015. On October 23, 2015, the Company entered into Amendment No. 1 to the Forbearance Agreement (the &#8220;Amendment&#8221;) entered into with MedTech Development on July 16, 2015. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. The acquired subsidiaries are also obligated to make certain additional payments to MedTech from recoveries following the receipt by the acquired subsidiaries of 200% of the purchase payments, plus recovery of out of pocket expenses in connection with patent claims. The participation payments may be paid, at the election of the Company, in common stock of Marathon at the market price on the date of issuance. In connection with the transaction, the Company entered into a promissory note, common interest agreement and in the event of issuance of common stock to MedTech, will enter into a lockup and registration rights agreement. Approximately forty-five percent (45%) of MedTech is owned or controlled by Erich Spangenberg or family members or associates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2016, one of the Company&#8217;s subsidiaries, PG Technologies S.a.r.l. entered into an advisory services agreement with Granicus IP, LLC, an entity owned or controlled by one of the Company&#8217;s employees, whereby Granicus receives a percentage of pre-tax return from PG Technologies after certain revenue thresholds have been met.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2016, certain officers and directors of the Company received restricted common stock in the Company&#8217;s 3D Nanocolor Corp. (&#8220;3D Nano&#8221;) subsidiary.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2016, &#8216;&#8216;Other noncurrent assets&#8217;&#8217; in the Balance Sheets consists of a note receivable from an entity controlled by one of the Company&#8217;s employees that is uncollateralized. The note receivable does not carry interest and is repayable to the Company at the earlier of March 31, 2022 or based on certain milestones. The note receivable balance has been classified as current assets because the Company believes that it will be collected within one year from the Balance Sheet dates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2017, the Company entered into an Irrevocable Stock Power whereby the Company sold the shares it owns in the Company&#8217;s subsidiary, 3D Nano to Doug Croxall, the Company&#8217;s Chief Executive Officer with such assignment including the assumption of all of 3D Nano&#8217;s liabilities. The Company engaged a third party to value the assignment, the results of which were that the valuation and assignment were deemed to be at fair value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 29px; line-height: 115%">&#160;</td> <td style="width: 48px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1:</font></td> <td style="width: 10px; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2:</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Observable market-based inputs or unobservable inputs that are corroborated by market data</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3:</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity&#8217;s own assumptions.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts reported in the consolidated condensed balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Clouding IP earn out liability was determined as a Level 3 liability, which requires an assessment of fair value at each period end by using discounted cash flow as a valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2017, the Company determined that there was a reduction in the Clouding IP earn out liability during the three and nine months ended September 30, 2017 in the amounts of $754,321and $754,321, respectively and a reduction in the carrying value of the Clouding IP intangible assets during the three and nine months ended September 30, 2017 in the amounts of $723,218 and $723,218, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined that the Warrants issued pursuant to the Unit Purchase Agreement should be treated as a Level 2 liability, which determine the value based on observable market-based inputs. in this instance, the Warrants were valued using a Monte-Carlo simulation utilizing market-based inputs for volatility and risk-free rate of interest, which resulted in the Warrants issued pursuant to the August 31, 2017 close being fair valued at $0.0364 per share and the Warrants issued pursuant to the September 29, 2017 close being fair valued at $0.0877 per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounting for Acquisitions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 &#8212; Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes pursuant to the provision of ASC 740-10, &#8220;Accounting for Income Taxes&#8221; which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2016 tax returns. After review of the prior year financial statements and the results of operations through December 31, 2016, the Company has recorded a full valuation allowance on its deferred tax asset.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basic and Diluted Net Loss per Share</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (&#8220;ASC 260&#8221;). Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 613,195 shares of Common Stock, warrants to purchase 7,487,894 shares of Common Stock, Convertible Notes convertible into up to 13,750,000 shares of Common Stock and shares of Series B Convertible Preferred Stock convertible into 195,501 shares of Common Stock outstanding at September 30, 2017, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company&#8217;s net loss.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of basic and diluted loss per share:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2017</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Nine Months<br /> Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2017</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Nine Months<br /> Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 26%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Net income (loss) attributable to Common shareholders</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(6,677,485</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(6,274,410</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(12,484,924</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(2,261,542</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Denominator</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Weighted average common shares &#8211; Basic and Diluted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">6,270,299</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,761,786</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5,564,465</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,736,213</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) per common share:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) &#8211; Basic and Diluted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(1.06</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(1.67</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(2.24</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(0.60</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intangible Assets - Patents</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company&#8217;s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company&#8217;s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit&#8217;s goodwill and if the carrying value of the reporting unit&#8217;s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2017 the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment charge to its goodwill in the amount of $0 and $83,000, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Other Intangible Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 350-30, &#8220;Intangibles - Goodwill and Others&#8221;, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Long-lived Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 &#8220;Property, Plant and Equipment&#8221;. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-based Compensation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company&#8217;s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company&#8217;s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the &#8220;measurement date.&#8221; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2017, we had approximately $0.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of approximately $20.3 million.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the Company&#8217;s current revenue and profit projections, management is uncertain that the Company&#8217;s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months from the issuance date of the financial statements, raising substantial doubt regarding the Company&#8217;s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; line-height: 115%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">raise additional funds to support the Company&#8217;s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;review strategic alternatives.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlements of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11, &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),&#8221; which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU No. 2017-09, <i>Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</i>. This ASU provides clarity about which changes to the terms or conditions of a share-based payment award require the application of modification accounting. Specifically, ASU 2017-09 clarifies that changes to the terms or conditions of an award should be accounted for as a modification unless all of the following are met: 1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted. The Company does not expect the adoption of ASU 2017-09 to significantly impact its accounting for share-based payment awards, as changes to awards&#8217; terms and conditions subsequent to the grant date are unusual and infrequent in nature.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-04 <i>Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</i> (&#8220;ASU 2017-04&#8221;). This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for interim and annual period beginning after December 15, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued ASU 2017-01 <i>Business Combinations (Topic 805): Clarifying the Definition of a Business</i> (&#8220;ASU 2017-01&#8221;), which clarifies the definition of a business and assists entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under this guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or group of similar assets), the assets acquired would not represent a business. In addition, in order to be considered a business, an acquisition would have to include at a minimum an input and a substantive process that together significantly contribute to the ability to create an output. The amended guidance also narrows the definition of outputs by more closely aligning it with how outputs are described in FASB guidance for revenue recognition. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. <i>2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)</i>, which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity&#8217;s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2016, the FASB issued ASU 2016-16 <i>Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory</i> (&#8220;ASU 2016-16&#8221;), which eliminates the exception in existing guidance which defers the recognition of the tax effects of intra-entity asset transfers other than inventory until the transferred asset is sold to a third party. Rather, the amended guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated condensed financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU 2016-15 <i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments </i>(&#8220;ASU 2016-15&#8221;). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated condensed financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers, as a new Topic, (ASC) Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. This ASU must be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are considering the alternatives of adoption of this ASU and we are conducting our review of the likely impact to the existing portfolio of customer contracts entered into prior to adoption. After completing our review, we will continue to evaluate the effect of adopting this guidance upon our results of operations, cash flows and financial position.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; (&#8220;ASU 2016-02&#8221;). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated condensed financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; ACQUISITIONS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Clouding Corp.</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 29, 2014, the Company entered into a patent purchase agreement (the &#8220;Clouding Agreement&#8221;) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Clouding&#8221;) and Clouding IP, LLC, a Delaware limited liability company (&#8220;Clouding IP&#8221;), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. The Clouding Agreement included an earn out payable to Clouding IP, which was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Clouding IP earn out liability was determined to be a Level 3 liability, which requires assessment of fair value at each period end by using a discounted cash flow model as the valuation methodology, using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rates. Based on the reassessment of fair value as of September 30, 2017, the Company determined the Clouding IP earn out liability to be $32,637 (current portion) and $681,175 (long-term portion) and as of December 31, 2016, the Company determined the Clouding IP earn out liability to be $81,930 (current portion) and $1,400,082 (long-term portion).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Munitech IP S.a.r.l. (&#8220;Munitech&#8221;)</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 27, 2016, Munitech S.a.r.l. (&#8220;Munitech&#8221;), a Luxembourg limited liability company and newly formed wholly-owned subsidiary of the Company, entered into two Patent Purchase Agreements (the &#8220;PPA&#8221; or together, the &#8220;PPAs&#8221;) to purchase 221 patents from Siemens Aktiengesellschaft. The patents purchased by Munitech relate to W-CDMA and GSM cellular technology and cover all the major global economies including China, France, Germany, the United Kingdom and the United States. Significantly, many of the patent families have been declared to be Standard Essential Patents (&#8220;SEPs&#8221;) with the European Telecommunications Standard Institute (&#8220;ETSI&#8221;) and/or the Association of Radio Industries and Businesses (&#8220;ARIB&#8221;) related to Long Term Evolution (&#8220;LTE&#8221;), Universal Mobile Telecommunications System (&#8220;UMTS&#8221;), and/or General Packet Radio Service (&#8220;GPRS&#8221;).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the PPAs, Munitech (i) paid Siemens Aktiengesellschaft $1,150,000 in cash upon closing and (ii) agreed to two future payments, one in the amount of $1,000,000 payable on December 31, 2016 and the second in the amount of $750,000 payable on September 30, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 1, 2017, the Company entered into a Share Purchase Agreement with GPat Technologies, LLC (&#8220;GPat&#8221;) whereby the Company sold its 100% interest in Munitech to GPat.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Magnus IP GmbH (&#8220;Magnus&#8221;)</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 5, 2016, Marathon IP GmbH (&#8220;Marathon IP&#8221;), a German corporate entity and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreements (the &#8220;PPA&#8221;) to purchase 86 patents from Siemens Switzerland Ltd and Siemens Industry Inc., (together, &#8220;Siemens&#8221;). On September 15, 2016, the patents were assigned by Marathon IP to Magnus, both of which are wholly-owned subsidiaries of the Company. The patents purchased by Marathon IP relate to Internet-of-Things (IOT) technology. Generally, the portfolio&#8217;s subject matter is directed toward self-healing control networks for automation systems. The patents are relevant to wireless mesh or home area networks for use in IOT, or connected home devices and enable simple commissioning, application level security, simplified bridging, and end-to-end IP security. The technology can support a wide variety of IOT enabled devices including lighting, sensors, appliances, security, and more. Pursuant to the terms of the PPA, Marathon IP paid Siemens $250,000 in cash upon closing.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the PPAs, Munitech (i) paid Siemens $250,000 in cash upon closing and (ii) will pay a percentage of gross proceeds in excess of a reserve threshold on behalf of Marathon IP.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 20, 2017, the Company assigned the patents held by Magnus to DBD, pursuant to the First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the &#8220;First Amendment and Restructuring Agreement&#8221;) entered into with DBD. In exchange for the assignment of three of the Company&#8217;s portfolios, of which Magnus was one, DBD cancelled all indebtedness owed by the Company to DBD.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Traverse Technologies Corp. (&#8220;Traverse&#8221;)</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 3, 2016, Traverse Technologies Corp. (&#8220;Traverse&#8221;), a United States corporation and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreement (the &#8220;PPA&#8221;) to purchase 12 patents from CPT IP Holdings (&#8220;CPT&#8221;). The patents purchased by Traverse relate to batteries and principally cover various Asian and the United States markets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the PPAs, Traverse (i) paid CPT $1,300,000 in cash upon closing and (ii) will pay a percentage of net recoveries in excess of a reserve threshold on behalf of Traverse.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 20, 2017, the Company assigned the patents held by Traverse to DBD, pursuant to the First Amendment and Restructuring Agreement entered into with DBD. In exchange for the assignment of three of the Company&#8217;s portfolios, of which Traverse was one, DBD cancelled all indebtedness owed by the Company to DBD.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PG Technologies S.a.r.l. (&#8220;PG Tech&#8221;)</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 11, 2016, PG Technologies S.a.r.l. (&#8220;PG Tech&#8221;), a Luxembourg limited liability company jointly owned with a large litigation financing fund, entered into a Patent Funding and Exclusive License Agreement (the &#8220;ELA&#8221;) to manage the monetization of greater than 10,000 patents in a single industry vertical with a Fortune 50 company. The patents cover all the major global economies including China, France, Germany, the United Kingdom and the United States. The Company determined that its ownership in PG Tech constitutes a VIE and that the Company is the primary beneficiary, as a result of which, the Company consolidated PG Tech in its financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the ELA, PG Tech agreed with the Fortune 50 company to pay (i) $1,000,000 in cash upon closing, (ii) a future payment in the amount of $1,000,000 payable on or before December 31, 2016, (iii) minimum quarterly payments of $250,000 starting on April 1, 2017 and (iv) split 50% of the net licensing revenues.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 27, 2017, the Company entered into an Assignment and Confirmation Agreement (the &#8220;Assignment&#8221;) with Luxone Ventures S.a.r.l. (&#8220;Luxone&#8221;) whereby the Company assigned all of its ownership interest in PG Technologies, S.a.r.l. (&#8220;PG Tech&#8221;) to Luxone. Pursuant to the Assignment, Luxone assumed the Company&#8217;s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8211; INTANGIBLE ASSETS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. Patents purchased are recorded based at their acquisition cost and patents acquired in lieu of cash are recorded at their fair market value. Intangible assets consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2016</font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Intangible Assets</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,403,408</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">23,637,813</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization &#38; Impairment</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(12,813,195</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(11,323,185</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets, net</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,590,213</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">12,314,628</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets are comprised of patents with estimated useful lives between approximately 1 to 16 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis. During the three and nine months ended September 30, 2017, respectively, the Company capitalized a total of $0 and $0 in patent acquisition costs and during the three and nine months ended September 30, 2016, respectively, the Company capitalized a total of $3,550,000 and $6,450,000 in patent acquisition costs. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included as an operating expense as reflected in the accompanying consolidated condensed statements of operations. The Company assesses fair market value for any impairment to the carrying values. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company&#8217;s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent amortization expense for the three and nine months ended September 30, 2017 was $457,419 and $1,803,264, respectively, and for the three and nine months ended September 30, 2016, patent amortization expense was $2,030,886 and $6,018,196, respectively. All patent amortization expense figures are net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">401,804</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,517,219</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,447,660</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,154,767</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,004,600</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2022 and thereafter</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,064,163</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,590,213</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, our operating subsidiaries owned 170 patents, as set forth below, and had economic rights to over 10,000 additional patents, both of which include U.S. patents and certain foreign counterparts. In the aggregate, the earliest date for expiration of a patent in the Company&#8217;s patent portfolio has passed (the patent is expired, but patent rules allow for nine-year look-back for royalties), the median expiration date for patents in the Company&#8217;s portfolio is September 13, 2021, and the latest expiration date for a patent in any of the Company&#8217;s patent portfolios is February 27, 2033. A summary of the Company&#8217;s patent portfolios is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Subsidiary</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number&#160;of </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Patents</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Earliest </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Expiration&#160;Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Median </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Expiration&#160;Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Latest </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Expiration&#160;Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Subject Matter</b></font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 18%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Clouding Corp.</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 5%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">25</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/3/18</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/10/21</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5/29/29</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 37%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Network and data management</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">CRFD Research, Inc.</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5/25/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/17/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/19/23</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Web page content translator and device-to-device transfer system</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Dynamic Advances, LLC</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">11/6/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/7/23</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7/9/25</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Natural language interface</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Magnus IP</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">55</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1/28/22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/27/25</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">12/9/31</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Network Management/Connected Home Devices</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Medtech Group Acquisition Corp.</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">45</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">12/8/18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/9/29</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Medical technology</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Signal IP, Inc.</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/28/20</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/17/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/6/22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Automotive</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Traverse Technologies</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">20</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/27/22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/25/29</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/27/33</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Li-Ion Battery/High Capacity Electrodes</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Soems Acquisition</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">16</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">11/11/17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4/6/19</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7/18/24</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">N/A</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Median</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>09/13/21</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 20, 2017, the Company assigned the patent held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) to DBD.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 27, 2017, the Company assigned the economic rights to its more than 10,000 patents to Luxone.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 - STOCKHOLDERS&#8217; EQUITY</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has authorized capital to 200,000,000 shares of Common Stock with par value to $0.0001 per share, and has authorized capital of 50,000,000 shares of preferred stock, par value $0.0001 per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company&#8217;s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company&#8217;s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Convertible Preferred Stock</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the Series B Convertible Preferred Stock are summarized below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Dividend</i>. The holders of Series B Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series B Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Liquidation Preference</i>. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Common Stock and the holders of Series B Convertible Preferred Stock as if the Series B Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Voting Rights</i>. The Series B Convertible Preferred Stock have no voting rights except with regard to certain customary protective provisions set forth in the Series B Convertible Preferred Stock Certificate of Designations and as otherwise provided by applicable law.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Conversion</i>. Each share of Series B Convertible Preferred Stock may be converted at the holder&#8217;s option at any time after issuance into one share of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days&#8217; notice.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;<b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series D Convertible Preferred Stock</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issued Series D Convertible Preferred Stock in exchange for the outstanding convertible note issued in October 2014 and prior to September 30, 2017, all of the Series D Convertible Preferred Stock was converted to the Company&#8217;s Common Stock and no shares of the Series D Convertible Preferred Stock remain outstanding. The terms of the Series D Convertible Preferred Stock are summarized below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Dividend</i>. The holders of Series D Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series D Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Liquidation Preference</i>. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Series B Convertible Preferred Stock and Series D Convertible Preferred Stock as if the Series B Convertible Preferred Stock and Series D Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company, prior to any distributions to Junior Stock, which includes the Company&#8217;s Common Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Voting Rights</i>. Except as otherwise expressly required by law, each holder of Preferred Shares shall be entitled to vote on all matters submitted to shareholders of the Company and shall be entitled to the number of votes for each Preferred Share owned at the record date for the determination of shareholders entitled to vote on such matter or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited, equal to the number of shares of Common Stock such Preferred Shares are convertible into (voting as a class with Common Stock),</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Conversion</i>. Each share of Series D Convertible Preferred Stock may be converted at the holder&#8217;s option at any time after issuance into five shares of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days&#8217; notice.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 11, 2016, the Company entered into a consulting agreement with the Cooper Law Firm, LLC (&#8220;Cooper&#8221;), pursuant to which the Company agreed to issue 20,000 shares of the Company&#8217;s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $6.80 per share or $136,000.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 9, 2016, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors for the sale of an aggregate of 870,500 shares of the Company&#8217;s common stock, at a purchase price of $6.00 per share, and warrants to purchase 435,249 shares of common stock for a purchase price of $0.01 per warrant, or $17,019.95 in total. None of the warrants were purchased prior to December 31, 2016, and all were subsequently purchased prior to the date of this report.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 1, 2017, the Company issued 187,500 shares of common stock pursuant to an At-The-Market (&#8220;ATM&#8221;) securities offering with certain institutional investors at an average price of $6.96 per share, yielding gross proceeds of $1,301,923.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 12, 2017, pursuant to an amendment entered into on March 6, 2017 to the settlement agreement entered into on October 29, 2015 between the Company and Dominion Harbor, the Company issued 31,250 shares of common stock to Dominion Harbor. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $0.83 per share or $103,750.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 18, 2017, the Company entered into a securities purchase agreement (the &#8220;April Purchase Agreement&#8221;) with certain institutional investors for the sale of an aggregate of 950,000 shares of the Company&#8217;s common stock at a purchase price of $2.80per share and warrants to purchase 570,000 shares of common stock at a purchase price of $3.32 per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2017, the Company issued one of its vendors 7,500 shares of Common Stock in exchange for cancellation of the vendor&#8217;s outstanding invoices. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $3.32 per share or $24,897.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2017, the Company issued 250,000 shares of the Company&#8217;s Common Stock pursuant to the conversion of 200,000 shares of Series D Convertible Preferred Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 29, 2017, the Company issued 200,000 shares in total of the Company&#8217;s Common Stock to four different vendors in partial or total payment of outstanding invoices.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 5, 2017, the Company issued 62,500 shares of the Company&#8217;s Common Stock pursuant to the conversion of 50,000 shares of Series D Convertible Preferred Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 6, 2017, the Company issued 534,710 shares of the Company&#8217;s Common Stock pursuant to the conversion of $427,768 in principal amount invested in the Convertible Note.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 13, 2017, the Company issued 315,925 shares of the Company&#8217;s Common Stock pursuant to the conversion of 252,750 shares of Series D Convertible Preferred Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2017, the Company issued 598,500 shares of the Company&#8217;s Common Stock to holders of the warrants issued pursuant to the April Purchase Agreement following approval by the Company&#8217;s shareholders of the warrant exchange at a special meeting held on September 29, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Warrants</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the sales of securities underlying the Purchase Agreement entered into on December 9, 2016, the Company issued a warrant to the underwriter (&#8220;Underwriter&#8217;s Warrant&#8221;) to purchase 43,525 shares of Common Stock on December 9, 2016. The Underwriter&#8217;s Warrant has an exercise price of $6.92 per share. In addition, in a series of issuances in January 2017, the Company issued warrants to the investors (&#8220;Investor Warrants&#8221;) pursuant to the Purchase Agreement to purchase 435,249 shares of the Company&#8217;s Common Stock. The Investor Warrants have an exercise price of $6.80 per share. The warrants were issued in a series of transaction during January 2017 and were valued based on the Black-Scholes model, using the strike price of $6.80 per share, market prices ranging from $7.00 to $8.52 per share, an expected term of 3.25 years, volatility ranging from 38% to 39%, based on the average volatility of comparable companies over the comparable prior period, and a discount rate as published by the Federal Reserve ranging from 1.50% to 1.56%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as a liability and marked to market every reporting period. Following acceptance by the SEC of the Company&#8217;s registration statement registering these warrants, the warrants were reclassified from a liability to equity.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2017, pursuant to the amendment to the Fortress debt, the Company issued a five-year warrant to DBD to purchase 46,875 shares of the Company&#8217;s Common Stock, exercisable at $6.80 per share, subject to adjustment. The warrant was valued based on the Black-Scholes model, using the strike and market prices of $6.80 and $7.60 per share, respectively, an expected term of 3.00 years, volatility of 39% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.52%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the sales of securities underlying the April Purchase Agreement entered into on April 18, 2017, the Company issued a warrant to the underwriter (&#8220;Underwriter&#8217;s Warrant&#8221;) to purchase 14,250 shares of Common Stock. The Underwriter&#8217;s Warrant has an exercise price of $3.08 per share. In addition, also associated with the April Purchase Agreement, the Company issued warrants to the investors (&#8220;April Investor Warrants&#8221;) pursuant to the Purchase Agreement to purchase 570,000 shares of the Company&#8217;s Common Stock. The Investor Warrants have an exercise price of $3.32 per share. The Investor Warrants were valued based on the Black-Scholes model, using the strike price of $3.08 per share, an expected term of 2.5 years, volatility of 39%, based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.60%. The Underwriter&#8217;s Warrant was valued based on the Black-Scholes model, using the strike price of $3.32 per share, an expected term of 3.25 years, volatility of 38%, based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as equity.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Unit Purchase Agreement entered into on August 14, 2017, the Company, in two closings, issued warrants to the investors (&#8220;Note Investor Warrants&#8221;) to purchase 6,875,000 shares of the Company&#8217;s Common Stock. The Note Investor Warrants have an exercise price of $1.20 per share. The Note Investor Warrants from the first close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the terms of the Unit Purchase Agreement which set the volatility at the greater 100% or the 100-day volatility immediately following certain events and a discount rate as published by the Federal Reserve of 1.76%. The Note Investor Warrants from the second close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the methodology set forth above and a discount rate as published by the Federal Reserve of 1.98%. The Company reviewed the issuance of the Note Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Note Investor Warrants should be classified as a liability.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2017, the Company had warrants outstanding to purchase 7,487,894 shares of Common Stock with a weighted average remaining life of 5.35 years. A summary of the status of the Company&#8217;s outstanding stock warrants and changes during the period then ended is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Average Exercise</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted<br /> Average<br /> Remaining</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Life</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">116,520</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15.17</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.25</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,941,374</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.70</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.01</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">570,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.32</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,487,894</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.86</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.35</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercisable at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">612,894</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average fair value of warrants granted during the period</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.09</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrant Amendment Letter</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 11, 2016, the Company entered into an agreement with the remaining investor in the Company&#8217;s convertible debt issued on October 9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 5,834 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $16.50 to the lower of 1) $8.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company&#8217;s Common Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Options</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 10, 2016, the Company entered into an executive employment agreement with Erich Spangenberg (&#8220;Spangenberg Agreement&#8221;) pursuant to which Mr. Spangenberg would serve as the Company&#8217;s Director of Acquisitions, Licensing and Strategy. As part of the consideration, the Company agreed to grant Mr. Spangenberg a ten-year stock option to purchase an aggregate of 125,000 shares of Common Stock, with a strike price of $7.48 per share, vesting in twenty-four (24) equal installments on each monthly anniversary of the date of the Spangenberg Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.48 per share, an expected term of 5.75 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.32%.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 20, 2016, the Company entered into an employment agreement with Kathy Grubbs (&#8220;Grubbs Agreement&#8221;) pursuant to which Ms. Grubbs would serve as an analyst. As part of the consideration, the Company agreed to grant Ms. Grubbs a ten-year stock option to purchase an aggregate of 12,500 shares of Common Stock, with a strike price of $9.00 per share, vesting in thirty-nine (36) equal installments on each monthly anniversary of the date of the Grubbs Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.00 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.88%.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2016, in conjunction with an executive employment agreement with David Liu (&#8220;Liu Agreement&#8221;) pursuant to which Mr. Liu would serve as the Company&#8217;s CTO, entered into on June 29, 2016, the Company granted Mr. Liu a ten-year stock option to purchase an aggregate of 37,500 shares of Common Stock, with a strike price of $11.16 per share, vesting in thirty-nine (36) equal installments on each monthly anniversary of the date of the Liu Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $11.16 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.20%.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 13, 2016, the Company issued its independent board members ten-year options to purchase an aggregate of 20,000 shares of the Company&#8217;s Common Stock with an exercise price of $9.64 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.64 per share, an expected term of 5.5 years, volatility of 46% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.21%. As there were not sufficient shares in the Company&#8217;s equity incentive plans to accommodate these grants, Mr. Croxall forfeited a portion of one of his options to purchase 20,000 shares.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2017, there was a total of $7,072 of unrecognized compensation expenses related to non-rested option-based compensation arrangements entered into during the year. A summary of the stock options as of September 30, 2017 and changes during the period are presented below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Average Exercise</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted<br /> Average<br /> Remaining</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Life</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">879,034</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17.84</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.80</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,542</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">217,298</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16.71</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">613,194</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17.04</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.06</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercisable at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">591,841</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">13.83</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.91</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options expected to vest</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">21,354</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20.33</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.23</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average fair value of options granted during the period</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8211; DEBT, COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Debt consists of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Senior secured term notes</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9-Jul-20</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">LIBOR + 9.75</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,881,493</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,620,759</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: debt discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,686,090</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,425,167</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total senior-term notes, net of discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">14,195,403</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">14,195,592</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10-Oct-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Late</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Fee</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">iRunway trade payable</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">On Demand</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.5% per month</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">191,697</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Note payable</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31-Jan-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">103,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Siemens</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30-Sep-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,672,924</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dominion Harbor</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15-Oct-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Oil &#38; Gas</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">On Demand</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">944,296</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10-May-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,876,300</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: debt discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,851,171</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total Convertible notes, net of discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25,129</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31-May-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,195,932</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: debt discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(2,834,308</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total Convertible notes, net of discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">361,624</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Medtech Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1-May-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3D Nano License Fee</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31-Jan-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2016</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,582,156</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,832,509</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: current portion</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(15,582,156</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(13,162,007</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total, net of current portion</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,670,502</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Senior Secured Term Notes</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement with DBD Credit Funding LLC, (&#8220;DBD&#8221;) an affiliate of Fortress Credit Corp., under which the terms of the notes were:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; line-height: 115%">&#160;</td> <td style="width: 29px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(i)</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$15,000,000 original principal amount of Fortress Notes (the &#8220;Initial Note&#8221;);</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(ii)</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">a right to receive a portion of certain proceeds from monetization net revenues received by the Company (the &#8220;Revenue Stream&#8221;, after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes);</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(iii)</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;a five-year Fortress Warrant to purchase 25,000 shares of the Company&#8217;s Common Stock exercisable at $29.76 per share, subject to adjustment; and</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(iv) </font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">33,603 shares of the Issuer&#8217;s Common Stock (the &#8220;Fortress Shares&#8221;).</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 12, 2015, the Company issued an additional $5,000,000 of Notes (which increase proportionately the Revenue Stream).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Note matures on July 29, 2018. Additional Notes issued pursuant to the Fortress Purchase Agreement mature 42 months after issuance. The unpaid principal amount of the Initial Note plus the additional $5,000,000 note (including any PIK Interest, as defined below) bear cash interest at a rate equal to LIBOR plus 9.75% per annum payable on the last business day of each month. Interest is paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest. Monthly principal payments are due commencing one year after the anniversary dates of the loans.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the Fortress Warrant provide that until January 29, 2020, the Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company&#8217;s Common Stock. The exercise price of the warrant is $29.76 and the warrant fair value was determined to be $318,679 utilizing the Black-Scholes model, with the fair value of the warrants recorded as additional paid-in capital and reducing the carrying value of the Notes. As of September 30, 2017 and December 31, 2016, the unamortized discount on the Notes was $1,686,090 and $1,425,167, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Senior Secured Term Note Amendment</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2017 the Company and certain of its subsidiaries entered into the Amended and Restated Revenue Sharing and Securities Purchase Agreement (&#8220;ARRSSPA&#8221;) with DBD Credit Funding LLC, under which the Company and DBD amended and restated the Revenue Sharing and Securities Purchase Agreement dated January 29, 2015 (the &#8220;Original Agreement&#8221;) pursuant to which (i) Fortress purchased $20,000,000 in promissory notes, of which $15,881,493 is outstanding as of September 30, 2017, (ii) an interest in the Company&#8217;s revenues from certain activities and warrants to purchase 25,000 shares of the Company&#8217;s common stock. The ARRSSPA amends and restates the Original Agreement to provide for (i) the sale by the Company of a $4,500,000 promissory note (the &#8220;New Note&#8221;) and (ii) the insurance of additional warrants to purchase 46,875 shares of common stock (the &#8220;New Warrant&#8221;). Pursuant to the ARRSSPA, Fortress acquired an increased revenue stream right to certain revenues generated by the Company through monetization of our patent portfolio (&#8220;Monetization Revenues&#8221;). The ARRSSPA increases the revenue stream basis to $1,225,000. The ARRSSPA provides for the potential issuance of up to $7,500,000 of additional notes (the &#8220;Additional Notes&#8221;), of which not more than $3,750,000 shall be made prior to June 30, 2017 and of which not more than $3,750,000 shall be made available during the period following June 30, 2017 and on or prior to December 31, 2017 and not more than two such issuances shall occur under the ARRSSPA.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unpaid principal amount of the New Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Initial Note), the interest rate shall increase by an additional 2% per annum.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest on the Initial Note shall be paid on the last business day of each calendar month (the &#8220;Interest Payment Date&#8221;), commencing January 31, 2017. Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest, effective as of the applicable Interest Payment Date (&#8220;PIK Interest&#8221;). PIK Interest shall be treated as added principal of the New Note for all purposes, including interest accrual and the calculation of any prepayment premium. The Company paid a structuring fee of 2.0% of the New Note and would pay a 2.0% fee upon the issuance of any Additional Notes. The proceeds of the New Note and any Additional Notes may be used for working capital purposes, portfolio acquisitions, growth capital and other general corporate purposes.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The ARRSSPA contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,250,000 in unrestricted cash and cash equivalents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the New Warrants provide that from July 10, 2017 until January 10, 2022, the Warrant may be exercised for cash or on a cashless basis. Exercisability of the Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Issuer&#8217;s Common Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the ARSSPA, as security for the payment and performance in full of the Secured Obligations (as defined in the Security Agreement entered in favor of the Note purchasers (the &#8220;Security Agreement&#8221;) the Company and certain subsidiaries executed and delivered in favor of the purchasers a Security Agreement and a Patent Security Agreement, including a pledge of the Company&#8217;s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations (as defined in the Notes) is secured by a first priority lien and security interest in all the assets of the Company, subject to certain permitted liens. Certain subsidiaries of the Company also executed guarantees in favor of the purchasers (each, a &#8220;Guaranty&#8221;), guaranteeing the Note Obligations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Amendment to Senior Secured Term Note Amendment</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 3, 2017, the Company and certain of its operating subsidiaries entered into a First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the &#8220;First Amendment and Restructuring Agreement&#8221;) with DBD to cancel the indebtedness and other obligations of the Company under that certain ARRSSPA, dated January 10, 2017, which was originally entered into by the Company and DBD on January 29, 2015.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the First Amendment and Restructuring Agreement, certain intellectual property owned by the Company (the &#8220;Designated IP&#8221;) is to be assigned to one or more newly created special purpose entities (the &#8220;SPE&#8221;) as elected by DBD, which to be formed SPE shall be under the management and control of an affiliate of DBD (the &#8220;IP Monetization Manager&#8221;). All intellectual property owned by the Company that will not be assigned to one or more newly created special purpose entities shall be referred to as &#8220;Non- Designated IP.&#8221; The patents that are part of the Designated IP are referred to as the &#8220;Designated Patents&#8221;. Until shareholder approval and the close of the First Amendment and Restructuring Agreement (the &#8220;Restructuring&#8221;), all Monetization Revenues arising from the Designated IP and Non-Designated IP shall be paid to an account that is under the sole and exclusive control of the Collateral Agent as the IP Monetization Manager. In addition, until the Restructuring, the Company shall be responsible for the expenses associated with the maintenance, prosecution and enforcement of all of the Company&#8217;s intellectual property including the Designated IP and the other IP owned by the Company which is not to be transferred to the SPE, and for any expenses associated with the pursuit of monetization activities relating to both the Designated IP and the Non-Designated IP. From and after the Restructuring, the SPE shall have sole responsibility for the expenses associated with the Designated IP and the Company shall have sole responsibility for the expenses associated with the Non-Designated IP.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017 and December 31, 2016, the outstanding balances were $15,881,493 and $15,620,759, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Note</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In two transactions, on October 9, 2014 and October 16, 2014, the Company sold an aggregate $5,550,000 of principal amount of convertible notes (&#8220;Convertible Notes&#8221;) along with two-year warrants to purchase 32,375 shares of the Company&#8217;s Common Stock. The Convertible Notes are convertible into shares of the Company&#8217;s Common Stock at $30.00 per share and the Warrants have an exercise price of $33.00 per share. The Notes mature on October 10, 2018 and bear interest at the rate of 11% per annum, payable quarterly in cash on each of the three, nine, nine and twelve-month anniversaries of the issuance date and on each conversion date. The Notes may become secured by a security interest granted to the holder in certain future assets under certain circumstances. In the event the Company&#8217;s Common Stock trades at a price of at least $108.00 per share for four out of eight trading days, the Notes will be mandatorily converted into Common Stock of the Company at the then applicable conversion price per share. The Company repaid the Convertible Notes for all but one holder in early 2015, and exchanged the remaining balance for Series D Convertible Preferred Stock on August 7, 2017, with the Series D Convertible Preferred Stock converted in its entirety prior to September 30, 2017. The balance was $0 and $500,000 as of September 30, 2017 and December 31, 2016, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>iRunway</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company converted a set of outstanding invoices related to work performed by one of the Company&#8217;s vendors to a short-term payable whereby the Company agreed to pay iRunway over time for the open invoices, subject to a payment schedule as defined. To the extent that the Company does not make payments according to that schedule, the remaining balance accrues interest at 1.5% per month. On August 20, 2017, the Company entered into a release agreement with iRunway pursuant to which the Company made an immediate cash payment to iRunway in return for a release of the remaining amount outstanding. As of September 30, 2017 and December 31, 2016, the principal balance was $0 and $191,697, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note Payable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a short-term advance with an officer related to funds the Company was transferring from its European subsidiaries. The advance carried no interest and as of September 30, 2017 and December 31, 2016, the outstanding balance was $0 and $103,000, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Siemens Purchase Payment</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a purchase agreement to acquire ownership of certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest. On September 1, 2017, the Company entered into Share Purchase Agreement with GPat whereby the Company sold its 100% interest in Munitech, the wholly-owned subsidiary holding these patents, to GPat. As of September 30, 2017 and December 31, 2016, the outstanding balances were $0 and $1,672,924, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Dominion Harbor Settlement Note</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a settlement agreement with Dominion Harbor, a former licensing agent for some of the Company&#8217;s subsidiaries, on October 29, 2015 whereby the Company agreed to issue 75,000 shares of the Company&#8217;s Common Stock to Dominion Harbor and make eight (8) payments of $25,000 each ending on October 15, 2017. The shares issued to Dominion Harbor were valued at the quoted market price on the date of the grant of $6.84 per share or $513,000. As of September 30, 2017 and December 31, 2016, $0 and $125,000, respectively, remained outstanding, following an agreement between the Company and Dominion wherein the Company paid $25,000 and issued 31,250 shares of Common Stock to Dominion in full resolution of the outstanding obligation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Oil&#38; Gas Purchase Payment</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a purchase agreement to acquire monetization rights to certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest and as of September 30, 2017 and December 31, 2016, the Company had an outstanding obligation for purchase of certain Siemens patents in the amount of $1,000,000 and $944,296, respectively, with such payments expected to be made by December 31, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Convertible Note</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 14, 2017, the Company entered into a unit purchase agreement (the &#8220;Unit Purchase Agreement&#8221;) with certain accredited investors providing for the sale of up to $5,500,000 of 5% secured convertible promissory notes (the &#8220;Convertible Notes&#8221;), which are convertible into shares of the Corporation&#8217;s common stock, and the issuance of warrants to purchase 6,875,000 shares of the Company&#8217;s Common Stock (the &#8220;Warrants&#8221;). The Convertible Notes are convertible into shares of the Company&#8217;s Common Stock at the lesser of (i) $0.80 per share or (ii) the closing bid price of the Company&#8217;s common stock on the day prior to conversion of the Convertible Note; provided that such conversion price may not be less than $0.40 per share. The Warrants have an exercise price of $1.20 per share. The Convertible Notes mature on May 31, 2018 and bear interest at the rate of 5% per annum. In two closings of the Unit Purchase Agreement, the Company issued all $5,500,000 in Convertible Notes to the investors. As of September 30, 2017, the Company had an outstanding obligation pursuant to the Convertible Notes in the amount of $5,072,232.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3D Nano Purchase Payment</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">3D Nano entered into a license and purchase agreement with HP Inc. (&#8220;HP&#8221;) to acquire the rights to use if 3D Nano chooses, the right to exercise an option to acquire, ownership of certain patents, trade secrets and other intellectual property (the &#8220;Technology&#8221;). As part of the purchase agreement, the Company agreed to license the Technology for two payments of $100,000 each, with the first payment made in April 2016 and the second payment due by January 31, 2017. Under the original agreement, the payment obligations bear no interest and as of September 30, 2017 and December 31, 2016, 3D Nano had an outstanding obligation in the amount of $0 and $100,000, respectively. On May 1, 2017, 3D Nano entered into an amendment with HP whereby the agreement was extended for two years. While 3D Nano does not have the obligation under the amendment to make additional payments, should 3D Nano desire to do so, payments in the amount of $100,000 in each of 2018 and 2019 would be due to HP for the agreement to remain in effect.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Medtech Note</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 31, 2017, the Company entered into a note payable with Medtronic, Inc. (&#8220;Medtronic&#8221;), the original owner of the patents in the Company&#8217;s Medtech portfolio, whereby the Company agreed to pay Medtronic a total of $750,000 in ten equal monthly installments for patent enforcement related expenses incurred by Medtronic. Following two payments of $75,000 each in May and June 2017, the Company entered into an agreement on August 29, 2017 to pay a discounted amount in return for a full release from the remaining obligations. The note payable carries no interest and since the note payable arose after December 31, 2016 and was repaid in full prior to September 30, 2016, as of September 30, 2017 and December 31, 2016, the outstanding balance, was $0 and $0, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Total Future Minimum Principal Payments</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Future minimum principal payments for all items set forth above are as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16,881,493</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5,072,232</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">21,953,725</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Office Lease</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California. The lease will commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease. In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes. Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit. In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease. Minimum future lease payments under this lease at September 30, 2017, for the next five years are as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017 (Three Months)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18,081</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">74,540</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">77,872</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">81,336</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">27,504</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">297,333</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 27, 2017, the Company entered into the Assignment with Luxone whereby the Company assigned all of its ownership interest in PG Tech to Luxone. Pursuant to the Assignment, Luxone assumed the Company&#8217;s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio. Luxone is owner or controlled by a former affiliate of the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 1, 2017, the Company entered into an agreement to acquire, through its wholly-owned subsidiary, Global Bit Ventures Acquisition Corp., a Nevada corporation (&#8220;GBVAC&#8221;), 100% of the Capital Stock of Global Bit Ventures, Inc., a Nevada corporation (&#8220;GBV&#8221;), which currently secures and powers digital asset blockchains by running specialized servers. Under the terms of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), the Company will issue 126,674,557 shares of the Company&#8217;s Common Stock in exchange for one-hundred (100%) percent of the shares of GBV&#8217;s capital stock. At the closing of the merger, GBVAC shall be merged with and into GBV pursuant to the Merger Agreement and the separate existence of GBVAC shall cease and GBV shall be the surviving company. The closing of the acquisition is subject to certain closing conditions including approval of the Merger Agreement by the Company&#8217;s Shareholders.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of basic and diluted loss per share:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2017</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Nine Months<br /> Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2017</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Nine Months<br /> Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 26%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Net income (loss) attributable to Common shareholders</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(6,677,485</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(6,274,410</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(12,484,924</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(2,261,542</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Denominator</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Weighted average common shares &#8211; Basic and Diluted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">6,270,299</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,761,786</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5,564,465</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,736,213</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) per common share:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) &#8211; Basic and Diluted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(1.06</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(1.67</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(2.24</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(0.60</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 342.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">401,804</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,517,219</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,447,660</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,154,767</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,004,600</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2022 and thereafter</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,064,163</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,590,213</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#8217;s patent portfolios is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Subsidiary</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number&#160;of </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Patents</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Earliest </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Expiration&#160;Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Median </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Expiration&#160;Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Latest </b></font><br /> <font style="font: 8pt Times New Roman, Times, Serif"><b>Expiration&#160;Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Subject Matter</b></font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 18%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Clouding Corp.</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 5%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">25</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/3/18</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/10/21</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5/29/29</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 37%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Network and data management</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">CRFD Research, Inc.</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5/25/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/17/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/19/23</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Web page content translator and device-to-device transfer system</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Dynamic Advances, LLC</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">11/6/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/7/23</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7/9/25</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Natural language interface</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Magnus IP</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">55</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1/28/22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">9/27/25</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">12/9/31</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Network Management/Connected Home Devices</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Medtech Group Acquisition Corp.</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">45</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">12/8/18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/9/29</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Medical technology</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Signal IP, Inc.</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/28/20</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/17/21</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8/6/22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Automotive</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Traverse Technologies</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">20</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/27/22</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/25/29</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2/27/33</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Li-Ion Battery/High Capacity Electrodes</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Soems Acquisition</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">16</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">11/11/17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4/6/19</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7/18/24</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">N/A</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Median</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>09/13/21</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of the Company&#8217;s outstanding stock warrants and changes during the period then ended is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Average Exercise</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted<br /> Average<br /> Remaining</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Life</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">116,520</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15.17</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.25</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,941,374</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.70</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.01</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">570,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.32</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,487,894</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.86</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.35</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercisable at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">612,894</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average fair value of warrants granted during the period</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.09</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the stock options as of September 30, 2017 and changes during the period are presented below:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Average Exercise</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted<br /> Average<br /> Remaining</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Life</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">879,034</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17.84</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.80</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,542</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">217,298</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16.71</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">613,194</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17.04</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.06</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercisable at September 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">591,841</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">13.83</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.91</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options expected to vest</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">21,354</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20.33</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.23</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average fair value of options granted during the period</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Debt consists of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Senior secured term notes</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9-Jul-20</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">LIBOR + 9.75</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,881,493</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,620,759</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: debt discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,686,090</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,425,167</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total senior-term notes, net of discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">14,195,403</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">14,195,592</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10-Oct-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Late</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Fee</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">iRunway trade payable</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">On Demand</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.5% per month</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">191,697</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Note payable</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31-Jan-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">103,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Siemens</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30-Sep-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,672,924</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dominion Harbor</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15-Oct-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Oil &#38; Gas</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">On Demand</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">944,296</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10-May-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,876,300</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: debt discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,851,171</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total Convertible notes, net of discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25,129</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31-May-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,195,932</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: debt discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(2,834,308</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total Convertible notes, net of discount</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">361,624</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Medtech Note</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1-May-18</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 38%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Interest</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Rate</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3D Nano License Fee</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31-Jan-17</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NA</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2016</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,582,156</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,832,509</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: current portion</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(15,582,156</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(13,162,007</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total, net of current portion</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,670,502</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Future minimum principal payments for all items set forth above are as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16,881,493</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5,072,232</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">21,953,725</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Minimum future lease payments under this lease at September 30, 2017, for the next five years are as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017 (Three Months)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18,081</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">74,540</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">77,872</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">81,336</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">27,504</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">297,333</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 123630 95069 588864 225982 108878 202067 4863262 5521432 9803 28329 201203 7828417 12767003 12691679 18288435 1954836 7217078 21206379 20461015 4670502 1000000 37236 43978 718411 7114562 21924790 27575577 78 78 3111 1856 61833077 49877710 -450623 -1060390 -70427472 -57942548 -9041829 -9123294 -191282 -163848 -9233111 -9287142 12691679 18288435 1225000 609650 162713 43113 36452551 1544322 64836 1094378 19202118 1803264 457419 2030886 6018196 3718034 1871946 1252571 3406841 189819 133018 257420 903032 1686955 616125 432496 1336201 599416 213130 183771 612284 0 0 83000 83000 723218 723218 5531383 6525273 10265028 4079092 10782905 38086945 -9655378 -3916979 -10739792 -1634394 3151418 2252886 -37116 -68647 463191 480240 175850 238073 768200 754321 1954378 2122208 -1914786 -1909879 2793 931 931 2793 2416722 1283223 649065 2500321 -2675400 -2468316 1093278 -682040 -12330778 -6385295 -9646514 -2316434 29433 12191 -3347909 -26974 -12360211 -6397486 -6298605 -2289460 124714 280000 -24195 -27918 -2.24 -1.06 -1.67 -0.61 5564465 6270299 3761786 3736213 609768 482622 209159 306411 -11875157 -6194864 -6065251 -1955131 124714 280000 -24195 -27918 -11999871 -6474864 -6041056 -1927213 -283237 -283237 -1519875 -1519875 1248 3780 -531757 -638268 704678 6525273 1523187 1541615 136000 -4397381 952231 -768200 -2122198 12226 27435 27918 -182024 -96996 28561 -43763 -883695 269693 -6652 -201203 -5262242 557832 -14805103 11214122 3522656 6291 8387 2765466 -3561043 2411750 -2771757 5500000 11066704 -8911688 16509 -1592 -956424 -1260201 4041890 4998314 2555151 1294950 368923 1187074 29433 27682 115000 225000 257957 -4017729 On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis. On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. 1 250000 0 0 P9Y 0.20 0.10 25000 0.50 0.50 0.10 0.0499 0.0499 1.00 1.00 1.00 1.00 1.00 0.45 2 2 2 9 2375000 2375000 250000 2400000 1000000 100000 1150000 1000000 750000 250000 1300000 1000000 1000000 250000 2850000 2850000 300000 250000000 250000000 250000000 10000000 13000000 40000000 40000000 250000000 0.40 0.50 0.50 2400000 P10D 221 86 12 10000 170 25 5 2 55 45 2 20 3 16 1400000 1000000 2014-10-31 2018-07-29 2018-10-10 2018-10-10 2020-07-09 2020-07-09 2018-10-10 2018-10-10 2017-01-31 2017-01-31 2017-09-30 2017-09-30 2017-10-15 2017-10-15 2018-05-01 2018-05-01 2017-01-31 2017-01-31 2018-05-31 2018-05-10 2018-05-10 2018-05-18 2018-05-18 6250 1.00 1.00 1000000 500000 654000 754321 754321 723218 723218 613195 7487894 195501 13750000 0.1275 0.1275 0.1103 0.1103 108748 60115 9570 36832 3900000 20300000 122172 4998314 5564465 6270299 3761786 3736213 2.24 1.06 1.67 0.60 -12484925 -6677486 -6274410 -2261542 2 0.50 P1Y P16Y 0 0 3550000 6450000 10000 20403408 23637813 7590213 12314628 12813915 11323185 401804 1517219 1447660 1154767 1004600 2064163 7590213 Median 2/3/18 5/25/21 11/6/21 1/28/22 Expired 8/28/20 2/27/22 11/11/17 09/13/21 9/10/21 9/17/21 9/7/23 9/27/25 12/8/18 8/17/21 2/25/29 4/6/19 5/29/29 8/19/23 7/9/25 12/9/31 8/9/29 8/6/22 2/27/33 7/18/24 20000 6.80 108.00 108.00 136000 870500 187500 31250 950000 7500 33603 75000 31250 126674557 6.00 6.96 2.80 0.83 3.32 6.84 435249 570000 43525 435249 46875 14250 570000 6875000 5834 25000 25000 46875 32375 32375 6875000 0.01 3.32 6.92 6.80 6.80 3.08 3.32 1.20 8.00 16.50 29.76 33.00 33.00 1.20 1.20 1.20 0.0364 0.0877 17020 1301923 103750 24897 513000 25000 250000 200000 62500 315925 598500 534710 200000 50000 252750 427768 7.00 8.52 7.60 3.32 3.08 P3Y2M30D P3Y P2Y6M P3Y2M30D 0.38 0.39 0.39 0.39 0.38 0.47 0.47 0.47 0.46 1.00 1.00 P5Y P5Y4M6D P5Y4M6D P10Y P10Y P10Y P10Y P7Y2M23D 125000 12500 37500 20000 7.48 9.00 11.16 9.64 24 36 36 P5Y9M0D P6Y6M0D P6Y6M0D P5Y6M0D P5Y6M0D P5Y6M0D 20000 217298 50000000 50000000 50000000 7487894 116520 7941374 570000 1.86 15.17 1.70 3.32 P3Y2M30D P5Y0M4D 612894 0.09 879034 613194 48542 591841 21354 17.84 17.04 16.71 13.83 20.33 P6Y9M18D P3Y0M22D P2Y10M28D 0.0150 0.0156 0.0152 0.0160 0.0172 0.0132 0.0188 0.0120 0.0121 0.0176 0.0198 0.0999 0.0999 15000000 5000000 20000000 3750000 3750000 5550000 5550000 750000 15000000 P5Y P42M 0.0975 0.0975 0.11 0.11 0.0975 0.0975 0.05 0.0275 0.0275 2020-01-29 318679 1686090 1425167 -1686090 -1425167 -1851171 -2834308 15881493 15620759 15881493 15881493 15620759 1876300 3195932 4500000 1225000 7500000 0.02 0.020 0.020 1250000 P2Y P2Y 0 500000 5072232 30.00 30.00 0.80 0.015 0 191697 0 103000 944296 1000000 0 1672924 0 100000 8 25000 0 125000 5500000 100000 100000 75000 75000 P2Y 100000 100000 0 0 P7Y 2021-04-30 7564 P5M 42th month of the lease On Demand On Demand On Demand On Demand 0.11 0.11 0.015 0.015 0 0 0.05 0.05 944296 1000000 1672924 14195403 14195592 0 500000 0 191697 103000 125000 100000 21953725 25129 361624 15582156 17832509 16881493 5072232 18081 74540 77872 81336 27504 297333 1.00 4041890 4998314 3919718 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation and Principles of Consolidation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position, the results of operations and cash flows of the Company for the periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation and restricted cash, held in escrow pursuant to the terms of the Unit Purchase Agreement entered into on August 14, 2017, with another financial institution that is also insured by the Federal Deposit Insurance Corporation. The Company&#8217;s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). As of September 30, 2017, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At each of September 30, 2017 and December 31, 2016, the Company had recorded an allowance for bad debts in the amount of $387,976 and $387,976, respectively. Accounts receivable, net at September 30, 2017 and December 31, 2016, amounted to $123,630 and $95,069, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentration of Revenue and Geographic Area</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue from the Company&#8217;s patent enforcement activities is considered United States revenue as any payments for licenses included in that revenue are for United States operations irrespective of the location of the licensee&#8217;s or licensee&#8217;s parent home domicile.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had $0 in revenues from newly issued patent licenses for both the three months ended September 30, 2017 and the three months ended September 30, 2016. The revenue for the three months ended September 30, 2017 is attributable to a non-enforcement technology access license for one of the Company&#8217;s subsidiaries and running royalties from the Company&#8217;s Medtech portfolio and for the three months ended September 30, 2016, the revenue is attributable to running royalties from the Company&#8217;s Medtech portfolio.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At the current time, we define customers as firms that obtain licenses to the Company&#8217;s patents, either prior to or during enforcement litigation. These firms generally enter into non-recurring, non-exclusive, non-assignable license agreements with the Company, and these customers do not generally engage in ongoing, recurring business activity with the Company. The Company has historically had a small number of customers enter into such agreements, resulting in higher levels of revenue concentration.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 605, &#8220;Revenue Recognition&#8221;. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company&#8217;s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also considers the revenue generated from its settlement and licensing agreements as one unit of accounting under ASC 605-25, &#8220;Multiple-Element Arrangements&#8221; as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Also, since the settlement element and license element for past and future use are the Company&#8217;s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. There was no revenue from newly issued patent licenses for the three months ended September 30, 2017 and September 30, 2016, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets of $108,878 and $202,067 at September 30, 2017 and December 31, 2016, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Bonds Posted with Courts</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of September 30, 2017 and December 31, 2016, the Company had no outstanding bonds posted with the German courts.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related Party Transactions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties are considered related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 13, 2013, we entered into a nine-year advisory services agreement (the &#8220;Advisory Services Agreement&#8221;) with IP Navigation Group, LLC (&#8220;IP Nav&#8221;), of which Erich Spangenberg is founder and former Chief Executive Officer. Mr. Spangenberg is an affiliate of the Company. The terms of the Advisory Services Agreement provide that, in consideration for its services as intellectual property licensing agent, the Company will pay to IP Navigation Group, LLC between 10% and 20% of the gross proceeds of certain licensing campaigns in which IP Navigation Group, LLC acts as intellectual property licensing agent.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 18, 2013, we entered into a consulting agreement with Jeff Feinberg (&#8220;Feinberg Agreement&#8221;), pursuant to which we agreed to grant Mr. Feinberg 25,000 shares of our restricted Common Stock, 50% of which shall vest on the one-year anniversary of the Feinberg Agreement and the remaining 50% of which shall vest on the second-year anniversary of the Feinberg Agreement. Mr. Feinberg is the trustee of The Feinberg Family Trust and holds voting and dispositive power over shares held by The Feinberg Family Trust, which is a 10% beneficial owner of our Common Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 2, 2014, the Company completed the acquisition of certain ownership rights (the &#8220;Acquired Intellectual Property&#8221;) from TechDev, Granicus and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company. TechDev, SFF and Granicus are owned or controlled by Erich Spangenberg or family members or associates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company&#8217;s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company&#8217;s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. The remaining cash payment was made on February 24, 2015 and is fully paid. Under the terms of the Sarif Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement. Under the terms of the Pay Proceeds Agreement, as amended in 2016, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $13,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the cumulative gross proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the cumulative gross proceeds of such recoveries to the sellers. Pursuant to the amendment to the Pay Proceeds Agreement, the Company paid TechDev, Granicus and SFF $2.4 million. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 2, 2014, we entered into an opportunity agreement (the &#8220;Marathon Opportunity Agreement&#8221;) with Erich Spangenberg, who is an affiliate of the Company. The terms of the Marathon Opportunity Agreement provide that we have ten business days after receiving notice from Mr. Spangenberg to provide up to 50% of the funding for certain opportunities relating to the licensing, intellectual property acquisitions and/or intellectual property enforcement actions in which Mr. Spangenberg, IP Nav or any entity controlled by Mr. Spangenberg, other than: (i) IP Nav or any of its affiliates, and (ii) Medtech Development, LLC or any of its affiliates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 17, 2014, Selene Communication Technologies Acquisition LLC (&#8220;Acquisition LLC&#8221;), a Delaware limited liability company and newly formed wholly-owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (&#8220;Selene&#8221;). Selene owned a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav provided patent monetization and support services under an existing agreement with Selene prior to the return of the patents to Stanford Research Institute (&#8220;SRI&#8221;), the original owners of the patents.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 29, 2014, the Company entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP, LLC for an aggregate purchase price of $2.4 million, of which $1.4 million was paid in cash and $1.0 million was paid in the form of a promissory note issued by the Company that matured on October 31, 2014 and was fully paid prior to the maturation date. The Company also issued 6,250 shares of its restricted common stock in connection with the acquisition. Clouding IP, LLC is also entitled to certain possible future cash payments. Clouding IP LLC is owned or controlled by Erich Spangenberg or family members or associates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 10, 2014, the Company entered into an interest sale agreement with MedTech Development, LLC (&#8220;MedTech&#8221;) to acquire from MedTech 100% of the limited liability membership interests of OrthoPhoenix and TLIF as well as 100% of the shares of MedTech GmbH. In connection with the transaction, the Company is obligated to pay to MedTech $1 million at closing and $1 million on each of the following nine (9) month anniversary dates of the closing. On July 16, 2015, the Company entered into a forbearance agreement (the &#8220;Agreement&#8221;) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company agreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 500,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment during the year ended September 30, 2015. On October 23, 2015, the Company entered into Amendment No. 1 to the Forbearance Agreement (the &#8220;Amendment&#8221;) entered into with MedTech Development on July 16, 2015. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. The acquired subsidiaries are also obligated to make certain additional payments to MedTech from recoveries following the receipt by the acquired subsidiaries of 200% of the purchase payments, plus recovery of out of pocket expenses in connection with patent claims. The participation payments may be paid, at the election of the Company, in common stock of Marathon at the market price on the date of issuance. In connection with the transaction, the Company entered into a promissory note, common interest agreement and in the event of issuance of common stock to MedTech, will enter into a lockup and registration rights agreement. Approximately forty-five percent (45%) of MedTech is owned or controlled by Erich Spangenberg or family members or associates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2016, one of the Company&#8217;s subsidiaries, PG Technologies S.a.r.l. entered into an advisory services agreement with Granicus IP, LLC, an entity owned or controlled by one of the Company&#8217;s employees, whereby Granicus receives a percentage of pre-tax return from PG Technologies after certain revenue thresholds have been met.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2016, certain officers and directors of the Company received restricted common stock in the Company&#8217;s 3D Nanocolor Corp. (&#8220;3D Nano&#8221;) subsidiary.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2016, &#8216;&#8216;Other noncurrent assets&#8217;&#8217; in the Balance Sheets consists of a note receivable from an entity controlled by one of the Company&#8217;s employees that is uncollateralized. The note receivable does not carry interest and is repayable to the Company at the earlier of March 31, 2022 or based on certain milestones. The note receivable balance has been classified as current assets because the Company believes that it will be collected within one year from the Balance Sheet dates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2017, the Company entered into an Irrevocable Stock Power whereby the Company sold the shares it owns in the Company&#8217;s subsidiary, 3D Nano to Doug Croxall, the Company&#8217;s Chief Executive Officer with such assignment including the assumption of all of 3D Nano&#8217;s liabilities. The Company engaged a third party to value the assignment, the results of which were that the valuation and assignment were deemed to be at fair value.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 29px; line-height: 115%">&#160;</td> <td style="width: 48px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1:</font></td> <td style="width: 10px; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2:</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Observable market-based inputs or unobservable inputs that are corroborated by market data</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3:</font></td> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity&#8217;s own assumptions.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts reported in the consolidated condensed balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Clouding IP earn out liability was determined as a Level 3 liability, which requires an assessment of fair value at each period end by using discounted cash flow as a valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2017, the Company determined that there was a reduction in the Clouding IP earn out liability during the three and nine months ended September 30, 2017 in the amounts of $754,321and $754,321, respectively and a reduction in the carrying value of the Clouding IP intangible assets during the three and nine months ended September 30, 2017 in the amounts of $723,218 and $723,218, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined that the Warrants issued pursuant to the Unit Purchase Agreement should be treated as a Level 2 liability, which determine the value based on observable market-based inputs. in this instance, the Warrants were valued using a Monte-Carlo simulation utilizing market-based inputs for volatility and risk-free rate of interest, which resulted in the Warrants issued pursuant to the August 31, 2017 close being fair valued at $0.0364 per share and the Warrants issued pursuant to the September 29, 2017 close being fair valued at $0.0877 per share.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounting for Acquisitions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 &#8212; Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes pursuant to the provision of ASC 740-10, &#8220;Accounting for Income Taxes&#8221; which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2016 tax returns. After review of the prior year financial statements and the results of operations through December 31, 2016, the Company has recorded a full valuation allowance on its deferred tax asset.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basic and Diluted Net Loss per Share</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (&#8220;ASC 260&#8221;). Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 613,195 shares of Common Stock, warrants to purchase 7,487,894 shares of Common Stock, Convertible Notes convertible into up to 13,750,000 shares of Common Stock and shares of Series B Convertible Preferred Stock convertible into 195,501 shares of Common Stock outstanding at September 30, 2017, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company&#8217;s net loss.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of basic and diluted loss per share:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2017</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Nine Months<br /> Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2017</p></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">For the Nine Months<br /> Ended</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2016</p></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 26%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Net income (loss) attributable to Common shareholders</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(6,677,485</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(6,274,410</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(12,484,924</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(2,261,542</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Denominator</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Weighted average common shares &#8211; Basic and Diluted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">6,270,299</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,761,786</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5,564,465</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,736,213</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) per common share:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) &#8211; Basic and Diluted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(1.06</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(1.67</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(2.24</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(0.60</font></td> <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intangible Assets - Patents</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company&#8217;s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company&#8217;s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit&#8217;s goodwill and if the carrying value of the reporting unit&#8217;s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2017 the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment charge to its goodwill in the amount of $0 and $83,000, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Other Intangible Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 350-30, &#8220;Intangibles - Goodwill and Others&#8221;, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Long-lived Assets</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 &#8220;Property, Plant and Equipment&#8221;. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-based Compensation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company&#8217;s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company&#8217;s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the &#8220;measurement date.&#8221; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2017, we had approximately $0.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of approximately $20.3 million.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the Company&#8217;s current revenue and profit projections, management is uncertain that the Company&#8217;s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months from the issuance date of the financial statements, raising substantial doubt regarding the Company&#8217;s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; line-height: 115%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">raise additional funds to support the Company&#8217;s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;review strategic alternatives.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlements of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11, &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),&#8221; which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU No. 2017-09, <i>Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</i>. This ASU provides clarity about which changes to the terms or conditions of a share-based payment award require the application of modification accounting. Specifically, ASU 2017-09 clarifies that changes to the terms or conditions of an award should be accounted for as a modification unless all of the following are met: 1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted. The Company does not expect the adoption of ASU 2017-09 to significantly impact its accounting for share-based payment awards, as changes to awards&#8217; terms and conditions subsequent to the grant date are unusual and infrequent in nature.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-04 <i>Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</i> (&#8220;ASU 2017-04&#8221;). This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for interim and annual period beginning after December 15, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued ASU 2017-01 <i>Business Combinations (Topic 805): Clarifying the Definition of a Business</i> (&#8220;ASU 2017-01&#8221;), which clarifies the definition of a business and assists entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under this guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or group of similar assets), the assets acquired would not represent a business. In addition, in order to be considered a business, an acquisition would have to include at a minimum an input and a substantive process that together significantly contribute to the ability to create an output. The amended guidance also narrows the definition of outputs by more closely aligning it with how outputs are described in FASB guidance for revenue recognition. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. <i>2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)</i>, which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity&#8217;s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2016, the FASB issued ASU 2016-16 <i>Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory</i> (&#8220;ASU 2016-16&#8221;), which eliminates the exception in existing guidance which defers the recognition of the tax effects of intra-entity asset transfers other than inventory until the transferred asset is sold to a third party. Rather, the amended guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated condensed financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU 2016-15 <i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments </i>(&#8220;ASU 2016-15&#8221;). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated condensed financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers, as a new Topic, (ASC) Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. This ASU must be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are considering the alternatives of adoption of this ASU and we are conducting our review of the likely impact to the existing portfolio of customer contracts entered into prior to adoption. After completing our review, we will continue to evaluate the effect of adopting this guidance upon our results of operations, cash flows and financial position.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; (&#8220;ASU 2016-02&#8221;). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated condensed financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</p> 15582156 13162007 0.50 1.00 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2016</font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Intangible Assets</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,403,408</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">23,637,813</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated Amortization &#38; Impairment</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(12,813,195</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(11,323,185</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets, net</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,590,213</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">12,314,628</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 3 7487894 7072 1755635 1755635 200000 100000 -12813195 -11323185 EX-101.SCH 7 mara-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Debt, Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Debt, Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Acquisitions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Intangible Assets - Schedule of Future Amortization of Intangible Assets, Net of Foreign Currency Translation Adjustments (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Intangible Assets - Summary of the Company's Patent Portfolios (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders’ Equity - Summary of the Company's Outstanding Stock Warrants and Changes During the Period (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stockholders’ Equity - Summary of Stock Options and Changes During the Period (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Debt, Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Debt, Commitments and Contingencies - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Debt, Commitments and Contingencies - Schedule of Future Minimum Principal Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Debt, Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mara-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 mara-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 mara-20170930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Debt Instrument [Axis] Medtech and Orthophoenix [Member] Fortress Note Payable [Member] 3D Nano License Note Payable [Member] Medtronic Note Payable [Member] Siemen's Notes Payable [Member] Vendors Notes Payable [Member] Range [Axis] Maximum [Member] Concentration Risk Benchmark [Axis] Sales Revenue Net [Member] Type of Arrangement and Non-arrangement Transactions [Axis] License Agreements [Member] Advisory Services Agreement [Member] Related Party [Axis] Navigation Group LLC [Member] Title of Individual [Axis] Founder And Former Chief Executive Officer [Member] Minimum [Member] Feinberg Agreement [Member] Equity Components [Axis] Restricted Common Stock [Member] Trustee [Member] Beneficial Owner [Member] Restricted Common Stock [Member] Business Acquisition [Axis] Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] Related Party Transaction [Axis] Acquired Intellectual Property [Member] Affiliated Entity [Member] Dynamic Advances, LLC [Member] IP Liquidity Ventures, LLC [Member] Sarif Biomedical, LLC [Member] Range One [Member] Pay Proceeds Agreement [Member] Vesting [Axis] Range Two [Member] Range Three [Member] Marathon Opportunity Agreement [Member] Patent Purchase Agreement [Member] Clouding IP, LLC [Member] Promissory Note [Member] Interest Sale Agreement [Member] MedTech Development, LLC [Member] MedTech GmbH [Member] OrthoPhoenix and TLIF [Member] Options [Member] Warrant [Member] Series B Convertible Preferred Stock [Member] Clouding Corp [Member] Legal Entity [Axis] Munitech S.a.r.l [Member] Scenario [Axis] Future Payment One [Member] Future Payment Two [Member] Magnus IP GmbH [Member] Traverse Technologies Corp [Member] CPT IP Holdings [Member] PG Technologies S.a.r.l [Member] Patent Funding and Exclusive License Agreement [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Network and Data Management [Member] CRFD Research, Inc. [Member] Web Page Content Translator and Device-to-Device Transfer System [Member] Natural Language Interface [Member] Magnus IP [Member] Network Management/Connected Home Devices [Member] Medtech Group Acquisition Corp. [Member] Medical Technology [Member] Signal IP, Inc. [Member] Automotive [Member] Traverse Technologies [Member] Li-Ion Battery/High Capacity Electrodes [Member] Common Stock [Member] Consulting Agreement [Member] Cooper Law Firm, LLC [Member] Securities Purchase Agreement [Member] Institutional Investors [Member] Common Stock Warrants [Member] At-The-Market Offering [Member] Settlement Agreement [Member] Counterparty Name [Axis] Dominion Harbor Group [Member] Vendors [Member] Cancellation of Invoices [Member] Underwriter [Member] DBD Credit Funding LLC [Member] Fortress Purchase Agreement Amended and Restated [Member] April Purchase Agreement [Member] Investors [Member] Option Indexed to Issuer's Equity, Type [Axis] Employee Stock Option [Member] Spangenberg Agreement [Member] Director of Acquisitions, Licensing and Strategy [Member] Grubbs Agreement [Member] Analyst [Member] Liu Agreement [Member] Chief Technology Officer [Member] Independent Board Member [Member] Warrants [Member] Award Type [Axis] Stock Options [Member] Long-term Debt, Type [Axis] Senior Secured Term Notes [Member] Initial Note [Member] Fortress Purchase Agreement [Member] Additional Notes [Member] Variable Rate [Axis] London Interbank Offered Rate (LIBOR) [Member] Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] New Warrant [Member] Additional Notes One [Member] Additional Notes Two [Member] New Note [Member] Convertible Note [Member] iRunway [Member] Officer [Member] Dominion Harbor Settlement Note [Member] Oil & Gas Purchase Payment Arrangement [Member] Siemens Purchase Payment Arrangement [Member] 3D Nano Purchase Payment [Member] License and Purchase Agreement [Member] HP Inc [Member] 2018 [Member] 2019 [Member] Medtech Note [Member] Medtronic, Inc [Member] iRunway Trade Payable [Member] Note Payable [Member] LIBOR [Member] Dominion Harbor Settlement Agreement [Member] 3D Nano License and Purchase Agreement [Member] Senior and Junior Debt [Member] Report Date [Axis] October 25 2017 [Member] October 30 2017 [Member] Selene Communication Technologies, LLC [Member] Merger Agreement [Member] Soems Acquistio [Member] N/A [Member] Series D Convertible Preferred Stock [Member] Warrant First Close [Member] Warrant Second Close [Member] Convertible Note One [Member] Unit Purchase Agreement [Member] Convertible Note Two [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Global Bit Ventures Acquisition Corp [Member] Munitech Patents [Member] 3D Nano License [Member] SE Patent [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Restricted Cash Total cash Accounts receivable - net of allowance for bad debt of $387,976 and $387,976 for September 30, 2017 and December 31, 2016 Note receivable Prepaid expenses and other current assets, net of discounts of $2,659 for September 30, 2017 and $3,724 for December 31, 2016 Total current assets Other assets: Property and equipment, net of accumulated depreciation of $133,224 and $108,407 for September 30, 2017 and December 31, 2016 Intangible assets, net of accumulated amortization of $12,813,915 and $11,323,185 for September 30, 2017 and December 31, 2016 Other non current assets, net of discounts of $797 for December 31, 2016 Goodwill Total other assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses Clouding IP earn out - current portion Revenue share liability Warrant liability Notes payable, net of discounts of $5,837,363 and $852,404 for September 30, 2017 and December 31, 2016 Total current liabilities Long-term liabilities Notes Payable, net of discount of $57,763 for December 31, 2016 Clouding IP earn out Revenue share liability Other long term liability Total long-term liabilities Total liabilities Stockholders' Deficit: Preferred stock Series B, $.0001 par value, 50,000,000 shares authorized: 195,501 issued and outstanding at September 30, 2017 and December 31, 2016 Common stock, $.0001 par value; 200,000,000 shares authorized; 7,776,016 and 4,638,118 at September 30, 2017 and December 31, 2016 Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated deficit Total Marathon Patent Group stockholders' equity Noncontrolling interests Total deficit Total liabilities and stockholders' deficit Statement [Table] Statement [Line Items] Allowance for bad debt Discounts on prepaid expenses and other current assets Accumulated depreciation of property and equipment Accumulated amortization of intangible assets Discount on other non current assets Discount on notes payable, current Discount on notes payable, long-term Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Expenses Cost of revenues Amortization of patents and website Compensation and related taxes Consulting fees Professional fees General and administrative Goodwill impairment Patent impairment Total operating expenses Operating loss from continuing operations Other income (expenses) Other income (expense) Foreign exchange (loss) Loss on debt extinguishment Loss on sale of company Change in fair value adjustment of Clouding IP earn out Warrant income (expense) Interest income Interest expense Total other income (expenses) Loss from continuing operations before benefit for income taxes Income tax benefit (expense) Net Income (loss) Net income (loss) attributable to Noncontrolling interests Net (loss) attributable to common shareholders Income (loss) per common share: Basic Diluted WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic Net loss Other comprehensive loss: Unrealized gain on foreign currency translation Comprehensive loss Less: comprehensive income (loss) related to non-controlling interest Comprehensive loss attributable to Marathon Patent Group, Inc. Cash flows from operating activities: Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation Deferred tax asset Deferred tax liability Loss on sale of companies Warrant liability Impairment of intangible assets Impairment of goodwill Stock based compensation Stock issued for services Non-cash interest, discount, and financing costs Change in fair value of Clouding earnout Allowance for doubtful accounts Beneficial conversion feature Noncontrolling interest Other non-cash adjustments Changes in operating assets and liabilities Accounts receivable Bonds posted with courts Prepaid expenses and other assets Other non current assets Accounts payable and accrued expenses Net cash and restricted cash provided by (used in) operating activities Cash flows from investing activities: Acquisition of patents Disposal of patents Purchase of property, equipment, and other intangible assets Net cash provided by (used in) investing activities Cash flows from financing activities: Payments on notes payable Cash received upon issuance of equity (net of issuance costs) Issuance of warrants Issuance of convertible notes payable Proceeds from notes payable Payments on notes payable, net Net cash provided (used in) by financing activities Effect of exchange rate changes on cash Net decrease in cash Cash at beginning of period Cash and restricted cash at end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW  INFORMATION: Cash paid for: Interest expense Taxes paid Cash invested in 3D Nano SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Revenue share liability incurred in conjunction with note payable Warrant issued in conjunction with common stock issuance Note payable issued in conjunction with the acquisition of Munitech patents Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Business Combinations [Abstract] Acquisitions Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Equity [Abstract] Stockholders' Equity DEBT, COMMITMENTS AND CONTINGENCIES Debt, Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation and Principles of Consolidation Use of Estimates and Assumptions Cash Accounts Receivable Concentration of Revenue and Geographic Area Revenue Recognition Prepaid Expenses and Other Current Assets Bonds Posted with Courts Related Party Transactions Fair Value of Financial Instruments Accounting for Acquisitions Income Taxes Basic and Diluted Net Loss Per Share Intangible Assets - Patents Goodwill Other Intangible Assets Impairment of Long-lived Assets Stock-based Compensation Liquidity and Capital Resources Recent Accounting Pronouncements Schedule of Computation of Basic and Diluted Loss Per Share Schedule of Intangible Assets Schedule of Future Amortization of Intangible Assets, Net of Foreign Currency Translation Adjustments Summary of the Company's Patent Portfolios Summary of the Company's Outstanding Stock Warrants and Changes During the Period Summary of Stock Options and Changes During the Period Schedule of Debt Schedule of Future Minimum Principal Payments Schedule of Future Minimum Lease Payments Reverse stock split ratio Schedule of Significant Accounting Policies [Table] Significant Accounting Policies [Line Items] Number of financial institutions Insured by FDIC Accounts receivable, net License revenue amount Prepaid expenses and other current assets Outstanding litigation bonds Length of agreement Percent of gross proceeds Common stock issued Vesting on first anniversary Vesting on second anniversary Beneficial ownership percentage Number of purchase agreements Ownership interest held Number of cash payments made Payments to acquire businesses, net of cash acquired Second payment amount on or before June 30, 2014 Maximum possible amount of future payments Reimbursement revenue Net recovery proceeds due to sellers Payments of reimbursement revenue Number of business days to respond Number of patents Cash Promissory note issued Debt maturity date Stock issued in acquisition Percentage of shares Monthly payment obligation Shares granted Debt extinguishment Clouding ip earn out liability Reduction in intangible assets Anti-dilutive securities excluded from computation of diluted shares Impairment of intangible assets Warrant fair value price per share Income tax benefit percentage Impairment of long-lived assets Expected forfeiture rate Compensation expenses Cash and cash equivalents Restricted cash Working capital Net income (loss) attributable to Common shareholders Weighted Average Common Shares - Basic and Diluted Earnings (loss) - Basic and Diluted Earnout liability, short-term Earnout liability, long-term Consideration paid Number of installments Net licensing revenue percentage Sale of stock percentage Weighted average useful life, intangibles Intangible assets capitalized Amortization of intangible assets Number of additional patents Intangible Assets Accumulated Amortization & Impairment Intangible assets, net 2017 2018 2019 2020 2021 2022 and thereafter Total Earliest Expiration Date Median Expiration Date Latest Expiration Date Percentage of common stock outstanding Stock issued for services Stock market price per share Value of stock issued for services Number of common stock shares issued Price per share Number of warrant to purchase shares of common stock Exercise price of warrants Warrants issued, total value Value of shares issued Conversion of shares issued Conversion of converted shares Share price Expected term of warrants Volatility rate Discount rate Term of warrants Warrant outstanding Weighted average remaining life Option term Option to purchase shares of common stock Option price per share Number of monthly installments Expected term Forfeited number of shares Unrecognized compensation Number of Warrants Balance Beginning Number of Warrants Granted Number of Warrants Cancelled Number of Warrants Forfeited Number of Warrants Exercised Number of Warrants Balance Ending Weighted Average Exercise Price Balance Beginning Weighted Average Exercise Price Granted Weighted Average Exercise Price Cancelled Weighted Average Exercise Price Forfeited Weighted Average Exercise Price Exercised Weighted Average Exercise Price Balance Ending Weighted Average Remaining Life Balance Beginning Weighted Average Remaining Life, Granted Weighted Average Remaining Life Balance Ending Warrants exercisable Weighted average fair value of warrants granted during the period Number of Options, Beginning Balance Number of Options, Granted Number of Options, Cancelled Number of Options, Forfeited Number of Options, Exercised Number of Options, Ending Balance Number of Options Exercisable Number of Options expected to vest Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, Forfeited Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Options Exercisable Weighted Average Exercise Price, Options expected to vest Weighted Average Remaining Life, Beginning Balance Weighted Average Remaining Life, Ending Balance Weighted Average Remaining Life, Options Exercisable Weighted Average Remaining Life, Options expected to vest Principal amount of debt Monetization of net revenues Note term Warrant exercise price per share Debt bears cash interest rate Interest rate on paid-in-kind interest Beneficially ownership percentage Warrant expiration date Fair value of warrant Unamortized discount Term notes, gross Cash collateral account Increase in revenue stream basis Maximum borrowing capacity Increase in interest rate Structuring fee percentage Minimum liquidity requirement in unrestricted cash and cash equivalents Warrant term Debt instrument outstanding Debt conversion price per share Common stock trade price per share Monthly interest rate Short-term payable Short-term advance to an officer Purchase obligation for patents Number of payments Installment payment amount Share issued price per share Value of common stock shares issued Outstanding amount Proceeds from issuance of secured debt Amount of individual payments Agreement extended term Amount of individual payments under the extended term Debt payments Lease term Lease expiry date Security deposit Rent payment grace period Lease termination option available Maturity date Maturity date description Debt variable interest rate Interest rate Long-term debt, gross Less: debt discount Total debt, net Total Less current portion Total, net of current portion 2017 2018 Total, net 2017 (Three Months) 2018 2019 2020 2021 Total Ownership percentage Exchange of common stock percentage Amount of discount on asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Amount of discount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Amount of discount, as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. Amount of discount, as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Professional and contract service expense (benefit) includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support. Represents information pertaining to change in fair value adjustment of earnout liability. Amount of Amount of recognition of income (expense) from warrants.&#13;(expense) on warrants. The increase (decrease) during the reporting period in the value of deferred tax assets. The increase (decrease) during the reporting period in the value of deferred tax liabilities. The expense related to real estate commissions and closing costs that are not paid in cash. Is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all non-controlling interest items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities. Amount of increase (decrease) in bonds posted with courts. Amount of cash outflow supported by a written promise to pay an obligation. Cash paid abstract. Represents a cash investment during the period Revenue share liability incurred in conjunction with note payable. Warrant issued in conjunction with common stock issuance. Medtech and Orthophoenix [Member] Fortress Note Payable [Member] Three Dnano License Note Payable [Member] Medtronic Note Payable [Member] Siemen's Notes Payable [Member] Vendors Notes Payable [Member] N/a The entire disclosure for debt, commitments and contingencies. Basis of Accounting Policy: Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Consolidation policy: Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidia Disclosure of accounting policy for risks related to concentration of revenue and geographic area. Disclosure of accounting policy for prepaid expenses and other current assets. Disclosure of accounting policy for bonds posted with courts. Disclosure of accounting policy for related party transactions. Disclosure of accounting policy for liquidity and capital resources. Tabular disclosure of the patent portfolios. Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all short-term and long-term borrowings. License Agreements [Member] Advisory Services Agreement [Member] Navigation Group LLC [Member] Founder And Former Chief Executive Officer [Member] Feinberg Agreement [Member] Trustee [Member] Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] Acquired Intellectual Property [Member] Dynamic Advances, LLC [Member] IP Liquidity Ventures, LLC [Member] Sarif Biomedical, LLC [Member] Range One [Member] Pay Proceeds Agreement [Member] Range Two [Member] Range Three [Member] Marathon Opportunity Agreement [Member] Selene Communication Technologies, LLC [Member] Merger Agreement [Member] Patent Purchase Agreement [Member] Clouding IP, LLC [Member] Promissory Note [Member] Interest Sale Agreement [Member] MedTech Development, LLC [Member] MedTech GmbH [Member] OrthoPhoenix and TLIF [Member] Options [Member] Series B Convertible Preferred Stock [Member] Represents information pertaining to Signal IP, Inc. Clouding Corp [Member] Munitech S.a.r.l [Member] Future Payment One [Member] Future Payment Two [Member] Magnus IP GmbH [Member] Traverse Technologies Corp [Member] CPT IP Holdings [Member] PG Technologies S.a.r.l [Member] Patent Funding and Exclusive License Agreement [Member] Network and Data Management [Member] CRFD Research, Inc. [Member] Web Page Content Translator and Device-to-device Transfer System [Member] Natural Language Interface [Member] Automotive [Member] Magnus IP [Member] Network Management/Connected Home Devices [Member] Medtech Group Acquisition Corp. [Member] Medical Technology [Member] Traverse Technologies [Member] Li-Ion Battery/High Capacity Electrodes [Member] Consulting Agreement [Member] Cooper Law Firm, LLC [Member] Securities Purchase Agreement [Member] Institutional Investors [Member] Common Stock Warrants [Member] At-The-Market Offering [Member] Settlement Agreement [Member] Dominion Harbor Group [Member] Vendors [Member] Cancellation of Invoices [Member] Underwriter [Member] DBD Credit Funding LLC [Member] Fortress Purchase Agreement Amended and Restated [Member] April Purchase Agreement [Member] Investors [Member] Spangenberg Agreement [Member] Director of Acquisitions, Licensing and Strategy [Member] Grubbs Agreement [Member] Analyst [Member] Liu Agreement [Member] Chief Technology Officer [Member] Independent Board Member [Member] Warrants [Member] Stock Options [Member] Senior Secured Term Notes [Member] Initial Note [Member] Additional Notes [Member] Fortress Purchase Agreement [Member] Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] New Warrant [Member] Additional Notes One [Member] Additional Notes Two [Member] New Note [Member] Convertible Note [Member] iRunway [Member] Dominion Harbor Settlement Note [Member] Oil & Gas Purchase Payment Arrangement [Member] Siemens Purchase Payment Arrangement [Member] 3D Nano Purchase Payment [Member] License and Purchase Agreement [Member] HP Inc [Member] 2018 [Member] 2019 [Member] Medtech Note [Member] Medtronic, Inc [Member] LIBOR [Member] iRunway Trade Payable [Member] Note Payable [Member] Dominion Harbor Settlement Agreement [Member] 3dnano License and Purchase Agreement [Member] Senior and Junior Debt [Member] Series D Convertible Preferred Stock [Member] Restricted Common Stock [Member] Warrant liability. Disposal of patents. October 25 2017 [Member] Convertible Note Two [Member] Information pertaining to Significant Accounting Policies for the reporting period. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Represents the number of financial institution for maintaining balances of cash and cash equivalents. Length of time of an agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen day. The percentage of gross proceeds to be paid. Number of monthly installments from grant date over which an equity-based award will vest. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage vested on first anniversary after execution of an agreement. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage vested on second anniversary after execution of an agreement. The equity interest of controlling shareholders, partners or other equity holders in an entity. Represents the number of cash payments made as part of a business acquisition. The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, contingent upon the occurrence of agreed-upon circumstances. Represents the percentage of net proceeds due per agreement. It represents amount of cash outflow for payment of reimbursement revenue. Number of days after notice is given that the Company has to respond. Represents information pertaining to the number of patents. Represents the monthly obligation of the Company, due to MedTech in relation to the interest sale agreement entered into on October 10, 2014. Number of shares of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Clouding IP earn out liability. Reduction in intangible assets. Represents the expected forfeiture rate. Represents information pertaining to working capital. Represents the number of payments. Represents the percentage of net licensing revenues percentage. Represents information pertaining to the number of additional patents for which the company has economic rights. N/A [Member] N/A [Member] Earliest Expiration Date. Median Expiration Date. Latest Expiration Date. Convertible Note Two [Member] Convertible Note Two [Member] Percentage of common stock outstanding. Represents information pertaining to the expected term of warrants issued. Represents information pertaining to the contractual term of warrants issued. The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period. Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled. Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for equity-based awards granted during the period, excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. The number of exercisable made during the period on other than stock (or unit) option plans. Weighted average fair value of warrants granted during the period. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Convertible Note Two [Member] Unit Purchase Agreement [Member] Convertible Note Two [Member] Global Bit Ventures Acquisition Corp [Member] Represents information pertaining to monetization net revenues. Contractual interest rate for interest to capitalized. Warrant expiration date. Amount of increase in revenue stream basis. Structuring fee percentage. Minimum liquidity requirement in unrestricted cash and cash equivalents. Warrant term. The number of agreed monthly payments to make under settlement agreement. Monthly agreed amount to make under settlement agreement. Outstanding amount under settlement agreement. Monthly agreed amount under purchase agreement. Agreement extended term. Monthly agreed amount under purchase agreement extended term. Time period during which rent payments are not required. Represents information regarding the termination option for the Company. Exchange of common stock percentage. Number of purchase agreements. Note payable issued in conjunction with the acquisition of Munitech patents. Munitech Patents [Member] 3D Nano License [Member] SE Patent [Member] Accumulated Amortization and Impairment. RestrictedCommonStockMember Cash, Cash Equivalents, and Short-term Investments Assets, Current Assets, Noncurrent Assets Liabilities, Current Deferred Revenue, Noncurrent Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Effect of Exchange Rate on Cash Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Increase (Decrease) In Deferred Tax Assets WarrantLiability Debt Instrument, Convertible, Beneficial Conversion Feature Adjustments, Non controlling Interest, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Other Noncash Income (Expense) Increase (Decrease) in Accounts Receivable Increase (Decrease) In Bonds Posted With Courts Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets DisposalOfPatents Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Payments on Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash [Default Label] Cash and Cash Equivalents, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Payments to Acquire Businesses, Gross Finite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Stock Issued During Period, Shares, Issued for Services Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year Long-term Debt, Maturities, Repayments of Principal in Year Two Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments Due EX-101.PRE 11 mara-20170930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2017
Nov. 14, 2017
Document And Entity Information    
Entity Registrant Name Marathon Patent Group, Inc.  
Entity Central Index Key 0001507605  
Document Type 10-Q  
Document Period End Date Sep. 30, 2017  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   8,747,931
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2017  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Condensed Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash $ 122,172 $ 4,998,314
Restricted Cash 3,919,718
Total cash 4,041,890 4,998,314
Accounts receivable - net of allowance for bad debt of $387,976 and $387,976 for September 30, 2017 and December 31, 2016 123,630 95,069
Note receivable 588,864 225,982
Prepaid expenses and other current assets, net of discounts of $2,659 for September 30, 2017 and $3,724 for December 31, 2016 108,878 202,067
Total current assets 4,863,262 5,521,432
Other assets:    
Property and equipment, net of accumulated depreciation of $133,224 and $108,407 for September 30, 2017 and December 31, 2016 9,803 28,329
Intangible assets, net of accumulated amortization of $12,813,915 and $11,323,185 for September 30, 2017 and December 31, 2016 7,590,213 12,314,628
Other non current assets, net of discounts of $797 for December 31, 2016 201,203
Goodwill 228,401 222,843
Total other assets 7,828,417 12,767,003
Total Assets 12,691,679 18,288,435
Current liabilities:    
Accounts payable and accrued expenses 1,954,836 7,217,078
Clouding IP earn out - current portion 32,637 81,930
Revenue share liability 1,225,000
Warrant liability 2,411,750
Notes payable, net of discounts of $5,837,363 and $852,404 for September 30, 2017 and December 31, 2016 15,582,156 13,162,007
Total current liabilities 21,206,379 20,461,015
Long-term liabilities    
Notes Payable, net of discount of $57,763 for December 31, 2016 4,670,502
Clouding IP earn out 681,175 1,400,082
Revenue share liability 1,000,000
Other long term liability 37,236 43,978
Total long-term liabilities 718,411 7,114,562
Total liabilities 21,924,790 27,575,577
Stockholders' Deficit:    
Preferred stock Series B, $.0001 par value, 50,000,000 shares authorized: 195,501 issued and outstanding at September 30, 2017 and December 31, 2016 78 78
Common stock, $.0001 par value; 200,000,000 shares authorized; 7,776,016 and 4,638,118 at September 30, 2017 and December 31, 2016 3,111 1,856
Additional paid-in capital 61,833,077 49,877,710
Accumulated other comprehensive income (loss) (450,623) (1,060,390)
Accumulated deficit (70,427,472) (57,942,548)
Total Marathon Patent Group stockholders' equity (9,041,829) (9,123,294)
Noncontrolling interests (191,282) (163,848)
Total deficit (9,233,111) (9,287,142)
Total liabilities and stockholders' deficit $ 12,691,679 $ 18,288,435
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Allowance for bad debt $ 387,976 $ 387,976
Discounts on prepaid expenses and other current assets 2,659 3,724
Accumulated depreciation of property and equipment 133,224 108,407
Accumulated amortization of intangible assets 12,813,915 11,323,185
Discount on other non current assets 797
Discount on notes payable, current 5,837,363 852,404
Discount on notes payable, long-term $ 57,763
Preferred stock, par value $ 0.0001  
Preferred stock, shares authorized 50,000,000  
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 7,776,016 4,638,118
Common stock, shares outstanding 7,776,016 4,638,118
Series B Preferred Stock [Member]    
Preferred stock, par value $ .0001 $ .0001
Preferred stock, shares authorized 50,000,000 50,000,000
Preferred stock, shares issued 195,501 195,501
Preferred stock, shares outstanding 195,501 195,501
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Condensed Statements of Operations and Comprehensive Income (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
Revenues $ 162,713 $ 43,113 $ 609,650 $ 36,452,551
Expenses        
Cost of revenues 64,836 1,094,378 1,544,322 19,202,118
Amortization of patents and website 457,419 2,030,886 1,803,264 6,018,196
Compensation and related taxes 1,871,946 1,252,571 3,718,034 3,406,841
Consulting fees 133,018 257,420 189,819 903,032
Professional fees 616,125 432,496 1,686,955 1,336,201
General and administrative 213,130 183,771 599,416 612,284
Goodwill impairment 0 83,000 0 83,000
Patent impairment 723,218 5,531,383 723,218 6,525,273
Total operating expenses 4,079,092 10,782,905 10,265,028 38,086,945
Operating loss from continuing operations (3,916,979) (10,739,792) (9,655,378) (1,634,394)
Other income (expenses)        
Other income (expense) 2,252,886 (37,116) 3,151,418 (68,647)
Foreign exchange (loss) (480,240) (175,850) (463,191) (238,073)
Loss on debt extinguishment (283,237) (283,237)
Loss on sale of company (1,519,875) (1,519,875)
Change in fair value adjustment of Clouding IP earn out 754,321 1,954,378 768,200 2,122,208
Warrant income (expense) (1,909,879) (1,914,786)
Interest income 931 931 2,793 2,793
Interest expense (1,283,223) (649,065) (2,416,722) (2,500,321)
Total other income (expenses) (2,468,316) 1,093,278 (2,675,400) (682,040)
Loss from continuing operations before benefit for income taxes (6,385,295) (9,646,514) (12,330,778) (2,316,434)
Income tax benefit (expense) (12,191) 3,347,909 (29,433) 26,974
Net Income (loss) (6,397,486) (6,298,605) (12,360,211) (2,289,460)
Net income (loss) attributable to Noncontrolling interests (280,000) 24,195 (124,714) 27,918
Net (loss) attributable to common shareholders $ (6,677,486) $ (6,274,410) $ (12,484,925) $ (2,261,542)
Income (loss) per common share:        
Basic $ (1.06) $ (1.67) $ (2.24) $ (0.61)
Diluted
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic 6,270,299 3,761,786 5,564,465 3,736,213
Net loss $ (6,677,486) $ (6,274,410) $ (12,484,925) $ (2,261,542)
Other comprehensive loss:        
Unrealized gain on foreign currency translation 482,622 209,159 609,768 306,411
Comprehensive loss (6,194,864) (6,065,251) (11,875,157) (1,955,131)
Less: comprehensive income (loss) related to non-controlling interest (280,000) 24,195 (124,714) 27,918
Comprehensive loss attributable to Marathon Patent Group, Inc. $ (6,474,864) $ (6,041,056) $ (11,999,871) $ (1,927,213)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net loss $ (12,484,925) $ (2,261,542)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 1,248 3,780
Amortization of patents and website 1,803,264 6,018,196
Deferred tax asset 531,757
Deferred tax liability (638,268)
Loss on sale of companies 1,519,875
Warrant liability
Impairment of intangible assets 704,678 6,525,273
Impairment of goodwill 0 83,000
Stock based compensation 1,523,187 1,541,615
Stock issued for services 136,000
Non-cash interest, discount, and financing costs (4,397,381) 952,231
Change in fair value of Clouding earnout (768,200) (2,122,198)
Allowance for doubtful accounts 12,226
Beneficial conversion feature 4,017,729
Noncontrolling interest (27,435) (27,918)
Other non-cash adjustments 182,024 96,996
Changes in operating assets and liabilities    
Accounts receivable (28,561) 43,763
Bonds posted with courts 883,695
Prepaid expenses and other assets (269,693) 6,652
Other non current assets 201,203
Accounts payable and accrued expenses (5,262,242) 557,832
Net cash and restricted cash provided by (used in) operating activities (14,805,103) 11,214,122
Cash flows from investing activities:    
Acquisition of patents (3,522,656)
Disposal of patents 2,771,757
Purchase of property, equipment, and other intangible assets (6,291) (8,387)
Net cash provided by (used in) investing activities 2,765,466 (3,561,043)
Cash flows from financing activities:    
Cash received upon issuance of equity (net of issuance costs) 5,158,906
Issuance of warrants 2,549,084
Issuance of convertible notes payable 5,500,000  
Payments on notes payable, net (103,000) (578,804)
Net cash provided (used in) by financing activities 11,066,704 (8,911,688)
Effect of exchange rate changes on cash 16,509 (1,592)
Net decrease in cash (956,424) (1,260,201)
Cash at beginning of period 4,998,314 2,555,151
Cash and restricted cash at end of period 4,041,890 1,294,950
Cash paid for:    
Interest expense 368,923 1,187,074
Taxes paid 29,433 27,682
Cash invested in 3D Nano 115,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Revenue share liability incurred in conjunction with note payable 225,000
Warrant issued in conjunction with common stock issuance 257,957
Note payable issued in conjunction with the acquisition of Munitech patents 1,755,635
Medtech and Orthophoenix [Member]    
Cash flows from financing activities:    
Payments on notes payable (2,953,779)
Fortress Note Payable [Member]    
Cash flows from financing activities:    
Payments on notes payable (63,286) (5,379,105)
3D Nano License Note Payable [Member]    
Cash flows from financing activities:    
Payments on notes payable (100,000)
Medtronic Note Payable [Member]    
Cash flows from financing activities:    
Payments on notes payable (600,000)
Proceeds from notes payable 600,000
Siemen's Notes Payable [Member]    
Cash flows from financing activities:    
Payments on notes payable (1,750,000)
Vendors Notes Payable [Member]    
Cash flows from financing activities:    
Payments on notes payable (125,000)
Munitech Patents [Member]    
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Note payable issued in conjunction with the acquisition of Munitech patents 1,755,635
SE Patent [Member]    
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Note payable issued in conjunction with the acquisition of Munitech patents 100,000
3D Nano License [Member]    
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Note payable issued in conjunction with the acquisition of Munitech patents $ 200,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Description of Business
9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

 

Marathon Patent Group, Inc.’s (the “Company”) business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company. We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies. Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets. Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights. We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances. Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.

 

The Company was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in the business of exploration and potential development of uranium and vanadium minerals business. In June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October 2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company’s name was changed to Marathon Patent Group, Inc.

 

On October 1, 2012, the shareholders holding a majority of the Company’s voting capital had voted and authorized the Company to change the name of the Company to Marathon Patent Group, Inc. (the “Name Change”). The Board of Directors approved the Name Change on October 1, 2012. The Board of Directors determined the name “Marathon Patent Group, Inc.” better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change.

 

On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.

 

On September 6, 2017, the Board of Directors approved and adopted, subject to shareholder approval on or prior to September 6, 2018, the Company’s 2017 Equity Incentive Plan. The Company’s 2017 Equity Incentive Plan was approved by the shareholders of the Company at a special meeting held on September 29, 2017.

 

All share and per share values for all periods presented in the accompanying consolidated financial statements have been retroactively adjusted to reflect the Reverse Split.

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position, the results of operations and cash flows of the Company for the periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.

  

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

Cash

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation and restricted cash, held in escrow pursuant to the terms of the Unit Purchase Agreement entered into on August 14, 2017, with another financial institution that is also insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2017, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

 

Accounts Receivable

 

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At each of September 30, 2017 and December 31, 2016, the Company had recorded an allowance for bad debts in the amount of $387,976 and $387,976, respectively. Accounts receivable, net at September 30, 2017 and December 31, 2016, amounted to $123,630 and $95,069, respectively.

 

Concentration of Revenue and Geographic Area

 

Revenue from the Company’s patent enforcement activities is considered United States revenue as any payments for licenses included in that revenue are for United States operations irrespective of the location of the licensee’s or licensee’s parent home domicile.

 

The Company had $0 in revenues from newly issued patent licenses for both the three months ended September 30, 2017 and the three months ended September 30, 2016. The revenue for the three months ended September 30, 2017 is attributable to a non-enforcement technology access license for one of the Company’s subsidiaries and running royalties from the Company’s Medtech portfolio and for the three months ended September 30, 2016, the revenue is attributable to running royalties from the Company’s Medtech portfolio.

 

At the current time, we define customers as firms that obtain licenses to the Company’s patents, either prior to or during enforcement litigation. These firms generally enter into non-recurring, non-exclusive, non-assignable license agreements with the Company, and these customers do not generally engage in ongoing, recurring business activity with the Company. The Company has historically had a small number of customers enter into such agreements, resulting in higher levels of revenue concentration.

  

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.

 

These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.

 

The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.

 

The Company also considers the revenue generated from its settlement and licensing agreements as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, since the settlement element and license element for past and future use are the Company’s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. There was no revenue from newly issued patent licenses for the three months ended September 30, 2017 and September 30, 2016, respectively.

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets of $108,878 and $202,067 at September 30, 2017 and December 31, 2016, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

 

Bonds Posted with Courts

 

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of September 30, 2017 and December 31, 2016, the Company had no outstanding bonds posted with the German courts.

 

Related Party Transactions

 

Parties are considered related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.

 

On May 13, 2013, we entered into a nine-year advisory services agreement (the “Advisory Services Agreement”) with IP Navigation Group, LLC (“IP Nav”), of which Erich Spangenberg is founder and former Chief Executive Officer. Mr. Spangenberg is an affiliate of the Company. The terms of the Advisory Services Agreement provide that, in consideration for its services as intellectual property licensing agent, the Company will pay to IP Navigation Group, LLC between 10% and 20% of the gross proceeds of certain licensing campaigns in which IP Navigation Group, LLC acts as intellectual property licensing agent.

  

On November 18, 2013, we entered into a consulting agreement with Jeff Feinberg (“Feinberg Agreement”), pursuant to which we agreed to grant Mr. Feinberg 25,000 shares of our restricted Common Stock, 50% of which shall vest on the one-year anniversary of the Feinberg Agreement and the remaining 50% of which shall vest on the second-year anniversary of the Feinberg Agreement. Mr. Feinberg is the trustee of The Feinberg Family Trust and holds voting and dispositive power over shares held by The Feinberg Family Trust, which is a 10% beneficial owner of our Common Stock.

 

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company. TechDev, SFF and Granicus are owned or controlled by Erich Spangenberg or family members or associates.

 

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. The remaining cash payment was made on February 24, 2015 and is fully paid. Under the terms of the Sarif Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement. Under the terms of the Pay Proceeds Agreement, as amended in 2016, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $13,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the cumulative gross proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the cumulative gross proceeds of such recoveries to the sellers. Pursuant to the amendment to the Pay Proceeds Agreement, the Company paid TechDev, Granicus and SFF $2.4 million. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

  

On May 2, 2014, we entered into an opportunity agreement (the “Marathon Opportunity Agreement”) with Erich Spangenberg, who is an affiliate of the Company. The terms of the Marathon Opportunity Agreement provide that we have ten business days after receiving notice from Mr. Spangenberg to provide up to 50% of the funding for certain opportunities relating to the licensing, intellectual property acquisitions and/or intellectual property enforcement actions in which Mr. Spangenberg, IP Nav or any entity controlled by Mr. Spangenberg, other than: (i) IP Nav or any of its affiliates, and (ii) Medtech Development, LLC or any of its affiliates.

 

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly-owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”). Selene owned a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav provided patent monetization and support services under an existing agreement with Selene prior to the return of the patents to Stanford Research Institute (“SRI”), the original owners of the patents.

 

On August 29, 2014, the Company entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP, LLC for an aggregate purchase price of $2.4 million, of which $1.4 million was paid in cash and $1.0 million was paid in the form of a promissory note issued by the Company that matured on October 31, 2014 and was fully paid prior to the maturation date. The Company also issued 6,250 shares of its restricted common stock in connection with the acquisition. Clouding IP, LLC is also entitled to certain possible future cash payments. Clouding IP LLC is owned or controlled by Erich Spangenberg or family members or associates.

 

On October 10, 2014, the Company entered into an interest sale agreement with MedTech Development, LLC (“MedTech”) to acquire from MedTech 100% of the limited liability membership interests of OrthoPhoenix and TLIF as well as 100% of the shares of MedTech GmbH. In connection with the transaction, the Company is obligated to pay to MedTech $1 million at closing and $1 million on each of the following nine (9) month anniversary dates of the closing. On July 16, 2015, the Company entered into a forbearance agreement (the “Agreement”) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company agreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 500,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment during the year ended September 30, 2015. On October 23, 2015, the Company entered into Amendment No. 1 to the Forbearance Agreement (the “Amendment”) entered into with MedTech Development on July 16, 2015. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. The acquired subsidiaries are also obligated to make certain additional payments to MedTech from recoveries following the receipt by the acquired subsidiaries of 200% of the purchase payments, plus recovery of out of pocket expenses in connection with patent claims. The participation payments may be paid, at the election of the Company, in common stock of Marathon at the market price on the date of issuance. In connection with the transaction, the Company entered into a promissory note, common interest agreement and in the event of issuance of common stock to MedTech, will enter into a lockup and registration rights agreement. Approximately forty-five percent (45%) of MedTech is owned or controlled by Erich Spangenberg or family members or associates.

 

On October 1, 2016, one of the Company’s subsidiaries, PG Technologies S.a.r.l. entered into an advisory services agreement with Granicus IP, LLC, an entity owned or controlled by one of the Company’s employees, whereby Granicus receives a percentage of pre-tax return from PG Technologies after certain revenue thresholds have been met.

 

During 2016, certain officers and directors of the Company received restricted common stock in the Company’s 3D Nanocolor Corp. (“3D Nano”) subsidiary.

 

At December 31, 2016, ‘‘Other noncurrent assets’’ in the Balance Sheets consists of a note receivable from an entity controlled by one of the Company’s employees that is uncollateralized. The note receivable does not carry interest and is repayable to the Company at the earlier of March 31, 2022 or based on certain milestones. The note receivable balance has been classified as current assets because the Company believes that it will be collected within one year from the Balance Sheet dates.

  

On September 29, 2017, the Company entered into an Irrevocable Stock Power whereby the Company sold the shares it owns in the Company’s subsidiary, 3D Nano to Doug Croxall, the Company’s Chief Executive Officer with such assignment including the assumption of all of 3D Nano’s liabilities. The Company engaged a third party to value the assignment, the results of which were that the valuation and assignment were deemed to be at fair value.

 

Fair Value of Financial Instruments

 

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

 

  Level 1:   Observable inputs such as quoted market prices in active markets for identical assets or liabilities
  Level 2:   Observable market-based inputs or unobservable inputs that are corroborated by market data
  Level 3:   Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated condensed balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

Clouding IP earn out liability was determined as a Level 3 liability, which requires an assessment of fair value at each period end by using discounted cash flow as a valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2017, the Company determined that there was a reduction in the Clouding IP earn out liability during the three and nine months ended September 30, 2017 in the amounts of $754,321and $754,321, respectively and a reduction in the carrying value of the Clouding IP intangible assets during the three and nine months ended September 30, 2017 in the amounts of $723,218 and $723,218, respectively.

 

The Company determined that the Warrants issued pursuant to the Unit Purchase Agreement should be treated as a Level 2 liability, which determine the value based on observable market-based inputs. in this instance, the Warrants were valued using a Monte-Carlo simulation utilizing market-based inputs for volatility and risk-free rate of interest, which resulted in the Warrants issued pursuant to the August 31, 2017 close being fair valued at $0.0364 per share and the Warrants issued pursuant to the September 29, 2017 close being fair valued at $0.0877 per share.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

  

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2016 tax returns. After review of the prior year financial statements and the results of operations through December 31, 2016, the Company has recorded a full valuation allowance on its deferred tax asset.

 

Basic and Diluted Net Loss per Share

 

Net loss per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 613,195 shares of Common Stock, warrants to purchase 7,487,894 shares of Common Stock, Convertible Notes convertible into up to 13,750,000 shares of Common Stock and shares of Series B Convertible Preferred Stock convertible into 195,501 shares of Common Stock outstanding at September 30, 2017, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

 

The following table sets forth the computation of basic and diluted loss per share:

 

   

For the Three Months Ended

September 30, 2017

   

For the Three Months Ended

September 30, 2016

   

For the Nine Months
Ended

September 30, 2017

   

For the Nine Months
Ended

September 30, 2016

 
Net income (loss) attributable to Common shareholders   $ (6,677,485 )   $ (6,274,410 )   $ (12,484,924 )   $ (2,261,542 )
                                 
Denominator                                
Weighted average common shares – Basic and Diluted     6,270,299       3,761,786       5,564,465       3,736,213  
                                 
Earnings (loss) per common share:                                
Earnings (loss) – Basic and Diluted   $ (1.06 )   $ (1.67 )   $ (2.24 )   $ (0.60 )

 

Intangible Assets - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.

  

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.

 

When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three and nine months ended September 30, 2017 the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment charge to its goodwill in the amount of $0 and $83,000, respectively.

 

Other Intangible Assets

 

In accordance with ASC 350-30, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.

 

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

  

For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company’s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

 

Liquidity and Capital Resources

 

At September 30, 2017, we had approximately $0.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of approximately $20.3 million.

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months from the issuance date of the financial statements, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

  raise additional funds to support the Company’s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
     
   review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlements of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern

 

Recent Accounting Pronouncements

 

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted.

 

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This ASU provides clarity about which changes to the terms or conditions of a share-based payment award require the application of modification accounting. Specifically, ASU 2017-09 clarifies that changes to the terms or conditions of an award should be accounted for as a modification unless all of the following are met: 1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted. The Company does not expect the adoption of ASU 2017-09 to significantly impact its accounting for share-based payment awards, as changes to awards’ terms and conditions subsequent to the grant date are unusual and infrequent in nature.

 

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04 Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for interim and annual period beginning after December 15, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which clarifies the definition of a business and assists entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under this guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or group of similar assets), the assets acquired would not represent a business. In addition, in order to be considered a business, an acquisition would have to include at a minimum an input and a substantive process that together significantly contribute to the ability to create an output. The amended guidance also narrows the definition of outputs by more closely aligning it with how outputs are described in FASB guidance for revenue recognition. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted.

 

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity’s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period.

 

In October 2016, the FASB issued ASU 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which eliminates the exception in existing guidance which defers the recognition of the tax effects of intra-entity asset transfers other than inventory until the transferred asset is sold to a third party. Rather, the amended guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated condensed financial statements.

 

In August 2016, the FASB issued ASU 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated condensed financial statements.

 

In May 2014, the FASB Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, as a new Topic, (ASC) Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. This ASU must be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are considering the alternatives of adoption of this ASU and we are conducting our review of the likely impact to the existing portfolio of customer contracts entered into prior to adoption. After completing our review, we will continue to evaluate the effect of adopting this guidance upon our results of operations, cash flows and financial position.

  

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated condensed financial statements.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions
9 Months Ended
Sep. 30, 2017
Business Combinations [Abstract]  
Acquisitions

NOTE 3 — ACQUISITIONS

 

Clouding Corp.

 

On August 29, 2014, the Company entered into a patent purchase agreement (the “Clouding Agreement”) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Clouding”) and Clouding IP, LLC, a Delaware limited liability company (“Clouding IP”), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. The Clouding Agreement included an earn out payable to Clouding IP, which was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value.

 

The Clouding IP earn out liability was determined to be a Level 3 liability, which requires assessment of fair value at each period end by using a discounted cash flow model as the valuation methodology, using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rates. Based on the reassessment of fair value as of September 30, 2017, the Company determined the Clouding IP earn out liability to be $32,637 (current portion) and $681,175 (long-term portion) and as of December 31, 2016, the Company determined the Clouding IP earn out liability to be $81,930 (current portion) and $1,400,082 (long-term portion).

 

Munitech IP S.a.r.l. (“Munitech”)

 

On June 27, 2016, Munitech S.a.r.l. (“Munitech”), a Luxembourg limited liability company and newly formed wholly-owned subsidiary of the Company, entered into two Patent Purchase Agreements (the “PPA” or together, the “PPAs”) to purchase 221 patents from Siemens Aktiengesellschaft. The patents purchased by Munitech relate to W-CDMA and GSM cellular technology and cover all the major global economies including China, France, Germany, the United Kingdom and the United States. Significantly, many of the patent families have been declared to be Standard Essential Patents (“SEPs”) with the European Telecommunications Standard Institute (“ETSI”) and/or the Association of Radio Industries and Businesses (“ARIB”) related to Long Term Evolution (“LTE”), Universal Mobile Telecommunications System (“UMTS”), and/or General Packet Radio Service (“GPRS”).

 

Pursuant to the terms of the PPAs, Munitech (i) paid Siemens Aktiengesellschaft $1,150,000 in cash upon closing and (ii) agreed to two future payments, one in the amount of $1,000,000 payable on December 31, 2016 and the second in the amount of $750,000 payable on September 30, 2017.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On September 1, 2017, the Company entered into a Share Purchase Agreement with GPat Technologies, LLC (“GPat”) whereby the Company sold its 100% interest in Munitech to GPat.

  

Magnus IP GmbH (“Magnus”)

 

On July 5, 2016, Marathon IP GmbH (“Marathon IP”), a German corporate entity and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreements (the “PPA”) to purchase 86 patents from Siemens Switzerland Ltd and Siemens Industry Inc., (together, “Siemens”). On September 15, 2016, the patents were assigned by Marathon IP to Magnus, both of which are wholly-owned subsidiaries of the Company. The patents purchased by Marathon IP relate to Internet-of-Things (IOT) technology. Generally, the portfolio’s subject matter is directed toward self-healing control networks for automation systems. The patents are relevant to wireless mesh or home area networks for use in IOT, or connected home devices and enable simple commissioning, application level security, simplified bridging, and end-to-end IP security. The technology can support a wide variety of IOT enabled devices including lighting, sensors, appliances, security, and more. Pursuant to the terms of the PPA, Marathon IP paid Siemens $250,000 in cash upon closing.

 

Pursuant to the terms of the PPAs, Munitech (i) paid Siemens $250,000 in cash upon closing and (ii) will pay a percentage of gross proceeds in excess of a reserve threshold on behalf of Marathon IP.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 20, 2017, the Company assigned the patents held by Magnus to DBD, pursuant to the First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the “First Amendment and Restructuring Agreement”) entered into with DBD. In exchange for the assignment of three of the Company’s portfolios, of which Magnus was one, DBD cancelled all indebtedness owed by the Company to DBD.

 

Traverse Technologies Corp. (“Traverse”)

 

On August 3, 2016, Traverse Technologies Corp. (“Traverse”), a United States corporation and newly formed wholly-owned subsidiary of the Company, entered into a Patent Purchase Agreement (the “PPA”) to purchase 12 patents from CPT IP Holdings (“CPT”). The patents purchased by Traverse relate to batteries and principally cover various Asian and the United States markets.

 

Pursuant to the terms of the PPAs, Traverse (i) paid CPT $1,300,000 in cash upon closing and (ii) will pay a percentage of net recoveries in excess of a reserve threshold on behalf of Traverse.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 20, 2017, the Company assigned the patents held by Traverse to DBD, pursuant to the First Amendment and Restructuring Agreement entered into with DBD. In exchange for the assignment of three of the Company’s portfolios, of which Traverse was one, DBD cancelled all indebtedness owed by the Company to DBD.

 

PG Technologies S.a.r.l. (“PG Tech”)

 

On August 11, 2016, PG Technologies S.a.r.l. (“PG Tech”), a Luxembourg limited liability company jointly owned with a large litigation financing fund, entered into a Patent Funding and Exclusive License Agreement (the “ELA”) to manage the monetization of greater than 10,000 patents in a single industry vertical with a Fortune 50 company. The patents cover all the major global economies including China, France, Germany, the United Kingdom and the United States. The Company determined that its ownership in PG Tech constitutes a VIE and that the Company is the primary beneficiary, as a result of which, the Company consolidated PG Tech in its financial statements.

 

Pursuant to the terms of the ELA, PG Tech agreed with the Fortune 50 company to pay (i) $1,000,000 in cash upon closing, (ii) a future payment in the amount of $1,000,000 payable on or before December 31, 2016, (iii) minimum quarterly payments of $250,000 starting on April 1, 2017 and (iv) split 50% of the net licensing revenues.

  

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licensing activity, vendors associated with the patents, any royalties, and any other assets other than the patents.

 

On October 27, 2017, the Company entered into an Assignment and Confirmation Agreement (the “Assignment”) with Luxone Ventures S.a.r.l. (“Luxone”) whereby the Company assigned all of its ownership interest in PG Technologies, S.a.r.l. (“PG Tech”) to Luxone. Pursuant to the Assignment, Luxone assumed the Company’s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets
9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

NOTE 4 – INTANGIBLE ASSETS

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. Patents purchased are recorded based at their acquisition cost and patents acquired in lieu of cash are recorded at their fair market value. Intangible assets consisted of the following:

 

    September 30, 2017     December 31, 2016  
             
Intangible Assets   $ 20,403,408     $ 23,637,813  
Accumulated Amortization & Impairment     (12,813,195 )     (11,323,185 )
                 
Intangible assets, net   $ 7,590,213     $ 12,314,628  

 

Intangible assets are comprised of patents with estimated useful lives between approximately 1 to 16 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis. During the three and nine months ended September 30, 2017, respectively, the Company capitalized a total of $0 and $0 in patent acquisition costs and during the three and nine months ended September 30, 2016, respectively, the Company capitalized a total of $3,550,000 and $6,450,000 in patent acquisition costs. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included as an operating expense as reflected in the accompanying consolidated condensed statements of operations. The Company assesses fair market value for any impairment to the carrying values. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.

 

Patent amortization expense for the three and nine months ended September 30, 2017 was $457,419 and $1,803,264, respectively, and for the three and nine months ended September 30, 2016, patent amortization expense was $2,030,886 and $6,018,196, respectively. All patent amortization expense figures are net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:

 

2017   $ 401,804  
2018     1,517,219  
2019     1,447,660  
2020     1,154,767  
2021     1,004,600  
2022 and thereafter     2,064,163  
Total   $ 7,590,213  

 

As of September 30, 2017, our operating subsidiaries owned 170 patents, as set forth below, and had economic rights to over 10,000 additional patents, both of which include U.S. patents and certain foreign counterparts. In the aggregate, the earliest date for expiration of a patent in the Company’s patent portfolio has passed (the patent is expired, but patent rules allow for nine-year look-back for royalties), the median expiration date for patents in the Company’s portfolio is September 13, 2021, and the latest expiration date for a patent in any of the Company’s patent portfolios is February 27, 2033. A summary of the Company’s patent portfolios is as follows:

  

Subsidiary   Number of
Patents
    Earliest
Expiration Date
    Median
Expiration Date
    Latest
Expiration Date
    Subject Matter
Clouding Corp.     25       2/3/18       9/10/21       5/29/29     Network and data management
CRFD Research, Inc.     5       5/25/21       9/17/21       8/19/23     Web page content translator and device-to-device transfer system
Dynamic Advances, LLC     2       11/6/21       9/7/23       7/9/25     Natural language interface
Magnus IP     55       1/28/22       9/27/25       12/9/31     Network Management/Connected Home Devices
Medtech Group Acquisition Corp.     45       Expired       12/8/18       8/9/29     Medical technology
Signal IP, Inc.     2       8/28/20       8/17/21       8/6/22     Automotive
Traverse Technologies     20       2/27/22       2/25/29       2/27/33     Li-Ion Battery/High Capacity Electrodes
Soems Acquisition     16       11/11/17       4/6/19       7/18/24     N/A
              Median       09/13/21              

 

On October 20, 2017, the Company assigned the patent held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) to DBD.

 

On October 27, 2017, the Company assigned the economic rights to its more than 10,000 patents to Luxone.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders’ Equity
9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Stockholders' Equity

NOTE 5 - STOCKHOLDERS’ EQUITY

 

The Company has authorized capital to 200,000,000 shares of Common Stock with par value to $0.0001 per share, and has authorized capital of 50,000,000 shares of preferred stock, par value $0.0001 per share.

 

On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion. On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors. On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.

 

Series B Convertible Preferred Stock

 

The terms of the Series B Convertible Preferred Stock are summarized below:

 

Dividend. The holders of Series B Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series B Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.

 

Liquidation Preference. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Common Stock and the holders of Series B Convertible Preferred Stock as if the Series B Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company.

 

Voting Rights. The Series B Convertible Preferred Stock have no voting rights except with regard to certain customary protective provisions set forth in the Series B Convertible Preferred Stock Certificate of Designations and as otherwise provided by applicable law.

 

Conversion. Each share of Series B Convertible Preferred Stock may be converted at the holder’s option at any time after issuance into one share of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days’ notice.

  

Series D Convertible Preferred Stock

 

The Company issued Series D Convertible Preferred Stock in exchange for the outstanding convertible note issued in October 2014 and prior to September 30, 2017, all of the Series D Convertible Preferred Stock was converted to the Company’s Common Stock and no shares of the Series D Convertible Preferred Stock remain outstanding. The terms of the Series D Convertible Preferred Stock are summarized below:

 

Dividend. The holders of Series D Convertible Preferred Stock will be entitled to receive such dividends paid and distributions made to the holders of Common Stock, pro rata to the same extent as if such holders had converted the Series D Convertible Preferred Stock into Common Stock (without regard to any limitations on conversion herein or elsewhere) and had held such shares of Common Stock on the record date for such dividends and distributions.

 

Liquidation Preference. In the event of a liquidation, dissolution or winding up of the Company, after provision for payment of all debts and liabilities of the Company, any remaining assets of the Company shall be distributed pro rata to the holders of Series B Convertible Preferred Stock and Series D Convertible Preferred Stock as if the Series B Convertible Preferred Stock and Series D Convertible Preferred Stock had been converted into shares of Common Stock on the date of such liquidation, dissolution or winding up of the Company, prior to any distributions to Junior Stock, which includes the Company’s Common Stock.

 

Voting Rights. Except as otherwise expressly required by law, each holder of Preferred Shares shall be entitled to vote on all matters submitted to shareholders of the Company and shall be entitled to the number of votes for each Preferred Share owned at the record date for the determination of shareholders entitled to vote on such matter or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited, equal to the number of shares of Common Stock such Preferred Shares are convertible into (voting as a class with Common Stock),

 

Conversion. Each share of Series D Convertible Preferred Stock may be converted at the holder’s option at any time after issuance into five shares of Common Stock, provided that the number of shares of Common Stock to be issued pursuant to such conversion does not exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time, unless otherwise waived in writing by the Company with ninety-one (61) days’ notice.

 

Common Stock

 

On May 11, 2016, the Company entered into a consulting agreement with the Cooper Law Firm, LLC (“Cooper”), pursuant to which the Company agreed to issue 20,000 shares of the Company’s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $6.80 per share or $136,000.

 

On December 9, 2016, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the sale of an aggregate of 870,500 shares of the Company’s common stock, at a purchase price of $6.00 per share, and warrants to purchase 435,249 shares of common stock for a purchase price of $0.01 per warrant, or $17,019.95 in total. None of the warrants were purchased prior to December 31, 2016, and all were subsequently purchased prior to the date of this report.

 

On February 1, 2017, the Company issued 187,500 shares of common stock pursuant to an At-The-Market (“ATM”) securities offering with certain institutional investors at an average price of $6.96 per share, yielding gross proceeds of $1,301,923.

 

On April 12, 2017, pursuant to an amendment entered into on March 6, 2017 to the settlement agreement entered into on October 29, 2015 between the Company and Dominion Harbor, the Company issued 31,250 shares of common stock to Dominion Harbor. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $0.83 per share or $103,750.

 

On April 18, 2017, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with certain institutional investors for the sale of an aggregate of 950,000 shares of the Company’s common stock at a purchase price of $2.80per share and warrants to purchase 570,000 shares of common stock at a purchase price of $3.32 per share.

  

On April 24, 2017, the Company issued one of its vendors 7,500 shares of Common Stock in exchange for cancellation of the vendor’s outstanding invoices. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $3.32 per share or $24,897.

 

On August 9, 2017, the Company issued 250,000 shares of the Company’s Common Stock pursuant to the conversion of 200,000 shares of Series D Convertible Preferred Stock.

 

On August 29, 2017, the Company issued 200,000 shares in total of the Company’s Common Stock to four different vendors in partial or total payment of outstanding invoices.

 

On September 5, 2017, the Company issued 62,500 shares of the Company’s Common Stock pursuant to the conversion of 50,000 shares of Series D Convertible Preferred Stock.

 

On September 6, 2017, the Company issued 534,710 shares of the Company’s Common Stock pursuant to the conversion of $427,768 in principal amount invested in the Convertible Note.

 

On September 13, 2017, the Company issued 315,925 shares of the Company’s Common Stock pursuant to the conversion of 252,750 shares of Series D Convertible Preferred Stock.

 

On September 29, 2017, the Company issued 598,500 shares of the Company’s Common Stock to holders of the warrants issued pursuant to the April Purchase Agreement following approval by the Company’s shareholders of the warrant exchange at a special meeting held on September 29, 2017.

 

Common Stock Warrants

 

Pursuant to the sales of securities underlying the Purchase Agreement entered into on December 9, 2016, the Company issued a warrant to the underwriter (“Underwriter’s Warrant”) to purchase 43,525 shares of Common Stock on December 9, 2016. The Underwriter’s Warrant has an exercise price of $6.92 per share. In addition, in a series of issuances in January 2017, the Company issued warrants to the investors (“Investor Warrants”) pursuant to the Purchase Agreement to purchase 435,249 shares of the Company’s Common Stock. The Investor Warrants have an exercise price of $6.80 per share. The warrants were issued in a series of transaction during January 2017 and were valued based on the Black-Scholes model, using the strike price of $6.80 per share, market prices ranging from $7.00 to $8.52 per share, an expected term of 3.25 years, volatility ranging from 38% to 39%, based on the average volatility of comparable companies over the comparable prior period, and a discount rate as published by the Federal Reserve ranging from 1.50% to 1.56%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as a liability and marked to market every reporting period. Following acceptance by the SEC of the Company’s registration statement registering these warrants, the warrants were reclassified from a liability to equity.

 

On January 10, 2017, pursuant to the amendment to the Fortress debt, the Company issued a five-year warrant to DBD to purchase 46,875 shares of the Company’s Common Stock, exercisable at $6.80 per share, subject to adjustment. The warrant was valued based on the Black-Scholes model, using the strike and market prices of $6.80 and $7.60 per share, respectively, an expected term of 3.00 years, volatility of 39% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.52%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.

 

Pursuant to the sales of securities underlying the April Purchase Agreement entered into on April 18, 2017, the Company issued a warrant to the underwriter (“Underwriter’s Warrant”) to purchase 14,250 shares of Common Stock. The Underwriter’s Warrant has an exercise price of $3.08 per share. In addition, also associated with the April Purchase Agreement, the Company issued warrants to the investors (“April Investor Warrants”) pursuant to the Purchase Agreement to purchase 570,000 shares of the Company’s Common Stock. The Investor Warrants have an exercise price of $3.32 per share. The Investor Warrants were valued based on the Black-Scholes model, using the strike price of $3.08 per share, an expected term of 2.5 years, volatility of 39%, based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.60%. The Underwriter’s Warrant was valued based on the Black-Scholes model, using the strike price of $3.32 per share, an expected term of 3.25 years, volatility of 38%, based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%. The Company reviewed the issuance of the Underwriter and Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Underwriter and Investor Warrants should be classified as equity.

  

Pursuant to the Unit Purchase Agreement entered into on August 14, 2017, the Company, in two closings, issued warrants to the investors (“Note Investor Warrants”) to purchase 6,875,000 shares of the Company’s Common Stock. The Note Investor Warrants have an exercise price of $1.20 per share. The Note Investor Warrants from the first close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the terms of the Unit Purchase Agreement which set the volatility at the greater 100% or the 100-day volatility immediately following certain events and a discount rate as published by the Federal Reserve of 1.76%. The Note Investor Warrants from the second close were valued based on a Monte Carlo simulation model, using the strike price of $1.20 per share, remaining term of 5.50 years, volatility of 100%, based on the methodology set forth above and a discount rate as published by the Federal Reserve of 1.98%. The Company reviewed the issuance of the Note Investor Warrants and determined that pursuant to ASC 480 and ASC 815, the Note Investor Warrants should be classified as a liability.

 

At September 30, 2017, the Company had warrants outstanding to purchase 7,487,894 shares of Common Stock with a weighted average remaining life of 5.35 years. A summary of the status of the Company’s outstanding stock warrants and changes during the period then ended is as follows:

 

    Number of
Warrants
    Weighted
Average Exercise
Price
   

Weighted
Average
Remaining

Life

 
Balance at December 31, 2016     116,520     $ 15.17       3.25  
Granted     7,941,374       1.70       5.01  
Cancelled     -       -       -  
Forfeited     -       -       -  
Exercised     570,000       3.32       -  
Balance at September 30, 2017     7,487,894     $ 1.86       5.35  
                         
Warrants exercisable at September 30, 2017     612,894                  
Weighted average fair value of warrants granted during the period           0.09          

 

Warrant Amendment Letter

 

On March 11, 2016, the Company entered into an agreement with the remaining investor in the Company’s convertible debt issued on October 9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 5,834 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $16.50 to the lower of 1) $8.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company’s Common Stock.

 

Common Stock Options

 

On May 10, 2016, the Company entered into an executive employment agreement with Erich Spangenberg (“Spangenberg Agreement”) pursuant to which Mr. Spangenberg would serve as the Company’s Director of Acquisitions, Licensing and Strategy. As part of the consideration, the Company agreed to grant Mr. Spangenberg a ten-year stock option to purchase an aggregate of 125,000 shares of Common Stock, with a strike price of $7.48 per share, vesting in twenty-four (24) equal installments on each monthly anniversary of the date of the Spangenberg Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.48 per share, an expected term of 5.75 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.32%.

  

On May 20, 2016, the Company entered into an employment agreement with Kathy Grubbs (“Grubbs Agreement”) pursuant to which Ms. Grubbs would serve as an analyst. As part of the consideration, the Company agreed to grant Ms. Grubbs a ten-year stock option to purchase an aggregate of 12,500 shares of Common Stock, with a strike price of $9.00 per share, vesting in thirty-nine (36) equal installments on each monthly anniversary of the date of the Grubbs Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.00 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.88%.

 

On July 1, 2016, in conjunction with an executive employment agreement with David Liu (“Liu Agreement”) pursuant to which Mr. Liu would serve as the Company’s CTO, entered into on June 29, 2016, the Company granted Mr. Liu a ten-year stock option to purchase an aggregate of 37,500 shares of Common Stock, with a strike price of $11.16 per share, vesting in thirty-nine (36) equal installments on each monthly anniversary of the date of the Liu Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $11.16 per share, an expected term of 6.50 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.20%.

 

On October 13, 2016, the Company issued its independent board members ten-year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $9.64 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $9.64 per share, an expected term of 5.5 years, volatility of 46% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.21%. As there were not sufficient shares in the Company’s equity incentive plans to accommodate these grants, Mr. Croxall forfeited a portion of one of his options to purchase 20,000 shares.

 

At September 30, 2017, there was a total of $7,072 of unrecognized compensation expenses related to non-rested option-based compensation arrangements entered into during the year. A summary of the stock options as of September 30, 2017 and changes during the period are presented below:

 

    Number of
Options
    Weighted
Average Exercise
Price
   

Weighted
Average
Remaining

Life

 
Balance at December 31, 2016     879,034     $ 17.84       6.80  
Granted     -       -       -  
Cancelled     48,542       -       -  
Forfeited     217,298       16.71       -  
Exercised     -       -       -  
Balance at September 30, 2017     613,194     $ 17.04       3.06  
                         
Options Exercisable at September 30, 2017     591,841     $ 13.83       2.91  
Options expected to vest     21,354     $ 20.33       7.23  
Weighted average fair value of options granted during the period           $ -          

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt, Commitments and Contingencies
9 Months Ended
Sep. 30, 2017
DEBT, COMMITMENTS AND CONTINGENCIES  
Debt, Commitments and Contingencies

NOTE 6 – DEBT, COMMITMENTS AND CONTINGENCIES

 

Debt consists of the following:

 

    Maturity   Interest     September 30,     December 31,  
    Date   Rate     2017     2016  
                       
Senior secured term notes   9-Jul-20     LIBOR + 9.75 %   $ 15,881,493     $ 15,620,759  
Less: debt discount                 (1,686,090 )     (1,425,167 )
Total senior-term notes, net of discount               $ 14,195,403     $ 14,195,592  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
                             
Convertible Note   10-Oct-18     11 %   $ 0     $ 500,000  

 

    Maturity     Late       September 30,       December 31,  
    Date     Fee       2017       2016  
iRunway trade payable   On Demand     1.5% per month     $ 0     $ 191,697  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Note payable   31-Jan-17     NA     $ -     $ 103,000  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Siemens   30-Sep-17     NA     $ -     $ 1,672,924  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Dominion Harbor   15-Oct-17     NA     $ -     $ 125,000  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Oil & Gas   On Demand     NA     $ 1,000,000     $ 944,296  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Convertible Note   10-May-18     0     $ 1,876,300     $ -  
Less: debt discount                 (1,851,171 )     -  
Total Convertible notes, net of discount               $ 25,129     $ -  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Convertible Note   31-May-18     5 %   $ 3,195,932     $ -  
Less: debt discount                 (2,834,308 )     -  
Total Convertible notes, net of discount               $ 361,624     $ -  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Medtech Note   1-May-18     NA     $ -     $ -  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
3D Nano License Fee   31-Jan-17     NA     $ -     $ 100,000  

 

    September 30, 2017     December 31, 2016  
Total   $ 15,582,156     $ 17,832,509  
Less: current portion     (15,582,156 )     (13,162,007 )
Total, net of current portion   $ -     $ 4,670,502  

 

Senior Secured Term Notes

 

On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement with DBD Credit Funding LLC, (“DBD”) an affiliate of Fortress Credit Corp., under which the terms of the notes were:

 

  (i) $15,000,000 original principal amount of Fortress Notes (the “Initial Note”);
  (ii) a right to receive a portion of certain proceeds from monetization net revenues received by the Company (the “Revenue Stream”, after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes);
  (iii)  a five-year Fortress Warrant to purchase 25,000 shares of the Company’s Common Stock exercisable at $29.76 per share, subject to adjustment; and
  (iv) 33,603 shares of the Issuer’s Common Stock (the “Fortress Shares”).

 

On February 12, 2015, the Company issued an additional $5,000,000 of Notes (which increase proportionately the Revenue Stream).

 

The Initial Note matures on July 29, 2018. Additional Notes issued pursuant to the Fortress Purchase Agreement mature 42 months after issuance. The unpaid principal amount of the Initial Note plus the additional $5,000,000 note (including any PIK Interest, as defined below) bear cash interest at a rate equal to LIBOR plus 9.75% per annum payable on the last business day of each month. Interest is paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest. Monthly principal payments are due commencing one year after the anniversary dates of the loans.

 

The terms of the Fortress Warrant provide that until January 29, 2020, the Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company’s Common Stock. The exercise price of the warrant is $29.76 and the warrant fair value was determined to be $318,679 utilizing the Black-Scholes model, with the fair value of the warrants recorded as additional paid-in capital and reducing the carrying value of the Notes. As of September 30, 2017 and December 31, 2016, the unamortized discount on the Notes was $1,686,090 and $1,425,167, respectively.

 

Senior Secured Term Note Amendment

 

On January 10, 2017 the Company and certain of its subsidiaries entered into the Amended and Restated Revenue Sharing and Securities Purchase Agreement (“ARRSSPA”) with DBD Credit Funding LLC, under which the Company and DBD amended and restated the Revenue Sharing and Securities Purchase Agreement dated January 29, 2015 (the “Original Agreement”) pursuant to which (i) Fortress purchased $20,000,000 in promissory notes, of which $15,881,493 is outstanding as of September 30, 2017, (ii) an interest in the Company’s revenues from certain activities and warrants to purchase 25,000 shares of the Company’s common stock. The ARRSSPA amends and restates the Original Agreement to provide for (i) the sale by the Company of a $4,500,000 promissory note (the “New Note”) and (ii) the insurance of additional warrants to purchase 46,875 shares of common stock (the “New Warrant”). Pursuant to the ARRSSPA, Fortress acquired an increased revenue stream right to certain revenues generated by the Company through monetization of our patent portfolio (“Monetization Revenues”). The ARRSSPA increases the revenue stream basis to $1,225,000. The ARRSSPA provides for the potential issuance of up to $7,500,000 of additional notes (the “Additional Notes”), of which not more than $3,750,000 shall be made prior to June 30, 2017 and of which not more than $3,750,000 shall be made available during the period following June 30, 2017 and on or prior to December 31, 2017 and not more than two such issuances shall occur under the ARRSSPA.

 

The unpaid principal amount of the New Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Initial Note), the interest rate shall increase by an additional 2% per annum.

 

Interest on the Initial Note shall be paid on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2017. Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest, effective as of the applicable Interest Payment Date (“PIK Interest”). PIK Interest shall be treated as added principal of the New Note for all purposes, including interest accrual and the calculation of any prepayment premium. The Company paid a structuring fee of 2.0% of the New Note and would pay a 2.0% fee upon the issuance of any Additional Notes. The proceeds of the New Note and any Additional Notes may be used for working capital purposes, portfolio acquisitions, growth capital and other general corporate purposes.

  

The ARRSSPA contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,250,000 in unrestricted cash and cash equivalents.

 

The terms of the New Warrants provide that from July 10, 2017 until January 10, 2022, the Warrant may be exercised for cash or on a cashless basis. Exercisability of the Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Issuer’s Common Stock.

 

Pursuant to the ARSSPA, as security for the payment and performance in full of the Secured Obligations (as defined in the Security Agreement entered in favor of the Note purchasers (the “Security Agreement”) the Company and certain subsidiaries executed and delivered in favor of the purchasers a Security Agreement and a Patent Security Agreement, including a pledge of the Company’s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations (as defined in the Notes) is secured by a first priority lien and security interest in all the assets of the Company, subject to certain permitted liens. Certain subsidiaries of the Company also executed guarantees in favor of the purchasers (each, a “Guaranty”), guaranteeing the Note Obligations.

 

Amendment to Senior Secured Term Note Amendment

 

On August 3, 2017, the Company and certain of its operating subsidiaries entered into a First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement (the “First Amendment and Restructuring Agreement”) with DBD to cancel the indebtedness and other obligations of the Company under that certain ARRSSPA, dated January 10, 2017, which was originally entered into by the Company and DBD on January 29, 2015.

 

Pursuant to the First Amendment and Restructuring Agreement, certain intellectual property owned by the Company (the “Designated IP”) is to be assigned to one or more newly created special purpose entities (the “SPE”) as elected by DBD, which to be formed SPE shall be under the management and control of an affiliate of DBD (the “IP Monetization Manager”). All intellectual property owned by the Company that will not be assigned to one or more newly created special purpose entities shall be referred to as “Non- Designated IP.” The patents that are part of the Designated IP are referred to as the “Designated Patents”. Until shareholder approval and the close of the First Amendment and Restructuring Agreement (the “Restructuring”), all Monetization Revenues arising from the Designated IP and Non-Designated IP shall be paid to an account that is under the sole and exclusive control of the Collateral Agent as the IP Monetization Manager. In addition, until the Restructuring, the Company shall be responsible for the expenses associated with the maintenance, prosecution and enforcement of all of the Company’s intellectual property including the Designated IP and the other IP owned by the Company which is not to be transferred to the SPE, and for any expenses associated with the pursuit of monetization activities relating to both the Designated IP and the Non-Designated IP. From and after the Restructuring, the SPE shall have sole responsibility for the expenses associated with the Designated IP and the Company shall have sole responsibility for the expenses associated with the Non-Designated IP.

 

On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.

 

As of September 30, 2017 and December 31, 2016, the outstanding balances were $15,881,493 and $15,620,759, respectively.

 

Convertible Note

 

In two transactions, on October 9, 2014 and October 16, 2014, the Company sold an aggregate $5,550,000 of principal amount of convertible notes (“Convertible Notes”) along with two-year warrants to purchase 32,375 shares of the Company’s Common Stock. The Convertible Notes are convertible into shares of the Company’s Common Stock at $30.00 per share and the Warrants have an exercise price of $33.00 per share. The Notes mature on October 10, 2018 and bear interest at the rate of 11% per annum, payable quarterly in cash on each of the three, nine, nine and twelve-month anniversaries of the issuance date and on each conversion date. The Notes may become secured by a security interest granted to the holder in certain future assets under certain circumstances. In the event the Company’s Common Stock trades at a price of at least $108.00 per share for four out of eight trading days, the Notes will be mandatorily converted into Common Stock of the Company at the then applicable conversion price per share. The Company repaid the Convertible Notes for all but one holder in early 2015, and exchanged the remaining balance for Series D Convertible Preferred Stock on August 7, 2017, with the Series D Convertible Preferred Stock converted in its entirety prior to September 30, 2017. The balance was $0 and $500,000 as of September 30, 2017 and December 31, 2016, respectively.

  

iRunway

 

The Company converted a set of outstanding invoices related to work performed by one of the Company’s vendors to a short-term payable whereby the Company agreed to pay iRunway over time for the open invoices, subject to a payment schedule as defined. To the extent that the Company does not make payments according to that schedule, the remaining balance accrues interest at 1.5% per month. On August 20, 2017, the Company entered into a release agreement with iRunway pursuant to which the Company made an immediate cash payment to iRunway in return for a release of the remaining amount outstanding. As of September 30, 2017 and December 31, 2016, the principal balance was $0 and $191,697, respectively.

 

Note Payable

 

The Company entered into a short-term advance with an officer related to funds the Company was transferring from its European subsidiaries. The advance carried no interest and as of September 30, 2017 and December 31, 2016, the outstanding balance was $0 and $103,000, respectively.

 

Siemens Purchase Payment

 

The Company entered into a purchase agreement to acquire ownership of certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest. On September 1, 2017, the Company entered into Share Purchase Agreement with GPat whereby the Company sold its 100% interest in Munitech, the wholly-owned subsidiary holding these patents, to GPat. As of September 30, 2017 and December 31, 2016, the outstanding balances were $0 and $1,672,924, respectively.

 

Dominion Harbor Settlement Note

 

The Company entered into a settlement agreement with Dominion Harbor, a former licensing agent for some of the Company’s subsidiaries, on October 29, 2015 whereby the Company agreed to issue 75,000 shares of the Company’s Common Stock to Dominion Harbor and make eight (8) payments of $25,000 each ending on October 15, 2017. The shares issued to Dominion Harbor were valued at the quoted market price on the date of the grant of $6.84 per share or $513,000. As of September 30, 2017 and December 31, 2016, $0 and $125,000, respectively, remained outstanding, following an agreement between the Company and Dominion wherein the Company paid $25,000 and issued 31,250 shares of Common Stock to Dominion in full resolution of the outstanding obligation.

 

Oil& Gas Purchase Payment

 

The Company entered into a purchase agreement to acquire monetization rights to certain patents. As part of the purchase agreement, the Company agreed to certain future payments of cash consideration. The payment obligation bears no interest and as of September 30, 2017 and December 31, 2016, the Company had an outstanding obligation for purchase of certain Siemens patents in the amount of $1,000,000 and $944,296, respectively, with such payments expected to be made by December 31, 2017.

 

Convertible Note

 

On August 14, 2017, the Company entered into a unit purchase agreement (the “Unit Purchase Agreement”) with certain accredited investors providing for the sale of up to $5,500,000 of 5% secured convertible promissory notes (the “Convertible Notes”), which are convertible into shares of the Corporation’s common stock, and the issuance of warrants to purchase 6,875,000 shares of the Company’s Common Stock (the “Warrants”). The Convertible Notes are convertible into shares of the Company’s Common Stock at the lesser of (i) $0.80 per share or (ii) the closing bid price of the Company’s common stock on the day prior to conversion of the Convertible Note; provided that such conversion price may not be less than $0.40 per share. The Warrants have an exercise price of $1.20 per share. The Convertible Notes mature on May 31, 2018 and bear interest at the rate of 5% per annum. In two closings of the Unit Purchase Agreement, the Company issued all $5,500,000 in Convertible Notes to the investors. As of September 30, 2017, the Company had an outstanding obligation pursuant to the Convertible Notes in the amount of $5,072,232.

  

3D Nano Purchase Payment

 

3D Nano entered into a license and purchase agreement with HP Inc. (“HP”) to acquire the rights to use if 3D Nano chooses, the right to exercise an option to acquire, ownership of certain patents, trade secrets and other intellectual property (the “Technology”). As part of the purchase agreement, the Company agreed to license the Technology for two payments of $100,000 each, with the first payment made in April 2016 and the second payment due by January 31, 2017. Under the original agreement, the payment obligations bear no interest and as of September 30, 2017 and December 31, 2016, 3D Nano had an outstanding obligation in the amount of $0 and $100,000, respectively. On May 1, 2017, 3D Nano entered into an amendment with HP whereby the agreement was extended for two years. While 3D Nano does not have the obligation under the amendment to make additional payments, should 3D Nano desire to do so, payments in the amount of $100,000 in each of 2018 and 2019 would be due to HP for the agreement to remain in effect.

 

Medtech Note

 

On May 31, 2017, the Company entered into a note payable with Medtronic, Inc. (“Medtronic”), the original owner of the patents in the Company’s Medtech portfolio, whereby the Company agreed to pay Medtronic a total of $750,000 in ten equal monthly installments for patent enforcement related expenses incurred by Medtronic. Following two payments of $75,000 each in May and June 2017, the Company entered into an agreement on August 29, 2017 to pay a discounted amount in return for a full release from the remaining obligations. The note payable carries no interest and since the note payable arose after December 31, 2016 and was repaid in full prior to September 30, 2016, as of September 30, 2017 and December 31, 2016, the outstanding balance, was $0 and $0, respectively.

 

Total Future Minimum Principal Payments

 

Future minimum principal payments for all items set forth above are as follows:

 

2017   $ 16,881,493  
2018     5,072,232  
Total   $ 21,953,725  

 

Office Lease

 

In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California. The lease will commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease. In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes. Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit. In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease. Minimum future lease payments under this lease at September 30, 2017, for the next five years are as follows:

 

2017 (Three Months)   $ 18,081  
2018     74,540  
2019     77,872  
2020     81,336  
2021     27,504  
Total   $ 297,333  

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events
9 Months Ended
Sep. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events

NOTE 7 – SUBSEQUENT EVENTS

 

On October 20, 2017, the Company and DBD satisfied all the closing conditions related to the First Amendment and Restructuring Agreement. With the close of the First Amendment and Restructuring Agreement, the Company exchanged the patent portfolios held by Dynamic Advances LLC, Magnus IP GmbH and Traverse Technologies Corp. (all wholly-owned subsidiaries of the Company) in exchange for the cancelation of all indebtedness and obligations to DBD.

 

On October 27, 2017, the Company entered into the Assignment with Luxone whereby the Company assigned all of its ownership interest in PG Tech to Luxone. Pursuant to the Assignment, Luxone assumed the Company’s ownership interest in PG Tech and the Company removed from its balance sheet all the liabilities and debt associated with PG Tech and received in return a revenue share associated with future earnings from the PG Tech portfolio. Luxone is owner or controlled by a former affiliate of the Company.

 

On November 1, 2017, the Company entered into an agreement to acquire, through its wholly-owned subsidiary, Global Bit Ventures Acquisition Corp., a Nevada corporation (“GBVAC”), 100% of the Capital Stock of Global Bit Ventures, Inc., a Nevada corporation (“GBV”), which currently secures and powers digital asset blockchains by running specialized servers. Under the terms of the Agreement and Plan of Merger (the “Merger Agreement”), the Company will issue 126,674,557 shares of the Company’s Common Stock in exchange for one-hundred (100%) percent of the shares of GBV’s capital stock. At the closing of the merger, GBVAC shall be merged with and into GBV pursuant to the Merger Agreement and the separate existence of GBVAC shall cease and GBV shall be the surviving company. The closing of the acquisition is subject to certain closing conditions including approval of the Merger Agreement by the Company’s Shareholders.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position, the results of operations and cash flows of the Company for the periods presented. It is suggested that these consolidated condensed financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.

Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

Cash

Cash

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation and restricted cash, held in escrow pursuant to the terms of the Unit Purchase Agreement entered into on August 14, 2017, with another financial institution that is also insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of September 30, 2017, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

Accounts Receivable

Accounts Receivable

 

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote. At each of September 30, 2017 and December 31, 2016, the Company had recorded an allowance for bad debts in the amount of $387,976 and $387,976, respectively. Accounts receivable, net at September 30, 2017 and December 31, 2016, amounted to $123,630 and $95,069, respectively.

Concentration of Revenue and Geographic Area

Concentration of Revenue and Geographic Area

 

Revenue from the Company’s patent enforcement activities is considered United States revenue as any payments for licenses included in that revenue are for United States operations irrespective of the location of the licensee’s or licensee’s parent home domicile.

 

The Company had $0 in revenues from newly issued patent licenses for both the three months ended September 30, 2017 and the three months ended September 30, 2016. The revenue for the three months ended September 30, 2017 is attributable to a non-enforcement technology access license for one of the Company’s subsidiaries and running royalties from the Company’s Medtech portfolio and for the three months ended September 30, 2016, the revenue is attributable to running royalties from the Company’s Medtech portfolio.

 

At the current time, we define customers as firms that obtain licenses to the Company’s patents, either prior to or during enforcement litigation. These firms generally enter into non-recurring, non-exclusive, non-assignable license agreements with the Company, and these customers do not generally engage in ongoing, recurring business activity with the Company. The Company has historically had a small number of customers enter into such agreements, resulting in higher levels of revenue concentration.

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. In general, revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.

 

These rights typically include some combination of the following: (i) the grant of a non-exclusive, perpetual license to use patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the dismissal of any pending litigation.

 

The intellectual property rights granted typically are perpetual in nature. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is reasonably assured, and when all other revenue recognition criteria have been met.

 

The Company also considers the revenue generated from its settlement and licensing agreements as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, since the settlement element and license element for past and future use are the Company’s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. There was no revenue from newly issued patent licenses for the three months ended September 30, 2017 and September 30, 2016, respectively.

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets of $108,878 and $202,067 at September 30, 2017 and December 31, 2016, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

Bonds Posted with Courts

Bonds Posted with Courts

 

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of September 30, 2017 and December 31, 2016, the Company had no outstanding bonds posted with the German courts.

Related Party Transactions

Related Party Transactions

 

Parties are considered related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.

 

On May 13, 2013, we entered into a nine-year advisory services agreement (the “Advisory Services Agreement”) with IP Navigation Group, LLC (“IP Nav”), of which Erich Spangenberg is founder and former Chief Executive Officer. Mr. Spangenberg is an affiliate of the Company. The terms of the Advisory Services Agreement provide that, in consideration for its services as intellectual property licensing agent, the Company will pay to IP Navigation Group, LLC between 10% and 20% of the gross proceeds of certain licensing campaigns in which IP Navigation Group, LLC acts as intellectual property licensing agent.

  

On November 18, 2013, we entered into a consulting agreement with Jeff Feinberg (“Feinberg Agreement”), pursuant to which we agreed to grant Mr. Feinberg 25,000 shares of our restricted Common Stock, 50% of which shall vest on the one-year anniversary of the Feinberg Agreement and the remaining 50% of which shall vest on the second-year anniversary of the Feinberg Agreement. Mr. Feinberg is the trustee of The Feinberg Family Trust and holds voting and dispositive power over shares held by The Feinberg Family Trust, which is a 10% beneficial owner of our Common Stock.

 

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev, SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company. TechDev, SFF and Granicus are owned or controlled by Erich Spangenberg or family members or associates.

 

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 97,750 shares of the Company’s Series B Convertible Preferred Stock. The remaining cash payment was made on April 1, 2015 and is fully paid. Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment was due on or before June 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014. The remaining cash payment was made on February 24, 2015 and is fully paid. Under the terms of the Sarif Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.
   
Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement. Under the terms of the Pay Proceeds Agreement, as amended in 2016, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $13,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the cumulative gross proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the cumulative gross proceeds of such recoveries to the sellers. Pursuant to the amendment to the Pay Proceeds Agreement, the Company paid TechDev, Granicus and SFF $2.4 million. In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

  

On May 2, 2014, we entered into an opportunity agreement (the “Marathon Opportunity Agreement”) with Erich Spangenberg, who is an affiliate of the Company. The terms of the Marathon Opportunity Agreement provide that we have ten business days after receiving notice from Mr. Spangenberg to provide up to 50% of the funding for certain opportunities relating to the licensing, intellectual property acquisitions and/or intellectual property enforcement actions in which Mr. Spangenberg, IP Nav or any entity controlled by Mr. Spangenberg, other than: (i) IP Nav or any of its affiliates, and (ii) Medtech Development, LLC or any of its affiliates.

 

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly-owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”). Selene owned a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav provided patent monetization and support services under an existing agreement with Selene prior to the return of the patents to Stanford Research Institute (“SRI”), the original owners of the patents.

 

On August 29, 2014, the Company entered into a patent purchase agreement to acquire a portfolio of patents from Clouding IP, LLC for an aggregate purchase price of $2.4 million, of which $1.4 million was paid in cash and $1.0 million was paid in the form of a promissory note issued by the Company that matured on October 31, 2014 and was fully paid prior to the maturation date. The Company also issued 6,250 shares of its restricted common stock in connection with the acquisition. Clouding IP, LLC is also entitled to certain possible future cash payments. Clouding IP LLC is owned or controlled by Erich Spangenberg or family members or associates.

 

On October 10, 2014, the Company entered into an interest sale agreement with MedTech Development, LLC (“MedTech”) to acquire from MedTech 100% of the limited liability membership interests of OrthoPhoenix and TLIF as well as 100% of the shares of MedTech GmbH. In connection with the transaction, the Company is obligated to pay to MedTech $1 million at closing and $1 million on each of the following nine (9) month anniversary dates of the closing. On July 16, 2015, the Company entered into a forbearance agreement (the “Agreement”) with MedTech Development, the holder of a Promissory Note issued by the Company, dated October 10, 2014. Pursuant to the Agreement, the term of the Note was extended to October 1, 2015 and the Note began accruing interest starting from May 13, 2015. In addition, the Company agreed to make certain mandatory prepayments under certain circumstances and issue to MedTech Development 500,000 shares of restricted common stock of the Company. In accordance with ASC 470-50, the Company recorded this agreement as debt extinguishment and $654,000 was recorded as loss on debt extinguishment during the year ended September 30, 2015. On October 23, 2015, the Company entered into Amendment No. 1 to the Forbearance Agreement (the “Amendment”) entered into with MedTech Development on July 16, 2015. Pursuant to the Amendment, the due date of the Promissory Note was extended to October 23, 2016 in return for which the Company made a payment of $100,000 on October 23, 2015 and modified the terms under which the Company agreed to make mandatory prepayments under certain circumstances. The acquired subsidiaries are also obligated to make certain additional payments to MedTech from recoveries following the receipt by the acquired subsidiaries of 200% of the purchase payments, plus recovery of out of pocket expenses in connection with patent claims. The participation payments may be paid, at the election of the Company, in common stock of Marathon at the market price on the date of issuance. In connection with the transaction, the Company entered into a promissory note, common interest agreement and in the event of issuance of common stock to MedTech, will enter into a lockup and registration rights agreement. Approximately forty-five percent (45%) of MedTech is owned or controlled by Erich Spangenberg or family members or associates.

 

On October 1, 2016, one of the Company’s subsidiaries, PG Technologies S.a.r.l. entered into an advisory services agreement with Granicus IP, LLC, an entity owned or controlled by one of the Company’s employees, whereby Granicus receives a percentage of pre-tax return from PG Technologies after certain revenue thresholds have been met.

 

During 2016, certain officers and directors of the Company received restricted common stock in the Company’s 3D Nanocolor Corp. (“3D Nano”) subsidiary.

 

At December 31, 2016, ‘‘Other noncurrent assets’’ in the Balance Sheets consists of a note receivable from an entity controlled by one of the Company’s employees that is uncollateralized. The note receivable does not carry interest and is repayable to the Company at the earlier of March 31, 2022 or based on certain milestones. The note receivable balance has been classified as current assets because the Company believes that it will be collected within one year from the Balance Sheet dates.

  

On September 29, 2017, the Company entered into an Irrevocable Stock Power whereby the Company sold the shares it owns in the Company’s subsidiary, 3D Nano to Doug Croxall, the Company’s Chief Executive Officer with such assignment including the assumption of all of 3D Nano’s liabilities. The Company engaged a third party to value the assignment, the results of which were that the valuation and assignment were deemed to be at fair value.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

 

  Level 1:   Observable inputs such as quoted market prices in active markets for identical assets or liabilities
  Level 2:   Observable market-based inputs or unobservable inputs that are corroborated by market data
  Level 3:   Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated condensed balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

Clouding IP earn out liability was determined as a Level 3 liability, which requires an assessment of fair value at each period end by using discounted cash flow as a valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of September 30, 2017, the Company determined that there was a reduction in the Clouding IP earn out liability during the three and nine months ended September 30, 2017 in the amounts of $754,321and $754,321, respectively and a reduction in the carrying value of the Clouding IP intangible assets during the three and nine months ended September 30, 2017 in the amounts of $723,218 and $723,218, respectively.

 

The Company determined that the Warrants issued pursuant to the Unit Purchase Agreement should be treated as a Level 2 liability, which determine the value based on observable market-based inputs. in this instance, the Warrants were valued using a Monte-Carlo simulation utilizing market-based inputs for volatility and risk-free rate of interest, which resulted in the Warrants issued pursuant to the August 31, 2017 close being fair valued at $0.0364 per share and the Warrants issued pursuant to the September 29, 2017 close being fair valued at $0.0877 per share.

Accounting for Acquisitions

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses. With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

Income Taxes

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is more likely than not that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is most likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

  

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions will more likely than not be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2016 tax returns. After review of the prior year financial statements and the results of operations through December 31, 2016, the Company has recorded a full valuation allowance on its deferred tax asset.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss per Share

 

Net loss per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 613,195 shares of Common Stock, warrants to purchase 7,487,894 shares of Common Stock, Convertible Notes convertible into up to 13,750,000 shares of Common Stock and shares of Series B Convertible Preferred Stock convertible into 195,501 shares of Common Stock outstanding at September 30, 2017, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

 

The following table sets forth the computation of basic and diluted loss per share:

 

   

For the Three Months Ended

September 30, 2017

   

For the Three Months Ended

September 30, 2016

   

For the Nine Months
Ended

September 30, 2017

   

For the Nine Months
Ended

September 30, 2016

 
Net income (loss) attributable to Common shareholders   $ (6,677,485 )   $ (6,274,410 )   $ (12,484,924 )   $ (2,261,542 )
                                 
Denominator                                
Weighted average common shares – Basic and Diluted     6,270,299       3,761,786       5,564,465       3,736,213  
                                 
Earnings (loss) per common share:                                
Earnings (loss) – Basic and Diluted   $ (1.06 )   $ (1.67 )   $ (2.24 )   $ (0.60 )

Intangible Assets - Patents

Intangible Assets - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded impairment charges to its intangible assets during the three and nine months ended September 30, 2017 in the amount of $723,218 and $723,218, respectively, compared to impairment charges associated with the end of life of a number of the Company’s portfolios during the three and nine months ended September 30, 2016 in the amounts of $5,531,383 and $6,525,273, respectively.

Goodwill

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.

 

When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated condensed statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three and nine months ended September 30, 2017 the Company recorded no impairment charge to its goodwill and for the three and nine months ended September 30, 2016, the Company recorded an impairment charge to its goodwill in the amount of $0 and $83,000, respectively.

Other Intangible Assets

Other Intangible Assets

 

In accordance with ASC 350-30, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

For the three and nine months ended September 30, 2017 and September 30, 2016, the Company recorded no impairment charge to its other intangible assets.

Impairment of Long-lived Assets

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

The Company did not record any impairment charges on its long-lived assets during the three and nine months ended September 30, 2017 and September 30, 2016.

Stock-based Compensation

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

  

For the three and nine months ended September 30, 2017, the expected forfeiture rate was 12.75%, which resulted in an expense of $60,115 and $108,748, for the three and nine months ended September 30, 2017, respectively, recognized in the Company’s compensation expenses. For the three and nine months ended September 30, 2016, the expected forfeiture rate was 11.03%, which resulted in an expense of $9,570 and $36,832 for the three and nine months ended September 30, 2016, respectively, recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

Liquidity and Capital Resources

Liquidity and Capital Resources

 

At September 30, 2017, we had approximately $0.1 million in unrestricted cash and cash equivalents, $3.9 million in restricted cash and an unrestricted working capital deficit of approximately $20.3 million.

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months from the issuance date of the financial statements, raising substantial doubt regarding the Company’s ability to continue operating as a going concern. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

  raise additional funds to support the Company’s operations; provided, however, there is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and
     
   review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets. The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlements of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted.

 

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This ASU provides clarity about which changes to the terms or conditions of a share-based payment award require the application of modification accounting. Specifically, ASU 2017-09 clarifies that changes to the terms or conditions of an award should be accounted for as a modification unless all of the following are met: 1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, 2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified and 3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted. The Company does not expect the adoption of ASU 2017-09 to significantly impact its accounting for share-based payment awards, as changes to awards’ terms and conditions subsequent to the grant date are unusual and infrequent in nature.

 

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04 Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for interim and annual period beginning after December 15, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which clarifies the definition of a business and assists entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under this guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or group of similar assets), the assets acquired would not represent a business. In addition, in order to be considered a business, an acquisition would have to include at a minimum an input and a substantive process that together significantly contribute to the ability to create an output. The amended guidance also narrows the definition of outputs by more closely aligning it with how outputs are described in FASB guidance for revenue recognition. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted.

 

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity’s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period.

 

In October 2016, the FASB issued ASU 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), which eliminates the exception in existing guidance which defers the recognition of the tax effects of intra-entity asset transfers other than inventory until the transferred asset is sold to a third party. Rather, the amended guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently assessing the impact of this guidance on its consolidated condensed financial statements.

 

In August 2016, the FASB issued ASU 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The standard is intended to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this guidance on its consolidated condensed financial statements.

 

In May 2014, the FASB Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, as a new Topic, (ASC) Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. This ASU must be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are considering the alternatives of adoption of this ASU and we are conducting our review of the likely impact to the existing portfolio of customer contracts entered into prior to adoption. After completing our review, we will continue to evaluate the effect of adopting this guidance upon our results of operations, cash flows and financial position.

  

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated condensed financial statements.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Schedule of Computation of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per share:

 

   

For the Three Months Ended

September 30, 2017

   

For the Three Months Ended

September 30, 2016

   

For the Nine Months
Ended

September 30, 2017

   

For the Nine Months
Ended

September 30, 2016

 
Net income (loss) attributable to Common shareholders   $ (6,677,485 )   $ (6,274,410 )   $ (12,484,924 )   $ (2,261,542 )
                                 
Denominator                                
Weighted average common shares – Basic and Diluted     6,270,299       3,761,786       5,564,465       3,736,213  
                                 
Earnings (loss) per common share:                                
Earnings (loss) – Basic and Diluted   $ (1.06 )   $ (1.67 )   $ (2.24 )   $ (0.60 )

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets consisted of the following:

 

    September 30, 2017     December 31, 2016  
             
Intangible Assets   $ 20,403,408     $ 23,637,813  
Accumulated Amortization & Impairment     (12,813,195 )     (11,323,185 )
                 
Intangible assets, net   $ 7,590,213     $ 12,314,628  

Schedule of Future Amortization of Intangible Assets, Net of Foreign Currency Translation Adjustments

Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:

        

2017   $ 401,804  
2018     1,517,219  
2019     1,447,660  
2020     1,154,767  
2021     1,004,600  
2022 and thereafter     2,064,163  
Total   $ 7,590,213  

Summary of the Company's Patent Portfolios

A summary of the Company’s patent portfolios is as follows:

  

Subsidiary   Number of
Patents
    Earliest
Expiration Date
    Median
Expiration Date
    Latest
Expiration Date
    Subject Matter
Clouding Corp.     25       2/3/18       9/10/21       5/29/29     Network and data management
CRFD Research, Inc.     5       5/25/21       9/17/21       8/19/23     Web page content translator and device-to-device transfer system
Dynamic Advances, LLC     2       11/6/21       9/7/23       7/9/25     Natural language interface
Magnus IP     55       1/28/22       9/27/25       12/9/31     Network Management/Connected Home Devices
Medtech Group Acquisition Corp.     45       Expired       12/8/18       8/9/29     Medical technology
Signal IP, Inc.     2       8/28/20       8/17/21       8/6/22     Automotive
Traverse Technologies     20       2/27/22       2/25/29       2/27/33     Li-Ion Battery/High Capacity Electrodes
Soems Acquisition     16       11/11/17       4/6/19       7/18/24     N/A
              Median       09/13/21              

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Summary of the Company's Outstanding Stock Warrants and Changes During the Period

A summary of the status of the Company’s outstanding stock warrants and changes during the period then ended is as follows:

 

    Number of
Warrants
    Weighted
Average Exercise
Price
   

Weighted
Average
Remaining

Life

 
Balance at December 31, 2016     116,520     $ 15.17       3.25  
Granted     7,941,374       1.70       5.01  
Cancelled     -       -       -  
Forfeited     -       -       -  
Exercised     570,000       3.32       -  
Balance at September 30, 2017     7,487,894     $ 1.86       5.35  
                         
Warrants exercisable at September 30, 2017     612,894                  
Weighted average fair value of warrants granted during the period           0.09          

Summary of Stock Options and Changes During the Period

A summary of the stock options as of September 30, 2017 and changes during the period are presented below:

 

    Number of
Options
    Weighted
Average Exercise
Price
   

Weighted
Average
Remaining

Life

 
Balance at December 31, 2016     879,034     $ 17.84       6.80  
Granted     -       -       -  
Cancelled     48,542       -       -  
Forfeited     217,298       16.71       -  
Exercised     -       -       -  
Balance at September 30, 2017     613,194     $ 17.04       3.06  
                         
Options Exercisable at September 30, 2017     591,841     $ 13.83       2.91  
Options expected to vest     21,354     $ 20.33       7.23  
Weighted average fair value of options granted during the period           $ -          

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt, Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2017
DEBT, COMMITMENTS AND CONTINGENCIES  
Schedule of Debt

Debt consists of the following:

 

    Maturity   Interest     September 30,     December 31,  
    Date   Rate     2017     2016  
                       
Senior secured term notes   9-Jul-20     LIBOR + 9.75 %   $ 15,881,493     $ 15,620,759  
Less: debt discount                 (1,686,090 )     (1,425,167 )
Total senior-term notes, net of discount               $ 14,195,403     $ 14,195,592  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
                             
Convertible Note   10-Oct-18     11 %   $ 0     $ 500,000  

 

    Maturity     Late       September 30,       December 31,  
    Date     Fee       2017       2016  
iRunway trade payable   On Demand     1.5% per month     $ 0     $ 191,697  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Note payable   31-Jan-17     NA     $ -     $ 103,000  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Siemens   30-Sep-17     NA     $ -     $ 1,672,924  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Dominion Harbor   15-Oct-17     NA     $ -     $ 125,000  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Oil & Gas   On Demand     NA     $ 1,000,000     $ 944,296  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Convertible Note   10-May-18     0     $ 1,876,300     $ -  
Less: debt discount                 (1,851,171 )     -  
Total Convertible notes, net of discount               $ 25,129     $ -  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Convertible Note   31-May-18     5 %   $ 3,195,932     $ -  
Less: debt discount                 (2,834,308 )     -  
Total Convertible notes, net of discount               $ 361,624     $ -  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
Medtech Note   1-May-18     NA     $ -     $ -  

 

    Maturity     Interest       September 30,       December 31,  
    Date     Rate       2017       2016  
3D Nano License Fee   31-Jan-17     NA     $ -     $ 100,000  

 

    September 30, 2017     December 31, 2016  
Total   $ 15,582,156     $ 17,832,509  
Less: current portion     (15,582,156 )     (13,162,007 )
Total, net of current portion   $ -     $ 4,670,502  

Schedule of Future Minimum Principal Payments

Future minimum principal payments for all items set forth above are as follows:

 

2017   $ 16,881,493  
2018     5,072,232  
Total   $ 21,953,725  

Schedule of Future Minimum Lease Payments

Minimum future lease payments under this lease at September 30, 2017, for the next five years are as follows:

 

2017 (Three Months)   $ 18,081  
2018     74,540  
2019     77,872  
2020     81,336  
2021     27,504  
Total   $ 297,333  

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Description of Business (Details Narrative) - $ / shares
Jul. 18, 2017
Sep. 30, 2017
Dec. 31, 2016
Reverse stock split ratio On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion.    
Common stock, par value $ 0.0001 $ 0.0001 $ 0.0001
October 25 2017 [Member]      
Reverse stock split ratio On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors.    
October 30 2017 [Member]      
Reverse stock split ratio On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.    
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 9 Months Ended
Oct. 23, 2015
USD ($)
Oct. 10, 2014
USD ($)
Payments
shares
Aug. 29, 2014
USD ($)
shares
Jun. 17, 2014
Patents
May 02, 2014
USD ($)
Payments
Integer
shares
Nov. 18, 2013
shares
May 13, 2013
Sep. 30, 2017
USD ($)
Institutions
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Institutions
shares
Sep. 30, 2016
USD ($)
Sep. 29, 2017
$ / shares
Aug. 31, 2017
$ / shares
Dec. 31, 2016
USD ($)
Significant Accounting Policies [Line Items]                            
Number of financial institutions | Institutions               1   1        
Allowance for bad debt               $ 387,976   $ 387,976       $ 387,976
Accounts receivable, net               123,630   123,630       95,069
Prepaid expenses and other current assets               108,878   108,878       202,067
Outstanding litigation bonds                      
Clouding ip earn out liability               754,321   754,321        
Reduction in intangible assets               723,218   723,218        
Impairment of intangible assets               723,218 $ 5,531,383 $ 723,218 $ 6,525,273      
Warrant fair value price per share | $ / shares                       $ 0.0877 $ 0.0364  
Income tax benefit percentage                   50.00%        
Goodwill impairment               0 83,000 $ 0 83,000      
Impairment of long-lived assets                    
Expected forfeiture rate               12.75% 11.03% 12.75% 11.03%      
Compensation expenses               $ 60,115 $ 9,570 $ 108,748 $ 36,832      
Cash and cash equivalents               122,172   122,172       $ 4,998,314
Restricted cash               3,900,000   3,900,000        
Working capital               20,300,000   $ 20,300,000        
Options [Member]                            
Significant Accounting Policies [Line Items]                            
Anti-dilutive securities excluded from computation of diluted shares | shares                   613,195        
Warrant [Member]                            
Significant Accounting Policies [Line Items]                            
Anti-dilutive securities excluded from computation of diluted shares | shares                   7,487,894        
Series B Convertible Preferred Stock [Member]                            
Significant Accounting Policies [Line Items]                            
Anti-dilutive securities excluded from computation of diluted shares | shares                   195,501        
Affiliated Entity [Member] | Dynamic Advances, LLC [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Ownership interest held         100.00%                  
Number of cash payments made | Payments         2                  
Payments to acquire businesses, net of cash acquired         $ 2,375,000                  
Second payment amount on or before June 30, 2014         $ 2,850,000                  
Preferred stock, shares issued | shares         97,750                  
Maximum possible amount of future payments         $ 250,000,000                  
Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Number of purchase agreements | Integer         3                  
Affiliated Entity [Member] | IP Liquidity Ventures, LLC [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Ownership interest held         100.00%                  
Number of cash payments made | Payments         2                  
Payments to acquire businesses, net of cash acquired         $ 2,375,000                  
Second payment amount on or before June 30, 2014         $ 2,850,000                  
Preferred stock, shares issued | shares         97,750                  
Maximum possible amount of future payments         $ 250,000,000                  
Affiliated Entity [Member] | Sarif Biomedical, LLC [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Ownership interest held         100.00%                  
Number of cash payments made | Payments         2                  
Payments to acquire businesses, net of cash acquired         $ 250,000                  
Second payment amount on or before June 30, 2014         300,000                  
Maximum possible amount of future payments         250,000,000                  
Advisory Services Agreement [Member] | Navigation Group LLC [Member] | Founder And Former Chief Executive Officer [Member]                            
Significant Accounting Policies [Line Items]                            
Length of agreement             9 years              
Feinberg Agreement [Member] | Beneficial Owner [Member] | Trustee [Member] | Restricted Common Stock [Member]                            
Significant Accounting Policies [Line Items]                            
Common stock issued | shares           25,000                
Vesting on first anniversary           50.00%                
Vesting on second anniversary           50.00%                
Feinberg Agreement [Member] | Beneficial Owner [Member] | Trustee [Member] | Restricted Common Stock [Member]                            
Significant Accounting Policies [Line Items]                            
Beneficial ownership percentage           10.00%                
Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Reimbursement revenue         $ 250,000,000                  
Marathon Opportunity Agreement [Member] | Affiliated Entity [Member]                            
Significant Accounting Policies [Line Items]                            
Net recovery proceeds due to sellers         50.00%                  
Number of business days to respond         10 days                  
Merger Agreement [Member] | Selene Communication Technologies, LLC [Member]                            
Significant Accounting Policies [Line Items]                            
Number of patents | Patents       3                    
Patent Purchase Agreement [Member] | Clouding IP, LLC [Member] | Affiliated Entity [Member]                            
Significant Accounting Policies [Line Items]                            
Payments to acquire businesses, net of cash acquired     $ 2,400,000                      
Cash     1,400,000                      
Patent Purchase Agreement [Member] | Clouding IP, LLC [Member] | Affiliated Entity [Member] | Promissory Note [Member]                            
Significant Accounting Policies [Line Items]                            
Promissory note issued     $ 1,000,000                      
Debt maturity date     Oct. 31, 2014                      
Patent Purchase Agreement [Member] | Clouding IP, LLC [Member] | Restricted Common Stock [Member] | Affiliated Entity [Member]                            
Significant Accounting Policies [Line Items]                            
Stock issued in acquisition | shares     6,250                      
Interest Sale Agreement [Member] | MedTech Development, LLC [Member] | Affiliated Entity [Member]                            
Significant Accounting Policies [Line Items]                            
Ownership interest held   45.00%                        
Number of cash payments made | Payments   9                        
Payments to acquire businesses, net of cash acquired $ 100,000 $ 1,000,000                        
Monthly payment obligation   $ 1,000,000                        
Shares granted | shares   500,000                        
Debt extinguishment   $ 654,000                        
Interest Sale Agreement [Member] | MedTech Development, LLC [Member] | MedTech GmbH [Member] | Affiliated Entity [Member]                            
Significant Accounting Policies [Line Items]                            
Percentage of shares   100.00%                        
Interest Sale Agreement [Member] | MedTech Development, LLC [Member] | OrthoPhoenix and TLIF [Member] | Affiliated Entity [Member]                            
Significant Accounting Policies [Line Items]                            
Percentage of shares   100.00%                        
Sales Revenue Net [Member] | License Agreements [Member]                            
Significant Accounting Policies [Line Items]                            
License revenue amount               0 $ 0          
Maximum [Member]                            
Significant Accounting Policies [Line Items]                            
Insured by FDIC               $ 250,000   $ 250,000        
Anti-dilutive securities excluded from computation of diluted shares | shares                   13,750,000        
Maximum [Member] | Advisory Services Agreement [Member] | Navigation Group LLC [Member] | Founder And Former Chief Executive Officer [Member]                            
Significant Accounting Policies [Line Items]                            
Percent of gross proceeds             20.00%              
Maximum [Member] | Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member] | Range Two [Member]                            
Significant Accounting Policies [Line Items]                            
Reimbursement revenue         $ 40,000,000                  
Maximum [Member] | Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member] | Range Three [Member]                            
Significant Accounting Policies [Line Items]                            
Reimbursement revenue         40,000,000                  
Minimum [Member] | Advisory Services Agreement [Member] | Navigation Group LLC [Member] | Founder And Former Chief Executive Officer [Member]                            
Significant Accounting Policies [Line Items]                            
Percent of gross proceeds             10.00%              
Minimum [Member] | Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member] | Range Two [Member]                            
Significant Accounting Policies [Line Items]                            
Reimbursement revenue         13,000,000                  
Range One [Member] | Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Reimbursement revenue         $ 10,000,000                  
Range Two [Member] | Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Net recovery proceeds due to sellers         40.00%                  
Range Three [Member] | Pay Proceeds Agreement [Member] | Affiliated Entity [Member] | Dynamic Advances, IP Liquidity And Sarif Biomedical [Member] | Acquired Intellectual Property [Member]                            
Significant Accounting Policies [Line Items]                            
Net recovery proceeds due to sellers         50.00%                  
Payments of reimbursement revenue         $ 2,400,000                  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Loss Per Share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Accounting Policies [Abstract]        
Net income (loss) attributable to Common shareholders $ (6,677,486) $ (6,274,410) $ (12,484,925) $ (2,261,542)
Weighted Average Common Shares - Basic and Diluted 6,270,299 3,761,786 5,564,465 3,736,213
Earnings (loss) - Basic and Diluted $ 1.06 $ 1.67 $ 2.24 $ 0.60
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions (Details Narrative)
9 Months Ended 12 Months Ended
Sep. 01, 2017
Aug. 11, 2016
USD ($)
Patents
Aug. 03, 2016
USD ($)
Patents
Jul. 27, 2016
USD ($)
Installments
Patents
Jul. 05, 2016
USD ($)
Patents
Sep. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Earnout liability, short-term           $ 32,637 $ 81,930
Earnout liability, long-term           681,175 1,400,082
Patent Purchase Agreement [Member] | Munitech S.a.r.l [Member]              
Number of patents | Patents       221      
Consideration paid       $ 1,150,000      
Number of installments | Installments       2      
Sale of stock percentage 100.00%            
Patent Purchase Agreement [Member] | Munitech S.a.r.l [Member] | Future Payment One [Member]              
Consideration paid             1,000,000
Patent Purchase Agreement [Member] | Munitech S.a.r.l [Member] | Future Payment Two [Member]              
Consideration paid           750,000  
Patent Purchase Agreement [Member] | Magnus IP GmbH [Member]              
Number of patents | Patents         86    
Consideration paid         $ 250,000    
Patent Purchase Agreement [Member] | Traverse Technologies Corp [Member] | CPT IP Holdings [Member]              
Number of patents | Patents     12        
Consideration paid     $ 1,300,000        
Patent Funding and Exclusive License Agreement [Member] | PG Technologies S.a.r.l [Member]              
Consideration paid   $ 1,000,000          
Net licensing revenue percentage   50.00%          
Patent Funding and Exclusive License Agreement [Member] | PG Technologies S.a.r.l [Member] | Minimum [Member]              
Number of patents | Patents   10,000          
Patent Funding and Exclusive License Agreement [Member] | PG Technologies S.a.r.l [Member] | Future Payment One [Member]              
Consideration paid   $ 1,000,000          
Patent Funding and Exclusive License Agreement [Member] | PG Technologies S.a.r.l [Member] | Future Payment Two [Member]              
Consideration paid   $ 250,000          
Clouding Corp [Member]              
Earnout liability, short-term           32,637 81,930
Earnout liability, long-term           $ 681,175 $ 1,400,082
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets (Details Narrative)
3 Months Ended 9 Months Ended
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Patents
Sep. 30, 2016
USD ($)
Intangible assets capitalized $ 0 $ 3,550,000 $ 0 $ 6,450,000
Impairment of intangible assets 723,218 5,531,383 723,218 6,525,273
Amortization of intangible assets $ 457,419 $ 2,030,886 $ 1,803,264 $ 6,018,196
Patents [Member]        
Number of patents | Patents     170  
Number of additional patents | Patents     10,000  
Minimum [Member]        
Weighted average useful life, intangibles     1 year  
Maximum [Member]        
Weighted average useful life, intangibles     16 years  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible Assets $ 20,403,408 $ 23,637,813
Accumulated Amortization & Impairment (12,813,195) (11,323,185)
Intangible assets, net $ 7,590,213 $ 12,314,628
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets - Schedule of Future Amortization of Intangible Assets, Net of Foreign Currency Translation Adjustments (Details)
Sep. 30, 2017
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2017 $ 401,804
2018 1,517,219
2019 1,447,660
2020 1,154,767
2021 1,004,600
2022 and thereafter 2,064,163
Total $ 7,590,213
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets - Summary of the Company's Patent Portfolios (Details)
9 Months Ended
Sep. 30, 2017
Patents
Earliest Expiration Date Median
Median Expiration Date 09/13/21
Network and Data Management [Member] | Clouding Corp [Member]  
Number of patents 25
Earliest Expiration Date 2/3/18
Median Expiration Date 9/10/21
Latest Expiration Date 5/29/29
Web Page Content Translator and Device-to-Device Transfer System [Member] | CRFD Research, Inc. [Member]  
Number of patents 5
Earliest Expiration Date 5/25/21
Median Expiration Date 9/17/21
Latest Expiration Date 8/19/23
Natural Language Interface [Member] | Dynamic Advances, LLC [Member]  
Number of patents 2
Earliest Expiration Date 11/6/21
Median Expiration Date 9/7/23
Latest Expiration Date 7/9/25
Network Management/Connected Home Devices [Member] | Magnus IP [Member]  
Number of patents 55
Earliest Expiration Date 1/28/22
Median Expiration Date 9/27/25
Latest Expiration Date 12/9/31
Medical Technology [Member] | Medtech Group Acquisition Corp. [Member]  
Number of patents 45
Earliest Expiration Date Expired
Median Expiration Date 12/8/18
Latest Expiration Date 8/9/29
Automotive [Member] | Signal IP, Inc. [Member]  
Number of patents 2
Earliest Expiration Date 8/28/20
Median Expiration Date 8/17/21
Latest Expiration Date 8/6/22
Li-Ion Battery/High Capacity Electrodes [Member] | Traverse Technologies [Member]  
Number of patents 20
Earliest Expiration Date 2/27/22
Median Expiration Date 2/25/29
Latest Expiration Date 2/27/33
N/A [Member] | Soems Acquistio [Member]  
Number of patents 16
Earliest Expiration Date 11/11/17
Median Expiration Date 4/6/19
Latest Expiration Date 7/18/24
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders’ Equity (Details Narrative)
1 Months Ended 9 Months Ended
Sep. 29, 2017
$ / shares
shares
Sep. 13, 2017
shares
Sep. 06, 2017
shares
Sep. 05, 2017
shares
Aug. 29, 2017
shares
Aug. 09, 2017
shares
Jul. 18, 2017
$ / shares
Apr. 24, 2017
USD ($)
$ / shares
shares
Apr. 18, 2017
$ / shares
shares
Apr. 12, 2017
USD ($)
$ / shares
shares
Feb. 02, 2017
USD ($)
$ / shares
shares
Jan. 10, 2017
$ / shares
shares
Dec. 09, 2016
USD ($)
$ / shares
shares
Oct. 13, 2016
$ / shares
shares
Jul. 02, 2016
Installments
$ / shares
shares
May 20, 2016
Installments
$ / shares
shares
May 11, 2016
USD ($)
$ / shares
shares
May 10, 2016
Installments
$ / shares
shares
Jan. 31, 2017
$ / shares
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Aug. 31, 2017
$ / shares
Dec. 31, 2016
$ / shares
shares
Mar. 11, 2016
$ / shares
shares
Common stock, shares authorized | shares                                       200,000,000   200,000,000  
Common stock, par value             $ 0.0001                         $ 0.0001   $ 0.0001  
Preferred stock, shares authorized | shares                                       50,000,000      
Preferred stock, par value                                       $ 0.0001      
Reverse stock split ratio             On July 18, 2017, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-four and not more than one-for-twenty-five, with such ratio to be determined by the Board of Directors, in its sole discretion.                                
Exercise price of warrants $ 0.0877                                       $ 0.0364    
Conversion of shares issued | shares 598,500   534,710   200,000                                    
Conversion of converted shares | shares     427,768                                        
Unrecognized compensation | $                                       $ 7,072      
Employee Stock Option [Member] | Independent Board Member [Member]                                              
Volatility rate                           46.00%                  
Discount rate                           1.21%                  
Option term                           10 years                  
Option to purchase shares of common stock | shares                           20,000                  
Option price per share                           $ 9.64                  
Expected term                           5 years 6 months                  
Forfeited number of shares | shares                           20,000                  
Spangenberg Agreement [Member] | Employee Stock Option [Member] | Director of Acquisitions, Licensing and Strategy [Member]                                              
Volatility rate                                   47.00%          
Discount rate                                   1.32%          
Option term                                   10 years          
Option to purchase shares of common stock | shares                                   125,000          
Option price per share                                   $ 7.48          
Number of monthly installments | Installments                                   24          
Expected term                                   5 years 9 months          
Grubbs Agreement [Member] | Employee Stock Option [Member] | Analyst [Member]                                              
Volatility rate                               47.00%              
Discount rate                               1.88%              
Option term                               10 years              
Option to purchase shares of common stock | shares                               12,500              
Option price per share                               $ 9.00              
Number of monthly installments | Installments                               36              
Expected term                               6 years 6 months              
Liu Agreement [Member] | Employee Stock Option [Member] | Chief Technology Officer [Member]                                              
Volatility rate                             47.00%                
Discount rate                             1.20%                
Option term                             10 years                
Option to purchase shares of common stock | shares                             37,500                
Option price per share                             $ 11.16                
Number of monthly installments | Installments                             36                
Expected term                             6 years 6 months                
Common Stock [Member] | Consulting Agreement [Member] | Cooper Law Firm, LLC [Member]                                              
Stock issued for services | shares                                 20,000            
Stock market price per share                                 $ 6.80            
Value of stock issued for services | $                                 $ 136,000            
Common Stock [Member] | Securities Purchase Agreement [Member] | Institutional Investors [Member]                                              
Number of common stock shares issued | shares                 950,000       870,500                    
Price per share                 $ 2.80       $ 6.00                    
Number of warrant to purchase shares of common stock | shares                 570,000                            
Exercise price of warrants                 $ 3.32                            
Common Stock [Member] | At-The-Market Offering [Member]                                              
Number of common stock shares issued | shares                     187,500                        
Price per share                     $ 6.96                        
Value of shares issued | $                     $ 1,301,923                        
Common Stock [Member] | Settlement Agreement [Member] | Dominion Harbor Group [Member]                                              
Number of common stock shares issued | shares                   31,250                          
Price per share                   $ 0.83                          
Value of shares issued | $                   $ 103,750                          
Common Stock [Member] | Cancellation of Invoices [Member] | Vendors [Member]                                              
Number of common stock shares issued | shares               7,500                              
Price per share               $ 3.32                              
Value of shares issued | $               $ 24,897                              
Common Stock Warrants [Member]                                              
Number of warrant to purchase shares of common stock | shares                                       6,875,000      
Exercise price of warrants                                       $ 1.20      
Warrant outstanding | shares                                       7,487,894      
Weighted average remaining life                                       5 years 4 months 6 days      
Common Stock Warrants [Member] | Investors [Member]                                              
Number of warrant to purchase shares of common stock | shares                                             5,834
Common Stock Warrants [Member] | Investors [Member] | Minimum [Member]                                              
Exercise price of warrants                                             $ 8.00
Common Stock Warrants [Member] | Investors [Member] | Maximum [Member]                                              
Exercise price of warrants                                             $ 16.50
Common Stock Warrants [Member] | Securities Purchase Agreement [Member] | Underwriter [Member]                                              
Number of warrant to purchase shares of common stock | shares                         43,525                    
Exercise price of warrants                         $ 6.92                    
Common Stock Warrants [Member] | Securities Purchase Agreement [Member] | Institutional Investors [Member]                                              
Number of warrant to purchase shares of common stock | shares                         435,249           435,249        
Exercise price of warrants                         $ 0.01           $ 6.80        
Warrants issued, total value | $                         $ 17,020                    
Expected term of warrants                                     3 years 2 months 30 days        
Common Stock Warrants [Member] | Securities Purchase Agreement [Member] | Institutional Investors [Member] | Minimum [Member]                                              
Share price                                     $ 7.00        
Volatility rate                                     38.00%        
Discount rate                                     1.50%        
Common Stock Warrants [Member] | Securities Purchase Agreement [Member] | Institutional Investors [Member] | Maximum [Member]                                              
Share price                                     $ 8.52        
Volatility rate                                     39.00%        
Discount rate                                     1.56%        
Common Stock Warrants [Member] | Fortress Purchase Agreement Amended and Restated [Member] | DBD Credit Funding LLC [Member]                                              
Number of warrant to purchase shares of common stock | shares                       46,875                      
Exercise price of warrants                       $ 6.80                      
Share price                       $ 7.60                      
Expected term of warrants                       3 years                      
Volatility rate                       39.00%                      
Discount rate                       1.52%                      
Term of warrants                       5 years                      
Common Stock Warrants [Member] | April Purchase Agreement [Member] | Underwriter [Member]                                              
Number of warrant to purchase shares of common stock | shares                 14,250                            
Exercise price of warrants                 $ 3.08                            
Share price                 $ 3.32                            
Expected term of warrants                 3 years 2 months 30 days                            
Volatility rate                 38.00%                            
Discount rate                 1.72%                            
Common Stock Warrants [Member] | April Purchase Agreement [Member] | Investors [Member]                                              
Number of warrant to purchase shares of common stock | shares                 570,000                            
Exercise price of warrants                 $ 3.32                            
Share price                 $ 3.08                            
Expected term of warrants                 2 years 6 months                            
Volatility rate                 39.00%                            
Discount rate                 1.60%                            
Warrant First Close [Member]                                              
Exercise price of warrants                                       $ 1.20      
Volatility rate                                       100.00%      
Discount rate                                       1.76%      
Expected term                                       5 years 6 months      
Warrant Second Close [Member]                                              
Exercise price of warrants                                       $ 1.20      
Volatility rate                                       100.00%      
Discount rate                                       1.98%      
Expected term                                       5 years 6 months      
Series B Convertible Preferred Stock [Member]                                              
Percentage of common stock outstanding                                       9.99%      
Series D Convertible Preferred Stock [Member]                                              
Percentage of common stock outstanding                                       9.99%      
Conversion of shares issued | shares   315,925   62,500   250,000                                  
Conversion of converted shares | shares   252,750   50,000   200,000                                  
October 25 2017 [Member]                                              
Reverse stock split ratio             On October 25, 2017, the reverse stock split ratio of one (1) for four (4) basis was approved by the Board of Directors.                                
October 30 2017 [Member]                                              
Reverse stock split ratio             On October 30, 2017, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for four (4) basis.                                
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders’ Equity - Summary of the Company's Outstanding Stock Warrants and Changes During the Period (Details) - Warrants [Member]
9 Months Ended
Sep. 30, 2017
$ / shares
shares
Number of Warrants Balance Beginning | shares 116,520
Number of Warrants Granted | shares 7,941,374
Number of Warrants Cancelled | shares
Number of Warrants Forfeited | shares
Number of Warrants Exercised | shares 570,000
Number of Warrants Balance Ending | shares 7,487,894
Weighted Average Exercise Price Balance Beginning | $ / shares $ 15.17
Weighted Average Exercise Price Granted | $ / shares 1.70
Weighted Average Exercise Price Cancelled | $ / shares
Weighted Average Exercise Price Forfeited | $ / shares
Weighted Average Exercise Price Exercised | $ / shares 3.32
Weighted Average Exercise Price Balance Ending | $ / shares $ 1.86
Weighted Average Remaining Life Balance Beginning 3 years 2 months 30 days
Weighted Average Remaining Life, Granted 5 years 4 days
Weighted Average Remaining Life Balance Ending 5 years 4 months 6 days
Warrants exercisable | shares 612,894
Weighted average fair value of warrants granted during the period | $ / shares $ 0.09
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders’ Equity - Summary of Stock Options and Changes During the Period (Details) - Stock Options [Member]
9 Months Ended
Sep. 30, 2017
$ / shares
shares
Number of Options, Beginning Balance | shares 879,034
Number of Options, Granted | shares
Number of Options, Cancelled | shares 48,542
Number of Options, Forfeited | shares 217,298
Number of Options, Exercised | shares
Number of Options, Ending Balance | shares 613,194
Number of Options Exercisable | shares 591,841
Number of Options expected to vest | shares 21,354
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 17.84
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares 16.71
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares 17.04
Weighted Average Exercise Price, Options Exercisable | $ / shares 13.83
Weighted Average Exercise Price, Options expected to vest | $ / shares $ 20.33
Weighted Average Remaining Life, Beginning Balance 6 years 9 months 18 days
Weighted Average Remaining Life, Ending Balance 3 years 22 days
Weighted Average Remaining Life, Options Exercisable 2 years 10 months 28 days
Weighted Average Remaining Life, Options expected to vest 7 years 2 months 23 days
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt, Commitments and Contingencies (Details Narrative)
1 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
Aug. 14, 2017
USD ($)
$ / shares
shares
Jun. 30, 2017
USD ($)
May 31, 2017
USD ($)
May 02, 2017
USD ($)
Jan. 10, 2017
USD ($)
shares
Dec. 31, 2016
USD ($)
Oct. 29, 2015
USD ($)
Payments
$ / shares
shares
Jan. 29, 2015
USD ($)
$ / shares
shares
Oct. 16, 2014
USD ($)
$ / shares
shares
Oct. 09, 2014
USD ($)
$ / shares
shares
May 02, 2014
USD ($)
Jan. 31, 2017
USD ($)
Apr. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
shares
Sep. 30, 2016
Dec. 31, 2016
USD ($)
Dec. 31, 2017
USD ($)
Sep. 29, 2017
$ / shares
Sep. 01, 2017
Aug. 31, 2017
$ / shares
Feb. 12, 2015
USD ($)
Warrant exercise price per share | $ / shares                                     $ 0.0877   $ 0.0364  
Lease term                       7 years                    
Lease expiry date                       Apr. 30, 2021                    
Security deposit                       $ 7,564                    
Rent payment grace period                       5 months                    
Lease termination option available                       42th month of the lease                    
Officer [Member]                                            
Short-term advance to an officer $ 0           $ 103,000               $ 0   $ 103,000          
iRunway [Member]                                            
Monthly interest rate 1.50%                           1.50%              
Short-term payable $ 0           191,697               $ 0   $ 191,697          
Medtech Note [Member]                                            
Debt maturity date                             May 01, 2018   May 01, 2018          
HP Inc [Member] | 3D Nano Purchase Payment [Member]                                            
Agreement extended term         2 years                                  
HP Inc [Member] | 3D Nano Purchase Payment [Member] | 2018 [Member]                                            
Amount of individual payments under the extended term         $ 100,000                                  
HP Inc [Member] | 3D Nano Purchase Payment [Member] | 2019 [Member]                                            
Amount of individual payments under the extended term         $ 100,000                                  
Medtronic, Inc [Member] | Medtech Note [Member]                                            
Principal amount of debt       $ 750,000                                    
Amount of individual payments     $ 75,000 $ 75,000                                    
Debt payments 0           0                              
Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | Warrants [Member]                                            
Number of warrant to purchase shares of common stock | shares                 25,000                          
Warrant exercise price per share | $ / shares                 $ 29.76                          
Beneficially ownership percentage                 4.99%                          
Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | New Warrant [Member]                                            
Number of warrant to purchase shares of common stock | shares           46,875                                
Beneficially ownership percentage           4.99%                                
Siemens Purchase Payment Arrangement [Member]                                            
Debt maturity date                             Sep. 30, 2017   Sep. 30, 2017          
Beneficially ownership percentage                                       100.00%    
Purchase obligation for patents 0           1,672,924               $ 0   $ 1,672,924          
Settlement Agreement [Member] | Dominion Harbor Settlement Note [Member]                                            
Number of common stock shares issued | shares               75,000             31,250              
Number of payments | Payments               8                            
Installment payment amount               $ 25,000                            
Share issued price per share | $ / shares               $ 6.84                            
Value of common stock shares issued               $ 513,000             $ 25,000              
Outstanding amount 0           125,000               0   125,000          
Oil & Gas Purchase Payment Arrangement [Member]                                            
Purchase obligation for patents 1,000,000           944,296               1,000,000   944,296          
License and Purchase Agreement [Member] | HP Inc [Member] | 3D Nano Purchase Payment [Member]                                            
Purchase obligation for patents 0           100,000               0   100,000          
Amount of individual payments                         $ 100,000 $ 100,000                
Senior Secured Term Notes [Member]                                            
Interest rate on paid-in-kind interest                               2.75%            
Unamortized discount 1,686,090           1,425,167               1,686,090   1,425,167          
Term notes, gross 15,881,493           $ 15,620,759               $ 15,881,493   $ 15,620,759          
Senior Secured Term Notes [Member] | London Interbank Offered Rate (LIBOR) [Member]                                            
Debt bears cash interest rate                               9.75%            
Increase in interest rate                               2.00%            
Senior Secured Term Notes [Member] | Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member]                                            
Monetization of net revenues                 $ 15,000,000                          
Note term                 5 years                          
Number of common stock shares issued | shares                 33,603                          
Warrant expiration date                 Jan. 29, 2020                          
Fair value of warrant                 $ 318,679                          
Senior Secured Term Notes [Member] | Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | Initial Note [Member]                                            
Principal amount of debt                 $ 15,000,000                          
Note term                 42 months                          
Debt maturity date                 Jul. 29, 2018                          
Senior Secured Term Notes [Member] | Fortress Purchase Agreement [Member] | DBD Credit Funding LLC [Member]                                            
Interest rate on paid-in-kind interest                 2.75%                          
Senior Secured Term Notes [Member] | Fortress Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | London Interbank Offered Rate (LIBOR) [Member]                                            
Debt bears cash interest rate                 9.75%                          
Senior Secured Term Notes [Member] | Fortress Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | Additional Notes [Member]                                            
Principal amount of debt                                           $ 5,000,000
Senior Secured Term Notes [Member] | Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member]                                            
Principal amount of debt           $ 20,000,000                                
Number of warrant to purchase shares of common stock | shares           25,000                                
Term notes, gross           $ 15,881,493                                
Cash collateral account           4,500,000                                
Increase in revenue stream basis           1,225,000                                
Minimum liquidity requirement in unrestricted cash and cash equivalents           1,250,000                                
Senior Secured Term Notes [Member] | Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | Additional Notes [Member]                                            
Maximum borrowing capacity           7,500,000                                
Structuring fee percentage                             2.00%              
Senior Secured Term Notes [Member] | Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | Additional Notes One [Member]                                            
Principal amount of debt           3,750,000                                
Senior Secured Term Notes [Member] | Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | Additional Notes Two [Member]                                            
Principal amount of debt           $ 3,750,000                                
Senior Secured Term Notes [Member] | Amended and Restated Revenue Sharing and Securities Purchase Agreement [Member] | DBD Credit Funding LLC [Member] | New Note [Member]                                            
Structuring fee percentage                             2.00%              
Convertible Note [Member]                                            
Principal amount of debt                   $ 5,550,000 $ 5,550,000                      
Number of warrant to purchase shares of common stock | shares                   32,375 32,375                      
Warrant exercise price per share | $ / shares                   $ 33.00 $ 33.00                      
Debt maturity date                   Oct. 10, 2018 Oct. 10, 2018                      
Debt bears cash interest rate                   11.00% 11.00%                      
Warrant term                   2 years 2 years                      
Debt instrument outstanding 0                           $ 0     $ 500,000        
Debt conversion price per share | $ / shares                   $ 30.00 $ 30.00                      
Common stock trade price per share | $ / shares                   $ 108.00 $ 108.00                      
Convertible Note One [Member] | Unit Purchase Agreement [Member]                                            
Number of warrant to purchase shares of common stock | shares   6,875,000                                        
Warrant exercise price per share | $ / shares   $ 1.20                                        
Debt maturity date   May 31, 2018                                        
Debt bears cash interest rate   5.00%                                        
Debt instrument outstanding $ 5,072,232                           $ 5,072,232              
Debt conversion price per share | $ / shares   $ 0.80                                        
Proceeds from issuance of secured debt   $ 5,500,000                                        
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt, Commitments and Contingencies - Schedule of Debt (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Total $ 15,582,156 $ 17,832,509
Less current portion (15,582,156) (13,162,007)
Total, net of current portion $ 4,670,502
Siemens Purchase Payment Arrangement [Member]    
Maturity date Sep. 30, 2017 Sep. 30, 2017
Interest rate
Total debt, net $ 1,672,924
Dominion Harbor Settlement Agreement [Member]    
Maturity date Oct. 15, 2017 Oct. 15, 2017
Interest rate
Total debt, net $ 125,000
Oil & Gas Purchase Payment Arrangement [Member]    
Maturity date description On Demand On Demand
Interest rate
Total debt, net $ 1,000,000 $ 944,296
3D Nano License and Purchase Agreement [Member]    
Maturity date Jan. 31, 2017 Jan. 31, 2017
Interest rate
Total debt, net $ 100,000
Senior Secured Term Notes [Member]    
Maturity date Jul. 09, 2020 Jul. 09, 2020
Long-term debt, gross $ 15,881,493 $ 15,620,759
Less: debt discount (1,686,090) (1,425,167)
Total debt, net $ 14,195,403 $ 14,195,592
Senior Secured Term Notes [Member] | LIBOR [Member]    
Debt variable interest rate 9.75% 9.75%
Convertible Note [Member]    
Maturity date Oct. 10, 2018 Oct. 10, 2018
Interest rate 11.00% 11.00%
Total debt, net $ 0 $ 500,000
iRunway Trade Payable [Member]    
Maturity date description On Demand On Demand
Interest rate 1.50% 1.50%
Total debt, net $ 0 $ 191,697
Note Payable [Member]    
Maturity date Jan. 31, 2017 Jan. 31, 2017
Interest rate
Total debt, net $ 103,000
Convertible Note One [Member]    
Maturity date May 10, 2018 May 10, 2018
Interest rate 0.00% 0.00%
Long-term debt, gross $ 1,876,300
Less: debt discount (1,851,171)
Total debt, net $ 25,129
Convertible Note Two [Member]    
Maturity date May 18, 2018 May 18, 2018
Interest rate 5.00% 5.00%
Long-term debt, gross $ 3,195,932
Less: debt discount (2,834,308)
Total debt, net $ 361,624
Medtech Note [Member]    
Maturity date May 01, 2018 May 01, 2018
Interest rate
Total debt, net
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt, Commitments and Contingencies - Schedule of Future Minimum Principal Payments (Details) - Senior and Junior Debt [Member]
Sep. 30, 2017
USD ($)
2017 $ 16,881,493
2018 5,072,232
Total, net $ 21,953,725
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt, Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)
Sep. 30, 2017
USD ($)
DEBT, COMMITMENTS AND CONTINGENCIES  
2017 (Three Months) $ 18,081
2018 74,540
2019 77,872
2020 81,336
2021 27,504
Total $ 297,333
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events (Details Narrative) - Subsequent Event [Member]
Nov. 01, 2017
shares
Merger Agreement [Member]  
Number of common stock shares issued 126,674,557
Exchange of common stock percentage 1.00
Global Bit Ventures Acquisition Corp [Member]  
Ownership percentage 100.00%
EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"8.=5Z8+UAWO#E3&.IV3X^:1S:-\$3J[X*F 5).NY@[MSG3< MM0].&L<'3^%&+?ER %^ E4SJR75@V[NO@8IF8Y]$X8QEG@G)''O.6??'Q]J5 M,1L2=1#?Q5C];O ,Q.0Z0* _- *Y/[X/1>#]+ X1/$6\KP3211@E($1B?(5\ MPSSAF?W6L<7Q9; L"69..0],ROEBP#=SE_(;0Z\[4BR(\C> >E8)U0*DFQ6! M)^W]HZ.3E0'^/ ('F$^:C?;*H%Z-V6]8J4"=&YZL M3#IJKU0H_2&"?A@M#'6KO4J9-#?0BRB"JY?L9="\!.JE0TX?H5?'02O[OK>$/[Y+S@@;S#1BW;Q MCZOKNW.GZ=2=Z^]?.E>7_Z]S=WE]Y72NSIRS\]O3[Y75 M^>TM@=Q='?#N:/SK?S4/&RO&W74T= ,9P-YME,Q(Q6?(CEO-HU]C N9]["2AX[+?WQES$8CC!GWYMQ-YPWOY"?P0+'R1 M>/\1#J[Q@+Y#)QS /\)8."Y%VO%70Q%@PI,@<"+Q( +X';TS"@=>X@S"B%X@ M(=MS_B'F &$ @ ?\R(G?(0% (&/]Z%#G3CX2R^@2IP44.X%V$@1;AN" 6!" MO3(-A ,W((@57-<3\1[@,TIP"V$:,0C<_]#!@H9$#"$VO-Z]XV)*4^RD?"< /_Q*X M&JR:A 2#S]HZ(#.&&PNK'8&J\%EOP"B!XT^#..WU@%D&J5^#1X% 7*I'$ $0 M$B"]!#'@#EULL@*OF:CMX:_'0&F$("^YIP,)B0C@%!599,"#DR8W MH1OUD5]&N#G$CY:9^):8B^*%P$ MWA>$05W\A.]B!44D0+>@O3###E(,%&HB">$DA45-0!;F4 %Q1/-@!27PZ@1_ M'J<"/XZ$+]Q8R@I!J)@PR_9$E "ZG)[O>J.X)@F##F3DQ3%P,E(T8'(LV#GK M Y*'=",0@"%F^SC8$DC2,-*>.P9!,XXP.HE\BN_K>1&H*8C1'K+]-="-9O%[ M-V8R[0/'^>%8] D,?5#BYQ@.BM=DH@!6P4('T%E2GT2!Z_AA,*PC'+4,9RKI M!XL)=S0E^7;Q+KLS^W<> ?5 G6$$3(SA*'EES5?$3/-6LHZT"^ M@>3IDQ"AIX%@.R/81\\-G%NF#J]'L'SS2/3$SJD$5='?HP!Z$\'0'6K@S>6* M//US[-N_'X?(-QX@4A(;<2K\, 6^]-(1_>C!#=P^_F,DER48U&OW8%?.W_ N M@YVT:"])$1LE@-@OU?#\ BBB[X]/;]V_A7"AWU"V,"+1A*; M*., )3WY&I7$K5X!PB1AYJ0K,_%&PN8G6Q?B(T4"4^<,&Y^E1^T@*UZ;HVS6 MY&DB.JDP^C[T@;>8]O!OE+XNO/5?8>2!^):RO CS#R'=,#UW["4 Y[W;QX_@ M!/",71.MM9['P^%S,LR<6T$JDJOM=7?/0=ET.<0[U98Y P4 MGA[JBGQQ/$C(K(=1]N00Q;Q0\IZ^P)M TS?MQ@)K#FT>P 1V1?406&F J3CR M7?J>L534@&!A44-7.UV*X7A,.J_42@)^GM6VJ?-SAB$^"7S^"+LAF:F%;;-- M6]ZO91X8>+XZ0A0: Y":B59E= VJ47=N10^T"WP??*]E.WV3$_0@?,*(Q'KH MB,& TI 2D3^37678OZ6@ #>/Z4C@-K-9%7$() C(>X)I0RO:G6/6'%EHCG!) ME8EB5&70-1./01.;)00\2@?0YD:8";!CJ%B^"/1R>#?>D*R2)HZ/=P4H6D & M@:@#2<+_HGD&;\&O1V$DLE\GCT!ID_H ]*X:$QQH[/?RI5+3[PJ;*V'1I)!U M4<%WT-:*0Y^OM8C2Z8DC]+775MC'EQ3A1>\'0'3>-S\0"*C\T4[>'X %CGXO MNIXTBDN!RBR^W[ 7SW*C2_JTY$72G#4?2C3@UH@YI33^SG=TW^G 0-EMZO.P5%GP)X2=0Z[ M*DMNQ3AAO?C0)JII"F0VUK( K_%^",_V:]J9@=:>D462JE&@("V ;NF%1 [Y M)8]KI2>/ #E8J *""T@2[RUIIF(5"U_B >9F=][?GIV"'GDKWIX>NY)$A 50\_1 ;/,4.H\[7;EP2F(5;TQM"CV0/ M[0!T=QIGIJOE$=['DL8LMSI\C]>9ELC8T!S^1=H=;5!ZQYSWO^_=[CE?.IV; M#Q8^-?+QP@]'7H(/*^0I\YTU\R(,TH4>BY(#+=ZQ$O!XL;#@Y\_?XTN\F!W= M@3]ATP+Q*%50="R1;60>^L!QF)K:?3CV CP/>!1(U>5V[S5R, <"XP&H"<.. MY$7F#%PO\B?2H:5@'8<<4%*F CJ,-5NCNTU2#^*BY\;WSH""0#DU1+F-I^[. M/>>28A1Q.AP*OO7009W,A4@"PT)F%P%TZ?3AU_]*@UY6_W_Z3E9.A@#3&_ O MN)K##-V6Z'H$RBB,$[1?$9F=(, P'C=_(MEDL:CPY%$D M9:3Q16<&IJ,Z-X^XJ8]F$JJ&C&U)&?Q> +NK//^BKU\\2('0)L*-EJGE%8C9 M;H'D7>$5H"#ZG6,ZY_#5B&0$$D '#+81:4[QJN%<_57%(ID%.V"JB&O8+B>> MPTL K19BN=]O2<("J5-(-K:D$(7BW1\"/>P6YEV#>1D,(]M;BA[D)#3>1M0D MPT2*\5$9#.7N),I=:"XA#CZJEB;6P.'+[+ = M);#0+258S>FFB18FOC?RV,ZHJ38X1 MI+X&I"]K "D&AZ$4]R>2>!KPHU*-@D_U/28#22JBTS,M;RSM8B=-8"T43^$: MKP2?4EUZLO]13#K:O3>\A[O7ITID J8ONLA?JJET;$7UXWO@00H\="Q:*2<9[K.ZOP1^"RUK(P+@=V@?.=,$$\YE_BU MUM/S\660: FHW*3! 10U/).)$$^)Z M> H6ZJ1#.#VG><#Y%^P(9(LAX*.8O4/7C\.YMVF'T$M]>&P[R7Y.O&>Z71B= M"@"05&-*EF)9C-O^I=5NU!J-!NOISX')>6]%ZB[.+D\SD4,"K$,8-JZ_8I<\ MACV[;O##D(OXB0G ZI+ =S.$! )M 1""7JM^"A^@JS[RXA\HK<,>E=K3H>@< M&;@@?'DYDU55>$A9F 3>)ZPO8)S%I30EU+2EX1*Y*CWO;IP[$1X:2C"A$.5L8@PHU!'Q_Z=HB(5 M!I13J-F_ZY)/@>-R74Q<40J;(E16($G3BL(N9R0"%P%Q@OX:DSVGZ)F#E$E1$Y Y02CT!ECF^IN!I%$,ZOHAW#XE--^"L3F)PD%W&;Z#W MA#\)7'_"SD""88QLV4\M#)@[<>!RAH&5V]?G:)\R_/-JGZLU,_I]EU+B^M@R M#]5F_D)+J#[>$'WEJX'?IJ 84B<0CXY$9H7*;!I*=@(I1W>X5-3!YL"D!;SL M1\)EOYAZ!0!DO$7BY[W+CGIE#YC<*!4OP&#V@X@H"UTD/H' M:MT8+^)@A,:P32HU((,$Y>_<,/-M2 LSXG]IMO9KA_L-7OJD76LYG:UP%^V6T9K9"C$NP+@ZILPG*B47'>3CNYR$O.7!F>.2B\-D@T!$HA']*MR MOH9T>>C#)8$:2D]RQF+C9)0283COKP_-]:VH1OELYUL,S9@$3*UNFJC[W.4$ M>8O:3;([Q4KB6&?=XV)@"BH75AD7Q6D7&,1S(^5CB](@0(4D"B>N3VPTDPME M6;=5\T!9^J4[95Z90I9)7$)$%6S]I6#M))]T6/]2.1T?JV5K1/B?8(_"WHE4IHI.K/H6'4Z5?!Q;* "!2C[4/!281T_9 M8P'EHZ).HR)U)I.=KYS)U$H9;P)9&_>@[H>1U.!1=+E.C+%4)TB)'U WU2 1 M#J0S7@4JS;YJTKG,]3GDR!+H:@)E2^9=,C/U;-6CBA+9^@78Q.$P\*H<]6YS3BNG+MP[/6B%QV- M>6I/Z\U>; "5U5'H7GWO?4 K.4Y=JD@3. 8-K2=I=IHIZ6QY Y+>>_ (0><2R\&B-BZ+V%Y_!!&;L"S4PF>/SD; -E>K/C .3->^_A M@[([9<]]SH?E%]!^W)@\#1.*Q4043 ^41*I9RJ?>!0;>0]RCNG&EN3Y113P8 M(\.227:H6?G& \%.B)X]#4#?VQ3&H>=U.HCIOZG*)Z#US8&[^ M?H23&@LZ-G4URJ+)PA-S"DY+A1\S5RBSC2ZOK,/=64_".I57,FLD\Q5-[NKA MSV8I&4=EOYBY]5B3GXACFE*,96YV0JO,]X? MW=-TX=)&U>*1N?"=7N1ANI1KW<,CD>RLI-"Y_QC5-.%KRV(F6%23B[[L/8$U M0T45^11N,*0+,@!#QC3[$Z6T4>JXE!GT-M32ZJVLHO8-30^@H?JY7*!CJ266 MRJ9L2[H.F)#1H0;VO[:YZ)0YKP1S3K3]0W4RW'/ 1Q"I,J;&67PRZ85@5"\5 M?C:?)^(01VAAQVP0J:]180M5!87M(1ISP%7W54#%P&1# MD5C:2;;K *O5\%!Z?&%8C"0,0V70J3XO16M47AE.Y9 .F^F^55MN7]8RQ3:6 M=WKR&.I35CR&3*+-?C7>5)4/JG2W;(9JUD71#RF].Y%YIIQ,S#>;\02A>TAR MKOI2:ZNJ,8B%KS#2E(1K15P"'X3&+8K2ZDE7[3R.4YTL0K@O\C)6$2GE Y$3 MMIQSE](PI5PD85:R_*MS;J=;/=FMF)B&3U6AR*\WLC6<'/MBTIP8 M76PJR?1@R0*FD9J':_6I4!\OJH@RPOA?2+%1F [O255%!@DC61PU$C(*75.N MQYI:WGB-R5N#G[)IRBT7I&E%/RL(P:DS5NWN9&ZPNN:HZA =E-3!,5?G5B/5 MV2ZV&Q$+ZM]Y(X);%TB,/-^3%1:SW\P]_3(OM]2*3&L^V5DJDQ&.8@5=@-S/ M@]O7211(+02P TQNN9'(N3P (UO9--;*F"O )@&6L,C2<-V;A4#"] -T/"6Z MD1\=(?\D49QCV@H2%",RMKND3CRPMYFT?:Q:FW"J.(4O$W(\@]5 I4F2(D2< MY,T3KO\1G+H?60<[,2"@4;.+/'L=.-^ +IK[JC?2H\CFU;M. %I8'14_-ABE M,J:=G%:GQGS?JH[Z[:WZK4[>SP3UB& O;YPK]T&Y:64OJ:]?3S/A0/Z1_7!- MJ<],\.<1_O=VC$ZE 'ANB-?L(&3.ETDF([16[CTQ #.&G)2@^5T/@-X%Z+;? MX']SCV,,4(V)RS$D4QHIE+93=<;&M?6+W% K#J:Q$TZA-RYQ^MM^.9(R>>E* M"CSHX\B%I=CMBN017:7-QI\(/RWXOW(7PRB,I?]7]&,[L&>6[KE8J35D-Y.=LJ89E)G2LHPL?B2^^IL8#)P+L(6(G#-5 M(>K#0J[,-@R0)J$TD>@RYV@%\HMZ$6N>;2QI);-7_\( EYY8['K69 MW/CU\ Q0+/5TE%&$4(H>+.^@=J2N\5E.@Z^]:^R(Q#@.(N2)-6*!1>4+++.7 MV32U5J;;#-/ A2/&%=[4.UG M9.50=^*4OE39O2BMD)4Y^DH-EZGPA;0)=1CV":R.OG N0@4KMVX %UXB>]JK; MX=J0$AQ%T)Z!FO>(.K\J;WX9L)R+,P6QPB/GITJ@;\$@&3B?O1"5_!X<^5.8 M?158[9M_;_J #4UAI5UQBCUT_N<6N-/_WJ=*E-8!W#V>XX%I\<]=<[ Q#"$JF%'K"_(="& MDDY).#8_Q3Y<]/.^^KE$X_<)B/5\*YL>0'>7:E-4?_3![S:UNB%[0BZCK M/19LM6K'7)B,3@3J8HK),>4+:99JB^R>HU0\&X&T?P579QQYOFQVW&;W2:P<":[75P'[?%@@1TI2G.H+V:5N MZ8F7^*P*@^H6$Y@RAT!5,*\6>G[:C*A\+6ON9U*A):)T(S&M5QA6JC<:8GZ MM%)4"=5-$ZIEQ#5E\%3RM9*OVRE?V3A@X7%WM295^ID)>YV0]P5$UU6ZF%F>Y6-FDJ'UP=&,9L^X/%2R7*6 *:L[+ MTUYW*F= ]O14(FNAT,XSW+0WHEC_T3(R)R=*Y4D94C$E7,[$ QPKH^7S1^0 M^(LQV5!+"MEK3J%BB%,3C#G0,=T> Q2I]Q1[9_DM?R5/[=?2U520\9?FOEZ5 MLAP/#!1SK&Z_F^,X2#<'YJ[LI:-4)N9/!R^Y9;,AH#SP>EYBP08H&+,0M 6 MME\%T.FZ+7LZRMQ<1WF3Y2&'7UI[!\!2OD\5]Y*@'7TW MT4V9+?BSQMJ5W#[<2BYS<2UT WTD]V[FHR74I*]7M&HJ0R.P9F1Q!X+RE P] ML^O:/#(K*V,J)L#3:I^5%3%[[4QB!&Z2"GP28'N="-QW)[%LS,5]J+CJ#ZYJ M60^03]XPE0@$![=9M-APD'+*XR T>9W9>6.O16^"'A2 E!2SZ2W MW]EET[G 8+;Q0?:[;&;&/*8<#QJSXXQV )%S[V=Y<:F2R;' W\%![HZ(B-^K= M2VR (1O]P$U%::Q;OW)*H ZNAZ'/EA:SK4>]PODM@L8N85DQ-4IT$]?.AXPG M,14H@A[V*'"20^P,_;!+1==F+H8$(I:=63AYA.SW *M53?:4$EVZLDF.BW9U M5UU5*:^=HXYRIQ$7::L,:(O)0]5$7V M7+]?9DF4C/[(&U)A83:952ZQJZ)"MBF6@[9RZ2>2[P@8R7N*%Z8R/.R)[F[Q M_'"Z%4_]D&LY+V^8(DW;/A^E?N1]/QFWFWF7DA/R=9N0T;'./*FGXC;F8\I >UR= MV/5%7LR"VG17J#;9(E/^**-S6QS-"JU\48%#.)>"5>8,OHY Y;ZY#T7@_20V MN?MZ>6%?4?:K#=VKA;^,NK^1_5=$Y5;VO.EO894WR;8;TJG)BR,RZ)#MK"AG'3G_V=@N M/&2E\8"8ZL*%1UUT9V2XEUM.ZG@1G@P=X"OD=$D2@S=&#%Z5BL&:P_.*\H0Z M[0W(V?MHA=E&&"V!HI**,OI\-MFAT&WMD:(?\[AUM]>+N.Q"$W[B\O02IE13 M1= F@L'LJJG.[<8Z[>OA+TKRC;!E0X)HL,M(TQE%=^R"C]D15#HT:]W<@2C^Z^3+W]#;U@G(.[2B.FX$JXUQZ_7P[; M!P@YI!=H.SOK=W\&S1O!9@9>7X5[3E/1 MU(7%#)UR9E /9Y@APU=ETA'WJGA3U2^V"VA;K<#;0!>D/:8GSTEE9"Z1<SH5NF4J\Z]\($W16(7FZO:O6II/[QJ"76U+0GH3J[3Y7R!4Y>2"@_%@NS1"J8$0(I]6?6=!5I MHHC"@YKK'IUU)^44YII=RJC%LIN)*TBEFUVW%BS<"L#:ESGQ&KMXA>FEZF(' MZA_I6(TZ!-M2*M,R]=TTD2)8.MCNYB>--F#O@YQJKH(ZSON#]I\^V&K&AJBP MZZ:MJHINJZBR; J-S8PUY^9+QD_CW.ZY>]&>OS?E69Y5[D?TJR,'TKBID?N! M79,SV@+.AM@1H[$?3@0WHP" X F]$+M^Q720$$1F'8=\*9&.@BN_4?8>2]%' MP*B&,NA3BKDNIVH@=L8Z!E.7]HQSC:2:JF?/5 ^GXF:")K39^? M.5=N$/;@Q"(::+27L9KDUQD5P_@Q=_*P.DE1EP>-U,-?K3^I5P^!%81!K@^- M.07K3W54GWFVBG-[+T02*W]LK+J')L*>(D.L9^1 5J+/(:PT^SMJ-AON?AZF&,MEJ4 M0J3&W6B;Q?/A_;"CN!@@.9&&>F;R<&$?D,W*(7R4/0#X1<_%IE])KI"W*P"L M!XT-&8/%,7#W2LE"[KW%"=IKJ?,C%_N$9LAPJVYWL,XEEBS\BP&HA @@#E'%+J69@. MG5/0J%S?KY6^H*2BWSL4^-="XC,.M:HU*P;E=O> M8_0&2#'2'19"U:21%Y(09 9)&]_RHXC,""A:GR>]J8B'M07Z*0]ZDD,171Y> MS>NMG,A7VJ+F O'PAQJZ>J$'X%V:#ER[W:O&)MR1<'E$?8: ,DJBC 2828(4 M3@R#NO5)\31AD PINS;M=P.O1GB[3)C8*5;A)=0^G\.!XY2M<$W^[%]%5=;# M\7)ZV*X$WJ9\Y\(L)(O3V2[ES H:*MP51DG#*1'D# YX$]3<&$,H>$NB:3J@ M!E3:URSM34H\P;I'/]-'12=[*9-8&>'48U5:RPPTN[- M]03K55^>["M?=W \XW4OR5K]BL3A-#\MF%2K4?HZNWRK'-WK+MKR1&92SJA, MA'^G(>J2MB\KYC$>I%'PYS(W FNQJ;I=RCV+Y=!+N!E9Y$NCI=:BM+21Y,,$ M46^8'X12)T=7#G=FB*.R&W'*E?Y+ M3A+9(U<.=T4\JLF5JOM\ -:LQ]%GK,/"($Q?.S9B>4JS9*MZ0DV--5 &A PU.S4_NLT(G"8;UNHS6&-_#ONH8B>-, M(#E&*:&>Z%978M85-5X>E &%;AWV3"D'DNFZZ(?!D%]MJ_T6L+&M;KIJ @-W M(=0>JHBGF5M;Y$^DAPBUX@?7\XD<5:*B%:O>11/.2JNB:244+S0),51CJ"4Y# MB14GGRNX+VM:)]/SNP*KWS86,L(25&KBC612K"HAJ:F&8CP4.Z)\M\^*';!2 M4NU-F;99^LSW$Y[VC]F3*I2S1G;H=V&!?LJ&H/)VS3PGSM;X M/#GOU!YGS66I1^V#VGZK23D6\N]L9W26,0909<\FA;R?WP+.!@J&/$><5=_7 M@EX=QR]'K?U:JRD;PU5"(7 8)YHQC6@DG'YA< M%K@AI%LD 0Y)V#VOA$5K6ECH]>FMN2O'L+/,()E2D_?XZ+V8;A_N7&]O@;V; M]-J^]A]] YR*^JD;^:$3>UQ !JNE"4#V'_Q)D3ZN9M _A/ASDHP4Q??B'_4! M$FNDLA3D563$(?IFM3)@0"O!K$QKE@&H(TJ[4TWX4PU]@\/ M4)"REUPGG3VUT+3S?FHM)[O.\=&166V1QA3CB@-BS*O\K]7[\>(RC]R]&H[)>-EZ1(/ YHO MB.!$^'K>%ZM4@>M/8B_>LV\3.:$USOYDJC:<($7E/"*'OU6AQ>%7?2H9HVF( MW8_Q0%0-^6Y+H,N@%XZ$<^?^%#LNE:?>R6SF_BP+N:G!7SR.3.AY M:O@(((/6<<*ETB >TB,!'>&+;F MDHTDY[^Z(S446B:LP-)$VFER3P%H.?W+EPV;&!ZKU5*JMJ,:#731F.>0;N09 MO4.!)"&2#,D<-/V;3%@:N]C+S&$-?V$MAN)!U&-42K,M"W$-;H$N9UPCGO6B MV:&8NFA81?/UX$.=M",]/M+8)SZ4L6FVVWD\K?;2Z2GR-;M$>(I3X\0ZW"3+ MJ1I6E>Y5?IXUZ<.PLWI BH:^'L$+$A8X6\;IU' J-=R7YBC3K.T](M \1?'8 MU$0)*Q;)F*O6&QD44;%JN@6)[X _JWS$=>1?^N*?^W+ M3><>$Z9E=D1?.8M]@("R& W[X+4C25ME2)*@( F!#2XD4:%Q05:Q$NM,.6;0 M9E9QIN)V3G'+20:91D%Q%E,E(6&(3?J]FAA60$0$*#=\B6UQH+:K7+2F(QE( MEP=AN68B,9#ICN2<,>K#@**.2M):V-'ZB@OQ]2G:GJ!S#CO M[/#VQ"HV*T.CT6\D*G=6(QB(/@V!II8+"4^:4DJMNKB+LN!S=V?!]7M);1_@ MU=^EEU_."[*6*KJAAVJJO%1UT8V'6;]RI"^5.,#K)^Q%)'4B2V^>N=7D='>, M @ 1R*N#BN.LW0$QR:X[#QX@4UW@5&'/Z<8%%Z>V%G*9GF:,L*/FNCTYI-"N MCJ0B_T*5.N2AQ;;NK-AY1^LXM-7]V8V]'H_Z\$ I .1<@>C[2JW' .^WZ!G= M;6L<\>$K?*AB%7), [[",2"Y==CXY)R[$384C9T;A=UL=Q_X M-?PNTP?'X3/2,)C%@0U2F2[3]T"MI IX:8[3SZ4X>:2<#>01'!,_!)TM):[" M+CBZ CI;S6C-_;3"6*SKRF@XK>YJ(UR23R#1Q5>5!E=78*A9B?1[S![+K(M6 M/G"PK5]/ :] -B#6I$8T,3>O"Z967:W!U8=W.='C;W:\V3MH66 M[%BJ1Q6#L!\ZJAT<']6.3PY*'[.::W/R?$@Q?*OE-E433[_6S>U;ORM''\4M)G?=&:UU(]]$=*;K?.*?B'',JP$V?GGFSMI_RI(I]0!: M!H#O#VN'1VATMU_]#%X U8>*(%9($*VC@]I!LU$1Q#H3Q.&;$42S!>+AH';2 M.J@HHJ((I(A6K778K+4/6IM!$*^D6CW>>XF8I5@MK>SU3=\P/PEMV,8JU%2H MV4G4O)UI^?I2_4P$(65TA-&"ETUU]&O]A@HU%6HV$#5OI4O*,&S=%P,9"5Z& MSOR/?#Z(G9,3FV*TYJ_.5'+35HOC%^ 4_2>-6NOD9 ,1M"$HWJ\=@?UY='Q8 MH7A9*&[7VH<'M8/#1=W"ZX"@#4$Q4/$^"(OF_A)1O'+5?VL/?L,V5J&F0LU. MHN:M%/;7OQ]T>KN,H^=SYM^^D^$6D,/ZOJ%"386:#43-RC7,5Y2P&^'O>,%^ M%XTLOU%^P5[CE0SY%T"Q:#I!=;SS'^_A476\6WN\K;V%\X*JX]V."W3QCTO3'K?#;:OJS@WU0]SQ;F^74WV#58DTMXN,=:&Q[(2" M_4;D-WJDKA< (XF4ZKBQQ33]NR>"F-LJZNZ(>@!N[LW4DT*W4LCT2.]A+R(S M?YY@@,]'SER 9-[+_8N\:+HMNRHICW6KJ%BC@WK CK#!#/:IP2G "@8/.T^, M7"^@;MFQ&*0^K/Z O=5^M_XEN]CFL(ROY7IVU/9]TRJS3]TSL!]V&"!;8CM+ MW836/,Q B%@]@&7)7L0CR.[A(8"3Q^M2;R5 5>@.LG9KI9OK$< M]0@-0NHG#Z_D 4V(!81MNK)=(]N"!Q;'3D%XBMSZYK4[53-AZC9$G@0ZH:3_3C@EJ)NKD\U!\V"$4M*I>:+ _FPU76_.RE?5(VIG6LYQUIJ M>@HKM8"FMG1X5SC)8U@'5AK;;(14SGI%V;?.P(O@O_(FB@MHMZS#B*9H H:H M6EZNFJ1Q+' 8_E#ZS>74A,&I(47T&M4(;YH]:AG44"\==1($A5RA>%+%C%4, M2"7#/.3LR1$BNS]K!QH9&5QIJ&G:\OQ %K_$AGP:I!KW!G>#/,]0-Q/Q;Y)^ MW(S/]/55/3]9;5):;^%X(]W%+-NP+-M%37&?EN*6V%7]7RW0X$T&14G1:;'8 MMW07V$>$?=>FM96=E*&J6'N&2D> %.BO29'J'!1HI(J_,]0\>'IAN6,*DJ::(,UT.-][!I5380Q*B>-M7>F? ^[K8$6]$R6VF)]/]LK MWB".A5G=^6*3/V'7[AJ?I6K64\SU80D\'A,Z\.1H*[W*(J8SB_AR\YFO%K:> MD[S=[%RXO22,X@S */0]K.V7@\,][ &?N&318Y^S'FF_2>0-T1+/\*HT^:@- MIO+?)'8GKD_.^^8'!Z>4P[9[^,X4Q$,D[PHZ">H6CBH3-065/>KOO1C@I(FJ M.'XY"O^5Z5TO[R#JY$N=-)F&WK>R:UDXI.;#<".QW6R/2%8^'%=/;L6/XP0G M 0TG6M@1#K'QM!SU\2O1POO]S(H$18"=H*EE&ZBW\)X)OA,. CCM(^CO M9H\V;N]>IFM94^ZG]22;68II6[KOJ/$OCSL $A*R$7H8T!A-4K_5N5,W9K6&TC>H'O@BPLJA6@H5F@^()1>''171@7L!=?AUE=R\QH1P/( MR!CMPG2M]0L'\8W "@K-,*W,?+RL84- 6$W;64A@>A,HARG]7KNJ<(X6X!3G MWP6)5BIY:*/F'#B&OO!WD@->H++ACZ<=="4*U2Q5CH>93'E#=_(\3)PF Q\$R)E4,@70P,NGDI#Q4P@X; MM@)V0S.R<+S@C8_W.-+^.5S38UK&*%Y9H0@W+*@$Y!IDF16"%8F272I5^);2 M@ 3=/ZSI/!F;B(MW5J)S$2S?U0?<6MZ,QV%I2CWK$;Z49A7&9N@!.9;85>/% M9M1 /EH2#O18(H57:QPP*4U2-TG*[B.C?#%,W%9=-EK6%YX(R^!R]?IX[AIU.L4+ 2$Y4O)Q-RZZ)SR M(,N9>Y&A^RYYQGAQOS MTX HT_Q=OTIX).%PB)+KX6?RVHZRLQ6H?72LQ]/DT65A9@][#).*+.>\Z[OP M7VE_2'^@:TJAQ-ZP??E.OY?@Z"B&P/ 0J.?H,U']X9D@'_"EEI:)G>Y1Q:#Q M;&JEG#=&3W/)J13L$GI4FEB7Z8LEAGV,DST3<]-?F60V'QD$"))6&SVU>\C96> MA17D=GGE*^&-'GY;:LL9=3P=2O(^M?BO\Y3M&W="@H?' :BI5,WC_)QQ>P)0 MD3M:#]4@,*R)5.I*Q(P-E&.CL1].))OTX=7H\7!B'B5"RPCB+@\'Q,@H'VX* M[\]'-Z)8.\*43&@:<93*51YXC(C,GM!>;KT<:3YR-7*M2[\"]LQG=P=+7 5( M?GV2F03 >QQ FH[&*F< OWF07G1>_0,)>[X^ )LT2U4C4MYR2IE]5=QD3GZ( M0P'J>#KY:UU= ?@,C]XIHR\YQ#TW@,S8L?B&K&KR0%.9 :H!7/1L!&.J#*" MH##WN%3>X)\$$$'+TY[% ^H%-.3+5F1P)FJ7YR$F$M$<+^9+V5Z2PRBJZ3^. M6S;W\!MF/6RJ-5N3+AHUD5)CEOT/CV[L-%M[1^T_%8W?=@W58!3@L%%K-ML< M"F@VCFM'!\>U;(A".W/FN33S"3O38_&*(J-%- T:V<5SP3BYV*491_X*N$38G:Y-S1[),9L5BQG4 M"WJ8RX8>/J7#RO#A;GHZ;JR9N68X3[O1KF.V#-("52K6S0C',=_;9*+B10S4 MY2HS6@_$C3 9,N(Y7&5RW?(F2I%LF?KV984WR9YEWNL[KOB2T#=R]F[,73Z_ M S7Y[/[/+<6OHWG8S&U)F.!<,VW%V!O*P,'IE[&9#I>;)Z8S4I17MQ UF;NT MY/*<"HT3'(RH':1BK<5_]4#9Z=.L9"#'4W?L)30W+@[3J+?KD[0[)5.+Y&0A M'"[]4PZ5)8!^:>PUG1'(7JEZIP&.>(R\GG80D>L,_[ F5=7@-MD[L9\K>LK- MO>XQC'X@K_;DD?7%P.MYB7)"9(!S?FDU]O;5"CM)\)]M&5%XLW)P105B:6PB MI:A'(8Y#E5$@S-;)3-[U8GM"J/)S%BU <30^,76DR@7,YH++$6P>RLNV63K M0Y7!HD&*"5!H04U/.M0YG;AZ #APDD<<5Z2T$#U4RXOQ]NH)%MQ20A:-602- MQ/5B)2A1G\=;"W_3#],N^F&&;J2' A=M6/EH^=IC5<3$FVG4ZC DA(2(P8"2 MW!YQUALY>FC4+4@A1YZ&UOJF3T3%FG5@K.>STY"'7ZLXLLSN>A1R,KD@.Z@: M394I'"JO9$["\:Q:9;G8P?'X9R$;OF(3ZM;!HFL45F+ABG?SZ M@GJU94)([GD'2079 15X$!6D;\;I&/6=4AXUHN17GD;?1QWN/GS$)!KB%YX5 M&83H1$TC$AUY,:<'B:MQ%PP/>=6G@ HI>PAN5?XQ*+1R2#A.3/9UHJMVO^.K MXNG7="+E-<]FR76K5O"LSCQ M-1&R)+%028(LA(@UF4PFTZ^PKX-/0Z$3*G!;A/RWM[H49(W;QZQN4!58K* ' M%)4/'3#E8JQ'H62([8T&L0-JGT]*BJ63@3+"9KU61[!X\H$'MN.775(6I8Q6 M"AP.AAU*1SRE 9F30\= (.08;O5V&6E'L"1,3AJSJP?H"CX )9-JI-GOH#14 MT;L/0C\<2EC&(19@HE;'Y90R^)D9:V\'#SC0IO/9BQ1''KW:Q7JA,5C;KHQH MIZ._H'M:!@TC T?Y'UZ6HZ#D.N15)XIO@AII( M[YE,1DE*H(='[.-39\:%3U(551F9E+?11PI2#AUI+@Q\&L:.08TPCBD92/K* MQ& 7\4FQI-)7R!ST >(*2"=VX$*9G?YCRB&:G])M\%3CQS.CV=]W 3A4&(B!Y51>F7@?.WU)]8(8J+SNUG MTM@P%>SV=_JFWFRR>+7D[0!I3,R&>@H$7W0+V76D3EX]/DJ M^6H$HAWR)'E.*3S4 ,H9")>5/E^CJ?60<+_H$"!6>,] MYD:/NJ)/,[3EHQ_XDI"B0,H\="'] $D5>3V4TYS\C<67)G_(C;U8>9)(JL%O MJ2AMH.4:(SK$Z!V>UYYS*K-3+&1YS)%#"YF(/KR#Z!"YQ _) M)!>FSFR5+8O8C%/G5]HCRO6O/Y1B7^&&+T_+;SP=]V6G-0 9V>^FZ@):-2;) M30/A.58U3KL^$)?6 -0&:U*DBZ _4E/J;^!Z=RYY)3"U?A^3:\;5EP=FP .2 MF":\&%/Y)\*-Y!7EX=Q%;Z3#K+A;.FB,I69_W@5M(J!F!^X R[_.0(:1:[/9 M)M?F,:,*?NSC//, FMOY-^0Y!DW]Q9@NPJY/ ;";3&28T4?P\?M9-B MG+I#F2&93!DE@HZ:QQ\^.;<]T'^0"KZ%?:,.F N&MD\O1AT-" 57ES8[>KS< MB#2*;I@FE@Q3>9KRMB=[6](M6]0QUUA;02M'!JQDX$0Q"!$N5LP:165D0VKX M?L^Y'8L>?>/[DYK,KI ROW'"L XTN\\)HLJ2T!&_#A586MKCFR &_L7EBI\)0>OVT%$AGQF- M1-\S,8*N&(02F_E?QGH]8,TY-IW"%QD)K IQ37FM M$KI/25;.(,P)5GB])5OS(?Q^*+A*FU,7F/W4HY3\90!%1U\FJU4&^+TDSBLJ MI7P>,Y\"BBU^Y&\LVT!RI[QO%559V3Z2B3E'2%]D:9#&B#F^L :1_#'<4P'= MQ6_ MEZJ$_3R03>9Q)J$#^B(S:!KA6<-3((BYNLB%+A3C0%#ZJ6@:9 M<3'(V/;HS&;PBHODICJ@E+1?X,*$,.$"T!Z%MXK3RA74><1.23RE77($FJ2? M3 XI$WD$A!1[H W-U"BE4)WD3RM6B9YX=]#;%?R,/L"A?]:%F*D.L[GG<7HFK)##UF2YWO:$]!ROW M92"M)C4PAZ+"NA:5JW.0[3*>4!N#[+J1?:I"H=\FED5!AV/D==-$Z%T"MLK2?X$7 :L'5A'>JUS\IG3 MN0,0?UAN,TUV_"Q3!(A@*FKN^6 WTXDB--10B@ ?GQQQ MH5Z6^_]Q"HF5C#]+V.I$TE*!.X>2^82TW56A>06Z N')I ,O6_6:1_.Z"O>, MA$;0ZMCD\-;N$'2*F4(76"S&4DLZ0O=1V_IN4L'H9^]=8E\L)=>:,+$Z\(9%BTCC1,6GJ0/-9:Z%R-UH[ MLFL![_A+1IA1S *6^_F&62@L@?\S)I_FB'HXJ%OE)&1L!7WS:28CE:Z*Q^ ) M^&S9AD6N9=E[^J6Z@)(S2[5X<./"?+[\9]8K&35XIVHCD 27F$9Q-.L]+..[ M)(8E4C.93U13B?*.0V$N=P11O;3XM:8]%<(SI1^6^3DMYRXY]\ M6K[M.>?E%G1-GA8]KW\0\%5$"W,R-BV^JZ+PNI>$.4E8K#^",#JT;<)>. *# MSOTIM-IX=(!2Z!+5E_HYT]8=JF,#P2U .JR;L)UXAR6NEP&6CX?19+82B4L7 M*)'L@O<]FHPL0S)HY.B#UJD_^H)ED0:L(V2C'KLR3M)YXOXT,5IJCP+[D;S" M:EAB=H5[44%67%/NQTEU:KSZL2[C1AJ-0Y_8S;42_2=[SG<7WUZJ "&S'UW5;!ZA!I\Y#4;IL7.: MC"_78%"6YD6_3G@.RMQSN9H"G>KKJQ93RN@Q93$9C5\5%)?T]"LKI]Q5&=-) MA_#!7"*F;41,B=[C9'2>TRG'[ZF,B](3&)/WQC(<2)_^[*95G)[SW& _37GASV RRW"ON.R5@Y(' M%HNMBU%$D]+NT@2DSXQ3M>3AX-F5(S)_"EN#RHD@V>F0#0 FQ>\UYW[D] M_2!KZPX;ATQ=^'V!76VX5$=#7:"7!\%->]W ]2>QQS>'Y3"2S@=35N-?<$1*G)_R*0YY8K2S^F7T7*PIR1SNZHK#, ?49\5 M=,^2+TH7E%.VH<26U&JE-U_@!YY2L3(1R"S(5E!_ MA%B5)4#[>\#E2O):7$ MZZ$+=-5)\E#9IY)T<,,\- 1;0P >R(]I=M*A(^54HQP0-5T%9">@JA$>%D69 M;=+U)=.B]*5%71+YM=QH*-/7N6;[$ZCAKQ;1XY"]J;O3Y $QH7H1BI^,4,Y ME&+CL-YH9=K):F7Q*Q:DFP#&0S=V6! M!GN#K&8V=-! 4LA2E'XKK8SR@M]I65PKEN*4BV;UFM-G\^>/:5P?NN[XTZT) M71G%^0:(K0=PWP&^/_MA[\=?_^?_P,J@/ZNG5%"U8X)K-U%X@>=Y:9KWZ<>Y M^N%G\ET,_O+N K0H&7&%_TE"F0I4WV^\^VN&4O3!CQ.=P;ZZM/FKZ[MS9]^Q M,DNVL>8VE4S]D1_9I&(WW=ALIU\;..*E9)J]R-4@E M4!HOY&7EJ7(FI\>%JY;=)N^3;-,4C>B.^DG&FE5SC[+G@6D_9\+'W#BR!4%5 M-3$R%P1BZ/N3>O@82*@P^NWU/=1[LB-A,OJ)6B,# #FRU.*7-S7GZ]?3S/+H MAT():%(G>[/>C>!F>U12>Q2B\M=]"O:M@H)5,7\9Z8C(L MM5&3-9>E.J5:.N_N8*G,25[>%*$>CD?&.G5?(O8HN,Y7&CFS;WX\G8"GIU!1 M58G)FG&3C&6+0_NZDZG^ZG;'7:F/]'&VF0 MPR,PHZ/FJ)(2N_6'ZJ^%RJR U?!WB3>2A3"4R"+Z7(;!>+![OX,FG^DY@DVT MRG9,"D=9<[>I'O_L\"@Z&X+"G \?QB_[K=KA_I'S7K6/I^A(&'R08P>/F[7F M41OGP0?#.BZ1_0$#IZV%_691OW0#FV:K)VA'P@:+G^PWRF!KU@X:C5KCN%4$ MW4YRI581OF$B*"C:B-[;/7P*H?:IQPUQ66S5P2M6"VK1.DSR&O:M0TCZ31UI\-0 M$Y64N/_"K$@_[,I(D!P'(V(K_>/T'DR[FG,1<;[F%X$# #NN_X7?] M<*3G\LJ/*0H)DOO63D6D?D_ZD*1R.7!'GJ\R6DW%>U]@KJN^"'7HY#R.99V] M'%J=X=7;\YOL(6B-Y3S%#OZ@^=P)7^"HD#30Q=_ZY99-WRY^9YYPTY>*G9+2ZL"C^D=!821E'R4W@=@ Z^OQ($S+0KP M[FZV&SA/3F?/D:\<\\U(D\.93QZ\B(PS[D;P&*KJ8A49K]' H?S .@("%L!A M=;B ,B+@]5-ZBN;P&"5%?^I=SB]'[:FW3*MB.TD7'#_)^5P'%'HAR3PU34V) M2"GY9^BOY+#U8K+P="Z2>HZ"B\#]%)'R1&P!0K'ZHY8"'T<1R*.SUCG',, M6<37Z%U1.'%]+OWFC*B)]*ZZLN+ )&"9ZV4W'=#7T\&"HR>=/=PC8EHKXB/Y M MNJ M>>UDHKC# %@1#)0OH^YO6>.$OJI,DXQI G9"6ULF;N0F]W 5%6./ORQTY[E2 MW]6>29WU\5)SQ)$<5VZ(L'8PTQC)&AC'AX7VA7,+S/L?$?D(\M>$4^+4=Y=J M&.1ET-NK@>VC31M;HY:&RE167U;&M&UGAH*$(F"8?C>4 \GMPP#HF7AK3A=$ MMXF T;2F0H1Z(LZAU"08%AM+UGK&7KK$4PA$@E4-=_?4(^?]Y?7=!\M@VE.* MKXK/:J]M)O(%D&'G5 R6)3*I KN+TQ0+4L6XSX+P!_5[[*W%+022*,3*@00; M#\O\_C0)Y8"IF)3S.&L!(DH ?E @I'?9PW_AW$+!M0OWF+H,OW()ALR[4^XX M#QNLR5X0@1QHBL_T!:=%<:$'J6TQ5A_S.$4O1D4!P*YEHHH\!EMVBP0$Q5RO MC 'H;N114R 34L?RD22LH_<13D$]).?!&PL5+$3=8]/%?JOH>X03YR9! +T$ MKZ]!-F:JC]W9"$JLV@DI#0[!)7V*(3' (DQ8H+;G/*6M9X5'1D__I35#)=]) ME>/%IL],E!HKAY(1P,+ 2(J(,)SN#JT"4>5+EO-BD$=DW3]DR=8&2F5D?+&JIJIHBJR493FH",AZCJDV91TO9->C$FE MG\^R\5>N38W LNBH%F$T9T16!^'98-TGG:;*IT4#2,F:6]T*6:MG[*O55I%Z M193V$AZ'URF-CN9M9.?U44(,]W6<(I.5E_*:"]: MIT'OD-*^)$Z14\, >!H6Q+L9GA)W*JL^,SV4FZ MUF;;7>2B+U9DS&;.?,A8(>IWE14WG:JRK^R*0F02-/,A%.VY3&QB*N'DQ18= MJ[SE5MT3T:6L0==LY9)#;NY0"_T-5!>V6.RLE)N[Z4Q<^31?4;91I#%I+*(N MV2\J5B$+,J@?!P>-4!,/02IT8L\-BD,]NNWQ+M+K',JOILF,\HNG^DNSMM]X MD>J+(Y1E/V39D7E!U5#EL$B E&'7R MV)P[G>E?H4=5(*Q=$L^YCD]M#K$&:L@ZJ2RKP':C:2!K18H#"!?PO=(4SG_2 M#0+W_5>2Z;/TS_.O4_HG#V3C#"'@S,0:!V&761$P317N3U0#;MUWS5.A!376 M1NWR N0!IHZU&PH;64]W>9*24Y"@Q/K_BY.4[F;24@L]=!IMI* MK>YQC7]5S#^O%@ZTCMRMQ:!*E]$)8M.42?88J-NHK5M),D5*>DVFX.32;@J2 M9/1[I ZE4V6P82)W5RY($8:WP^M54T Y-A@DB&Y\@:]6#G0@ ^[:@EW/@>A\ ME0(@38F'#TX\!D$#6_V3K="B&6$409F_O4/#PRM#H#($5F4(',V7I!-@LJG2 MOZFF*0P&GJQOG''3FZ>FLV-!9<'ARLB5VZVI[;DX.$M5?!3-;YP%H68< MPX?8-[O/KCG<8*9JBO4!JTT"0O,FBE6LM?A&;;<#C42.'B5- 39>X.2 MM/*/JU$R:N0/@J6-)?5N;8H5%MXN6$*;K\ USB?ZN+R6X]M*>K (R+FY-EL&81G0;\$>GC7I3IOHPCE.8'(?-6_3ZJ/6// MMZQP=*810'61,;64R0U.J28F&X#\6=-0NV&2A*-Y!Z+VZ.)\[7FHK_!6V#9@ M.?C+NY9&J40-;Q VZKL@*9M[;4 Q67U93GL"!O\% T^G4_5I(\^;S%J=P#-. M8,KN>^,#\!>93_PT1ZYT9G/!.:_##.E-WM$SR ,D/S#3D*8%HO0/HT_.?YV> MGI]?7,RB''EWM _^M!0^LVYH5E87Y#-UM95#M\ )//VREVSUE^=MK867MBU. M:/[Q4B!L-6H'C7WXW^/U/H7J2.<_TGULDU [;NZ_S9&^DF!ZO/<2\8P+[26H MZO1D=TELVC?"?@PRWL([W3_^-3_J:WYLOIR0G]:,WF*-MR':]\T64FRM>=)^ M'3R_!)@/U5$O]:B;M7T04LWCM3[JM].W-EPS+C!_9A//AFUL"U"SP5?TE#^O MAH'2]1#0K;T62L]^F )X:Z%MS@/FVTCYHUK[I%%K+:R$K@._5H>](.2@O.TW M#VJ'K46MR!<*L8_D/L]\M#6#EO-A#&[2.1I'-%G!-*_D0#"U\(?'1V3+I+$8 MI#Z<-/:W5\T_J1WU3_J%/W&:&,1M'G)7[3WG&J.G8Z @CKW(\0C9>#@EP+ML M)G&.&L9P]"QV;PID2B;C2$T);"$EK261BQ101VK D)$' )UQHBPE$E&6*]6( MX ^XO[C#E63:;4X@F(:#D3 S!G+Y7.[82P#C_Z%VH#Q/#]-W&MRJCQ*,9&^L M?+A*1I#+(",0BJ%33OW#YT#V_[/WK,Y[;9OV[,3]],&EDHV.PBT@.SV_OJ;656\)/1 @12;RXLGV*2D:"1SC9L\T5;7 MM#TD37/CU-$<4*%$VQ>Z-#\>\R66F7"F&!40E,)#B9KI7YHFT!D@IWGW.].: MU4DRF''O5-[0&B#F?2U9NTLZ.(2DC9&&O(PLKE-=AA7(BT>JJ7LM^1@)/DDCAF6<\VT MC0)73%/[C+?X+_-<2E').:@ UH+*)-KN%%[O.F,^^MN;46A8#I95CJXL6-]Z MHV:^[(\5YQFRH8/;V=?C,V1HAJQ9.JOKS>[V*&NA>"6SG3V$\>GB5P]X04LI MCL-ZNW<]PY)[ZB#NA-I7@,7,WCR+T:DB_)+#BE5817B!6)VNV $%0Y,5^':_ M;\8<@*,BU,&<1 9!1&]YK4"'\X1U6NP8!:QL$]O@^@&8,1Z?\3#D4PI=?K\Q MF5@#PDF7-WDU R-]/>FIZ#0ZHEDRGH^K=/]VW]P;BCU+-DVE_=RS'\FCU8F9KO..:O1DRRQK0QR1Y-%4P3U+N4=1>K*I",FSC'>T M^'9*0.A PG:DI@ZT=@"<>+,GJV:=6:5."[,'C!JW@P5%PFR_V=&CRI>=+QT] MA1-3DY0!!2;?T)@V@5 M)4V)V*$4LIFWT;/T2%S_E84GG^U1W 5AR'B#ANEI MEHLW8\"0%H;E;#=]7;Z],D]F4$#^.+T_3:\^X1UGD"ZVXZ41/SHA+)C:0<0F ME=.P]M-30)[H_' ::*=SN<.(3<#&$"KY,76")*Z8C!%TEHX0I<#$PP:3^7C/ M@()M;U4^E<"F>3R6+CNO4O:R:&NU$^XJ!"O*O4 M\=:&5*$FZ&^D"/#91_SA/FER2-'\F(CP1O3X7NYEE<30-YI 3+<#1VH%JAX# MZ2S'&3NOSZ^Z[H,\QT'@JUB3-4K6JU3S)(B\!%(+.M=%YQNF\@65#YK*7YFU M):C<;.RE \[$K-VSLRGK<-A=1B4W&?LED]688*!AGO_^=,/RN=W!<$:HY @S-5.2N=QA(4:HY"QIDV@'\. MC4*Z58NF_<9&J+%Z>SNR>6/P*[(R*DTC;FA7?/]\B0W"B1U@]UF99I37-@+K.^MX2V"]::SWSU30VUV\Q5H]+OXDC](4 M^]/35J)XT8E?1*!7H.+1H#ANE/W$/A^3@(]5;4& H'JD7+YY-B:$STW1NZRQWQ#1A%.1/D" MH$RES,23K?+JQWVJ>D*,-8OP*U;[+K#>M/+HEZ] $%C?#>O]LRU2UFU >BTZ MB\[RB^*!:6\'Z#7? TBPQ^L[D8,60>R6X[M/7>>NMWWH'M9%#GH?6#>[&26J M'A7G,U"7/O;J.TC7^"&P <*0Y :S"CU<1@\+E= PPFDTM8O2J>-8-[KIFW4< MZ]:9WL4D?O6X^.J<7/N>](E> GL[^PU>+5W8V @>I.NL!EWX(_JCV#OPTWV MR23,QJV%@BX3RBL[5[4-QZ?3"%?/\)\Z^_\)M!=D9L!IZWQ+TZXAW3I3^V=: MV5[-;.0(&7>4*"+#K=/Y:TGW0XC'QL4:DF+RB@_:0H>XH-N,FT7GXD[DA[?I/GK M1GC;2):2>F?IR^3Q-WH9JS"4S"JLI ^VZX+G[+ONVPEK@)GOB9EK5OB1@>)+ MEY\N&Q^.Q/_HX+@N>*]R:CA>V^AH;43'@LZA..!KX@;'OZO__U?>##_ M%C]R'\$?@>8CX(JK?\^G7')83I$VC1 $TW[8RUCK?;A^N)$,ZD>X?;B_^Y[?;KY=7W^\9S]"V MF]+5__WC^N'_S2FE(YOZE9U%A]U>[5GT[ =TCA\?^P=<2$'1%,JG?B>1!F+37Z;V@$?BP?L^TXYA>^KTA0O@.)#<1O=PI7@?4;1(M. C F. M+Z2 A+B6G%EG89&CG-\&XNCW&4[U[,>RB.*"GW9$(YLU2*'!OV(7*^RJ\2^@ M0I2TI_5G40ARA7[ZXM,9BQGRY,0;#A.E4R#AS4S/4-)(X=1UHE7M;ITPG'%B M(C=DEQPR?F(O ET'[\9F;O@VSX\DEX0A$Y4@%4_&?@#_G[&;Q_AQ*DGCCZ-7 MD*1O)V/G!5B/\FB[\ 0(S8!@Z!.T!#TU]WCPY&?5X3Q 9O,OQ?<27H)_$OWPC+_;(1AS29G8H M'Q'QU0M:G?3Z%(7T;G M5$]LQZ,F(Q_LGC<&@5_8>4MHCH.]YP[&DE.43&?8YIRS [;Q*4(N?R3$RYQ M>K"6\GOBO(^X'4./QU9D.>X3\ _F3'RGH8]Y";^QTGRV07Y[?NR:\$ *^3$D MTXB9HZD@C$>I# $0_^E WFCJB BP!^+C;1K<# *I,,Z!XD<##A0.&XY^Y%3%5P.]E2Z93[ M)4(%7@H@]T!OK,I>-OLM]Y)!X!#G=@A3=\"YZZ#\#7J M:XA& 44D>3QH H.H?1A]3ZW@X"YBJN?HQ!$_]B4CG0ZJ4U('>HY.7;.:$ MIE-[V& A.E]O!I\$'Q%(Q$E(-SHX'0S>4RBX:DO%;@8!&0D5P05'N#N=ZSLZ/9PNE'T=D*]1Q/?"AOF$$Z<&4B?IQL,DKM MT2,W#1R?QF>*9JFQ\Y5819M0E8:R,AZ/OS2@LV 5>EG+;-EZA0AA!FL6!\S2 M*/+55T,O_/3=_/0UO-$]/WWUAH2?WF76%GYZT3E>$P".$SF;B=-R#ONF[V5I MK;+>O52-9R\SG1E722"B\S(*_OC[S$.URMV&W"30<".%>-P'>CBF0"2!LS] 6];EHB=^C= R PG,3Y)#DE6*;V@U83^(GPTH3=> M0BR9 ?G-C9JY=&MB(B7Y4N#DPC?GG49<)V1#7!',.>"X(\==S7GY3KF9.V9V M,DDU]D1CV(IV17F?;0LX7<8CZG&'-+L(3GX-L3++"9^IAQ:E)XA^^879EE)D M_T7HF4&.IFYJ@(BB)S/DTBT'E$/SJN!H1OA>H!BM/-C,H:8K+U 1L364N&XHRZWGG0# DI5:83#S-?.T(KLY#"A:4<5&)Q(RK%PY&GKQK00 MYL+'0?/25_M5^NP$$SH)0/H06CG),VS##,V0VX"E765#CQ M8KRY$KF-#$CT78:LR62F>@>U-0YIL(?,Z,VN30MGV''G:W%Q^N^9'XLZP/%? M)$(+>$CF3>JG +<%S[PS3_M*MO(FD-ZINHF[.,J#"%QW288LN#;8D//"5$H# MQX"8!JF8LN '?#K#:'?Q5\[CKV29CA$_SI Y'D 645\%=N> J@NQN"RQ*4/; M);%):V=T'9*X;RFRL1$OYNNR4,>G^^#<,T9&493Y>M%7.T!&HGY4_ @%IJ<; MLM8;9!;/%1 B_(6+**>\#HR_668,:H+J3=Z1!U^SQH8GLG)#9-=60%]_G"3.RB9 M4^>/P:Y%P;_\\/#S&A\@:LA*> L#V^UGF7Q@9IG\S2&L(/JK"NJ/-#T8V6!<\";*ZE:S !SI$P*69G;S^1FG+L%W0XG3#+9LTGDET3@ M %.QF0K0^2>3O B3SP88W=$K!I?FG?I+'RQN5*B_V<$C.,\+GC]W*D @:,92 M!D71D7_13OJ: E&DLZ7-]+5RVM?G];6BRY9QM/J:LV&_2 [MK*W9RRO4V8S^ M3&]+\SI[8&QJ/^98=)G*UL"V2UEE3F$S[1@_9%CS*V^T@GZJ:\W<[YAGMI:P MG=9;H_ZXF8)%_"\@#Y$3YO5ASO.>3Q@/,43@NBSSP1F"O2@?H,DX[,!S/G:H MGY-3:?QC)]]B0SF5YPPJIP!7_8%UM&)J]@1_X$[%W5J=NTI#=D5-+6TNN/&9C_V1CNF'0%.\7C9PQS6E&B92 5TUM( R^ M+.!OS:0@,P<^MFW9H3]2@J4U,<8:DIG:AGYQB0.V<&C%^=J47.8:1&WV5A,FZV53U;AW6Q!-U5?0SA=-< [ M-BK69(:&OHXX:5M0;*TR,P;];40C$"I3F9(+R!6D[?#S95X5Z$+7]5]CG<:N MV0(B\AFE'"3SEZDSRZ>&-'5?PBG!Q)PT(81F"6BQEE^$H*-DE<(4E/0GI^1Q MYZ+NYO@7_7?*;6DP@0)"\ZWN&W(7?JV P>>#6:N3#?%%ZH2C^?IT'4RWPH/9 M&.D?Z=^SAX3"QBF9"UQDPO923Y>-G+2>+\F:!Y75EBY9,F8]B4L-J&G\N^W1Z/,R>99+3>#':2 FB[!K M_M:#>'N_B?7'OYU'0<^!/IG85Y)FQ1TC\U-,8NV:03X&'*AO%A106^ M73\%MGTC-G:">/$Q4N)BWXS<6_7^>WRG/G@OYW<2IP R#[+8%_A>]!H8_=&+ M#[C_0@)NE23?8!DB -+Q>16&3;M04%LRH$T4,-3(:[-B7?:9P+D!X?2= %V MPCEPU5-#H0###^9[1MB8A_X7+59^<<@K#](D)3B6.()'P_3LR 59Q8!D-D.)E-E.7&!*:.^FAN\5[:6C#1<7 MJE*4_(G#W-E6)HSI@;!8_$F+IY>H.JPA.\'CG%5ZEY\N\V+6E/O6!JX%!2-W MXR"6H_3H+A9 R)@'_A<(&)K$&N&V<0,YV4KOS903BPFKC2\H]:9W,*ROR*!BQV,-*-I#S M>1DGU2_?6)7"&AFWY/43$E?YTOKEF,$7Y!V3!BSO@B+DT??_8I^<-S!MF:OK-S"7LQ4UFAAS^4W MXNE)M:CZ@ 9.HE=?PN:Q<"JP06(9N8WIC46R945V[.XD,IE:XUM+Y>(%5XEE M]52CYG%:3+7R3=1=0WC&3@!80[R08J%M2S?88!?;'H5A5E7LKD[L0O80]>F!Z2*/$Q,N_EE1OP91L/)*XA M\=IA^/ED9+]EO^U,)MB9/P(G(XW$)X5-]%9MN%8!4#!6BJLXHK&.6B'V91YM M0RY6_[Y6,U1,+O +GOT1G4"=T(/U+[(?_1>RF^H<],L(^1QJ\];.UL&?)>3: M(-ISE [->538IR-K3C_;/,X:XS);Q965KY;$9_!?:UA_QS^V3 ME*-=9TP81^OSE1(\"V7(&XEDF(OEW,(XLHQOX99. MA!?R6"-;)T0>84(F;&O7CHB9YSW]_2?E)_K[%%TJ_GL>1'4:@3AR MG21[E:;O-P!3D MJ-6LQ.8UQ9=4*?S9^2B/@726H]/6:^0RK9N/8!&TW9&V?W*962-IS[DTOHJ3 MH/4M=4?M4<%"R$)YD1B_JW*=PC:WP$LYFL8 <$Y8^OGW6%_/J:2F-O 5K(3, MTK43V5T<,%33L#NN8!VV:4S?>MU<'Q-9\J"GRKIU0(-]6X=C]=0JJP+;@)RNH-Y*U/ C6Q1D->!JM;[> !/R8J8;%H!TET. 3H@)3>AUF:R2\M M5A6U0VYKIQIRR\B?/;JDAE5V([IJIUU&([ M@*/7WC?L'35[-SYVDDOSMTG&MA.P.UAX/22Y]/'$2F06+WQT\#CNG6,:?L-N M7E]^_>TJSNM3"LJI,N@@"QX $Q>(O3-ZF2KWIP-IAX0+/&;L..D\:7OTE>#@ M1@K58X*8]MUSJW^.%\[ZV'22EUGEZ19@"DUP3AK\[F8%$[+[U,+[T&M].'R5#F9);FWC;4N[K MRRYMR@N]_D%K H[IOG&H'KNXBWTE^ WL>$8G/=,A:V#*[PRG4U/3GKGI_D^E M<[R0RV<6\B\EW;GDQ=O1V'L#J#(;A>?, UW]E"ZH?L5>?,C=% M3/O(V_A,2#P\)_F8K6'GQNM*(5ZSS* *)R;DIN$Q#J$#*,>S:$8G/3VZSC = M_[-IUX%C/(:)E,K=&[ZE_FXZDLG($.4 MF7!"SH?_GCDA[0<%6/H*)]&C'1+H0&_LDDB>WJB\P.D#&8$2.MB58&%<" 4C M'87(!H#,@0JB)R(>:^K'+HSS>;+9.^[SLW!4;;ZC2%YX\BOO11+[G77:R_50 M0HW!=(<4O0*FWT[HT(4/6N\C'VF,4WMLUYW0%A>P")WQ#*M%SRYV]VZ2Y2TLF7@_$YMUOMBH<&1<6HM:1G5L]Y7W]N( MT:."CE&Z]OYX.@)Q0:1M+HB6BI__L:/G-^E+,'M\S'?WX7_:6.B$I_%;YF0- MYS3;L]VW,"HA,:0%:9&N4590Q!:2.C_38X6LR#2 &OW:Q41;39; M?I^Y\0!.D[H3<.K^-?/2L82<)3:R6"[M%V<$!L$L)R_P]S(6"GY_,ZN$PG;Q M<"LO].K\?0:'3BOLB!_'&N.EMK$L].P MEB";"8P5/54-7>7&$6610S(O,3( M$:!>BR(&87&;-R;I@ZI]9!^PL9K$&])@@I?T:,U--VS J)_;78J'!:-^F4UOMMFFU]3WU%R$ M+P2\L9_G1T##\=@9.LANF6EZ*W0'[Z_M>-AY!'7;U+49,]I#.KV4TBVBK?V? M>&-_U!L7@?\#.6(<7_7!V:8X4OXH740:"\[84X#(2XM#,UH-SSO9. 36)C MA#AA/)U[D(9EGPA3KSE#@J4C*1#(17A0,BWO8DF4M1IH3SHZ4FQ^=VL:V[&@ M)L'@+/(^$]WKMEI*=*\3W>M$][KE M?9=$][H*7M9<@ZV^-9 5O6Q5:OLQ>+3=ZZS3_C%1L]6'"X>E-4.+BL2\Z%[7 MOGL#HM^&P*W [0'=61#]ZM9AJ->7C=YQ]KCH_MEL[QNZC]L.FWFB:=TZ#&FJ M)6N#?@?QTQ4,J^:I56<;W?:^08@^T;[NX!NC==&J$?1I-WT$]@_<+A5=ZQKK MHF6JNJQVL@.*Z%E7/@VE=)'0A]2T3C]5ZNP;N'>#O&.,L?>.%^U]@T!->U'3 M8=..UWO&58&B9UUI#!H#5>[W#BADUJ0UUI"EI9_V]<,A4.N.@'8Z$)/7U@C8 M]-:73^^P=9 =FTKQR+IQ0'[1X8E333G5A3BM<7+!J58G>CMLK:YI91I?_Q.= M3#NPL:,1E\>9TMD[WQ:(N?GFI>F_W,R-IN2"TC1*B,^N(OWM;!:>/-GV]&?: MW8 U:PROZ/WU;WY$+IUPZ/KA+" /L/M/+GSGU__^+]S&WV[.OY__?$D>HW-O MA!T2'-K:(*2_>=AZ!-L5D+#@#=@,!I'YG8S__M/GP)^@-WZBJ/!/Y+.?!R>Z M\M.O&VYBR:ZKNL=5V*SPV^W#E61*R=5_]1?I\NK3@RQ=W-[<7#_<7'U[N*<@ MG7^[A+]]>[C^]N7JV\7UU3V%^['F'11Q48TK(1NPQEIAE+32&/NNZ[\"(X@; MYZ5,D[8'Q5MSQ3@YC#=V!'91]#9WM!I14&V^@YT@Z)JVG^ N>L,(.A(4Y^++ M L^UX3E[#;@1-&_A7 H)7IJJV#)32.]BY'S?$W*.!+U)+E"@MR;TFD)0=S3D ML)[AVH FL:,V[6B+<[A;\QF]7T_?CWOB86O7D QG0=SM;=NUISFN M4 VYWU?EWJ!L;K3]1^N(26IJBFP99>?['5\'H*\D#']F0]#B=LV-^UYMLZ_% MQG8/71W.W;T/JFSV35D9E#6]:H#E8^-G\\@HW=,,634K*DJOA]+-.78U;.L! M&[^#+X<-=N3U8$A]Y0#JHT]6"H9@SI[IQ7( M_KT.SNY20<]6'M<&LC2O.A@*CRLGM,#I1N]A,0Q%#JOO5G[6.1LFLK9U#/]-Q.-JW>!=D8TJ\SM M" +50*"ONT3)#HPN&()#_!X;YTH3>.JY@V@ZFNBH"%VWF#CJ0)7- M09T#5 ITC@A=B]!UAX,B(G3=<@)5>7VAXP0Z4@X0X6O!!D\B?"U"-")\W2G4 M[W0UHTNH/Q:"BOCUX1%4Q*^W0B&69Q]XV%I73WZWO1,QD'+4'8Y^B#AURPDDXM3'S@$B3BW8X$G$J44H1L2I.X5Z M$:<^,(**./7A$53$J;="X:4_<3S']Z3?[ #HVGA3]8&9HTD*M U(FXMXM8=CH:(N'7+"23BUL?. 2)N+=C@2<2M16A&Q*T[ MA7H1MSXP@HJX]>$15,2MMT+AA>]1$#'\@$VL&P^+-13V4TYN[+<3M=_!L%\S M&!(!T18'1%6Y;YFR+J+6;292G:7P3?EH-:#E*PG#GZ41>8RDD1,. 9RHQ4JF M#4=#;&P3&[-I.[8^P?$!Q+NARJJE5G,P=H'E8PW4A'OS(=J6L(^&! M(P%?\4@D^6,A]<7&A*TX!Y5FR*HVZ*"L/1H*-2SN1?6)J#[I<$Y35)^TG$"B M^N38.4!4GP@V>!+5)R+!*JI/.H5Z47UR8 05U2>'1U!1?2*J3U:.3A?5)RLQ M9%2#F5U >-\6XNRRB7;&4G59'1CR0-?:@F)!I+T'O$7YBLCW'>[&CJI\19/[ M>D_6E8K,FUU@:;Y\Y9@HW0$5(4I@CD/ 'NS&CL;>U$U5-FL=I2A(U"UY+VI@ M1 U,AS.KH@:FY002-3#'S@&B!D:PP9.H@1%I7E$#TRG4BQJ8 R.HJ($Y/(** M&IBM4'A#1A$9/A]R_8LH?Q$]PT485!"G:\0IT"LB1BUBU!V.?(@8=A&C/C""BACUX1%4Q*BWJ]6\E+[9GB]]=6#K M(9$^DT,-5>OJR>^V=\)/?K=B?B)6+<*A(E;=8N*HM8\>+= R(F*]H;IMWBO= MX0VP1<"H]_>?M)_::W#E0EG23O:T0':9@)&TDZG;3K.6'WE3>U\+'ND5OI*( MRH37*HUWMD AQM"8N-_!DXI:U0R9N *>)&@L@50=Z334L!//^:A9$S?IN/='B.'\"3(/C(2'H@P806](=S3G@] +8!%;>> M]+OMS>S@3=(&- !AR%+T3*0+?S*UO3?)]D84DB$H,MOQ4$LX42B%L\?0&3EV MX -$P"^'.\R)=L*23TK_#-\Z> D E\',)G0W>&H4/X L6W$^&7[F;!\-D. M2?I5Z=6)GJ7+3Y?2!;S3B:3/H"3A.0K%UZ\7LO2!X:RO:KUIS\*<5&A*Z\-RJZQD]WJE/4+FH+L'9QNA64S)!\4 MEN,!PTX#.)O.%'ZR)]CM*G=LJ#24/N"QR)RZ:P].+SQ +S]ECM_RD&4I(WD- MX]3$*\VQ1VOYPV96#!! "LB0."\$I#5W!JA_P)7 -/"'A(Q":1SX$VGB@_O@ M_,>FWT)/(B OQ)O!6OPE(^GQ+:=4YOGI.WM N@>FLR<9CI)!FH-L9B^"+ M:8-3RY2FP*KT13(:2/\B0[J4/<(M(]O]0LTIP6,;\-C+1ZFE/*;KLJGHEF&0PW72P#/Y3!X#ZIJH6I%KXB#.F7>"9C\8 MOBCU8?%W.97 31AF[(.I RH&CCVH,*[8P%-PF5K)JR%.B/99_[4N_X#,G#'O MX)EH1AD=/,692]U$"@G0HW\JG:=89WAF1$'Q&LZXJ,TIV@*'CZT@]334WM%S MR'4^OLGVAN140IAFWM1V1JFQRLB>&*S1/-A3=Q;2OQ;S!?IXTH>,4PK\='?] M/U)\D0L,CU :D3&(#[!>B.N_?H3_@"X9VB%R$;_N18&(P$@*T-\D_Y[!*K#C MK]>?;K\S$$ O&.^I8K ];S:1P "A2@/0B="Y=@A6S2R$=0 Y(YO:-,0&3J6X M.$T G1(% -@?E$8R(\A 7D5/=L,#&UN(8Z4&%1I-*.+TG0$") MYKJP2[K.B>.=_.5X(QEM+GYJ$%'XS@*/@8* GS$NX'9:2I]P-DS1=BK=X.: MF=(W<<,,B ^L@+ .07P2#YU; )M(5)$SQJ!O]CQ0[T&(TF%D1U00)S"X/OBT M1WMZ<[&,!=,'Y-Z+,R(<5\"[0"#'G0L":0J3M/%#$^!+X MN],")&/O\),!_ M@:EL^HN+ZSP"FX2GTE5L'SFN$[TM@X9" 8SM.A,GP@#26)9F4^12OA(#X]EW M:;C&G[EX&#TXED,XZ, __JL'!P4X!K;B2;W3P>#]IB8<$ROQ0A02X,8AB9]_ MY7L'\+AUAQY$]I.Q[032B^W.\$\H+1#S5&" " !TO=/5OFQ: VD&&';^$Y^> M3QA)/KD?PJZ VA-_1%R9!KT2_LV\. \,]:@P+#-"\921;/S$ AFF#O:T9L[. M:#:,%QW""][PE]QKZ6$%(4[9)2G[HG#$I5_T50M%2HPN,P\...C0_P \<:_L M6+ Q.8!X>:?*9M^4E8%"WP6_]G".MFG) &(X!2,93K+[=I3G=5D 6CH'V3=" M@7B,6,D$I=68#7>*2>/#%*-X<( 'OX,2LE'@)!8?6.',#!BMB4YG@\_GW[_? MW]^=9XUW"M>2"+9$H]?SH>?,IN@S=@;.((8S9YUN"BN%942?GX_Q+_@CMW$T M,'TZ&U;/FG,,] _.QU2'^C%7H+!FWX? M!,) 1SGKSR+8+\.5G9=)22FJ+&'\#./\B67C>$L%?A+]H8$JSB_,:D.QPS"' MB$P$[%:A@2'3*V&J5SAK,&J&66(RJS3&-X4EY2YK+!L9VBFANW..N1D)C]G#?\^<@!Z,Q(L;Q02&)=%E2\.7L6A( M&. )S(: GH4Y/$;/@3][>LY'#F$O_BP M1K%YPB=Q;'O.GY. MQD'^('-._, MY[@AAIOQP!SLU')"V$%#:HSU\D]SS@@I/,@>U!;W$41T>V)_"8&?3>F+K(0[ M\M3T"J/Z\[Y<=A^90PL/IS87A>6=+EN&$I\5YD-,[!%U%!!,'SQ',.%S)D7Q MZZ2EK[)?;,>EGM-H%B2."*@4?\3QX8*3AA\4K.6AG9H ,V_-L"_EX8A>?>ZS M<*R&'!Y_"!*7"_$,LQZE]5+DETMYGQQ>3V'YMH6_'3/ O-Q0TB,[)$QF/FD7$+C'YY.G6= M(16^Q?!E52*<:@I*@J2\KL^<^71;J "CQ*DE67&2RA'&#:CW\"DP0J9^B&R6 M"I540 R'P2R.$7*O'7AB.',3]8X":)KF ^''B0.GCRKH7172=\'?GP+_-7K.Q1%\6#_@]I,+!P-> M025;_+(Z)=:\<-J_OHN-,5078&"&B:4YA"_">[FG@Z9=1*DW8LI#9I1S0[_@ M41^^;<]7206$&KS,+T YDK5:)_ ,X$A(KKP+='/-:&%B2SHKA1#VH: M#T;@#/&840F%X#!1!0^^H,",&B5E*\*C&9\D7 R-4J>1)CV2,$0^6LK^K&F5 M1TL38?YG&H6L(TBZ)FUYZ/RPZ'E2QQ/U4,@B*V]Y9XMK"SP[H,_'" >*/.6B2ZE42MI;+\@NXP3UYREM;CO'2RZ;XNO MR[GZ\[&F6/CDHV8_X"41CSZ-B(LYECPXJ9F10F(7;86*.S 3T#TM^%S.R;JI M2T9/9%6()=;M(36Q,H&<@N ?C6B/9P%57"&)\ !&S\O1+B\6!E%DKZ$?JQF* M9RXDNL0YF_$7)4+7J$Y0\VL$&"=CS/E*DF2^BM,-$1( M)WPSB&V$X:*(H/F7,?V3$/D)A!AP/R'A/,/E^ P-4S@365[[PIY\RQO-R?NR MYN@\)H_2P4G"^4C%94%_%@L\\L#_^>P)_B#I<;1WB=C*'GU_BI$]%"2KJM(_ MTR.9(T0U*8'$R\!7I)Y")F4P7_LS!\F*9W,2/$DKH"1 O>-R/Q+'G),1>L$) M+,QH]S,";$X2Q!$L,'-BJ1+'7:5\SD!-(N\L8( MPU^\:7"4HF#>YBC@!@K($HZ0$W*A"G%=T PS6L2-IR"BQM[Z>MM+$@)8Q'H1ZJ,X"MQT,RG-1A^P.Q(C[P"X8?<:<<4+@9KN#^(#,&.RH*!5 M3S[ &47X&;S (S&',0C0NH*/X*E\""B-O0(![*?4VD"_*O!='KW+70-!!ER( M MU)N?#]#7U;D(]7G-/@70&BF0 J0C8]4Z^.2\/L651*VZ$QB9($9$R"@+T' M<)=-K?C>"04H1]C3S%984($:8R&#$.MLIG:06#RY1^FG<^LMYR%FY&7S!:?2 M'^@HQ0&R@'#OQ)ZBD\4#"S0JX^)>X_*0S05C00EYYGMYLP31EZ4T/UYQ77C@ MT,(FZNP5( )@0/3F_YH/^B%^/ PZT9@:Q2Z$(QJEKY. M^97QC^O"^P.:A*7;9SA?PJ<8ADR"R#)W3%F>.(.)O +-L%(('F2(,\]S#@[Y M,<5.@2'RK#]TZ':IVF''#4^"AYI'QG. QBR%B&[-@W<,26Q#VZZ[SIHO/E*I M5U!,"_PK4V[PA\+SQPL]0WK\F"B)P"P-4V:F7L#=%0O)T( B/!9OG:G0@NW3 M'+@3+=PRR&22 ^(R0P27]?ESQ7M8X*E3Z3-R('6;L,PM,: +Z)G*Q&?[A?-7 M0E(60]B(HL6@Y;B%@K';*HM;/4:]#[;M[3#R,>^H*4NL6R;#05>%P$;AV$'; ME#N'*"AI.-?WV)'GW)9R= GI>2K]&1-G40#GW9!5K\G##\+MV?:>>+4*TS5I MG#F4GHG+%/V;9T^F&)55H6;,0V?#+Y/&WQ(Y]"&PL\R3@)0V? M/=_UG_"9TQI#& M#/*GRZ/DX?,E13FY(D%6/I@K%,P6]CS:+B,[7K#-50"QZD!#-N%\6,9 E >F M%]4O?(]> ,(47#)QKN[[Z:U%RS6KSZ!:';4OS5SYJ7QE[F4O.;WQWY$=\8,Y MHPA,4VJ_/8%<>T*'X9TA&T92-U.43QUFZ,&+:3*VZ#RUW8+F2E]_PPINNG&+167SA+3$> MDFP*M1GL-$LA)=75[W0]]RP+7SXD*6I^'R1#4!Z"Z--5:$%(MA:$UE)Q1T]5 M,YEV.;EM\>\9>#HD<-^2!'V<<.=[CIY!I[&*,\_QP+[%?[--O>)=^1-629!> M.\AHF"2CBW&3N."(U2%09(>H7? S1I=LNG;H3T@^TPSE1O1FEFA@CY"%L/0FH23\ MYA*LPGBG*OT\/Z"&'6,-'6HIC2BD7SH>V(TY(#+6G!0L9$C"P4[;+Y?HQ ^#$]N_\P>%%!ZQZ!_?C M96D _(CWHNC]-.[E90RA@*#?E-%\]&WWK$?&96ZQN\3CYCM,PJ%6$H++WA/8 MZ"59--)P*086 A*]I05QBPJ=X28&F%;Q\^I]7E#(O:0-S(',G8&F]'F[J@82 M)>Y\GWFO]OP0M\/-KF:/5\J%-LW(T0+;Q"CDPN[%=X8DY]=@$4N<:642D@;0 MENLI$&HC/Z Z%!9Z!N_C!!/^B2)X?0:!.A5XA1DH"48IR7_!" [L M.W$8?/!SI1C2_"WO)#L<#I_):.:23$DCG">?.\I183W'R"^>%1!?I@O("\1,#0\B<2YI2D>LIKT/B]PC354NB-LB*6? 8%Z$*OSMKY M5CTQLA;O".0+5D;4'' F0$@:EJ5J.,89/!._AU9M@S;SDLA4NC2G?+KEV"1+ M>6GA.M-:L90OFLL+O<2&?*<.5-D2%77SW; 2(<1X MB44]V-&Q,>HP!E$29(7>>(971G(A30P%QS',)%B-ROQJAL%3VYNK?T!XXI7P MZA]&DCQ_[MZR-UIZRV;542EPYG,6@JKH] J0."C)0;EW4%YFDL>\>E8():*H"LCFMA)WVBX.7286P+P_%2OAN-R MZJPA!L!'M.; ]WBY;EP]E,0)J9L:9@\=U;GI45.+8L Y--#6( G/L+!L7O5^ MN<-48X%)0V,:*!^PE5NNV.AFYCD1P8(>_'YQ]/2-.C<\!Q,F>4,YS@7CLMNI MV16!P.1VL&EI\D#K"?F1RH]+'\M\@:E^LX-'ZCU&D!$]S@H25 MTN2QBB5NU,\())<.3*/V)>15<"Y:&1RYY8?U,1]7Y0^M'F* M9&W5D0K3$G-L@@>*^A(L^/*A_S'U*G@EYSM^QY6&JP@[F-G FY&-!W"(>(N7 M@@7I2:8=!D9Q/.;?,Q_-&J#C7R2*(T))<&; MWQFJSFY$EA4[B6!A.\V+%9F[$KS.)2.>9"F]44B#PS'K/)+HE1 OKS]PZ1@7 ME,SY.\FL3"#&-7Z;XU"GA?HZ'FE2T);052@XLPNU M=W_@]PH*HQ>*E^-S@ %*[(Q"1[V)!B;6Y8VB(OS-0%,_OP=ANAMTFPA\D[Y;2OY VZN.M(4MCT MR+H(#%<:V;D&(XD9F4EEI>F^K&4YO]VT)P /J,_RR5H&!Z9H>0DOO:S'&E0H MISUE/HFX-.G-%%>2^%9/M85G%TF1YK]O[.3:^0:Y[^PE%=!)AGI9.CO-Q(EQ>Y$I_?\MS(K IWRK2L@M:1!%C] MD=[_*;XB,J\FDM+*M[RB6&*\YU&TS("/D8N?I@LPU0YB*6O,O^,#EB5VT3"I M&^:7*+E)3ZU9O*4$XI158J!EGFA6V+SOC9)O8T\-,'T7>W?\D53E)P,0YO:R MZ$.$3.[.^1!;E4#$C+!:["T*M22WHA3E5A"26Z8NDK!R,=-[K"-9CKFS >0, MZ^/U',Q6C_@-=B0;%JJ!>/_SV0$!'*^ N6M6.07*DFI BMYT.^E-B'1Q (:& MIG)-+!E/R)@SPUOLR0(DI"<+EY)"7TZY)X>H6,4E_.2D-5Z)!H4?!LDE>[;V6/V.:K7>D:$.^I 0% MCQWB,O ]9R@OZI;DL[Q;DI-95!\DDCD?3B@RG#GMF#T:U^3+J\MA:!N;!!C8 M1H3# JDXBGNTX8K$XVVX)KRIL^.!3'-==D)I*(3=!5B5X[C"AXR&D+N#79-=Z[+CWO:;4=C]A;,0[LI+LM M&L1,*"=5*JPX, [,LC*5Y"Y96JB2T2;,[L_R!(6$Y>D70U5@O@^92,VQD8T7 ML'A'[ 5%PWM:AG%98QPY7E[R9\I;Z;,E23TY5Q'08"W OL)/=(ZF])EEC6]X M3YZ[I*CH+LXC'XO)S3$1=RYF?-NJ&2JX948:M6NT M.WH,)9$DQGN707 2IZL1RQ7QWQYG<[>#!<5XYA6"0I4'ABY;FM$L(Q_NZ*^T MA(,61TM?:>OD8S&=K[.- E1]?7"!1"?<[03?#HL^J1=- X<4?6BLTM#I5S^4 MSKTG<%(!(#1*X0'/L9D_REY!+^+QYL=)"HIY>STVQ6#F,:<^Q N$% X:%)3B M/OHT/LO]1C@:+-P1AP;8(G&$E80@?6W:,(-Z\/0:+(]IT&_.]3AA[CCK&#@B M4S]TDM%3V.K>["71X'B]1UR.+3KTPX4,5]QC-8EV3 ,?TVEVG*<<9YJ+I3TN MZ# 'H#5K&29%]@_">_"ET>52B"N.8PC8+C,,MX/!K>0)Q@ MG"(-3P+%IJZ#GG=:&U(,!4^28JMSPH*PO)$L382ROJ'1/-YS^3KL]^B#Y*+W MHM)T!1M^1/'!4_=L/1Z4ZFDQ&\Q1.':6><5UCD/2)CK8_Y1=/HJ*THH)MCPX M5 Q9E"N9ARG\R'WYD7VM/C]2^O" E[;9++FP[$3:PWW&W,J^K/15X5*V MT:6L=NAO?3QD]62CIPA?<"GK# 3K+&,=2^Y;'0@C[$?F:'4>JFXS3E^5==UL M/^/L2^9H976ZB("60C#.9^NUG_W6RBWNMIRX9,QW7PN^1$"T&P'1@05BM6R& MJ>)H:+%KGWCJTRC9)_/0_W9V<_[]_.=+\AB=>R,L:WZ*H\$_DLY\')[KRTZ\; EUS4<.WVXEZM@_%W1?*$G1V)WW?PAQ@QL?)VG*\+JPQFY!< MJ^I/J]>:;7 =DXK]@A7/<42=N:1,^$Q(E7?]HP-IA [KBF='(9PL-K[/K M!&1(G!?6>8\7"]KIU%_6-G/N<1X%)W: 58-A4DE(@8C?G1S*TQ@G3AA7A ;Q M& 0WF47$>AKDYB%D,'"L!^$;D'UM(Y9,GLV3BFY"RTG>"WEG23L56?KB^L!7 MTB;%'=C)E,;['EBT/_O+I'^<7^=)@VN4E M)BL?W9@TR2Q8FQ4=%Z\GS:U5<#>2E:NR)*/[QN]@LC,Q]5]Q9M3(>6+S([$? M*=BB I(;IQY""P9S#Q:$LLG7CC_0621 /5$]GY&+G>5GRMVY]K)_;X;$CS! M$_.76OB?"R^C%F3B6.<-53-E$P.1AK7-W<=Y#859LF?PHS"U]P%I]!$OZ TS M8\;213*89C<=.1GY3/GS*&=%\,IBHH8GFN3UD MYH^B&"N8=E9@.F5FQ\431?CKV':8[DA[=KPM)>)].ITD.YKL;V=KC?D%JY]W M9;P=GX.[,'*P0\<+24='7>'PCQ$9H=V/D,PB>MYNQU=) MM($*2WC2UL2LP)?RF-6Y&Y+Q7)6A6RRA!M2 M;5=%9*WBM\*V WW_2?MHT=I??<_RN.?[H[\KJ;&^LTIV[(MEDM'2%M^;F M6*@A>!:K(S)P-$U P1:M90M3L,4>V>(;CA=@7$'#;8%TM@!*F[A%"!'!+2V5 M+S]*=A0%SN.,F9S@$'&',S-0,2R9 M9&E#U=MFV-ACT=MF '[ 4($E]_IER_YK15L7RR /AR$TJR?WU++U-H(A&F4( MLS&&4#40#SUL9BTX0G $U+EM0^:'&\ TXQ?J+(VJ"+%]TZ@F)=ML#_ MM/IUWGEJ[QL:0;&!C2CDGEEG-YCVOJ$I+M9!6*@-7S%IUO0_6,)W;&,"-0(U M1XF:I@SVZO5#7% ;Y]&Q?C1KG__<0=6\=W9H[QL$:@1J.HB:O5N8%4K83L0[ M=MAOV NMC]Q8J]5V%7';9TA]_=CQP,+_B/?MK+[*])QP.>8[WCD,VA.1\ MX@?QK.HKUL/W 3=Z"-H1>/QWX /.;Q-M'# M-QP?Z(6\BX8]PO?SZ6IA0WUS^0:Q=0>^0N]II[T8K:EHJ>:G);OHTKW.]O;D M+2GPVE!:>C!->'N**O=+MY,377@/+EZQ"W)4V5 M6:NUV6P[ Q^B$6\5W-/K M6;)9E>%[>))'].)=P3NJT9.MJD(>ARAY]M".MSO$5"^]HP]R[I%_NP<08SZ60[755+T36+I@"E&D9W'0 <76C MT8.* :Z2UUMKVD)1L5FF 9]]Q!_ND[:G%,V/"=\V(NBWZ.I3U-:F5@Q]FV&O MG'0[<*Q6H"K7[*>2]9FDFI]%WQ&OH@L$OK(#U\&^TXV2%726PUL&)XB\!%(+ M.M=%YQL"TS=V% =$5N.V.9<[-AG[M71\ MN7!]UCV;]ITOR4IU)6WKZ1K)%YA/P];'7:7'P#>=,/RN=_14$ M:HY @S-5.2N=YQ 4:HY"QIDV@'\.C4*Z55=3UU<_^(O--+ C6X*OV4]L(DG- M5L8>+MY=?/]\BKC.1U_ ;=L#%G^11FK*N31X=2?L)_8 MYV,<0_061F32@@!!]4B9G^LIXV!/H;[+>)<=/%Q=QK>JGIE"D32OOJUNZI$N M(]TZ ^7=1?>@!I?:CF:![4JN[3W-4(G3,;]C>T@.T*-.QFH+15S&K^OB2>DR MPM4SK7^F"?NG:4VL6=W4"EW&NJJ!+M:[:'76%]Z^2:+:9Q>^YY$AMD;^#4>9 M75('>OF"=5 > M_?(5" +KNV&]?[9%RKH-2*]%9Z%&E5!Q>: [G]X.T&N^!Y!@C]=W(@?NLY=[PO0/:R+'/0^L&YV,TI4/2K.9Z N?6R+=Y"N\4. @Y%"(CW$=H:S M(@@@SDI1RX8.GI-.(YQ&4[LHG3J.=:.;OEG'L6Z=Z5U,XE>/BZ_.R;7O29_H M);"WL]_@U=*%C0T HC?IRB7#*/!']4>P]^$F^V029N/60D&7">5U<8A>IQ&N MGN$_=3:($V@OR,R T];YGI==0[IUIO;/JIH/T'$%_>WLO+T^\G%Q=!LX:>\[ MVTN7$0K68\+SW9()!T$'97"FZG',6%#B."1(F3<4Z*+=&QENTVQPV;"4V_%] M!!\_^^Z(!.$5N'W1VS<_(G_:06![47@;?,>-A@?9M3",[&@6KNAA2.'R9Q%\ MT:/-44)$EO3*D4,OA@V?;>\)(!O- OP&OFD*(/FTL:XG$6]$1BWK>KAD^4/I M==@)@;:7-E<;MGAEW0CA7"QHLPW:6FVX1BQ@2BI,0=L=:?LG?5M!D5]UI#V' M(XN7<*Y^D&#HA(O9S.J6N@N<%7=\CHN%\B(Q?E?E.H5M;H&7"^2L@=4Z_&/146;<.* W3.ARKIU87"]VZ@E[C5*FSR+DY M&[<&W%R@5>NZ0@ NQ=!)!S$C<-OF-W0?MQVV]S[[P9@XPN(3AU+@5N#V*&R\ M."W1O,@[IG&GAJ7(2JVS=P65JHB)Z5V\W70X!.B E-Z'69K)+]V3:<033 I- M,#5?[+]^^&X-KVQNGF^O;\G]01*TZK@=AEY78CNFJG748CN H]?>-^P= M-7LW/G:22[R:5;)Y_?+8=@+IQ79G!*^())<^GEB)S.*%CPX>Q[US3,-OV,WK MRZ^_7<5Y?4I!.56Z>"7_ )BX0.SM?LMOYYMZ*Z[\/=L!^62'9(1WWH@7VMCI MA?XU/)]%SW[@_(>,_O!@(;KF[10_OW-M+_ST%J=/Z-6+[WCW[4#O!N*&?+IS M>GG/'U-(%JW4-;< :G2%!!+J-)X)*[_6N<%P"(V%7?]=I H!WX?K(F[?DQ^ MB*M^XJJ?N.I7"0OE)6+\+G'53USU$U?].G(;J6\-9$4O&\)K/P:/]JJ?==H_ M)FJV^G"9I_V&+M%6).;%5;_V)5E$<;+ K<#M 25XQ.6^M7U]^[+1.\Z"X.Z? MS?:^H?NX[;"9)V[XK<.0IEJR-NCB ,ZN8%@U3ZTN#E;K"GX[(/K$7;_#O476 M1:M&T*?=]!'8/W"[5%SQ:^S*D:GJLMK)\95@>*"7VD,&@-5[O<.*&36I#76D*6E MG_8/:%IRZXZ =CH0;6K7"%CR8TJ&>*TD\J47$D8=9,>F4CRR;AR07W1XXE13 M3@]I^'SK3H!UJM6)W@Y;JVON?<=7 ,6U[PYL[&C$Y7&F=/;.MP5BKI:;WC5= MT%Y^)?R2/$;YB;&MO\Q-WX]P(Z2A$T;))%&:5[FB&K9D6UV/50NCG'KH9M/?B1[8(O MAR[=2>K*R9)'(LQ8"QTD-B;*F^:LV9ZL#@RYIQQ02>C!4LD8U-DRK$#VSY=< MN:*@IT*/:X/8YKZ=?#U%48OR33L7 [4_NM).Q.]<9-1^Q!\!%:NI8VH_]H^ ME)642G4S,-FRF-2QE%,=,$J[6X1UP$3I;NG681.EM05?G=4Q!QM,.]B-"=0< M,FHJDCU[&L'@>Q1$#*'A\-K&%6=#@5'EY'88G:A=["G>$(8JZNVR"PQE2]!$ M9F!CJ"JJ&VB#;C@\XAB*(BM*G20JT%$B9]-4SJ:>H;>9:%R]"[0SHEEE;D<0 MJ 8"?=TE2G8XQ#E2ZE>>.^HXE8Z4#:K..[5D"/A:]=^).?>M#1OOE+,2J-\% M]9_)<6#^6.BY4UJL2Z@_(H)NGU)KB?K<3ZC;^3[S7NTW*0KL$9&F]AN-?S0= M%FLFHG3K29<$/CKL7JB[8 @.\7OL%RM-X*GG#J+I:**C(G3=8N*H U4V!W7. M#2G0.2)T+4+7'0Z*B-!URPE4Y?6%CA/H2#E A*\%&SR)\+4(T8CP=:=0O]/5 MC"ZA_E@(*N+7AT=0$;_>"H58GGW@86M=/?G=]D[$'-KE3'#>0=0<333T@(: M'1YQ5$475=8B5"T"(")4?3@$$J'J8^< $:H6;/ D0M4B&B-"U9U"O0A5'QA! M1:CZ\ @J0M5;H?#>(1/BE1V.U948K*Z<@-$MHM0B2MW-0*B(4K>8.*IL6IH\ MT'HU$JE MX@XM8A3=SCZ(>+4+2>0B%,?.P>(.+5@@R<1IQ:A&!&G[A3J19SZ MP @JXM2'1U 1I]X*A9?^Q/$W<60J(A7 MMY@XJF:(JFH1K18Q$!&M/AP"B6CUL7. B%8+-G@2T6H1D!'1ZDZA7D2K#XR@ M(EI]> 05T>JM4'CKN!+;EM[_1?IB'VI]M6A>+>+5G0Z)8D"TYJ"H(-*.4 UZ M/5D;F#62J$#7B+BUB%MW.!HBXM8M)Y"(6Q\[!XBXM6"#)Q&W%J$9$;?N%.I% MW/K ""KBUH='4!&WW@J%%[Y'0<3P S:Q;CPLUE#83SFYL=].U'X'PW[-8$@$ M1%L<$%7EOF7*NHA:MYE(=9;"-^6CU8"6KR0,?Y9&Y#&21DXX!'"B%BN9-AP- ML;%-;,RF[=CZ!,<'$.^&*JN66LW!V 66CQW4,$*\[]6%>/ CVY6RCH0'C@1\ MQ2.1Y(^%U!<;$[;B'%2:(:O:H(.R]F@HU+"X%]4GHOJDPSE-47W2<@*)ZI-C MYP!1?2+8X$E4GX@$JZ@^Z13J1?7)@1%45)\<'D%%]8FH/EDY.EU4GZS$D%$- M9G8!X7U;B+/+)MH92]5E=6#( UUK"XH%D?8>\!;E*R+?=[@;.ZKR%4WNZSU9 M5RHR;W:!I?GRE6.B= =4A"B!.0X!>[ ;.QI[4S=5V:QUE*(@4;?DO:B!$34P M'(&AC!!D^B!D:D>44-3*=0+VI@#HR@H@;F\ @J:F"V M0N$-&45D^'S(]2^B_$7T#!=A4$&KE;S4OIF>[[TU8&MAT3Z M3 XU5*VK)[_;W@D_^=V*^8E8M0B'BEAUBXFCUCYZM$#+B(CUANJV>:]TAS? M%@&CWM]_TGYJK\&5"V5).]G3 MEE D;23J9N.\U:?N1-[7TM>*17^$HB*A-> MJS3>V0*%&$-CSH4.:U2.AFST-5DURLY];I@*@J2;D]22^[HF&TK93M=;4J$B M8;2_-A/#61" JI"F/L#J>XWKR&.ZS/YA:X%3 S"B;T&]I-9EU=3 ]ZHHK%,/ MJ9NSI>JRGY*&!ZT49-JIAJPW\F?@E+9")6\"IH@;"2)7!'E/-BT%S+$Z^[!M M$('*18B26%026II&R4Y92.EO9[/PY,FVIS_?#Y_):.:2V_$E>8P>\+4/@+E/ MKC_\Z]?__B^$_&\WY]_/,U_D%6\."6_']\\@CAY(,,&GS[W15]][BG_-OPQ< M?@]I\IV,__[3Y\"?8/#B1%'AG\AG/P].=.6G7S?&O MT;-D/_HO1++A!39^T77]U_#G&O=Q@''$W>(;EE6/MYA$WUKK6._!%]:4YGQA M4^[W5;DWT(4OO)Y5F[\J=$S^D"$KEB9KM?9C[;XSTPX6%/;L"D&AR@-#ERVM MHO;1S1FTE1BIL<6[:!TS&_"&F8#?P>BSW3MN_7WV@]LI">P(C*:OQ Y)>#"6 M+]^O-&86L(N[2ZU>$"J$V;W1LQ/R3^U(6DQ2RF@+2]$SD3Q821H[8!&_$3L( MA5V\/[NX7U/>#PDN?7AX#@B1;N#!Y[!L+/;PS618NS$SN2\K_;)SL(6)W)&( M73,\9/5DH]=PE55W;%M@G2X.'FZ(=2RY;W7 +=J/S-'J/%3=9IR^*NMZ18GD M0Y0Y6EF=+B(ZI1!LR8929R_MIN06=UM.7#+FNV]-M9\(\#0?X!E8(%;+1LSW M'MVI-" S'^4Y'])1$N%W,B3."W[U&XDN>+U%-GAS'MZ.,P$;:>8Y[(,_[B]_ MDD9DZ$QL-\0 P:^JIINZD@*^:HU=X3%/5.U$5U?",S 4<[ =.-A&+:1A,]NK M%$=&O]\W>RE0:Q>J!+)-L*5IQJ"O[0#974"FMC.Z^C'%VWWPY&WT3(+S,"11 MN"MG*?V^U4]AVV"IBJ#;"'-@TIK63M!5@J5>W]0U,T/"W9;<9.N&H:D]?=,E M[P(?9%3T=N?:'@:EK_X]8'*@( M@)WA+\!KHZ^._>BX-/&TJYP?&+V^;B[J[ W6K!C<33!G::JE9/72#N!6AT0- MCJ:I9[FFJM4WDPP]4U54H]3J/#E)30Z.NPHEWZ:OWV1[/1 AI)1>$4OGP?@ MDHP);'STG;P0;T9J$>^EUMA(+"CT?^E.EZY0J&DR5-]=XNN6EI4*RQ?8#92- M&$ ?9$_\YJ!4BA!+!0VH%IZQ"B#82/:I:L_(&IME0=A>O VTGC50"E#82*@-^I9EJ4IY.(;#V63FVA%A3B[@;QJ09_![G1=R[0W]"?GJAR&X M.[?C!_O'MG@ZZ1F*J>DY0ZO,NC6 O0E:3U3%5/2!4AG9UH)V=H;.U0CFQE)YF]:R,0%^_6#7@;81)PQKT-' .=@&/'NMGWQV1($1/ M/'K;&EL#I0=N4\;$7GSW=JMOA(R!JNG:H%=F]1O'\[%E<]P9>.N=J[!X-DPX M_^)M%M[L+)EZ/TO_=0LOX@3.ESO#O- =NT]X'D6!\SBC@?H''XT6 "WP71>^ MLC.>!IJ>5VC5P-/<+C?C1*UOJ3VM[EUF+"[PJ:L[QXL!EG4K50'9=D&9LI#- MN6L[YW8T8Y4WN,2SWQR()4A9Y_;R%^>M^Q4%QRNM,65@&DI6P[!WEUS3*K.F M:FJ6JN^VIIE9T]PD3P"":?M:=VWGY4E0'3UW15'73]<\GJ"'^8Z.6 MN!V#+K"])P?#J(OA[6UYH:_H6C;]NGK)2@ LQ2T]P^JI@^;@*\M0FJ(K_;[9 M*("E6,Y4U+XZV!K K_:C'X!Z_4ZH(\%3N%6PGFXA\V58KWBIG0 JIWG X"?TS"D$9.X)L7:-O:P^B>!"_. MD(3\D4_$ QR; R/C[3&TGP#HK#*97P7Y9 MNA8NLA,HI?BL1E#*,E1?SX6$:@"G%/=L!4[ZZ:)W\!E8+B(N,-RH"B:R-%W+ M.L,;+ETMQ*5X;?\0EV5)PP IW-?W#'(YH0=NCV;M#G)2_\^E8S6&F:*9AJ)E M*U[FE]D6CG*!$<4:* .M:C#*!]2LOC90C!K@*.>:]A4PF'M;P9&FF:M@D).! M"6?.*F*0=*'M82G%)"?Z0#4'V71.=;"4Y9038!4=8"EBV2J *<4NF#SMZ=F, M\2:P8('"-]_S\U^M,B:F&FI/G:^F6[ID)0"6L^E!,N?"G74#6)K+=$M5FX6O M'..!7]^SMH7O:CPF0U""5S^&SZ %"0Y'O/4N[/"Y"N[KF;HZR+A#RU?;&:YR MJJZO:#VE?KA*ZS[+Z!O-P%6*QS10AEGS:3U<- ;VQ7:\6^\S6%JTTN]\A$V@ MF-%UX?JT8@%+B_Q9)6%:R^QK2APVW'SI:B$N9_L;/3#^]PEQ:08=&"S;N5>0 MR_&NJFF:LB/(%ZX=AK?C/^T@L.&[P7>\L\P$ZVW 1>MW,O2?/.<_U7BR6 76 MLU Q;@% ];"7,Q)5<"3ZUJ -L&_ X"&-3MG)A4=F6 MC*99@ZQCO&2E'2$JQ3X#7:T7H+)2KPF RLFT+6G&_EZA>Z'U5-/*5O[,K;$= M".6RG'@A6-.K!*$L?YB]@6(:%4-0CB$,1:&FQ(8@U.ISGF@F6#;9./'&[DBM MKN:)UC/[>M:7JP>N+4K(="T;WJD-K+*.I:;TMJ%B&O# I3'U[7@S>(A'1'PO M_$3&?L!O8SS8/S ?'@6V'X#]90=OUSCK8(,RZJU-*XU>"N#>/_(*7=( M3+UO: /C&'!3.A0T,'NFH?:.!#?EI(4&DK6G[Q,W\(KJB[^T04_7YS>UL-)N M )6T=W(AM>H!*A\@U?&R\*!FF$IRHSFP%GAQ+418A>-45M& >L;$ZNQ\F8]3 MF"1?NW19*0[[[YN[KUR:&TQMT#<5HY*52])WMDWT M:CTKJSQ* U'7+LHE;/KYGA7MV$5I-@7/-6ODM&87)5G>&F23>SOO(K[I>T>" M^V<[()_LT!ENQ?MW]/DP"_#UM\\(\JF6.0.%"^X"U6I>7@J5>JJ8=4&UEC=7 M0)5M>ER+?9CC' T>HX JWLRB,; ]C M[UORVQ)(#<)X]=XAV^/02V%]I#>J?;&]'?7.HZ81J+ MROC "6&-RUF M[])X/BCPHX:VU_7M MKLMU]W%0/M*@8%VW>F X*%EU.C ,56\%#O851MD1I&9VN%.(I?T[W#7\THD= M[A2::6Z'%2G9P6#0MS83++L#5U+Y]:R-E=^.L&VAE'JJ,M?OLC[8RBH+SS*I9UZJZ^L7IF6'8,P#G#&U"5A_[WV MXCY_:##LTJUK9;7SELN6UD2&KEKHP6^ZZ.9 +FM'W@2"UJQ=O@!/[VMF?Q,L MK>B7ONJJ\]4/[A'&%_DKN8>C]$QKPQOM"P!4#GVM5\77@A]GQ,@(32VPLZJ3 M8(:FJ_V,#5*\U/8 E6YI8_14,SN49#. KL-P9GM#T"6TW^JY-^)7+7#>7MPM MZ3:X<&UG4O6)K@R&\NU_S)R#7PJ G#Q";]$.GR]<'T.ZV/LQI-VF)A.'=A.J MQK#"B1QZ/[ZIMG;-W2$LW7K+T#2]-'PQ^C_-X(LD#.$KCXY'V925*S[!J8>? M0F?$2Q;/D2I/A)HZ%_3JX[5W/L&!1+?C)8_$HOE-K804\2W'AF%O$^\XNPO\%P<9$ [UI3][C,8S-QYG59-D*[MD:4&F:5J^R'#IKKVDU<+Y,')>=C'^ MYJY9T?;@#4'< @1M<0\M:3#9'()R^5 N[*N_Q*2"G,U6JBU=;2>P2@NS@3D8 M%'2C6 O5HONP.*RWDC/3-\Q\>?K:9:L"M30N>[IEZMO!NL0E^^1[H_ .+ XR M^M.)GB_\6="4H[[QTJ71U._KYL!8ZH86+KR>IGR$;^S$%H[RK80A33@R*ZF\ M"23U[:=\5 !O- :@6]-(VO*JI/35; MO+@]Y$ @:@$^^.?#?\\"ES0D=['6E MMUYN;0!Y'+3$^0U8')\M@\_!6F86;4]5K6Q/M%6+[ I0R0E9U""^=,*I']KN M[?C.CBI+96N6E<*Y%$ \/L9>-@90"H&OCR M>-=,1UMMX"QR9!VPS!40]UV M!YOD$@:]@;$&17$P&4=F@^BJ@L-ULS\HZA_&E]@"@O(>6-]2\NTJUH"0=$RI M$ _+.ITDBVP'1OF<@MG7-@&#M6>D<6^T3+=NN[FZ_>.:]YB.MH$CRB=G\V-=@?8*&CNVR/]+<-K&C65"-<=6#[UG9(??;0%+7;BI [.(,;10$ M04CH!_=3=T5/+-6,\0@_]_\YG(61/_GG[3#R'TGP\$I@;V^?G1?R\.H_//NS M$-SZ>Y0R$7QR0_ V_D^_WGH2?T#2#%G"U\E2]$RD@($AA0B'%%) :/V&Y(\E MWR/2!_6C-/8#^/\LD#[T/DJ/=NB$TJL=2O9T"MX2Z(/'-_JN3[X=C/"Y2R< MN]X/PE,I4P:W'@7-8>W9":*W#1&F*UF$80V?[;U)8\>%G=O2$'D*F E<%]RZ M#:PVHB' R)<<\)K.\0_X36\D?0<-A],\I7-X9NB"*PM/H&(/ICXKFI%>06[1 M=>[1^([LX V_D JI@4>.#L]IIX?24&R=C$!PRX[IP-GSF+P5.>B0@HL'ZGCC>JA,N(_LAGX<^F"@C)T2N!4;> MCN*L;)%W$.&A%]M%&>Y$LXC54]W8CA?!_VE+$1>5.KA6&X0LECJIF=7T!+P3],V)5=7.0__-V_$_SG[KR3]S /_F3__R.,9/S'TZ8 M_.7&_N%,9A,NQ-8U2E;F?,P%*.9!_>H,>0H]KL4M-[T^@1,OS<3/@B?#X(UE M=+S*4T!8P>$&V\GL9"F0.^VFX,Y0VW83.4]4AX"6@:^2$A&:==;+1N_>)F?P ME7A/T?/M.,%.$>KU$P7C,A3U[&<]1N[YZ,4)_> MQDWRGCP-OMDO'/XO@3^; M?OUZD?_\,S [2"= ,ASE"0DNGATROOI!AC.< 'H[!O5.@M@RN!O\/RX3%J#/ M[>V.!$-Z60+6#,,XAM_Z#:Z5)7Q?]A-9$);*:3JNNG#WAX4@$/>E$:1NAJ"< M[F3N;;9-#6NN13/!H1,MNSR@GZCJB6IQM.'/B1W\F3@>0/TTCZY$M8"E&CA# ML%4I!'ED/03P7T+F'DF=JMM7+SDN:_N)\1A+Z0WG6*GXBDVF:/W36_H5GDH_ M?P5;AO[K'RR?F]+MLQ.$T;GG.6BFH G>>N2NY#DCYKF:T50G2>ZQ9'HD:%(: M3PLI/VJ!WY#H&1,]\7UENH/PV9FF;RK2\1LBE7^0&VMQ-]GE&?;T%+Q64#$AH05)5$:[.@"):C\)!()BZ.R78T=ZO"VC?RRA'72;P- '4)*SF( M@ 0CL3A(A469':JGRMZ/BH4"!?:7N%*SQY#\>P8/7+TL4/J+ZS_:[BVC *EK"OF^>/7&&8,?2J,$"]_)R MOQ&NX;HTN.?&M7]S8O,JQ<'WWU8%]PBE^BXE[ MI)BX!P$X_N3X$Q!I0]L]'BRH2D9!Q,]B:&6)W+\AHP'ZM/(UQ545 M&%!.>\9V&(BOU6;%$Y:6\1+>(LN5,0$++^U30' 0%[TTCHDU6ZL1#8U+B/:B MHE$1L7"I:7\\?,DI$WG:-J D[#%LJ(@IZ!;^6!. MF9TVB*6F14EW,=6DI%F?H]HSDOHG6BR'\.?$OV>7#=9XJ?%0;>"]\A*HZ#;( M_!V!O>)F[S*Z:)AHBS!D(%8TEL!@/^MMP5 [$$33JYH9IU?A9RO9/6X!M@^R MR,WC9>7!VZ#ZM#U[SY27T23JCGM/XK,S5&X?$U'Z$-BTK@B% MI>>[_I-#PC0N6$Y=WSUY+%CG+#@^/ MI..M8FSLB$VQY\M8NB9*FL/)H0C?/6-L,Z%SM^'86X<6Y\!]8N?Z;\U1X+;-= M!Y7=_]^]N>DR#.P=ORTXU@>/XS:$[AK$[W?B3!YG8/SC4ROJN#=7SQDFQ7*4 M/#HKQF52,45W&]N*J3GU%M>';F%_9TA0A*0#1F1B0JY'Y-JBWJ4NGT!O*?1N M?$&E=_3<^QR0C06!0' I!%>*R )=MPJ3O W T'\A00+%Y8PL*93K!#[+RH.- M*W#2[@LK\%4;9F]L,$B>?>]V.O6#"$%^6\8NNU4:&?O=9VLXJ(S(JQ&W<13I M=GP8XFXGY*Y(/F^ K,*;O;$K<&F_A>?C")L51\Z07(=?''BH\4/ZZYVJ7,[= M\UT-8N&N5C<=K"^]R===K-#2YB\O%S5-W!3ZNK)-RZ#OFY4!O_=\T;(]JEJ% M>VPF5+_V\N.RK68DQHZ[+7=F3? MV)Z][!;'LB-NU _]]\^7>.O;!OZ_]H;Y#?Q)'N\ 9HSC8&PWL+W0M2,?[]%> M$KR/^^#S_^)'8Q+NE#O-^P*9+M?08/.;)QZ!*I@; \7LWE+ M253[%F(97,A;*5,!D3R"E_%^ VN#467SVH/P72Z0GLT\$$BK2-2"_6?&?7W8SXDQ=4]0'")3<3:CX5? MXZ)C/=.2=_F.=ML[N]G=YW6\<[>\/0=GE YG.(F8!!.*\?P&JKO3? VD=VQW M#@]]ZEHN[:)8'1X6*KZ5! ^9-HL+T-'2\(:@4XU,/;K9(NA6"?T5/(1 :@KU MOAL@\(J:Y/8 N56X[6 (@AKS?[. 1A5$4N13,>5.>P4O5 MP5[QVTIXUSOCB_8%6CU[Q>2>(5OE3&."Y=*S/3]MVK@L_MT6"=I:F"T:QM9C M/,//O25:X/(\],.:*+)/V^79K^@4M[Z#I*D9!66FNZ%G Z2G MM0.WXW_0-N#)"H5U^[4TNLE_)9.%K:(N)=\C:SL4= R1MT'T[-\]^^#C_@!5 M^/#U^G-+$9JKO2B(<)Z/1O25MAL;\XN-Q3MQ?W_+C18VGLG7GJ<5YW%Z$L>$ M%PD+8(586C IT5(T+I&01A:5E>-BH2'@#V1<8.EG>O-QC*JM8\QG&KU<]'SY MEO*7NV(%.+VR ^]VMO-,H+D+Z#T]*>E9OM1N$,VW[*\I@YHASM&M&/Y$2@1>C"7G[D59O7ME';7WMCV4G5UD E55 +R7O$02XUE+6.7(,+J M]:W^H'=(F$CB_0&L\2GCSMP%A.F'4F8Z\(F1C=!T'T'KK@HL0X0^WTJD%E1< M3Z:V$S!]]=7WGK["RT=,T/Q&7)QS\,?6DW'7#0S99>UUHK6VM0M&O#2Y]DXS M"*]^3&EM%ZPP)@[>J/V^>4AEX\[JFA474!6OMSU(*XB^%Y!6\\)JD%1%KPFD M%2Q2#4B)0')='R?:C8JG$^!+O&K&:JM*'U1G1A1NM'*E\):RY4Q%S:9FF@9W M QF5 W=@6,I>H2TU%%@W^[JV*[B96.(.0^$*@!LL7/);O5!^@*L?_(4UX'Q0 MX)8P:$JNNT;^I46#Y1:A.H\NP+)]@\?H7?IM(5$U3;4RM-IHL$9C3&6+5.UIQVTS@7A:Y,S\P(G.W@J757 M*^3GTHB]I?S_]KZTN6TD2?2O('I[-NP(2B; N_VF(V3)ZM&N;2EL]W3TIPV0 M!"5,@P ' "5K?OW+HRY<)'A3QWN[O;($H#*SJO(^''.XQK%AM9C-5F#5ZG7M M'I8M'3%6"]AQ)5:MKF.WMHU5WH;9^ (! [BI&C%VZAAL8,G*VP%TL4Y1!:A] MVNSN$]"EVD0UH-W>G@%=K$A4 =H\[3;7!O2+E^)PYJGWJ2(!?N4QY[;3[K<' MCL'/,VNL \!*VNM)M]L#=;N[K?5754=/@/.WVV;FP,;KKZ1@GCA.U^ZTG27K M9PHF,"KO!L&TJHACI[6]YN)+ZX/,A[.H>"FG]\#A%W79V'5M<;^ @W01K5?) MOQ2?@@DC@J>7/FX(>67RSO><6/L]\2;SX),_J9V74EX9^^N-_:=AT6P QT%Q MRG@X :?NCI!:\(WS*,&K.D?'\_?HJQ=Z#]?QQQ]PTM;3%JIG+J\'Q$Y168G+ M'S$JJPJ,5B?G*C]"A%:20-WV5A'*\'\S$X**_/[PT[N/ '0T]4=?\0;NOIZ^ MI,R_!E@K[$^Q&G$E_TF[V6HW^[7(7UHCN YD=;P53JO;ZO5-.VN+D(%L7)=B MOH-?Q;!K%J?\?\C6N[R:# M/1V8'N/5U]X-]+7H;+> TOV]06^\)IR[7[VIZ^-D]NO)I9^,W.!/SXW7W8QV MT^XWV_60J0G*9MCA%[X_1&L?KH[=<^S!N@B)U;> A81K(U$&VORZ@G$1>MO MCL9E-%_[:-DVEA;V-L$"E]\"$O#LVD@TF^UN3=UDP?*;(4'-MC;%Q&EVVW:W MGM1:!D,AQE^4+YRI <;H;U$T?O"#M>,[!6E;9[%L/!F,<;#)X:F9S_F<*]16 M_/0K]E9Q0QDK+OW6]I;;N$'2K\Z[UCN56;G7SCL'_L?>,T8;-D$" M[O>NNW^H-^][]*O]SNF_XZ_X9UAP(! ML.GM%YM-A<'@'0# M#31'VP? VU#''0"Z9>\3Z(W9S%/ 9V>N/%?C0V&PY<8E>@F&Y#19BQ \#*,&,'DS%D MC*[0,L'H0)', ZQV;V%? OPF>M7HJULO4:_8S30=V!NVR'HN[A;;\ M!%)&]S'?K[*I8MTZ=ZLM%^[]#XP@U7^,+/-?"M;'&G]-M,1SQ2P.H2I&5G.OXSEM_NF%8X6CXIUH]@2!*'D&0D2E PNJRO$/>F,.WB:Z MQAT".=,Z)(5 95 4PI\':W(._7BILK'@?!SVFE2W6]@#^@?GH-BOO2G0MY$4 MBDM\FP\3[]]S0.CC?4F[G\7S&JHDJ-/M]MJ=3F]CE V3IH:QALA/=6=:*%N RZ>\#E,/)]83E;?Q][N$<];V$!5[^U%V1WK:@LP+%U:E:] M[P;'G0K9Q;Z2]AJXG0=N H"+)DS7,:6)JU)3==?.W2#PQA\>Q7.)>+ Z"]OT MJ:A-EF\?1&-OMSI.V\CAW!#S/1#RV&R>3B]K\QP_!7=V%'_'_.0'>-2+5SE_ MG:=$/-*=S3;+K_=X T+J;IM+";ET*-%E%*= FB*=S^ _8^H^JWV4R)(P=>XK7%SJQXFYZD=I9PLK..E+0HUT8H :<)]#_;A MR'WJI-X+&74VTL.*?7V?G *R8NI E4O":3U!M.OG(#P7M'O;&XUTG!K"QQ]> M//(3C[Q%ZH_J&_8Q>GH6NC/-%MAK8;PSLAVCKSOK&CTN>AW$B[,X'G*TM#JT MTZ9V-M\1DNU87#1/EX9[]<@LY&9FZYGG3Z9GQ_+7<+C MU5T6+3GL^74&M5'I]WI;1H64!#"OY(,5-3W9V6K&\W6K= YH8>=+F7I-)Y]D MO $!5JGY.DS]3EDU5],>.,OS[+- ;Q/3 U7NE#67P[%W!Z7$/NM22GK2M?N# MY0GH.\)_;_461;P[=JMV1>-.-GX_E18E&UZKQF0QWJQ_)'36Z -F!JU=@7!? MR@3^V=AIG.1Y<;[I)$\G5V2V&,@MH>08*&4$^:(:]?T".0#&H@]:L[-MNG>= MSMXQLAV-D=W:-D8MNY.9AK(7E/1)&M0Z29U!?_]T;QIT;W9K -EJ]^QM RGV M]X".WV0CL=)Z/E[7/#5KPQ;:?7Z_8W )7^3N;? MT40\-W&[]XJE@83:A;8#M\814"[5S1X+0 MFL%/,T)<1(=:3E7XHWBP,V:K%MU1-4RC ^1G_'K3^M/YW&I>B%Y::R"V.\(, M-&$.>[&12D='H$('E%U>G5]OG#^[GU\6#8K\<(NW)<-@"H.US_ E[M;XX5$_ MO'Y+DX X-B.L.W$KGT/R/TC@5^^E@URO[@G&>IGK1P#F$K MSZ)W2\'73:NIY2W>M,'+W;2C$66O>[5XK_8J55\WXX";L14^-?ISZAF5 M'Z>S('KT/-J1ZUFQ=>^W&0(7PF^J&G5>^#$ $N&P2MT$.E$SAK$&+8T!--7V MN>9FM7LO=K-L8[.<%3;KMW@^'"85^W0&6L%CLN+8Z!>["3UC,&W/S')8N@F? M_'E52]L[WYOH+NC7DPE INS1Q)@25 M:Y3.<>A&/%TUN:>Z- =IT_[K0U8:\SXVB^C7&[OY9VYGCX)X3W!;]V [O6[7MK9K[U;6Z]9M:>MV M98^];M!6-FA1ZK;>%ZU<]/YT/CNMO'9Q%.AM3:GCM!%I".#L'_KU4U 0:G3I MSR7,;YE(!]N$O;I"%Q'WV='V@![.J@2NWC.D\^X=EXOROX^(FDG5 D)B_,:5 MC2&7]N2D0Z9B]&EQ[(49I>U5(I+;H^ Q;MY>.?V"31FLYDM]SIMR0!&QJ.S? M/K57"<<\XQW:O7!9>%&Z^?$D+W(;5K.URDG[(_%_"?W@[S^E\=S[R7J7B:^L M+;IE/]'/ /1=0"Y?-PB((M43@H]%;IK0%I4;.4)Z%[0Y'/%W+O<6$K75?89$ MW;/<.CR!)5=<%,Q%Q\I3T*(QZC7XW#3\4LNPVAH5]A)'Z/[9/01V!W"['P;3 MW7FI.P? 9XUTG&,%M)CGLCFD:S-5H:!=1O'$\],YEOH+5?"9NG2J$3X03==5 MH:OH9/>L3*EORSW"=S=.[*/;_XXW+=!.!9\U^!YF-7[S8UD#35Y6I.*MMWM.-M@V\=+Q*P#9;-,M^6G>-= MT;/*V;1[>@I!^AQ1XX2'/5V!_+#%?:%U +:<\\;2C;QP4T]9!YO(O87-A?O; MJ/G8(J)/A?AUQ>4BXG=.[6T4.CU)ZB^,1BS9@@U8S<*[T-L+LUD1\WW+XX-L MQ<&%-5J]+PSSK- [AAM8TJKK&##?TPUZPX*GYN;U[PJ^(U9YH+;(.W&'@[^! S=/FP-!G+5 W+9GW> 7M3U7Z_C2^[U!L[4-9TL5W ]#0VL&HF:8QL8 M/A,%F:"V$S+L?C>5.-CI;>T,['[;WN8&YN#>-F&6%U#ME%Z.W>ILD;G5Q6:' MPJ!V6N<:LG.1[Z1WVM^-E-AJBNSNZ+AN2FR1CLTG0,=EJ<8EC/^8\HVWAF=) MRL0A\"S.@>VM(@2VC.4.3A-__6F?I?JB]E"\IW7:;^U$=]@G#U^Y)'M?Y'6: MIZTMDGG@;Q&S]V?SL M.!E7Y $PV?;)K&9#.VTUX?QI S6W>3370*0RR_DJG,'V7/C)*)J'Z1/HY[Y. M$_ZF;.LR?J'&-K]Z;=W=<=.LYFZ@#. M7O;_V&K2:I.GM3_R'$_#\*;=[^\)[6-MT=VTG;UPAH,WQ09$[0.H$5MK0TT\ M;(\2?@>-GQ&%P6H7CFP8_VVX[3;M=&;C"0 M0??E$.\#P16FO&X?,;G)%]XPU1D6E^[(.YOB+I>Y:#J(D3FPOJ96O52OO (\ M?3?0\]SU$J&/$]]A(:[3Q$=*_4&YF>]V)U]I587HA@1Q@&O6@7:I"KTBR<[& M8Y_-E+HDV0M%OWKT7SCVTTX76M/%)6T@9IU"6]Y)(4W&BKL.B M\"B2CMKLO5(N0[GO#]&Q4*Z-JIP>!V\(',UK%S.-SKZ@M+M'#F4/#2+M=/KL MC5/0[8LR"_\01Z$_N@I'-6!?]1B0G/\A%>B[>MJG/$X3'G\1_54#]1O"K5-D"X[7Q>'^,/;N(GWV:Q MYXZOPW\"HT8W/-H;53W?;<-LSRK8"^@@[=I/8"1%X15\-QZZX5]@GWOP-"[W MZ>K#]==5E?!>IPKQ:K2V28X-C\7&BNDS)2N+4";KBN)T(6:V?01XV1V-5WT! M?-1X+32[EU^#)WE&LYPPFVKX7'&&O>V?V"VYS_!SN^+\*DM&ARG\M(+-U<9_ M ^Q)T\F^1-P2#!5\[CJ\E#5PWC*YUM06]HNF M<.#JQ,Z+"B?PP75 ])HX35Y9EC*5 5_= F[\+U@"5]2E3L>)Z4(KWNYW>X,2 MGWD9>HO9W^^A.X4[B7V?I*N]3I[\NP>,H]J-*\B^!O=^Q[5ZEWKJG/:@+ M^[(4Z1W0L9Y'$[ATJ]UJ]H^+CI6PKT;'<^#AC^@X7N0?W YC[O3[=GO0JB)C M%I)-H=X:/^YTG6:O,]@/U,<:$3BBC=VVI#K:8UE+/NW]>&XLE>Q^K]NJ#@SL ME-R[$46;TJUF7,T>= 9FNMSAZ+8MT1,% ?"KV V>&4-L=Q:&W?-X9RSEJW 4 M>P#052BA3N'?4_*^K)@7_32(93MB+.-2]/.GZ9,?8CH0+^F._,!/'T4.^X!\[>[*"9VA%_(E2"; M6EB-2W;U=1X^N"O7FAFA[;K 5"*AM.(F:L.0ZICJ-NR@8P[_.YW'L+?:02/5_P:6FOA=,RLHB7^ LEKNQ]DZ&D$,SPL-9#8!G.1N7E"J&ZW6*Y ,,"N%O! MKQ#,VRU^]I)MK$12W?@X&L$.)W@@L6DNSNRXG@B/3\' W5<^:EG94V&:X!+ MLV7-A27K7= N=@[1+NOV$4@CVRPBJH/75@BQH"71BR-$!TZ!),3.RN0.@%<7 MQ(_$JVN<]*/ 2SWX\4=*#N<%0Y0[QDG%NO453ZIY WW:2D$BVEO/KG*^=H( M_'4NFEKB(?I^%\T3$!G8")*<(%ZX\65<0H=G3<0O?NCMDXCE7CEN<^N/!+(W ML1^._)D;5#3(<22+R^DSVV(%E=[#*CBWAQUIH$ZO+)IX--A]\I+$\SYY+K72 M,OH:7\\\K#<(;_%O7H)' ;N?<)/&\GB1O@G\LP,\K6>4ZJZW5A%B>"9;#E%1 MBE<"C]-T;%:N3+"*'RPX.SFN^'CAS:+$KZBWYS46RZ6NV2$]^]$,;_H*=/D- MT/>JYV>4$[SS6=SJW!(GHR!*0.>M#4O;2>^L*?(/*YI8Z9UG M!?A5 =]&,"R^I)_=E D+6WGA):/8GQ7<(\LC_L)5_3UVQ\BYL>),BNKKT+KP MIL!UJZY?!01; WM!;>(Q@[V VO5=KH='8P'U#XZ&&4#Z1DD2%2DOVW/3FY&O MU9(P5P5V"V[Z@P&[NO][?Z!N[*H_&%5W5%6_"*J=DO[)XU-;B*X3.3^237H> M2.5V"H];'63VRHF. Z@,EOJ. MCH&&QP[NZG5EBWC[X?GZZF5GQXW/ZO5K:S:9.98M.A!*GZ+P5F8E'BRARP1B M50#WD\2U10C73(E:Q@Y7W,B=)&9MDTH;%UFW[0$\T]H.=%LOHD;H.@-G)[1; MO4AA2R=]1;-V>;'$%HE2QWS;%V'6@R6?&[U%XBRRN';!?9:NMS!]>8N(KVXJ M[8(<:T)1FJJU R(MLH=V08Z=K[<5TVH7F&\ R<+$VZT+9H#K?^;X [Y5)QT4 MQ%VKYW3V(>_J-05Q.K8SV(?86[OEQV94J-GBHVMWMZ7![:B#!ZE60E@L(,.2 MGC6=OI,9&VA^==45!:*+5^SU6\"1!_56-$DK H"^EWSU9B(K_'JBVMW\ZV*-@5U ]2O0OP '*2=H5NH>5T'NCR&N=2&RSD. M)A=EY#+M?]5=7=+OJ-DW@D)KK[\.(A 72V\/NC^_69D=WJ=9GL=T.7" M:X*^-KR#7LL&N?EDRUJ=V$V=76YC/HLJ)_TV'R;>O^?P M\L=[+Y^&^MF+;[UXK0[?]JG*.5T"<:$7@IO4R)BOQ;_N]W6/9# *>[ M9D+<3[_^=Y"^GUE)^AAX?_]IZL:W?OB+U9RE/_WW;?H>__AN1C_]E]T2_S%? MF, JOU@V//\NC&+8 .N[/_42ZXOW8'V-IF[8X%\T+!R8.'EOJ17>6PC>B1OX MM_!/[+3M3Q[5HD/\@3O!11/K)O82O*J4(N>&8TLH/X&7$$CP2(8B!/;P< BX MT]G[_[*[S<,L__W.LUPX,].9&SZ*R9:"-A[E]H[1PA\3,!,?C/Z1#^M2CR/F M$W?NO6<-/2^T9C%HG#&\-7RDE-IS_FC#>O#3NVB>6NY\[*<-:S:/L50MM=*( MGHOGL#6T4[%W.P]H4Q*9EZO;)A$(^)1DT+C U$^PM8;UYMO'\[>GUCG86J MCO:)]08_XB>$:A0":@ \TY'@B'&3L,^5^=);Z^'.']TU)/;1C-R'^"H<59<# M. T+"&R%WLA+$C=^Q",QX_MK35P_#O@D:5@I'1V^TN"3XR7S(%77.F+]!$\/ MTF($?->:!-&#.DSB1%IP..C?,\H_3^22WOC4NDHM8"/)_/86V#B0*;US4WRV M!B$)#(.80P30I=V'I_\U#T=T'NGHX.J9[Y5N!V*!3X9HE>-/L0<$,L^M@14S MDKYC]]XS1:91D@($J+=89V$XAV^#30AR%[;0NH3= U9R\K]T3"0EK2P5)9U\ MC-7Z4T4OVK,H5?OFTVT:PU%.0545U!8G@[\+8 ,YO!\S;T38B@]/YG#0'D&U M/=7,3ZAAF\BSO$C^/0%M[B, M+ * 4F7WBX#AVXGB MNATN7\_1OQ8K@4U#4O,?@5'N0I]G/P,I1W->698[B3 M"?)19E)XY^#0NU2B1G<,GO?X?A,,@>\.L0>I+SZGQ14^C,<5SC^NKM^S,N_P M2LA))*M;R$_R($D&&LNYDO@@7E9@<(DUIA:,QHLD\(@5G%IGHQ09B[SG<%D# MA!_;DEH3N%OP6I08Y#JUOL%V^1/@%8"/^C4S+'?LH?)@D%OPNH8U1/U!L)W MGY(@3:.&_(($<)YXP%/@B7N6L#/XN*(;"PUSK^8)?09$13!"N&7I(AHV6 M<[\RD[!HI#Q# P$Q?&6+4@4BA0X[:9&N=^??WH$,#ZA?* $SQOB)K[*UQ.E' M%<1*T'8_2;'TW#<@"@LZ*H#[<(>F@@@7P@5BS8!T M-4^?OU,"P@087;^HVR?\K%+P]$O6T U002=^&(4F#T1$_'1.MX7X,^AX\+NY M8:U<>F-4VRU91WF%?U;Z_GD4 ^?3!H7NH$I0-*P[+R"%#(NAHH>"C8/44FHH MV@&6C)A:RE]E>902AY^!MV"AL_DM[)YEMQL$ ]XS-J8 !-Z*Q1BZ01+51M,R M4&2=L$JO%.PF89Q)]C Y)0# QV:(N,N<&M'^V>DT&\UFD_7]=6"RWDA G.;[ MRXNK<_5/^_U;/BYG1.%O:'.AY\]JP7),-%/YOP.5'%MGZ^/B_< N*E*$X+<9 M0@*!4 ""1+#GXSG\PD<[R4_^0EX> >WQ#."F,,=&T>OZ@1#=9)V5;E(6)@^E M#6L3*96B@L@BC5T80.QV+3R6H3\/A_SU$ABT** M2BM&,73)BQ'2W1GBP$:I^,DCS8HH:6QQ-.28-C7!!N4I0274YY>]'\(+H;X= MJWTJRHR9:#5 ]PB46]][2.@S)6\CPQI[*95T>RBEB,&Z(<4'@7P855W=%?.MNFS%T!P_JU-O^T6F3FN$8\)#&.S) 02O42Z2_11 M^[G5[S4&O2XM)/^!VGN";@K0UX-'16'SJ#3@&*3(J6O +"4W?)<79L+_;#NM M1K?5Y*4'G4:S.\BM7,:PJWEO)A9P'H7H]6'!^15DE>A&CTGG7@2VRPR$Q!D< MLV?(P#.XXRX+W(G2&GM6&( $+YN[2^((4[U4Z1-&- 'DH:=DQ.JJBR>5'1#9 MVYWU<\>2_L@%@2>+0#'Y -.($QR/DTWU6_%=)7%-PD&Z3_7?DH_UC='-?2( M1NH(T+]Y*2^#F0;!RV%,_8WOT#0?1U-_Y*-X>8'GXWN.U_[+VES2DW M<(H/#%/.R;[AE$0W7)<)TDD?K08F)O2B59UBY+Y$"Z([\;2RQ?/ MPQ!5F3AZ= .Z1@MOH4@XMM #-P&^'=%'JC'ENU(@EHR<,*%*4-\4K!=Y3\Y8 M+AA2R5+=%J&75C!@ \WS2 M)6>@WL;X OQ7>&G-(XO>X5MMT.-1I655A%*P=%3WR.> 9U[%\AI\!7X 8TZ MK_(_P>8%W.FHR./O2O]%HD-;*O0K[G%BD 8*GEQ\U#<8CH0$"(*;R-:7D<5 ME==3B)S'PDH9CP79*7=@*$2QT/V1=;E6@G%?*Z3.QJ359G;%H .9[1JOAG!O M(R@ (#K+/'1G@9J66-IMCB)0JQ[%B-:Z6EG1 *?70!>,;D-?!\&>E1HG%1,# MRY>MJ9GG.V:B_,?0KBI2%'3X%-6Q<.S&XP0^,Z8 3,&M=O8MXU6SODGJXDXV M]H%(;WQX!:]NI%JRFWDG*%@!-[0[ [+Y,9B'KF5X#U\483=0Z406RP].J9#6 M/OLJ@%&]\>_?2E.7@VODY9 ?('S,QOFY@4K[-3,HVV3,A5DT!S^3^F.626[Q9Z.7-H5 M7QL+'3 A+'T"0O7NCF+[Y2(@3, MKC9U.-!>U?L)US+$B)AWBO&>RHA01HO*.[@P8\V:S&/2^#0'9!5(V+W2WY?F4^N\5J8T$?:6\U\$^*B5+2.?#\&686?";U"@;*A9C**3=]MPXI#%5,^SHGPB'"M 4I(&(-Y;(5%Z(WI>+6?F%.. JV%1&LI6*,\:/ MY#0)7$)4+AYK@6^-8A]SPEQ##D^]],5R"GE=*>2J8^N&J4VPL*) &7!H4V,H M(E&%U"*M!P\B13CTT04>@/%LS 8G+JV5NCF60UF@MZ&6=N)D%;7/:+/ &3KY M*!8P>]D:*ILT2DD<\$%&3USJ396Q1KO,*3&8+J-L.8Q_6#1=PPT0Q"%F[34X M55'DZQ",\J->D$U%BCFJ$AG4"9C!LF$%EQW=30$G%@H.)R[KJ?5[ 7LZ^S-D MU3%&9C-'UK#4_"2C:!F*&!(H7)5"44 MIFMIQM'@L61]J!CH1"YB2R_RVIW!56O@IHQ88!@729!698Q+V^ Z"XNR4*,1 M $NF 3J$.+7>*J F+5C*D1;A.'0TR,0ZS*E##=%(_R.6.0?-?B3B^EQE8D"A MG;3C>S\!ML88L=^4]0,%2\F/#:+QAB@U MJ>AQ7?ON9ROKHG ,CV&FPQ] V/,(;+'GRS((6XO191N3$7[9W($U3>EJ&_GQ M:#Y%M7=$+EC,'%#+,A\WDQ6NM;(G0$9'^GQ>+10@BGG:O/Q!49!KENLU*E] M/W)S1(AL-VZ<8I.Q,'$IP6B;-VO'$0J"WR($+!.#EWU5D!X4XN9Y+#KEB\G% M-IQ(JA:W@T[Q3.+$&=52>LH)2^B1C?-5A@W2 MZ8F-C'S4(:&V]Q#M['5J?X5S8+9(3+4I=R%0CN%8(RMT)ZI.L M=0D=3^E_VEUEO<%=-:.*\MEO\EE5\I")-M*!O;JQOKCWTG_\&USX6XDXILOTF:F: 3=^=X$K"/RGMY[ MEA@V?VI]AO_-O8[!2?ASX!MIRYGL ])336_O L2568ZWH5$>Y6/OH"1O4A&- M,!V&Q&7RW)7L E#S\1964G?HI0_HP[6;?R/Z./!_!1:W<90(Q[0W3LR(HUYZ MY&+UVRUK/+0%!$+E M9&)=@HE%QSE32R-_67HKL^T:A*4IX@LDS#F,@O=%?HB5T Z6^UC)G1NS- "M MT*R:XMXZ%C77:5@=/F[\>7@'3BP6ELGX4218#Q;%H">5$O#%\2R"K\IJV4.* M 28DR)(U$@]+^E=8YC2#-'((EF:8$N_)2H#OYJN7*.)159P+UR.7Z-Q'RHD, M0HKK/>\QF?X! W[W5'%'5*1ZJ^&C5?E1:4XCM\*KS&%A+_2 J_E2FY";8>[ MP:_8 86>0U>JG;6-9/!-'R1W!(9:HB()D@>R@G;GSV18N"#]1L+ NS)YW8W@ M=1D!2.K-=V]T=^'=-X!=NJ$_FK,CZMOE9:'U1\XW@GY765=I!H\$:]>)"$H_ M54OAU\E@/+/.##2!4S=0\I/?EY-JX)T?;B(KL$6L0D841X9Z^@!G.W@\X5P% ME?KZF!.<[SE)(0.5Q%N#!6+D$U6FXB+_!*2HCXL!*<%1!NT%J'D/J//+DO'- M@.4DH0+$DHZ<<2N _@8&R<3ZX$>HY(]@RY=1=BNPFI+_M+C!^DQA?6)YUD]1 M=XJP:HFXC+)@8EW]N%.-F?__J=/Q0W&1L0$D?NV$?UN3D7!V\P@N8#)S1\!N ML?47_7OFCL?RWUEP[5EJG0/?&,9^P_J'%]Q[*6PDP C&PHD ],$?IW>(6O-O M[ZTAEB'%)QAG=V>)]XLE?_I) X2PQ'(A:CT+9T-RIS2:Z4?14T*/C^7C8C&G M/?M1RM7>PY$!27GG(2="!#I_4RX+Q*FX'8OWP:#MH-L;,''Q9>7:2,<+P-T7 MA/G,&N1B.OTA8S=+7HS[I5,_JJZ;..W(W)51B6]=/(9P'4:HWY,'L"'OZH7DAQSK?6H-?H=4R]L"K>BOL+3WRPC!;-&,D0?3-8;1&]BZ2* M9Q*0\)=PGCBM MO)OT8[P=!E1Q>;/<=VL\H?2SVT3GE856L=",QK5;9EJJW"F.NEPI>F6J3XVI M5AVN@L'SRE]?^>OSY*]L'.Z6L>8-T(UY:A4[E9U]CHF9MIJKL-+:+._2&\9S MM+:=]LILK[#GK^KD*[M[&>RN_-!EN1[&I2E*1;[X(*#6=%A*(R<%R(H6CYK: MHE\<59DW')Y2'0FF?@@:A/3.B/*]1_%(W-\HI*?5!$5<]6GG'D+%."T'S^;/R#HEV . MH^(4HD.?),6M&X\-<^!,=] ,D:7>4>R=^;=X2NS:^\K59)#Q9[NE5J7DR;:& MHL;JYK@4"%(Q9"=H20#M; ;18 M4$:;+GO4UKUUE(Y9'7+XV3EMPY4* NHAH&6C;)'J[F M(G-U@"ND#S?@RPBNE230.W+O9GZU!=_ST86!,]&J0H8&R'ZJB.U,8@0B295'*5Q[E5\\=A\3T:2, M>W)Q.2*(:E&HD$_>T"42! _>8$7\IP*.$G<<('3 LQZ[EQ@,-N1(?NW;&9&'5..-C$39S0#B 1,9<"S MD<\!F]* I7QJ21F6EHEA,8&+7REV'0GJ &&;/P7(A7/$]4PEU,"57 ]B@*VM/C:^M1_G;^"Z5@S MJG>FII%NZIKYD,EC0I63H(<]>#A'([%N@VA(U>!Z*HD (A&]9CAYA.SW$,MH M=?:49%VJY&H*=G8JVT,B/K(66N6*R30WHUMFZ8ZI]D&<*$.UEI',Q4U5U1H\ M@+U# /:Q]=43A+P2G6>][+Y^O43+Z8_^6*AZSR:QBB9?**D1S9V=0EGXB M[AT!(^Z>O N%# _*KF7K@YJSRKNBNM^+!E[G0<1%IERP#"K0XHT'&J9FE+O:%0@1FEDE#>T.3_"-;TQV3-.[_+%P5D)V01A MSNWFQ;L-)^-/IY[/*GE-%@IC^E2"+G/A+@N]W(070PLX+=)?=N@V?3Y2_SH#9]+U6;3)8I'LKH MW,:-9H56?*C$(9Q+P:IR!E_'H'+?W$5>Z/^@:_+]T]6E*:+,3^MS+Q?^;3K\ M!]E_9:?,2B?1#T0X-3D167[X9UMQB)R[V/@+=M,078*9=8C>.I23 M;KT9O.5Z8S-MD^ 8RSE;9&OSMT\M4M/@Y*-?!%VXI9LL-1Y@4T,0>-11>$&& M>[7E)+<7X&_55P[>M'AZ"C* >8S&77:B#G[H\$89/JJXBZ-"!P>RJ0K][;9V. MU4 =R?FFV$LB13*8U:GS!?5W[()/V!%5\Z33S!X>U8F:)B+H\X)Q#NZPC90"D7"G/'X_=SMM!([@P W1W:P3ZGUN M40.)XLO&5![*6:[H;MJA R]WUFDM./.:L9TI5]*7Z-2RY9FZ-"[#6?5ED"]G M+D/F7E5Q1\15WDU9RM@I.=MR!48#79#FZ*/\3:HZYH(87>YH2]HOJD2%DBE6 M@-"OY:J@$-=_"\=ID;ZTM5-JL^>-#= ?9=5-\#UF:4'SK; M;A9U0]0U,KPX<^_D136=><9]HMNMO9&BDX1DQ&Q C#Q_EDJ.50X(T,TQ)(W6 M.,62#6L6S!-+M8VG7'6>"P!WTTO-&G99NY<12$)-'@6N/Q4DH:(R+*>CIPQ/ M)?721RVQ(2=H>;++?:&4+[3R3$+ZL9B9I4+!C!%(H3^SIBN/)K(HW*A:VG_-9W+0)-B6 M0ID6J>^ZNQ5WE< ^/#]HS -[']+'DPE5-G!0QWK3[OSMK:EF/!$5]MBT55G< M;1155LWN,2]CP[KY+>.GL;Z=NJ?Q:7!:\"PO*O>C\ZLB!\*X:9#[@5V3"_H5 M+H;8\J:S('KTN,<% 1OJ(78]>L5@X3 ,D]P<)IDZO" M^N*&T0AV+*8Q4*<9JTG\.:-B:#_FB]RLL[2LX8,B:O>]\2.U02&PPBB436DB_;&);&N:>N9$';IZF@]D.7H-9J6NOR4GFO$P M&^#O,4])9 &?7U>UR!KAH'5MJHA<'5*I9+?[C!8FE W#GQ!'I;S('J8HHY# M*41R](^R6?P O@\8)>4 B>D\U,R31SL'0&Q6#N%7V0V )T8N=B-+T5K=2\)+R" MK;J/1K2ME"YKW5"=II1/F9@_B!'3H8)] Q_"9!';TSRL 2R0($ ^AR?U(IK? M6N>@4;E!T*C\0$5%NY%'YU(+?V.ZJE3@7348E:YS0!V!#2 RZQCC9[-N5&[D MC]$;.(JQZK 0R>Z1O)" (#/&6_N6'[Q8C\.B]7D^GHQX&"C0HSST2HR2='ET M.*]7[%:S4MN9?.O]2_CP/_&[UY-+.83O2G?)XK>?0QADM3,T,F>GJ/EMN.4QRJ5' MOB84Y?!3F@C @<39G.UW=7'8,XM*L(]#^M3H8P&\>6>L2[V0*&MGBY9S,FC$ M\]#3ZAU.S" W:('$4H$ M%+3,WO2T#W)!E^T$\/A?#F]U/JM*UP%6NFZ>)BP^U^XO^-PF^:Z?\'!8]B\K MIN,JDFX'RWUE]UX/T0M QTSP&9G#\.]YA%JHZ05+>#()Z2+\>Y%5@57<5![Z'YO>1(9((UW$@>F$<:4'/ ,#)/AFR,([IMD@PWA'[L M8=H,CT]#5T5V1N1#:)A&R1$F)A]*_R7WBFC:*T;D(AWE%$_94#\$.]CGN#56 M<&'X9JQ<(@DY)"CSUDWN&F63F1LE;4FY%ZGQN'#I<-(J1:F-L@\.)KHZ'H'0 M@08GIU"/6:$3!X;UNHS6F-P!7B<8P^,<(C$9*J4V[T:;9-85%5WNI0&%#B'V M:4G7D^[7&$3A+7_:5/L-8!-3W73E4 GN7ZA\6S%/CS=0Y-\(WQ)JQ?>N']!Q ME"F.1I3[)9IP1D(6#6"A2*-.I:'J1#4D@D\01AL$K]5/YIA+(NV@))&A8G/_ MQ,1K'DV.47MMX6&+2C$BFO*])D'TP*,G*JPX\5Z)O&PHG4R-) N-!N!8 @E+ M4)&*/Q7IM++XI"%;D?%H\9@RY3[(ZX UEA(W:=IFSV>^*7'1LV8.WY!N'C%T MP(4%QG,V!*6?;.$^<::/3H;@I& RKS$[:.GL5W,H.!>T]CKM1LNQ*3M#_)QM MU6JVD9&R?UVEJRU;J.CV+ZQE9=?I]WJX M#D?0<:W2N22UG,-YC_('4=5TKF<(/B,WLC%^%%4\HYKEA;N/K_A.B.^A-LO6 M"#J)U6RA0C(MURIG:LM4EK_I/\;4)DKWH@RO_//R^QBY^2-7]TRZ":D."[-Z M/59(2#4=I6_*6 MR'BHNBI4@)-AI5Q49T[G(H:LYCZ58BAY1RC2+Y,".A7S=4GD1R$-6$1P8OP\ MX\4*6.@&CXF?G)JR1XRH3;*/%&K0"5)4Y6,*#QB58!SF5;N2,;%NLX:P3QLT"Y+P7SH\RA3#2IN;J-R)12B0B S8G M3:D\+1%!8[R[O7;S!//2,U6,&3&0(;O.X,F940U4:]$R$:6K.!^SH6),*H"C M#38R?O'.8!V-&XSFHF9W+-M;F;B(;%F*]E1\1MES(KO5'"0HO\EWT/U1%;V3 M8]%X6)NGILWA*WAM80F/DMB1@WK3611C&>;8G\#G^0\R&I8Q+M1,:V9;"@K4 MW#@9IQ2<4^O,,B+IR)R)[_J)KC+$.323"9/ED;IM*/H9>&K?FZY\Y*0^F:3B M4\(.S>@(_+_0:L+J8TK+40IWYNN\%Y33@@]1@%%D^;ST&VG*4?.^*0F@[YTY M9R5W[7X/9;Z2OH XZ$G4I_U!O354XB0GC4_\ (?"5F^F $V% <,6K-(*AHI MJ!ZA#A8G@)I+YI:8CNM.Y!(9[5H=F2HJER6B0%J+*3*'!+.(^$WH'LHPMSL N#AOS(=PA9FH1<-$H4 .*@@QI5JNF"GO.L\MQ!I&102$;7:HA8$AT#8"<8%9RB A0 M[CJ3F.Q HBN]O;HM&G"7>\_P\L3>1.19![$UVGB M6B8.@D.4;QEL52:GT@9V,%A$JU_[GT@IA3@5.;/.<]2<+*[3@M/ M/31;I9OJ(J(1CIS<**@/Y>:Y%6&=MX@_^C&V*0R MN?'B;^B+?(9V^0LB:&O*" MPWV2QJ\JZ2WUL7V/9D!DI]O\Q9)'RKJ1U,TV(8*GX;E,NQZ+]TC!H!>'BS(7 MN3EC'Q1/*M07!CL]+AC. R6(X"VZATMX"UK=G.X=-NM1A=K9HDMC4JD1,V-M M6(3>:775"G4LCD\HR,7"3(&K"D7D2$=Z'E/5,NNB'P#NN*F!%X"7(&L0&T)G M>M2RV05C[$2NP462WW.\)9HIOZ8JCNW:K88]Z!ADR4[/>I !#_.E7J/=[S7Z M@W;E:T8/<,[QCRAAP.@,3D4/W"X-0.AU\F7TYO=83J@_U>DT7EB+P !,&YVF M7;6,>0A*AVTWS"("T/%P8\>Z$J;BA)3LGU0"C3VDDD"2J MZZ868F!7([!ZE=V"CVU C9_7Q*SSM^PQI59%NP#P3;?1[:'1W=GZ'FP U=O7 M W' ^'TVHVVW7P]$,=\(+I[.Q"V ^RAW1@X[=<3\7HB\$0X#:=K-SIMYVD< MB"VI5@]W?NHM4JQV5F.[UR_4/T)/#+%7TKR2YD629G^FY?:Y^H471I3S$<4K M"IO7K3_J+[R2YI4T3Y T^](E11CV)/ F(A*\"YWYCWP^B)F3D^A:-ON]54AN M>M;L> .:HO^DV7 &@R=(H"="XE:C!_9GK]]])?&N2-QI=+KM1KN[JEOX& CT M1$@,I[@%S,)N[9#$!U?]G^W&/S'$7DGS2IH729I]*>S;EP\JO5W$T?,Y\_MO MF_@,CL/Q?N&5-*^D>8*D.;B&N44.^R3\'1O@NVID>4_Y!:?-+1GR&T"Q:CK! MZ_;6W]YN[W5[G^WV.J,NDU=^B'8C)]PULSS:8VID;082^O$NJ%.CB^\%=U5H3^RK,[F M1I>)JG$6;5JP&8KXBQHZ[(=PA[TYE9!C*VWZ]\@+$VX(J<=^R1'!N2]3PPS5 MYR'3"WZ$C9)P&!RO13# [Z=6+4 RW^7F2GY<;#\OJ]D3U<2@7K=3['Z# M371P3K*$P<>V&%/7#ZDK>.)-Y@&L?H^-WWXW_B6Z]>:HC)_E4GHT- +=Y'-, MK3VP[W<4(D? OI&JF89^F8'P$OD"5D3[,0]INX.7 $X>0$R-GX#,X2U/A\E. M<_=#7#_5\]_R7>^HNVD84=]\^"0/HD(J(&S%HGI%; ,>6!S;&.$N;7;D MEIMA]$BJT9";ICC/W)@[MY7 ZN;;&F%701PB,(%-G7AB B>U4" (%HS5QW'S08H2]A^7D[\%D5C M[$=T%H[S[\H_/1]Y(3%ZV<)!4H'FTI7R&C=5%U"/=9ECUW8:X88\-P!6ADVT MPCGQN8K^**U.DR MD6WLA,R&QP>J]LRN]6_XDH\]*>X]*0Y%WQ 0:=27=EF;TRP8B3BIU$9R(EXV M1A$,'ZL7E5-_:RUG&4L5A]I2IVMJL(>"Q4H?HA.X2C/S&N$I9R6DZJ_6Q(_A MOT)L)25GMTK^J!--P-"I%I)8'6FR_",FY$60 M&MP"W0WS=X:ZKGC_)N[';05UAV+9O91U+*DBE\Y\4KW8LJW7LOW@Y.W3:I1F MN[*3K0$:?$F3*"W;+6;[AJ(#>,380:ZHVKQ('BJ+RA?H?P1(B;*;ENG988GZ M*N]WYC1/EB^L=X= D,IGHWQE8(3+5\[HK:2V-EE=[;>PNU7EF!RMI]96.PM^ M#07<=7SA)[,H<8/KR2>P8TC)Y4]$8YYY8OUFWC*BKMEF/WMY6!W24LK@JSRB=>*+L6)JE57,>98D MU28]2S"VZ-.\+6]=NJ,TBI,,P"A;?&QU(,:]^]@T/W7)RX!MWT:D9*>Q?XO> M@0Q+$&8H]0V5/J74;$SVB_7&?FOA;'E >X3?G ,7BH5(HIV@]NJHF5$75='4 M_\Y/ $Z:9HNCK^/H7YEF_T+44>MC:CW*9^B-DUW+H"%U:P;!Q^T0S?'4TJ_D MJJFY^.LDQ2E,MX^*IQ(-L5.WF//QGL["FU9F18(BQ-;9U,$.M&CXSB-^$S8! MJX5&.#LE'+_,EG7<#[]*I>.#S"9>01TS+TOYV18N1>J4S/,AX AYHG-\%-(( M4]+RY;Y3^VEQD?!*X"K9@RT]OUE+AGJ&.=I71#!#?$PPEC%]UM=L%PY.R.A6[Y6/D7G1NR'6O M*2DC*:3UD:TJYB*BVM=MFBK?#3*7C, \1EDBU#C\2F58AB0>ZU9+(S1).6856A[!\E7^@KO_ZPE&S+]IK #" M-Z?)E(F>2T$>,_9!^8F>!I&/&443-3E*TM48_DQJFM"&TBH)J-4]AHD[WXM. MUTK$BCDZH8>M[-T8MDCZF-S\D M793;S3[Q5)QSY?KX.Z$HQ-GQ%]2_.U$3A/+D M,BASBDV>22DGU<:0OO^:CV_I!_2Y29*8")OBOOA=@N-,7@@,DH%!@,X@V<*? M#^0]?M30:W$8 2HU-%Y/KI1S,ZF!.SDEAGU=#U+W2^93&4U3VY\Y'P6@:0P] MZ@WDF*TXB_JXO'1^.?;'QA"0G(9H:)2)F*A0PE?6#]:6:RGKZQ9+E ?*?:%! MVH@]Z*-TBZ^IXSLYD[#=(7P-F?HS&@)+?=O%4&$3\9>M-)A4&1E40?XAE @I M#C 88LH!,9B0IYH(;D)GZX2GM-^XC\3*>,*#'$5F]_-SZLVQ3V6>^\I)*E+( M8B8,Q<4;PZ?1:V,E/#^&EO'HOOHX%4@$1!$IE,@/;DPY# A3^DC3 MK,6\9/)A& ,>5$! +4>ZE%B-HA#"-X)C$-AEPSQ< I)?G[@P ? &1]+.IS.9 MBX%_N1T+8Y?R"H[]S35&Z":@.K ACRF( $)" JM&0AU$/Y) !&T M/"W(DYSC@N&XMV7=X@?.LXJE: MY WA9I)C2!5EV8?RX":6[9SV.G\K&]_NZE.# 9-NLV';'8Z:V,U^H]?N-[+1 M'.60JB.&\XE0Q5F(94'DLC,-.M[ENF!TZU#(/FVVZE!HT.CT1%BIU6WT6XYB MY*MG6FV3/(7L. H3",.0?"X@1#@DH(S7$?$Q\RJ67U _'&&.('HII58L(JTO MTW]\8PQ*UO.6.LW."286X5F@XM,3/;=SQG*;C%X4Q'"Z7&F8JRG(,2:9QCQ\ MK8JO&QY1P9(-YX$IK%"2G!H. R7CRH6$DLA9V9@3/K_#:0HXA)%;BC]'$]+Y MMJ51BL/LE%UD(I2!@]-:$ST2,#=$3B7O2,]T*6DRLK1">!:R" @.)E2)7;"& M3B_-@L]G7\]^^>2##C$&U0<>/G=G/M#CJY=$\QB$Y#/T(RITZ5 +A"V%\8^]Q#%?^&-'XDM&WL3?^2GTCF2 <[ZV6F>MN0*+Y+Y?S Y3:E\ MYC"3#$G3Q$TJ((@CG*0KXF&8'I49VNPGYG!9Z7\M6X BBKQC:4KO M;40$B9""(645/N 00') T91DX$*6V U=6U+8$1EU5R'"4<#.3)Z;+B/J(IWN MP1-#[3VRIEYGEF6*S*I+W--HMJB(72S6[L]^E%[#+78G=]JKKE%:HH<[6J-& MCP$<='N#]QL4,NX20@H;6'A4\#J@&0"L@K369#Y#K:GRCFI6\AXO%(ZE!TWP M+GK ="*Z+SQ$-(S0N3N/B77DV9R:02_GH# \Y.TO !51'A5(57X8U&(Q7QZ' M;05O$#!8*= T].;.04F]6J;M< M^TH<6QN-M6[B-@FR([;PR@FR$"+51%J=2$3#AA\!S1-/J?QPE>.?+SO>JVC< M;4XGL)TQIM&#JL!L!?VHJ'RH0"Z7RCUXDH>8/FU@.Z#V!:2D&#H9*"/L'%#J M"):VWA.'HC\.25D4/%HJ<#@Q^%:X\RDA2NV<<$7$:>C%^NLB P#!$C!9\X0= M1G"NX!>@9%+Q/'LOI(;JC>["*(AN!2RS",MC4:OC8E<1E$7-E/BO4,]4"((# M@*J H$QQY)F\0RS0FH'-[HI(^WR:TQ6+KBZFH5>B&C94+BD8W-,9CM+6]0BQ M!UO['U4()*/Z./W82]- AT@"GU527^=TBJ,$>GC,GD*Y9UQI)E11F9M*^21C M/$'T388 *3X)0!/ET$B4))06)3QNWF0"?TITI"B35D'F8 04Z \AX$,B(@4 MCN*SB!3!8")FG KT5['FKTR4])$39OD KZ*Y%S?%]+ZLZCK)1V+A%I^-9&K# M31R%$8),5'ZV:?9?/71%61IO*XOXR_:]7(76_\R#1R-6^!;?%<_T[<[;AN&T99%!# OTUEBG\R-3#4!%%0E5>N/1 M^2Q9M.:I9NR51 )E)U%S,6OBN>3E/[4NBK]4U?_J%^C*%=_GP.X)"(F_*&*A MUWB#B>;3H3>F^>SBU;?,400W$6P3O5!_ ;.+_1&R>LZDQX)9G1KE)GXBG5'$ M&.%9*B2<*-;(A(XPC(C[=6J=BU1?@S*P3UQQ@;$,X/HJ(F)Y$,QIAD@ M'9-9/;FH.FLWF0V!Y6HF0"#:$5/#",>,">W(#VH%UQ2N!M?;[C+P[KI(_ M6$X 1.(SX2=8%_'HN;&0 M1MY1NT/>T3Z3"AX.4%0R/OCA*>;7C5^DZQ$XV6=W$2/[$G$<4,BM!MD./KYJ MAC"L$XM25#(I.Y(%]>S^VU^L;R-0H? 4?([&6J/0 H;0IP^CF@<'!5<79C\Z MS=R8E))A-$\-'B934(7"0":[.+=LE"=<%V]$SRP1.1,1''E!Z.!BE;/6=:8F MI/K>GUK?9MZ(_A($CPV1YB%X?G/ L$[4=:\)HDSA2.XH37'HZ<0>SO% '2<# MT3RDU$%7U(M+?ZFL3Z(K-O7PR+RMB&'QYU 'IJ5]E@0)W%]CMOM*A7?3%PJHWGY:NO@PV!HG$XM\YS"'S(<6!9/ MZY)HR727<59.CLPQ5OB\P5OSN03CR./*>LZAX.LG7Z4L- TH^@HS";LBT\!/ MD[RB4GG/$[ZG0&+C/O)?#/-"W$XA;^6I,M*.Q"7F9"4ER.;A/$'*L<":Q.)A MD%,AR>)]YAP=2A]VX>S$&4FB=$6#R5.^40ITHKRQ#Q'ETQGZ,8H?0UM]JT21 MWF;]NE ES/?AV&1>YR/4UE+++("5^^[H?CDRCL-EQD* M3I-% V'R*%T% MWZFM!9PY54&KTWZU,,M#)R$RH10"3ZF3H)M%J,Y_2[T9"U_)!'1A>K:]1B.? MK>E:=X\S],60!U2U*A-:,8B,B+D+)F",O5BK;4!K"4>#C.KRQBBB[HIC5=&# M+-,0J1^3C'L _>$,7GG%8:%K347+#*ZYB%*NIAU1A*P\8UY"G2=L@>-)[9*# MV,3]1)9*%STI:JB)4PDJXX: MJJBM[_0':8: CCX= 685\B$3S'H!0M@LR6P\NU NQSCMA844@O#$* MQ\!"S+CM)"C4YT_..-+B+" ME,N>,.W1PI"]K,HDBQZ[D<_P0XD_]8&*XE-O&[KHQ6B/R"VQN $<[!)N"N$ M3BUL@R!B<0VA@5D46%:%O5QXA-5A\#^L)*H>.SXW4369U&%^"@ NYEV%*&A)EA\_.Z B8L72*4!HVL$ M\/'.T2U4RW*#1\Y",:H"%C%;E=%:R7!K*)E+N.U+99I?0%<@.NF\Y%VK7G4T MKR_1J>;0"-H)=K'\9G9U.L=DHTNL@V.N)1RA+=2VONIL,GKLC4O7%^ORE8U( MQ_+CU(O)X7F%X";6=S?Y"WU4(^^MYN:24VN79\[(XMP=8BDZGQ0=D[K$-9_X M%DEWHX&16>;XG?_(!-.*6AO6[50F ZJ.J-I137!5[<)/2E,#\[XQ/,FE0IBHCD!B75R1Q MO.@[S..'Q(8%43/)4U0NBOR.HVDNMU>1_<_XL[JE&,)3T ^K_)R&N:QV).^I M)'>Y]D\NYV^GUL=J"[HA=HO>5P^$+(IH80[%TN(OE15>C](HQPG+]4=@1EW3 M)AQ%4S#HW!^>4AM[;>1"5ZB^G'SDL_4=U;&)Q_U4SE@W83OQ.U;O7H58&1_% MCXN52%RZ1(ED%WS@T]1M$9)!(T=MM,H>4@*661I<'4]T/3)+],0Y3]T?.LQ+ MO68 'W%76 U+-5:(BU!AZ5@)?*RYRM&7#ZL*=3RC2130=7.-BH/'4^NKB]]K ME)J6)?R0TP.$":D4:9^W!M$@]H^.E9$G/:89="1LF?)]60F1P4<5;.M7J"EK M3H.1>FQ-DW%S#09Y:9[UJYSIL,H]ERMN4-G"@>S7)8T>79^3T?AEK71%'\:J MNLZ7RF/.YK?PBUHLIJ-93(7>8V5TGO."X_=<[RAZ5R0? A%*X3_R68."A,;HB!0&M!=DU)8$.*'8M1@V!1)/2KL($I,^,<[7G8>#9EB,V? TH@O"B2C1[9$$A" MU[UAO3G[=OY6%/EUFUT^7?CW$KM:WU(5#77AO-Q[W&C9#=W@,?%9&;UEH AQ2 MDNV Z)>!YC2YJGZT#PH D2])<_I.96R<_GJ"Y[3\-%C9D_ + 7&!*EOL*I_: M1\7*+N -DS%+A9.;LWMS-H8\\2H4T)VRQ*-Q/1B=Y%.*ZLJ:'91^ X>\*6* ME8E 9D$V@OI3I*JH(N*^XGB6TCC2AH ?U#=E+7M0"85:S6%ET M7!?B0+:1DDJ\FJI!HDX<#YG *HX.(LQ38;!'!="!_)@:DS/:4DXUR@'14(5$ M9@ZKG-%BG"B-)HDOD1:EA!:UG.3/<@^E3"_NANE/H";-BD7/(O:FOIQN"\ P M+KUA+.,7"Y1#P3:Z)TTGTYM7*8N?L#)>!S#:CN'),NNO2W6]II,/+9:ZH:CM ME.=EK"[A<%<>#3-U5Z7.!70PDCNL@$-6$S"PQ"WH9Q%#OR4?MF ,MB.*_0Q= MKND4_2V9A*Y*STHF!ZQN\E=C:8Z"E6D>EAIT*[<$YT05783+P;N!:CRJ\D,R MS(VK7X&W:5:T1)7,](]56TFWFZ(4XHHNTRRM%ZY5?J=ZL0?\#WL%YJ3O<84K MIY70/>5S-Q4M>61<74L@*E.@J#J(@HR2G8YQ)+<-\%I%! M)ALI^R)[5]1XL#?(Z*I#&PU'"J\4I=\**Z.Z9KC(BQOE7)QRT8PV>B5]"U;- M@"]DT$= 9S!6L6A%YM&:2?)GR?7$2(RG+ #ZP^_?+GX"16CDPQ%(L-#T5[O3 M 00[70.XXL?77!_L2^>D92]>OV5WG6:SM]+Z2L%C3^-W]\=7V,AS%LU TFN] M&35K!S2(-UZ,Q]>]]4Q(K[Y<_O1K\[33-.8JU@:BT(K.#;SK"25XZM6N)]WM?M&LLVMWCHO9V%OV&'6;F>"Z,&7+Y?L]G(@?A+,%T]NN)3!@Q M,DZ>0_U/<9PFV4DT.BV?7_S:FZ!FW?$P2H&9U2T]'I'9M^W*XRU\%= &*H=_ M_\E1)!6D800!T<"%TV^?=H#$I(IF#]H2I+2YVPMF@!OIU!];8 65OM=@, MZNYY U;J!+#\1AZT.T+)/A]#MX:GC-$:QP,X/URF6RJJ0^X?Q;]8_W5^_O'C MY66-5C.=]M]V,]K'&?@[M&]O!$]NP!YWMT'D38-Z^;O5. MM]INM(!)V?VCWNK]Z5M/7#,N,7\6'YXGAM@S(,T3%M$%?U[#"KTCD<7.J8/< M$SNV!MY1:)MUP-P/E^\U.H-FPUE9"3V&^_JZV2M"#LI;RVXWNLZJ5N2&3"S? M.['0\1?&DH,'_G4TF5+_EC;E< MI!"DQ&_7?M7]!M;,)>@U>XX1']\5>)G#C-D"(EF "A;A M:)U'X;_F(<6;__#3NS.C%GF=N')UQ',[ "R-O.8S)GJ=3K?5$:=\I>5W3KE\ M"@(G'!2OQ&'(NA)TQTGS!5A]Q\%&%U_<,/H$URU,O!IX.4W\?X=':\%1JHG6 M;@_3 OB^?>1C=&1G?#%8V<.]G4-@N"]-[R7.X3'ZW*PG64YLIV^W[(&\@776 MV@IP=5+83FR[Y;3L_HK _;]W/X9QX/^"_X5__G]02P,$% @ 53AT2\F= M/!9H%P JO$ !$ !M87)A+3(P,3SMERV(A"1L*$ #D+8UO_ZZP1=1?($H M60XX8T_5.#;0 )Y& XWNQ@L__N5AX3MW5"HF^*>C]JO6D4.Y*SS&9Y^.OHR. M.Z/S7N_(^J=,5[G&/3\6?G%NRH*?.%>54DD#( M/SD_$S_$%'')?"J=<[%8^C2@D!&U=.J\??6Z19SCXQKU_DRY)^2782^M=QX$ MR].3D_O[^U==UJ_U3Z\.;EM-N M_=7YZQNG>WG[ZF$*S'1) '28#63M-OQXW1JW6J?M#Z>M]W^OV6A @E"EC;8> MWK?:;UNMUKMZQ6^8T(436N&7&:@9UP%A+L;]%Z0%L@2_W@296Z0LE+2=Q$I2T@]FJ-3U'TU M$W3?#69RD-% MO3[_L_Y]*:F":G2A:TB("\8D%85N==?0U>C.J5QMT,E2OC,@Q3/26MTXBJ=J$[GAR^*R+GAXWFGKW(TLY4_6E_B586-*Q M9:%E)>DY4U"S6M_7$NF[1$5-GW:;6BQNM.E&S+Y.S7-+G M1,TO?7&?UY;E-&;9_;B/[+!R1]?^(J*3OIP1SG[5R&#Z=*ER)5OB7_WI6:@8 MIRH65"U*L[C>H3T!1K\O5"@I_)&M4T^D3*THJJ3>9RJ<4;B Y%5_.F(S#E:H M2\"B0'&M*(M,OI^9F*J./^$C*E M6XD%L9%B[N[W^>[.EGVF'=H#3OB,37S:42JUJ0NIYH[]D._8=7DGJN"9]NXH M$.ZWN? ]*M4%C+5@%6N/8KJQA]NM@J;(U/!?__'^=?NG/SE13<^TJ[MT$H!= MN&"!MCRT;:I5)N5KK;V-R"R$=EX(6-T?G4R%L76:J?*92F,43A3])02&+NZP M8Y)%,Y=J[N_7Q>4Q*>]$%3S;WJUC?.QCL-0S7-IO]C=9N M+[C/V7K^$%M;S[WGMUA4&[.@%JE9)@6/N88)]MQ%5">2U*4!8;ZZ)1+CK'>T M?@RJ4-(LP((/7C MI?!"G_:GN T21MS#?"2*N3A)F1\&U+L62@VH',V)I'$/[S( 'M&*<:B\+@8R MZ@\5((Y1Z7V%-2ZM)Q!9I$ B; Z"$JXK7C_3-4D9-1 M=R0\3:OF<52(YFP;1Q%()XNR='C]T0&HND $UDG0.AFX3@;ORW@LC(S$^$+C MA?"5&I V!U ST_!RA';!E;=XN814B.>M&&7!7/JQ"W^ 2PJW::S;O39B[D8 M7ZKPO;;3F05GC$AM[@*^K/ &\10G4C\,\& XWEC0Y%^QT^(@U1SF!KC$H43_ MB$HFO$V'ZLFJ-P^&XN&1ZL%@F,X9:%$-3@(NBJ1%\)P(GRX;@7R9]0:YZ[R^ MCF$]=@C5K\H\7 J!M[K#)1H4,8*7,?&8:'CYLK!K(;.<"[&X6A'RE\6BG@0S MMCU2;LSB_8H:I?FF$"ZK(\U-\QY+O$S,VK*)O*$;@+0(%P-0<"Y;$G] 5D7' M[]"5FH?"/J>/RCV]&(>3 G$2)"_C9#^17E.BZ"''2&F%YO%1B/H]>GQH$"]C MH^I,6]4&VQ8JLQ1+3E;ESKS]OA=K_($7>H=TZNB+P*=XR?33D6)X^_LH3IM+ M.OUTA$(Z3NY__@-8>_6P\!,2K-IP$5A+--\;<<-)%42ZA5H*%Y6A$K&D,H#9 M=)* 3RH(6(#%!YEF'&P'=,/)(5CVR617EJ$(]9^0UVNL_Z!,PNC;EB-]NVDB6W?B&]%VX;OO&MPY,[9<6/*%^H)*4XW55^Z I/FZP M/QQ=UQYX:KSK4&=P9$O>1@5QD'S P=E^]T@P^P'9AB)^'$*;5/BK[L[%&&^C\<$/QT%,D35AR^) MG"YU7&NL-7>D7((D:Q)=//]TY$KJ,4B.]'N4N1 \". T4: M8N=<21$N$U(&)";&->A;P=T(<;REG&-U&U%3F;L5 57@82"X"BF:2?9FS*.3 M)^3K6O#9F,I%%GR>L2TT#>4L<0?[/(L[G7)5N5NY\4(9/ZCR?4<@>LG10P:5 M =C4'1O3A^#,%^ZWA-U]"^_0&Q';T7L_IT%2QP$8W[J9K$]-%UC>O5@CF$W# M+#,I?1E+;TA=,>/L5WR *^)]YU*-Y1] M2XQH=FGT;X^#1TO!H/#&Y"&Y_1XQ78_TM\GI-2,3YFO-58O=3?JF3FJT?8F: MPW14,!O/A8J78EB8M4.!WS*/>V>J+HEZ/QZ\J\5G'#=C=QHCX+BW]AN;/F>"> M&L!@H=Y7%LS/12A-VJ**O+$<@YFZ%(KX_6EDSJ6\E64TE@L<>CU^1['?T_5K M,ZVI4WM([R@/J;ZJDFC<52_RYV$"P0S\9\A=K!8'5)GK]:@:FMHML=G14RHL M80*UMN#Z@!)21!'CJ#?V*=CP3DB%FN,QF][8J7D;+B94]J>7C$-[C/@]GE9T M*>0-6-@!_ ]+1/R@8_PL':[-\ \>3+LC?E8S';3&^L&6;/] "W1&Y2'B193/ M@GE_VIE)JK/2(%%)QLX>9$21I!["?Z32U>X/E%(*5GN74B^53&7N[JXO^+W+ MJ+9#! %0-9[! JV?K03');I@@9-HIDG/5FN2.)+5N2?2TS]^AB4D.G.)<,B, M7C*IP-OG#%\^AUF2Q@B>O)G?5S^.T)#TGKXCR]JQW)/]>PY0YFR9F-492SO* M2P/\=2AWU6*'92:YJ9^Y^JE]@3@DG'"RG6Q/_78X;9Q&<(,8U5AHM##48O T MNK:EUY,H9VUP[EFXL4LW.GHP8U:)(N^&=#VIUM:GF IF>X=S]-Z+CWRVUEL[%/O4[*Q0S$!#VOV!$QSK=\%5\R+G_#6ET6C MZ&)TW219T53DK(%]KGTR8$ZO[H6%XY 5[SEJE"Y_D)A\M'W06^(&0C\L.GE& MBL8.@B'U0NUM]WCQA=EDQ3"1--47QQT/-Z >>)A3RO"X]!!44,)39:[EY>^K MD-\PVDV6+, O-,3Q@WQJ0X\<),H>'7SB^XNRA2"79WTU OO&I92CIL,L?V M5E_1<*I#:'GT)'V<78STLHNAM MPJL2"N7I?L""6>D6L2PM4J\]@I8#YRZ*6 MNME9796[[^H1X+W) \"^ 1U.>#GHBCS;D*\!1E4_5^39AERZ YYH>CSFD>:I M.%.M%^]]BMJWNDMQ[\%J@UG<.[B4J+8;\//G_JIL47JBNFT'J?=F*S''84J& MD8.-QU7'<\+C:^7G:$;X/N[41#?)']V3>S5IVQOX#MQ^I3@%P1FZ Z]I1J]P M8J*>30\W?<>>KX-E7]-'8VNT2#(/;^0Z8D@7T<952'OK?DN-/'&(+/3OOUIO0Y;Z L"R2&; M#$^Y0P)F2LN!CQN,8<5/(M[29!\HU>C5V8V-R^*-A+4:2P+D&*3L\P%A8 S_ M+^->DIZ]YK)3*=OASDA!E4<9JC+WG3Q0^H!'3GL\.<<7P-\+?-6Z<,ZT@J:Q M@PY@AFZ@5XE+6K)W;,BWK0#BUU@8K/_00ZLAU?MST2SXPG&T2X:Q'/-1M<=7 MT]#(?#R7'&L9;T)>T.^K8?FOJ6MA[1+ MD,=8(^";6]"UJ9NZ+U?"0,:4V,IL&6U3[TP/0NG.81FH(]>:M(U=.E+<%P\! MY5X4-$\OJ51DVE2=Q94\J)%*;'2P MW2D\=$/QW3-4!&N73:47F/2;: K%$1]!65_P7A_9?EPE>PY?+N2"^'@)\V#= M-SRTHOVVG6Q/EI;A02("VD"&!7OS*S>KZ YS_ %[J#-*C7X6+GX_ MLHXF7/H&H"B1J)TA4]]B+P)XN*)B)LERSMP.>!057?"(\DU@?_,U&)4\!W.> M?3'%. 0>4T$3.J#T4J)YT.]2H@DL#JD/[K@W(#*(OJ%!] DS,Y>[%FH"HZDK MJ;U%?7YK2!7(QXV_X5MD<[(\$YE?*6RXMYAYLY#>E)J MQT)-=^.*2%7R0M2ZR#5!@?;R:QS/% WQ*?%^],I]+G,KPV[%+'/(64V1X4%&%YEG7$H#;P^4MPLM#'S75W>9YUS,EQPQ'QJT:*F<0Z!S>X MK^_.N_2.^F*)>87Q8B9I"@=7B\GG4MP;&=;1ZDCL((K$@G4^ONY=;J(V$=A' M'QT/SR'.)5I'.8*VJ#H[%_P.OR8$6 8R?DNXQ"VL36V=KT1QGPNY+%?I&SG6 M\=[@$@\S$"SOG,=:FF,=;_3IP?@89<$:K\QM%NZ"=5N9:QWW#9GQ4/4&):J[ M+,'#]4+$[FM\5*?,P=BEFG=-;&MP+^0W =DE ;@@G MLQ+&ME)9Y^-\>-D=4D4)>'<][N9F2$6F==1?Z60 78GW\E#1XR$BGP0"=TC M=(=!,Q;QO_$;9:.5@BHWN7ML)=9[X18_B4/\:\)G(3"BO:\I<7-K^58JZWPD M*V#YNM@&O0]@$ M;C#ZG2Z7JP(/%=G6D8_8C!._-RAHY+(,ZV@[82 6 K>BX&X5RB%E^=F!WKKO.')_M#7GZTIMQ-- M! U C[NTU^3^DLE%,1!=E6L=]XBZ\8?UMNP#U"&TSDWFHQ3XA0K\#HV0N3FQ MA<8Z#YDC&\G3'_G!5$U@'7TG&,_I#9'?\,UUL)IAMN:6!0.!=?1E%W-SLZ": MP#KZKE@P#H4^$SD14A?-'?B"QPGO09GG3QJ695A'VSWKGNL;!G&$J'C95II+'.0[E[ MU3R?*GJJK^Q 2FF.?;P4G RI P;16RKZ*E?>D3+26.>AQV%5(7[Q@%Y9AG6T ME<9B39NR.9RL/V%1,FBJ,NVC+MCDF>\#QR9)W4#;@>JRWB>W]#Y6I?E-L4*Z M=:RY@54X$67(;QKVPJDH0[YU[# 6BAHVGV@=9>; 9!%M5:9UU+UAR.])SG7* M)UI'N1F27(=7BQU=B](Z/WWFXPM-)-7,R9O3ZY?)*=RA@G;OX88&ZO-4G MM\Y9]'+%+>$BAS:W/;R5S#HGR:DY[FTQ-.H06N?F<_$4Q.=FG7^ !74\%Z$B M^+5K[T*_(4]Y;MB8:1K&PRWC=!L/!1KK/,2'DHH+1UE&(]#J%V8*P[LTQSK> MV' 82^*5/YEC(K".OO*AGT:^[W/=.^L/<[IZ(\DZPBI;K&*EJ4]NG;/""U;; MU]'=BECG,(J\ <;_"?$7_-I$66BNG, Z^KX;"( ROH>U)UA=LCN:69=&&"@I MKEP[EFD,CW.&;V369F\[N77.1I#"*1Y@@J'EZJ:R!RV++UG4I[?.VPV5,RJK M'@2HR+2.>B3H0D7;J%@VU_T5F=91WW9RRWBG.=BB6[;=G>[DUJ"VSE<._PD5,45 M\]G6D8\NHL[,K5OY5.LXN\+5'\S# !L/] =$I_B1#JRH W7B)QS7#FD=6A+_ MEO"T[YOGZE!?",$OE>$7 +N9;X#F63/3-(XE]"[U9ST6"Q9@EHH^\H'7?"AW MT39*O]92D.)>91O7!2-W3KW0I_TIWN]C4W!T8&1N?OH$>!DCR'3Z[53F.[/L M!:=SR)=N.-$?E-EVU[$2_C7CNH+U5YUK4EN4\<<3!;)9$/CU_P%02P,$% M @ 53AT2ZZS_:3M$P LPH! !4 !M87)A+3(P,3>3]"#"F("/W>^SL(8_$3WF&R!B^$_LS>^<2,W .)J0^W MM+ZV[USD7YA)$O)WX-6\VF?#_ MG(P?Q^.SR<>S\8=_&PX:@2AFVT''KQ_&D_?C\?C;I/L/(<(_GXG_/ $&/0X1 M9F>O#'TZRHGZ@DI9O\G'CQ^/ MY6^SIH66KT\TS,8X/<[8V5+FOT6:]CE.&#ICDKT;XH-(6EKE,)ZRA?C;*&LV M$C\:34Y&IY-WKRPXRI0O-4A)"._AW!-_N9DLC\6OCSE$ M\1+BZ!P'5SA"T4;@19>272Z"I+>@9>8A!OW*I&^T6?&YPY P_2/O MN#&?%P0'$#,8? :A4._# L*(57&H[]4O;W> P"L,5U2%[,;4;;NRM> M9_098/0_J1ZNG4O(?(I6XF^S^>>8(0Q9)<=U:'3%]T.\Y#_>S.8/Z!FC.3=0 M[@=\G\3<$>#G.Q(B'\%*SNM1Z8KW<_^7&#$D+;**P[*V7?$QQ7RE>$9/(3QG MS,";J=IWAFE$_)\7) QX>'+%Q8XVE?@I>W3%TR5\BKC+6*)(SD3I0*1Q\'#- MP, ,NW?MA9VNUL[6O67B+FAX3%%)KQ\0CX1*DV MD%94NY?M<([7E4+?OS]/8<9G5;^!O(:A4NL0&3(>N(010"&[!52$5>O*H*P- MS6$]45W)VE$=5K:1V*H&<0AY-,ECX#@"*0* (5_ @L(X@L$-8>P.TH<%C_U3 MQKO10OOQ^XB_ZB)NTK>O^*PNKZ;]^^(WA[B"E;H2F%,<0*;K..(+WOF2T"AU M;D6N;F'$&Q(*^ - MN^.[7AS=<2GFW'.0YHJI2;B_V*3VJF),H3^>B^J;Q9%,1W.7+IO_0S"3QB4+ MKGJ^SL54^'M($0E,EXZ^!QY"0_)WL]4VP]2+-FH/,E L6]>X&Y(;2)J<.Q4M M#7%K171XR9*%X@O":!DO[[@!^6@%PCNPJ;,0]32<96W<0,#@,)K0#=57/JC^ M_L:LOXY?'X1^G(07-_SO>SW@*U^2 QAD= 33K8^+^(\%E7'RS\0;>5FO_/_R M!<5+2'A[-'IDON(T:(_M$\[K]@" _S_ORWC4$O"?!-Z6D)=2\A)2WM<_81 ' MB+?Y4W8DETD2$G^/^U"<"1*Z;P$I\_+@;P[8DSS]B]GH&8#5L;",8QA&+/N) MM)71>)(> GZ5_O@_XK!"_"N6L#4(TTGQL."1UR.DRRE>PS3(S$8/P1,,)4__ M28G4H7%L5U0QX0\XC2[X#-EP%R!/FO52&G0_%#!GE>?4]PCE <.GHTDV#J#^ MGBT6SW+3%L=,1!>"S(C;S#+K/Z=DV1B,5/&DB9QYT#B+1]X+WZR8(S7 !\ULS]M2KDNF9DV(G0,G MR36R>^A#+L-3"&]A5(V5MI?MF6<"G8G->0 G?S=)C9*^EQE6W]C'RD1X MYQ#+26>RIU4TMRD P<_B(";OQC3\E[9V*,RJW!;JY'7.NAI$!B96V)*L0X%5 M)=R=:- YNSA8UDPPUW1Q*-2JQ+-2PDHG FLN$KH]#L9=9$E3?P36X-.K7ZJ-:]E$L&B@Z^6Z W8E+J,O&A:96WM'LDG#E?R57'_K+2Q[>FAJ>$O MG+NK1'7.HL1]<()-,"FVM#V[C0%1">D<&N=!("LV1=4!"J;X JQ0!#2':_Y0CY#M>,TU%$@F%P!2CF^SR6DXOO'I"/-(&W25_;"35C0,T5X1R&11FY 89Q(.O]J51U M%%'T%$OB!, MJ)2^"OEB2_?BH0XQ5"G&.01S.SI1'U!CQU3=T_8L-96M44/Z?W^C79Q9*F5E,-C ?\:;Y=EV?8:V;;Y2K5 M7<@QE$CGW.*H?W1'LUFMZ&?;^YNB9":_<[#=@"="Q74&*#==J9":2$;1WG96 MR!0FO;P=PE-\24(\\"[*>.:0,9F62I_)H,"/'B!=(Q^RE)_/$//=;]D601"I M2<-V=J<2F@8R.3J;\E)<0]T"6FQI.V=C.H-4,CH'1O(9"&%-Y\$28<2BY,66 M2A]7V=$,JF^M0V6H ?>02^MBILL50%1$TB*KJP%,T=X,I^_LXZ25USEX=FP6 M YVD[B\4=7]JO(P)F 'XP3J -37B'*);.7=G* 9[OWQCJXDX7C7PID] M7U'1A9.1?:G2D7!1K8K0S#9EZLR9-!TL7VOKX$T5?ULSZ)*D<[UAD6+Q6IH=/UL>TLZL)6+7^7OD.Q8?\1 M(#S#UWQYEQ=\=L]#S^87(9$G'>+PFL2JW7H= K:S*,8(U15LJ/3*10@8F\W3 M.IT9E54ZB20SFLIR#WWRC-'_2B-40:4N$=L)EEJH-=.0<[YQ]RA;PGOUJ;JZ MA^W,2UV_6"6[@V E#%8&'H6&MC,M]:$IE=2]&%YJ._%2%S9C;3@WM03G@O$9?@#B?>WL$H;!^\(&76WG7YK@:*0- MYW#<[9^ON1*2^K^82[V[/? 9S@E-KR<\@E=Q)A)1P"% &-#-E*N1U;UBV.N@ MMC>) VBT\,Q")SO,H;=EPRM*ES5R;6**XRY4%V=_P;D+(]-4OA.EP( MFVK(T7EK(G/)W'9MII7<<\TJI;HM7>E\(-M&WY/F=-/&62M2%=Z5?5(1^%(E M.,A]8#';HYU3Q+A.\I]OJRYM'&1PV^YF&&L;$$?G;%BCX49>S6D/I<"_+RM[ M0UCWMLIUN:I9\3/U;:;#,,]:(52^0D@<,U^'Y$7Q<;IOFI0""9J>).I(Q8_X MX KGB<>N:\0U]GGS$Q/O]6_S,^?<[Z\K'AJJ0\.575OC;::%W59-@-YD3'D) MN5OQD52(&IO]5K:]9VMHRH1V#AF[95T]WG1IB][@]5Z*&R]\=E/Q&=U+F/PY MQ=G[@V)15J$DNAKUM'ZWI3%.QB)V?T3?!"K]HWZ5PC1X[J_'"RW]@5:[JMZQ M^HBKUW1K5?TYFYIDK%^5:>M1&ZG-.?!_+;5+K>%\8T5-#PM X6?N;N1S$'SW M5A&,JMI;OS+3%C>](IS#;Z;\F-"L?GM&+$*"E9AK6 M)&.&\D=W46ZDMOZC69$W$E]C#HG(*8N7+]('6I9(EARK8B.#?H9;^;&#F!E* MZ.@,-7_?_EQ8X'.2+[N0)1]3S/=9L2PIJ'@2?Z*>VX,Q8&AB#J>+!L;*.5N5 MFA/3B7O!2Q(_1?,XS#Y\IKW_I>EE:!4.9ZI,M-+_VK K,!)7G"Z*QPN/1!2N M8!_)+XGOTIZ/I'F26XP\Q,"&1N)B0FPH%76?I^FVRE8LSS4+;$NZ&!J"BQFW M:N%&L/@'RA:7)"8 MULA^*WH;XN9B8JV6G&]G;MY1N (HR++"J7?ANZ'H9VX'!&KITF MWX)E;)>>Y&L[]4U!0< 0>X>S>C5U]1; -OD@=9-%6T_/T!1<3OVUTJ1S6W91 MGCO%+*+Q,DDXK"&-Q,E14A/D(Q F/Y0;6 BBF&IBN6;4#.^BN)A;;"6WJ\[" MA:KH$X?3?&WJI+L.X]-SAVUR4!&O%YL9PN!B7JU<(%=GDT+.Q%S:W1(MI6$S M_PLVTOX?R;G/YX2HM#2]\6;0U=';I!H@#Q/!INIQSX@+K',M\(D:;>Y"/@MY MR"-\X&JI_>9M'1J.7D]M@76EP@98+"X16Q$&PMG\#D2*A5PT+&GGZ(U3 T 4 M KDZTQ2"7B,,L-]NN2BE8?>XT(&YJI MQ[E-93GGV169NJCN^CFZ*K2%]% QSN%Y#U?IJRGI_Y9E-(W!V/CA=+7:W'R;L -E-,C2ME!%?V%??ZK0I2!:J**_P*L_ M5>A6#ZTJAGZS8D:? 4[+C[DJ+B'S*5HEQXMYWLO5WSKC;Q+Q/R0L)A" M_I<\*?F)VAPQ\6K%CMQQ?_(\".3I9C9_0,\8S9$O99)Y4X:BO>J,/8C7ZWW(H0]MD^*DR[KYF7]K/L+ MK=^8G#;W&][7V?_U^_'R'7MF C^*3:A"W/=MQ$T(#R7LH7?2B?5-I8\:AONB ML])Q75B%\]W_F#JK@=2N]UHZ*0HKKX'O&D8HD_CH$D8 A>Q6)*_%9U'+92RL MT:;QDO=U.H"W':%G"S1R$692%U;^.L["2;E'#_X"!G&8G$"MXBA]NN.M!_!4&)8"4N>X,GC M3'F2JZU^^]5J/A0ULIF30B23)S&X51RN(68R%,*:DM7$LB Y0U;(6"Y:(=PI MBK9OEVK1;;Y9F'Q/]T9\3_=0?+ZI5VYI.YUI!M=! M=L94(0,4'?M^O!3Z@D'^Q3>^7NS>M5$<6YIUM9UAK8>/N5Q&QYA#9\TTKO0Z M%E?:]:_ZR;=NR]['3O':%4%K'7%A(U;EB!/>O#QSI?[YSQ[G4'9(>/0R)KT< MEUZ.32<<>HF6Z[R29M3;3>>>!W3[ZXFH M8P#F"T5=Y3IWUEM/-B'*XPOIRE2VY&RO3X,9QX$"?PWFP(?7W )H3-#V2>BP M)I%7XJ_ **Y)W-EZLJ-G^T1X4)/(J_#78!&Y9$@G%B'IV;[B-ZQ%Y/-);]LB MSN<1I%V;Q0%1VU<'![.-4F6Z=9&DN"7.LNDB+0WPAB4%1^)30',2(J+?VQJ< MQNUERJ,%]-*!_LB\9"AO-]9 N>[BV9U9MEA[BK=_\6#X4Y&"3$5H9W'$.#S" M[F7SK(Y#G '*FX,L_UDO+?#%2SAJ56@L(,=10L'+>$I.$A.NO(0MV3?AS9JA M[)0J?S>3QX!-%%@X9S158**F=& GM%1QHFPVMPHGD$9GRP-/L@I)<_E%T5*' M_VGA/-%$WOT\H>CA!L2%Q.H7OFXNX^4=-T@?K4"85;]H5=+D:E1YZC0=WMN. M[V4,.)$"O2'X^1'2I;X<8[^5Q8@RS\@7\12,O"B;+RO;ZKEF/K,]9=O)S#(H M#V+(KM3GW$ZCAF!37)FP;$;-=KZR6_P+:G)K\]!P%;@1%_.-5H#"=8S6*X < MVRWOORU%D;RQ_04STU*L>T[8E(#-5Y(->*RY6+0@:7N5J GYX0O+;77IW,IA MJ(\IYJY0"**Y$M. E.TUHW]K*-7=&[8"<2C3F1WDB-D^VAK*$@KZ>[NV($YC MNC*%'"W;)UH#64)!>V_8$-"Z,Y^0HV7[(&LH0SC4GEL[C<.B-*,$6A9T0 Q0! 5 M;6%R82TR,#$W,#DS,%]D968N>&UL[7UM<^,XDN;WB[C_H*N)V^V.&)6UW]>U]4< D)&&*(M1\L:WY]0?P1:(D)@!2( ':[HV=JK(3 M8&8^"2"12"1^_8_GF==[Q$%(J/_;N_[[@W<][#O4)?[DMW=_W.T=WPTN+M[U MP@CY+O*HCW][Y]-W__&__OM_Z['_?OT?>WN]*77V+OPQ_4?O&LWP M+[UOV,#CH#>AL[N$(LU^D'_ZE=_3^\ #U]O84^OV. M?9<&?]Q>+/N=1M'\E_W]IZ>G]SY]1$\T^!&^=ZA:=W'#0W_^_5Y=WSA3/T![Q.50.?I>WXKV4M>M__?IU/_EM M3KI%^?P0>/DW/NSG["Q[9K]UHV6#(O''_?2715(BZ+K =$A^"1-)+JF#HL0H MI1SU0 K^K[V<;(__:*]_N/>A__XY=-_E."7*#JB';_&XQ_]DMK7\Z@PQ&YY2 M?SYA%C7;Y[_>9VC&,^Q'Q[Y[YDONU^1Q0W\5^B-T3Y''UWDTQCD(9A^)6S?)V@P*FFRF. MB(.\>HR6=J&=:SZ ,<6HTVFC MD@U0.#WWZ).ZS0A;Z^)U&$R03_Z5J(=IYQ2'3D#F_%_#\4D<$A^'4HZK]*&+ M[[MXQGZ\&([OR,0G8V:@;!YP'!JSB<"?W%"/. 1+.:_6BR[>CYV_8A*2Q")E M');1ZN+CPF/@X#!5F,XA>&Z81=7Y,J>W/[+Z=L=I7I':U.C M]I2$CD?#.,!J?-PC-E#D!K)3K_IEVQSC5:40MV]NIE#C4]:NI5E#4:E5.FG3 M'SC%$2)>>(T"[E8]2IVR7?IL=R:J*MENO;8KVQ[?U;JQAYDWR7S@.$(9 B@D M#H>%>'&$W4L:ACH\MR'0>1VS!.Y[1(,HFMVVNKG'$"&F V<@8Q ';3CN+^P#YH9?.ANX_ MXS"=WG?72*/\-*?/?/+@DP+R%^$-V_7ZT0V38LQF#EI?,14[;LXWJ;RJ*/?0 M',_;ZAO&41*Y9E-Z0OXG9R;S2Z9,]6R=BP,^W^. 4%=UZ6CZPVUH*/G=<+Z, M,#6BC:B@=5W]^HM1?QBP(G9[F,N,@ / M"5]3UD7@Q ]XSR4S'LKG!S[9AXHZ6?9"_&B?D>YG-/NE'33/]_)C>RZ=(5*1 MZ>W6+7"-PZ1!\WSY-#JNREK>IE6;Q&,4>U%M MH\R;K_/,?LPF/.ZW7+)_KO&-GYE'[F(WYYQWN/-I,?LQ[^4@_:_?V^OEK8I_ M9?YD+^VBM]9'<[Q+SH+7N#YDK"Z/_]C?6=N0[5E<]A.WM^RHE_742[OJ_?2' MCV*7,)J?VQ>D_*QX3:H/NTK5^VGM*S_G:0>YE!YUUD3S>-X##4H'1F+08Q0^ M)%8=AWL3A.;[?/7;QUX4YC])UL.]@WZ6Z/"W[,>CI1Q,G_B"_76)I(<>L)=\ M>Y01E]'N6\!Z$D%68#NCVV1Y95/'0/$HL\'?WD5!7"*R"90& M'@K#;/]W_$Q4[&R[B5;L2ITG&5;K$ X0;*60&84G"*?IYDO!J%21JL5CFVW M4(8%J&8JY1S"X_"@PX",^B7QJ@Y9(!^'VP2QN=SA@6^23&]8E M#@*>\\38OLIV#. \!S<:E=GA;DBN[V( E 1#A5;B'1Q?9B<\MA>A3]PK.Z?! M*8T?HG'L94=\X2UV,'GDTWMZHA#!R%7J9O31#);*[D5U:2!TZP["[8@-S[D> M,>N:(^*>/<^Y1\TV2T/F,@?IN4C&#L_8X(R68,6[J-"#O3#5$<1.?X-953R+ M/;Y1.L7S #LDV:ZROWLXRZHHGOO=!)1Y:-'BQD/I7OFOF,QGXI&IZ0OV6D,3 M@H*SM5%K.>?*QI?D$;N;IZ(%Z8M2PG91O2_K+:"F2* 'I7?N3N:G:^H[Z>24 M)3>(9VMA&WOQ4&,=TON17KU?TPB'-VA16+(E6A>TL%OG,L8AC7_4J_%+ZD_N M<3 KLB-1N:B)W3J7<@XI_9/1I61]GW*#@F&0R.LFM^WR/#UX^5!K;R]TU<6 ME9:OOMD0Q!;;LL4+:- ]?!26K7[=D$%#V"@M6J)6W4-)>;DJ1!E^ MW=^0BWWU1_-9-K4J&:SEW1RIY=VL/M2CX][J4TFNU-K'>NG76D\X$E=$6)/Y M8QV9>9^]I-,UT2Q( MDR\+T<[X-9-F!)P=7&$WPLZ4 MG^<'S%V83RGVR3.8.,3;B)J82AN2C@5:@7]P^-2=V@#=G],@8BYTR(\RLI,, MH>)!^M&1_5H7,P^>36I6^3W[+3[UD4\OB<,]5U7=RQN./MD/@J(4X!&:9C3X M2 RH3QQ5%. &HR_V:U_"/7B HEGK=X2O9&'Q %6H=)">+53V*UW"/;S'T*SU MM$*LNM9!^E&_ VNLA'LXV*I[AHEYBI(S34M6A.+)I8QVU._ VBK@'(['Z9Y5 MSM*OBZ>2-:)1OP-+9AG+H%)U+Y#I>GV]6J\5?)0MZE&_ VNCD'=0W[671CT; MVFL<\4CG34 ?B8O=D\4?(4^%S"*^_N38B<@CTS$.CQ^8&I CR!NNWM?H4/\N M6.]I05V9(+S-AB^8-&FXGE=6$P*Y(C.&T8ZJW\)Q4R0[HW^%LEL\%98I(#'/ M>WJ+'?9OXN$U4>ZIMN';])=?AB&UHR4P?F,X^KFZ)"&*>*ZHC&'>*DR;0=%- M^<%(J-F91E@=4#!/"-N]1L15- *&!_6ZVTS @!>3.L7IGQ?^:9:@=X^>061Y M4X66KPK;2CJ!T-5\34+(SR5!#\1+Y*H#<:'Y&\Y"Q8"Q9:/3^3>F7ZZ4H7^' M>(&YM&CDA?^(,XW",[JTZ:LRB&I*@8RA[AT/8.1GA4YS6UP (WR3[%4!!RL M/)/Q,'A,!AXB(CR?BMU\QI-HX:"X(->W44'$E4, M/!HRJ08TS,I'SV8D#(M/OFV5'I"T>U4X5] ("*S9L%S^"A+C]X'XR=2UK"$> M\:L+3#OI;8QC;KF3],I"^@; A7\\XU4$^(,)I4V6?G$?GD1:8N!5F:4)U<)Y M$X:O2C--\F%84BD--DI1J]=H27)]@/#7C4DVD4'/#/@1!Q'?CYU@GR'F$.2E M/TR$PXB_DB Z:ZK>VVLTE_IZ@A.%]+H_Z\KA4QS3+&LV83MV'. PVEE-@/_4 M_(=?E<&UJ5+0-LT6V%G6,>,*3V3+2D["\QC8Y%79CIHR0-0-1W.WSI"6T@_0 MG$3(DZ?@J/?Q,I)IJLH+0F\V+KLMQG;IWRJ@;[4^:[PQN M\H6&$W3])-!W0.*B0*E':NJ.@5980!,UP3'5+AJP ='ZV7UH(NLHX M5>FOHT:@06;0+,PF,9;HI:SN;*5%NJR#EP:\0$@0:;.15'C9R>YS\?K>CA/$ MV!7G3DF7,5%_+\T.U&4&S<)L %+=@]5QU>5E..I5Y06A-QM\!,1(D[KTW'82 M]-79VTY2F4"X#5 @0W8%EW'T1#(!*K><,'C3<.I\A\=A[>FO!#TAM]I4]>) MCL7S94!?55X0>BMOBY\3'_F.'O])T%=G_2>I3"#<9C?0MWB>35G#<;$."@PJ MU,*V4:R*"*T@'0BB\7P;!V,W/&>J6:4_%JH@"Y-NQ$U?!JR*8H+XFMW3EG.? MI[56!3=O]Y*179<1A-7T:TLKU@OY.CR11PW3C48O#]!2 4$T3;^YM.);;26% M6KP\'"NLI)K##?F&;.A+,$E>CRTE[C@<,L% ),Q&']2%U['_Z#C&->6%H"\K M)M@B]&?C,7:BX?CLV4G2XF_9UFSH<\GX'0_V!P^B/")/?..]2B_V;SNK2P." M:_A)IU*6;W! J+MY$@F#6Z47^\&M+@T(KN%WH)@$8M"Z 89$R69#-G?Q?)Z6 M^4=>_BS.A3^FP2R]5B0-RREV8#]4E00!T=1!M1 M$W,HU% NK2(3"(C977E^@8$SSQPJ4:[0&F'[0%52\V;.3PGO("!F-];I_8![ M],PW+E),-FD[!DLY^R RFG?+@^0Z!C^P*GV\,9-N;WXG) M3PU]=[E]2Y9"A5,WU2[L7^ KB@)A6O9>Y2[#Y!8_8C_&21&2Y97LBS1MECGL M ^K_,_8=KD*>1Z\0>*K?H;G 12UHJ#Z90; U5[?/CA+2AUZW^"H<(>6G#P#& ME?OI+K0U1041U5Z&9?FP#Q__DZ_03_9P]5I/38["AQ#_%;,/GST6#R+6N3[<'F]YLU[>SO1,(9PQ^A_J MSQB]G_*_-?I>^(H[-7F3)X0!:8]VD3;MN"59-^=W!H]5P*"$X!7[ JW)$Z'2U]$%;&=T6G\U:O43G_)W MX$L+^^:\,,/$[F_OHB N$;G-P]$ )V/BE(E0?'"[Y*!TBU(K4E,F:>#$#WAO M^9ZX')EUA5,)OR NA@O3)8^F9UM@Y"V%"SGGX*N%67.UUGIW^:OWWM?>)-R" M"41@LT:^%S))ZY&Q1Z)W0TM%+' 6-;L&;F_"^$%,$.+D%W=SCX@RA^2-1V6';3:= M*:K* .%G=A$L')[VYM\+-5<)4FG;=T OK(NE$6^OD&7/%QCH7NCMGBMV8/_\ECQI";%?JPORN MNXJJMQ?!.@KKQ@[]EF?6B[?F!9+V]^2UM4\A&>SB"Y0L]D%L]DH*R1F=KWEIDXE;"I?0NK2>U,5RIJ M+Y*-/EFK]BTV(;5_TOP^=<+;T(B1D2A89(%L=&@H.*6DRTT^06T:KL0ZH+[#ENST^:I; M$OXX69Q@WYDRK'Y(#L&D+3OK@*LJI01.R\#,N3Y=C<3!4)&8#E MBK#.VV\.09OW!0VA;/,>@C]H'V97+*YQ)'-J2\E'93*TL JCRZJ* .(D=D- MQSW[P'!<> 92O" "Y)U=!87BEX!E%*OB8YW'OGM-?;3ZR3W[6XB2*Q&A;*15 M[LC,PB@&A^XFDJ6+HRF,;5XZ&[2#5M-0+HF3/&(S8?NFA$'A7A"@-K4@UAU@ M5$TB$ /-]^Z.W4<2TF"1/\*^9$:(A:25J0-K#9BH2 9AH_N6ZSDF/OOF1 T3 M@'KTI;-8B"2",/BB&8,;M,B+)JK! #EK)C=QX$Q1P<>0S%V"-J-#0^=J6J8OJ6 @,)\TCXR\S!,/C:C!(F@Q.OS: M65"D8H&0?#6<"H,]GM]X@WC"<4'4DT7Q-Y*[(:0S6&>!E!L-;QSC1[))#DO^!;0>'YY.1"N$X]P MX<[8 ALMI 'M4GHVPBT'1L0W&$8XJ'O2!%TPP!ZS#WYOA>V5G63\WF-GZE./ M3GBNO62N4FUN;!.K-GE5$P/>NFK>(0T\&KN\&MJ-#(<22F/;5#65@QS#^T_- M@8$K['*03_$C]FCR[*5,RX(6QO:?:MJ6<@YO,1U6&LQP,)@2/#Y[QD[,+^(.F;OJ"#9)R4&E M>@^F=K-U!R*M+R4X6VOVY>^#.(PD%PG6:$SM735@L"T'N)O5OF,*V*)]4GC] M\8:18UX8/+GX+]DOJ30>'1G*Y=$ 3!4)P5"WX=S79;V'M 0'VQ?.J9\<\ B= M3TFSSCJA2NHHN;IG%,,-7F7N"$!NQK%44SA5$"G+ M!R*INYYS@:/O;*:( _E($C49]0W%3VNA(Y<$Q*%VG!2*;:_;@C3[!R ?]0T= M[M32OU@*4/>ZDWVR%(UOLX??59)05G3&4D]J:1M@'W3)OFH^OAD&T93>3"GV MR3.;_>XO+\[%&WR(?O2A2TNV1 S873);V0)(_:YUI:3C&U$%590$(FU$K\KM MA))F5ETE4;QU $IOW2:T"*D7<34#8G";+F MD^(.TH96I,_#HX96EP7>EIK-<-5TW<&&;&\I7@HB@-/B)[.>R/?LD7*AY[%& MU%E/HT34DL,V&]"0K4H;9&8\AS)UEBK<&?\6EVYR1D)> M'/&:"M[V3>HME9".#@V5OY,:/U5A'!PHNI\8N8[Y1X?CY4.HG'<2Q5Q'YS2X M8IQ'[/_9?'R"O.1@H'!Z[+O\#YZ2]8@\GG0+@*/O Z.CM@^\=GLE3[?D MD$T8?D^ L7I^>C%@PL4!=H]G7$7PQ%E*WB5DY7* #HC9")CGT2=N9;TI/[=% 6XF)$FO":OV$67T*PGF^[# M52BMEW_^!(7)A4J^X*%4?+%LHS5U:#]A:,>B[K!#?;=UD]KZ["NW*4 ?H%&9#1NE M=VZO<#2E[H7_R(3AXB5%;GFIFI58\%*DW$67#*.>;"#(FB_5;[T] 7IX6X1= M D$D :AJW5<=6Q)HY))>LZ?74)S1V%!#$U6RECO2QAND-/=^["6#C0IDMX M*@H#XF8V I7;&]OQ/! _V?"LC)/]+22,R\U]4)AD30['PSARZ R'WY$7X]_) M9 ICK?<[';2/)A0 VI39ZP2WF,P>XB!,1)">9Y91=Q!?6 PP;4!WECMVZ",. MEB^JGL98N&M/B\,)VG0)!45A0"STO^^;C-_A6'$PI,])BAIU#0T5:4 X-(=) M\@R]?!(^18OP>,SVKM*N2;VC+B&ZBX00E+KO(Y8'ZE;AN:0L2QKJ M+9VBCGTWGZ/2N4ER_*CM.UTSA(84 -J)X?R:9ZX8-H%-D\21,?> 9'?HX#9= MPEI1&! WS;&@Y5.Y\S,4^,,XNB3H@7C,OJ 32;!!EU!0D02$0'.^PPS=L3-2S9\>+ M7>R>,^WPK,DX2N;NX9A;&%-)R%RU9':6S75:NN^2+>B7&S00$#<%L<.QL/,8.G\8N?)ZL<(^>;U&$TR2' MF&>&SC/'7G!LH-Y'!R&O*AR(L]E UC=*W2?B>:O)ZU)X%%1.WT'\1(* 6)E- MQ2DN,)?4GUSRY21=7W[''G]Q^X]0<.:@U+R#2%:0"P+V2'/8B=^=YX\TLF^/ M,>'OEMR6'P=QZG+B+@$ADP)4N_GB.@XOM5Q^5RPK@"#8Y2BU[Q*0-00#L35; M2*>\)-=Q-&!>V(*I(DF^%#BN*LT[B&P%N4!@33][LGP!5[6@W3*I4]RR@W"J MB00BJ?GFUI\T^,&8'Z YB9 'K';K1%W2.<0]J-Y"I.;7_0W!V%=^Y+\K^=5: MI_@YPKZ["JJLZ8%C$4VI/Y^\9_N0_40%=_&,_7@A*=&[MRKENQ:58O,]<9@M MG?) %G:Y6YP'J$YQA(BWT@R)."<'R7^'![V]WBD)'8_RXGKL'QD;/3KN%1CI MK3CIY:QPXHP93EU@A_\S8:B'?+>7L=3C//484[V$J]Y/&5\_%Q2N7:G%$A79 M]Z[YEI[O R MQ>K?\5%L^YXQ?WL4^^U1;)M+HG?Y4>S\U'Y @[FP//HVX:A#;VJ61+)WF36%L\^3ZB DW(O(T//=6I# MKIJD$)9?=&S/0NR\G]#'?1<3/L\>\;]PG(\*TRO[T>@23Y!WEKPY#7@RC&J+ MR%+_I8Q5\)BN126G_(#;"T:R3M&R9R%0&P4X;-11:$:M5B[FE57?ZMI\%?/T M=6=ZAP)/.-%O$[:^"D,F2J5<@K:LN9[4%9KX<7AQ\VWV\+M8FUN$HT\6:K.< M2TB;GS1KDZW+O"0[OF> ^M2C$X)#:71=W&C4]BND"EI6X!C2^&?=]="^%9F0 MS@D0>>M>GH*6A;R"?IK9\XNE*W3'/$P4$"J.1 'DEGIR8J8A1,S>D M3CPJXZF%Z(%\&% EUD%5:[ZXO\;"_1-55_62>%1V<<9J5:^S#L8$3.>X>_SV MQ0T*HD4Q['2R*/Y&O,Q7Z_4X_%T^%@OR3G;IFQ](R^W?"IG&-S'&UZ5^$F(9-%9 MD5B^IFS*4J)M\\J6G6*O$1E:)+846:)HR[,*JNK:ZNE>'0^;LZNNF"YG\4P& MRAJ9J5/C,A.G$C;!4*+9*5[]79MEL;E!' 185 NL?I^COJF=O.J%K%UE@\S MCGLE%:2ZIK[3@"&LNGV1MK I'F0.FL]OZKW,82\ (+>@OV'K.QQ-O8]I+W:U MI0$=EV;&"G_? 'G>3&' %$DMUKR893 RJEF].$H3X]@TF3TFQ0&7/G4F;6>[ MXM7XM_1\$_&:$+$9U)XD4PM;M5A#9K%^J M5O#B<+/@Q:J;7MK/6]6+MZH7E8=4AZM>O+*8J=E$J+>8J;VZ?HN9VADS[4;( MU-K:$5?H64GG1;(&AH(NI6^Q"6K=K-K3S< ;7V()CMR%:1PTX7_'A&@XC\*RL#KO"88SZC"=M9#YP"^RT?-E=+ MS+!6OQ"S;9TM9Y\N/D2=,/$GB:9GS".G,^*D;[%)-*W00S=04!5$X=S9['ED MX>T"X*BR_(3R@_R$T1/XBS IS,?'&U"-4K+Z/2NI;/9(137$O^]"_A[WT4[W5MPHZL.#8>6N^ M>3LQ?SLQ?POMVQG:M_:TYBVT_Q;:?POM=S&T#R?T/M'@!W\^#$7H"OEH(B\/ M*FYD*$=AQTB^FERZ T'0RWSXX89]F]]'R2N9>KPQYPP_$@??T^Q/_JLQ#NX6 M(5N:A*#MU*>I' @-H.XN-[A*:T;]&K'=&/(NF9@QXY@)C(,QO)OU,F0F(]XEH'%7HP50Y)W_RI+"6XR&G& M[PJ[Q$'>LE3@0ES%LYS:5.TD#;B() *#NYHQ.(XC.J/\ H%0^9MDH[;?F]6G M]5)1P$BM9G5?D@OJGZ"(39J+W\ED.D!SY)!HP=Q>)PJH*YFO5)MW-&VCLH@0 M;)]TKS3'XF7DV&R='!UK1%$$2*V?=1RLOE72EQ19:U/);Y7T+5"KE6$6NROI M=^C]3X5RV>T\\PFI\O;\]!:'F'UB>N$[8FV6T;8>A%#1*,@HJ%7-:CU=^&A& MG&/W$?EL>W5Y.1!J%B*W\=T'(:_@_-O0ZP]*+S\8VL)7>/5!9?NM6X/8Y:]W M? MH/"^\2BR=4J7M6M^2J^A9B6EPUZU9]7=DXB/OXD8VWV[1M;[O5E!M.9/@ MCKJ%=TLJOUEB[ZLP$F[!#;!N@Z5XECU=SE4A-MHR6AO?@H$9!3? =I00.^A" MDN0:MY!"-6\+SE#@L0$2G3W/25HD[I1Q :BUG-AR[8J8;FG#P,/6R%=2<1FI MY0J&6=8=KX%"Q.R#BA9<1FJY>F&60;?75+)T4GUJ2CW&17C&%@FVE"B5;_JT MF:]:[.C?_O;EL/_Y'[VTP[>;E-:&MD'^=6]&NM! MX#2-!Y\3'_D.0=Y2N)!S+KL;KM;:3+HHB "M(4*CIP@VHV?E681^A%L]K!@Z M$67?O'_"C(G%.5OD[Y_H_93&(?+=.UZV-&*_$>ZIJW1A*BFPTLBB.\C65@@_ M9VQ*^*,_=2&3M#:5"K@K6BIB:3\+T.PK)GD169E9Q==>MYO8[9=(9;7M]GR1 M3]EUAC):,\Z'7,U4RKFE/L=N@-CL3^P.6JMNQ!T." Y/!M1_Q$'$4[QN&#GF M=4X2EL1!>:7&II)I!<.!UI*AM8.\A*7373"1-3:5:EL%$R49M)\(:O8&TI < MOSE.?>X'*7H$YT3%.),D1HC> MV!F?DJX56(?/+#2K//OX.0E"YN734'S+":!F'J7EZA8R#OK"#2G[#K.YU576 M]A;YZ,A0 +.JN@'.X;V'64?WGGU@.#[FK*?70,4.+D!NMV,KE%%?J3Q-A2)7 M;(;'OGM-?;3Z2?&1>=E:7+DC,TZP&!RZFTB6NL6F,+;9E6[0#MJ]A,0^R_1 M_,GQ),#R^BP@O2G7N>X@HZHR@9ZUYIPYMA+' =,5#F_BP)FB$*LA(FUGJAZI M!F349(,0^J*[SD!T/\57*/C!2VJ.<< ,1EQP *(?]0T=F&J 1"(4N"O273CE M#D=1.EFK#A. ?M0W=&"@97P(A0+!T%V!8\ OT7G>L@3M(Y66K1$U&?6[.V7) MY0)1^:*YAO@Y#:( A]MSY_$LR2)F$M[BD&])7"%4E?L9?3!4:$@#?C6%!?VU M#YI!/9X'Q*OF(8B:C#X8.IK3L11)Y0)1T5T3YV[.6??9AQ7]:+C!Z*B[DY], M*C"&H=M5^Q;$#P^A&A2EM*./AN*E&E 0" 0!\/% ]PT@$JMI?YMP]+&[WC$D M#:CWVF[Q6SFB"N6(/K:HY+.WI5E2&:&4VFX7221A294MPTOM?#,LOLF^? 56[L)0K001'IO+:T5U6.@[ MM0>HS9Y6$Z"WZFJQ3S(]4O]W%#S0("GE*8X%0/3&TA:J#R:J+ [H+QQI]KW^ M\%F_3P%A7 O5OT4W.C24Y[:3V@$QP,FN=@1,TVS'#UTDH9<5B=UNPY8L)1L+ M\\J69>ZN$1D*E6PILD31EF=25]6US4MQ!3QLOBYXQ70YB^'W#3.Z-;+1H:F- M>(F-4QF?X%CX8O;JR!5Z5M)\D6QT^-5:S6_S"6K^JUG-#^=<5Q?,*7C&[CV] M",-X61^47VP0+[UJK>U>E:MH8!N_KU:C)]L(JK8WL\Q70J8:J);O\=O!U6:7 MHG'L;79$SF9SCRXP3BZ3V[U>"F4LJX%@%R)_DFB:'+KP4]DIF=]323H9)+:L(T.7DH7H M2)!4TXUUJZ4IC&U>/QNT@W:#Y"3 #B,>C@O/7(67Q.%Z\B?'OGL7!6S6DKRV M7;4;8ZMFW3%)=Y457E)UWUKRD;<()=>4BC3&[E]HP*)$$$C1'P\T*WHP)7B\ M>HU].!XS$Q"?<8B:&+N+H0$&N5P@*H>:4>$.\9Q?'_2C$XJ"[.:@)%<%;C+Z M:.CL3P,J6.YNB@(<'L?1E ;D7ZOW>(0EYC8;C3X:.DI4?J9% MRCP$E345 &]0, P2>=WOR(OQ#0X2290 @QIW"CBQ$. &SBB Z^5WU0>;N)W] ML*GP#V['+$*L^JA3:]\U!.N-/;.Y%]LOQMWBY/76U";G'HE@&!4:VX^ALA#@ M[DFO\\BLANWB(C1AGE=A8A_&41BAY,H5X$+*&UH,1A4!0(_1_$A*(N#N:30>0K"X.!*_9S$7A1'*-GY)?U9U8E^T[ M"VBI'!"29E-:BG._ZDP*->D 7F+6+3U4S=[2R>J&#X-;,IE&US%7"5L7EH4Z M!\CSL'NRR$OF9X2BRV"[=6P_WEH$!*W";*BF5+:S9^:XDQ GQKW\Y5*@?D5; MD'7740M0$PO$W6S )WUGSG=SK@%_8CT>4J"7K,H[]&R_->B1$#0,"^)'@$3U M?;+UYAV!6$T,$$>S.>+I:WAA4L6V$(Y.91+-X,)V]B.GPC\(F=F $\!Z]JYA M'=1633L+W*8((':&0TFQ$Q1BE[]WA?T0I4I>UFP]6:Q(;M BJ>+] MA +W')$@68J/V:P^2Q+-PUP/WRG/9O'XJ0_3J60P-OMQB\VI;26 %F@V;K44 MX\*?QU%X2D*'W\D76XZ@D?V(2YD'\Q-TERLMF\QVG^!?SL1>9T(_M#"8)#[G M%@58NG'074D"$#C#T:"ZZT":7\%+\@5Q4G=]&$UQ<#]%?GK_*RQHX$_,58+= M8^;/HPF^Q5S_[.?,PX\"Y$0Q\KC-BX(+-K%IOTE:J"[0_@T'O;@:'N2:>MC4 M5*:/[SB,DJ=EEMXXY3^JKB;!%M\>'CMB^1;I"C1[LS'"VA-$&IK)G^[A^0;) MCQN8N8$O=<0$M4L,&I+A5#F9L"$D;3;@OJ4'*7X:9M\87&L';3O8F#XF7H#Y MZ58&:)EUX[+02UUUQU5^8'_%9NBIEW@WR/,250 ;S"8^9;'E-"LR:!]F4PQ% M@2R^@"N$@8"6%B-=20(0N(X&C[/YC:VK8TRBF)\-9I-< ^X+_#'[S:,QH4&+ M,AL,7I:O25-GR\6_IDE5=[82\JFN>+O!S2,KFGT7SBZQ0Z=^.(+;XU] MTG[K:EATR,:*I2Y^W=_0"N/Y1_Z[DE^M=8J?H^0]V?Q3:TKDODLTI?Y\\MZA ML_U$?]O7DO;NXAFC7"278^;(7Q3C*@EY'OUE.]'!E ^[L)B-'23_'7[N[?5X=-^C(1N![!_%[__;W[X<]C__HY?RP7^9P6.TAYZ.4\]]M->QE4O92MIF_+6^RGC[N=W)G.9(&,L2US:IC6:AE56 MU4G =D:G=<@S#^Y=W5HV%5*M2NM7E:9/Y[PPH\;N;^^B("X1V01*Z4#BPX;Z MW.<5EQ"3-+.[E)B2S+;=2-_@5593"B W4QU,3>%410#MA[OVH&-S72]M"+9: MQ2M?Z(5E;M:)1F:<3K&U4Q&W=DY7S9W<+3WJ-&!CXJQU@X61H0I5%ARCEFD" M,DBS,W1S.EB/,YNPQW4.7K$YEBA"]_2H.Z@OE6F ? ?S>WD""]LI\%V= WLM MS(0B0)?TA4467[&M MU]$49/!ULRK,[:SJ&&]+.XT.&ZU5&H*,U8*J4TWN"7CJBI53PTM8KLOB*S;V.ID"+[TR$M\9=M!,\(;X/%UZVDUE[+=MRG8$V MKKG0=\,;C"UGK.TW.))5@[]L+[ZQL4%F M]PV-4IDZE^(,%BA8B>>[-Q[RK]$,RZX,-/,U,_=!RN'55?Y!KEWKKH]TWY1L MOKQBRMQ:O>M2],>$]UVV"0W=>6ETA%.9P!U=4R05"PI1BL:NQT"?LG=?UJC$ MD"%9OJ)4*I[T+:!A$S%*^&,OWI@@F5_FO'3V/"=!TJ:%6C4E'WOQY@3)##J\ MG38GXZ6/7KHY03*#WJR-+SXE$H9%]R^O^B>RELI]V6\,]42"L.[HE8WMXY.F M/>2M3]EO*8U(#!F2!>\=[2"KO,)RT_:ERL&+-[M*BH"LL:/W=*3I";IJ#^MA MX,7;8A4]0*9H^:6$EU8*N_,FJ5D7HM//+MMER1[9D'%6Y.3E6V@=A8!F:GFH M3*:+DKVW(3.MR,G+-],Z"@'-U/(0G'S(II*:-M)*?+Q\$ZVN#M! .UHI9CL6 M869'I,A ]TU2HQY 6^SH79&ZKW&U9**[\?7B+5>#>D"#MB#X^2#7S$/E* =T M&^908L7M,M,-TS6@$]!>FZCJTJI\9] #OLOK.@;8L=<.C6L%M$0+HJ,[Z 3V MA@R\J%J#&7LMUK!.P$P;"Z*F.ZCCE3T,_-*M6[.J0*,OQ&#;O;-XBA\BIIH9 MB9)H";^:R!AG_&/?(3C,;@1>\[N8$7E<74!:NYWX=?-V(N_U[[U"O^G-PV+/ MR]N&O67G;_<.W^X=OMA[AY?4GT1L(N!#0W[]L)S:[EN((@EM2]#>Y%5V!PRB M-W,A4*AI,2B6W^S3@XO-M^MVQJ[=:W+8)S2XPPY;UY,G@J]IA"47Y@1-#%V= MDPP"JLZ\[MD,4/N U](.(L(30QD#0GV7TH[Z7VU7M8!O.);1K)Z'?B55+\E' M'[JF[0W6P>FDML+U+ =TT N=UNDU!&VVXB%4_6V5[QFOIH]9-[ M]K>0;7F)Z$YUUE/ECLQX6F)PZ&XB6>J#F<+89J^M03MHV9]CG@U3)PYOXL"9 MHA ?3P*<<"9QZB3M#'EV=<<B) M!H"D8L&1%BHNY.=HG 02$>'.J(M(7;>3^CCOHL) MWX0?\;]P (\*>V_VH]$EGB#OS(](M #"7(QJB\C2X%89J^!8:%')*3_@L1(C M6:=H.>PD4!L%.&PTBM2,6JV,]%16?:N!F].3TT& 71*=QTG:T>7E0#BM@_1M M!VH@>Z6*O.J>- #]_GYSX3M"C18HVE\2%;2XQ1^\JFG6W15VHX#ZQ)&I<)MP M=-2V[Z>@28A-4*&U?3D] 7M^^K=Z 4-\1%9&:ZD+(> 81,(B'%1*2\,MS!QW M"70M J4#)1),URVZ P=-DF-GDIXUCUM02<5KILH M(OV\.%NKE-;4B5$5!<.,@^;;K)IER4,0^:C?/6UO, ]IO-^PRN^?:!65+\E' M_:/.J7R#>5#E1YI5?HV?I!/T&LVH;RC>7D6Y)1R#&OVL6:.,*Z8*ZO^.@@>> M:YJ?QTC5+&]H[&"JBNY5Q8"/HC2'SOE^#SM3J?ZWZ-K?O=90-\ UO)DU7 \L MWQ.FK]GQ:WO43XX A/M:23.[M[A*,F]#9;;(RP:OLNT40&YFGZNF<*HB@*7[ M71WHV+S3U89@JSO>_$U3X3*S3F3JBK78W*F077!,: X\,R\N^[K,/5TC8Y!; MKM-RCD$/]$#^C^%XC /L;J7:;[,MFQ@I=F%FXA'C0NK)8NJ:U":C-*V 3H+=[W'H;^T]H(3YJ+=*, M#@VM7=4'#16* (ZLCV9CG;?8X[>=;KA0Q83FDT7Q-^+UK$H?=J]RU;6QC6C= MLJOZ\93/B=NT9E:S&GJ'@;-^,=L%(9N7IP90M'GKQK8IQ,&!;(NV1C8Z-'0R M+1@@5,8N.)!JW^G2 \!)'!(?A^&Q\U=,PE1_PH4*;&#WJB21L^2RL76P\+\R M-THVWRDT-;- R2"0 U:J >L6IR:QLWGITHQOJYNJ^RG_[C7RZ<857>$V2]+* MV)5+];%#*PH#X7%4^UZYIF)'O-BSO![K!IG=2U:I3&7'AN8KK==ZNFLEG^_> M>,A7"4$U\S4SZV$YOKH>1I-KU[J%L_NF9//R;,K5A$>7/$_:\X"6F?EFCDP%:%;;S(Z^O*:H"L3'H3N MB]E$H_6TYW/DX.,9/Q> YVJHQ>BCJ?&I^M:!F',((M[CIJ &IB@3Z*X=M+U/EQ$88Q=D]C7KLT?50\<=O":_R4_$IXC4FE MO?W 5I$#0M+L]:;U->@*17PR6IPR^577VF(;^Q&3\0ZA9#;Q?9UKMC$BX=T\ MP,@=^L4$6,',JMI#UQ"420+A63=[%+KLO,94DF6,PXCS,?1O$'$O_/]#?#?_ M.;"QJ-:)Q4C5%08"RVRZ4WJ=Z0I'4\KX?63<< *^4?A$QS M;:(+WV$[AA!?^/D3+!'[]RS93 !>@ZB)Q-SS M1,]D%L].:!#0)_X /9JSWT0+>.!4Z<5B)&M+ X)K4TRCN$',[?44IW^JSHFB M/NP'MJHL(*R:0QMLLHB=*(ENGF,LW.TF#^\ Y!8#(&<;U'7=R 1T$,V4P0;R M)6&;;#:^%[(/GQM$0)P(NP,43H_]Y ^^(7]$'B[?5B5'O[OU:CER M6J0# 6XF3@&<91=V^I:?8)=R"IY;FXU$%-Z$YG.LX/1QG=!B]8L8!E&P*;Y0 MX#S]*T_A3$Y"E<\P!%W8CUQ%44!,S<8=[M@4.APGAZ )MVS93(X^!0>_0 O[ M$1-S#@)D-M9P-Z5!,D%S>_L3)^FK[C$S,.;9%#U, 6"*/70 P$J2@( :3KS( MA5CN]419%MO$'8)IDVD0$<,)%#$^9\)F5YK#89!,$5/J,>;"01P$6!C44VAM M/V;J4H @FHU%Y#?ZA@\>F23G:S!DV[3V P3Q#,*A.X:P_1IOGO^8_,"]HGXT M]199MG]X3Z_0#S#"4*LSBT':52@01;MQMU#"10" M1,5LY80T-S'-651UVJ$F%J.EQCJ$D>&J+T!::9)84#^[=KUY![!3%P/$4?.# MX"7C?QA'8822!SVKSG];32W&I)H((!YFXQ4W 778+!UR9Y6;#_)YYGUR X/9 MF# V*&UJ,7;51 "QTWR?=?NIC8SDG9\\1]EWL"@XI M2FDMU[B 9U#%=4,+JB9?9&4'\Y=T8SDP]<0!,;,IJR'U6(B3[=J8!^H[9(X\ MU3,.J+W%B-:0 X32;(GO2QR&&%]B%'+OIE"?8#C'/ G;G_#?X9";Z7 \8(8: M($?@0M3KSWZH=Y$+A-[LE8^$X?5D>\&Y9!EU%V"#N 9!,1RY2&]*+T[QG(9$ M,- V".V'HI1A"(6R-UUW<4IN&8/?V(C$Z20-^!P;5!;K%.065*CF($&5^9#X MZ> CH>/1,"Z-PO%.=^K3!P[\Z98C?F*06< M\A1'B'@K[9"(=W^0_/?AH+?76PG,_\%:_+U7Z+V'?+>WUC^CRK_0H^.D1>^G M["L_OS,9V80L0O#6:8'6:%"VK":E@.V,3NNX0Q[?.^SXEJ1T.2JOOEEZPS#G MA1DG=G][Q_S]$I&-[;_$U4[+:.TN>0I+9W?M)I5ZDW +,^5'!;H6@=*!.J+Z ML+&YGN?.^+5:F/,.^X2_$I\$X[FGPQ\R%S^@*VHR,N/P57FP7<:^[GD-4'PA M]W;U=CR@\5+:T2?[=0TS#FGYDV8U9\]5W0?(Y773^1JG\D+7-KVQ5XVKZ%O" M/>Q0:=8Z!UM%VUMTHWY9F,$R+0-<@]K5O='?&%5#O]+LL20??>B 18N9AU?) M9E5^_T2KJ'Q)/OK0 ?,6,P^J7+>57V$WPLY4NCANT8T^&*HP747) -?PN839 M;=7;&_2FR^"^O4%OQR;V[0WZEMZ@ATXYA$_')W']PKOJ^M6MZ77X,D9!!]+L MS,-?/AB."PV"ZHY 6E-$<-6L MO66":BW3&=,=]7]'P0,/(&]?R1+!IMAZ=&CH;4H-L%42$9QW:]<+ 6 ;$H_) M\PW5'6_*[4>'AB+R&J"K*"0(GN[P??KXJ8]\>DD<-B4D3W!M76&0OP6KU(.Q M=V$U %A93 A"TR_&:GX8XNBKK2EHBKQ#.-ETE%_D^A2'3D#FXEH&2LV[C-V6 M&*"78A&,C;[OT3$P99+8&22&:WDF:G!5WHQ0[Z-KF,IEL3/>TT"9]8XA5\8] MZ,!8A)7FYPPZAAHH @2=X:K?U)_D==I@E(I4]@.RS2VD>[/75Y,['W3(I_2PG$EQ-U"8HUI"!##MT"S0:LV*,JH[8<$YAK"I' ) MU-8K5>-FJO_MEJ_3KO>SSO>7W>SD#;S>QWFYBO=W$ MDMW5L#M1X>TFUNXKV=M-K+>;6.K"@3&A1FYB,>_B?\?\+YPGA6M8)?2=N8,% M\&[G=%;<26>1?N:"W>)YYEP-QTN'ZQ9SN5U>0_>-$!_;8Q'+R9V_)QLM MF)97J1 [[R?T<=_%A.-WQ/_"83LJP,9^-+K$$^2=L4UXM #F.D:U163IS%;& M*JCE%I6<\@,.!T:R3M'R_"10&P4X;'0":D:M5DXLE57?Z@G:-X\^(.^$1-\9 M\W& PV.'S69AHJ\!#>;"XS2UQFW[LY ETSJ,V^DCO967L"R%_:V\Q%MYB;?R M$EKMH-5E\ H'$QRHW8XNI355-4G#-6A8'C"28W;UXV>O47;V*C]G**>V>^T3 M26CC%: BK[*0 $1O9B$3:EH,BN61&CVXV+SX[(R=U2<)^3PQ\% 8#L?)"\N* ML>KM)G9/=U)9;;MZ5^13-J[*: U'IT$U4RGGEDYVNP%B\R2W.V@VSW)IZ/P* M1U/J7OB/.$P2QX9//@["*9FKU%Y0[F)4)JM-.875)($0-;UL,;OC+Y9C]S0. MB#])7_6[FZ( A]?X*?F5< U3:6\]E!7$ #=9>G>X9\_.E.\+^:NNLQGU$PZ% MXXLWD[2R%P=5YA7BNU#:;O9S_C\/*,3L)_\?4$L#!!0 ( %4X=$M N0_K MWH< *-4!P 5 ;6%R82TR,#$W,#DS,%]L86(N>&UL[+UI<^0XDC;X?O7G[%<+),@VC MY/'?O_KE[GAV=SJ??X7R(DC"($X3_.]?)>E7__M__9__!R+_]V__U_$QNHAP M'/Z$SM+E\3Q9I3^CZV"#?T(?<8*SH$BSG]&O0;RC_Y)>1#'.T&FZV<:XP.0' M_N&?T'=OWK\-T/&Q1;F_XB1,LU]NYW6YZZ+8_O3MM\_/SV^2]"EX3K/?\S?+ MU*ZXNW27+7%=UM7L=H;^[_=GZ/W;=]^__?'#6_3N[7^A__J SBZNWWQ>DT/_Z_E1XN@V.7U1]]^_N'MN^_>OGW[ M9Z[^;W&4_/X3_9^'(,>(=%&2__0YC_[]JU95GS^\2;/';]^_??ONV__GZO)N MN<:;X#A*:%5%BU%IO?NQQ]__);]6HD*DI\?LKCZQH=O*SAUR>372"/? M0I)'/^4,WF6Z# K&-.-GD%*"_NVX$CNF_W3\[OWQAW=O/N?A5U7CLQ;,TAC? MXA5BU?RI>-D2]N81)=]7Y;^M,[R2@XFS[%NJ_VV"'TF/A_1#/](/O?LS_="_ ME/]\&3S@^"M$)0DEE?7ZL5-6J?2M:[ W.(O2\#P9A[JO[0D^&3M9L4<%VOK. MJW"?%D$\"GQ;TSGL:SRNQ1L]]RU-IA8\KJ5;FI/ +D3(@YM7WJXQ_<=+\J<. M1/RY(',F#BN0M B-!69?8!-#679=>KKLE!M3:YYFTKJS(E=!_L#*W>7'CT&P M_9;.FM_BN,BK?SFF_W+\]EUIOO^E_.>_T@D2;W!2G,9!GB]6=T6Z_'WV.\Y;GZ*DLW5C#*ADLM MA/\:/]3E\Y8F$!05Z8AE.&>KF4$=W:Z-;:N6"#D4@-MMTNTYQ$GV6VAD+ M>1>$L(9->6$4]DX/6X1]EI0J*$A"U%8ZF'U1$.8BS0I2]_PZ+?!-\!(\Q%C- M%HVP,ZH8 =<\44K"((D)7I\AE3RB"JC4F)H>]^17?)8$27H9+7&28RN>V&@Y M(XQ]%6KFF%5@4,@:9Y]+'\[0-=%"I9I32E%+EZ5)M+2BDD[:Z?2DA]R9G.2B M,"ACQ">;F)B"4Y+<173?QVQC;N2(1M@918R :X8H)6$0Q 1/V!@Q^3_R:2EW MQ0]^"&/)#XVP,WX8 =?\4$K"X(<)7I\?I?Q$]#C,KOF6 ,::S7+K=Y=[9 %6 M>VM<_^B=%BI$?2:PWT$YY:Z"S]%FM]&ZX7HR+OM?"J_-@8X &![(4 FK"BX# MS Z\G+RO<:$_()#+.CT:T,'M' K(!,&P2H=.6.]2650* M(R(-S(;=DP\L5K,LH[.MX1! (>N205JX;09)!<$P2(>NSR J2P\I6]+,[7N= M)L=!Z]_NR1_S8$E-5C[MJ4'I!IH]9IA].E?OI92BSG92!K#U/DHAYYTR%N#Z MC*G<=(WXU/OK6?@4Y6GVS)_+QO/ZRFAE&%6<,L01?,\4@#X,Q=B#[S*FT M4*76< C8O'6+8Q8C%V3%2]ORG;RT?]%MT@<4X'07/[ABG6V^M;9WFHZ&+#@* MN!AB)%F&YR=KB.\.O^,E[LB>B*H5V0ZSG2Q%@/4'49?#*Y4 M*Q[#6M<[PT8"%F,V6 F(%(%X&8@5@NI24%D,,'MV%25FSWA7QJEG7 :OXQEO M"WAGDPZ5X!GG,I/'?>$H(<4_6FSLE*+NK(X>;&-AY'+>^]\"G& Y2FFP^[4Z M-O_\[[NH>*%W*M.$NB9L;DG(=;S9%%R\+FRH1"UNUN7P.WN[&7"(+AD0Z=N%VO9"F'-F27=MB;$:K0U&R7%U@7 MA=H5WTI(PO:)RP";A$YP@LGR.0KBQ7.BV$T99%T:!RW< MMG&0"GHGBPVZ/F\:6<2$I[8*C3'BMD@]:9C%G5D,"]"U_=#(.B7($\X>TOJ> M\J"6]32/',CD[/(HP7D^6Y)E4QY1KZ1FQ:N4=FIV]) [AD4 M1BWQ:9U^9R])L(F6L_")IA[)YS>7$?ER2-;7LR2\"[)H=1*E&QQ&RR!66Z4Q MI3@S5N.K6-NPX45X)^!^N(4[H;P@5)5TA.8WJ"Z,N0M9<:@I#Y@95!SR#3^? M!7,@._ $%I19-&/4G[&V=*:UC\P09SB<)P6.8[PL=D%\DZ5;3%!H0DLLM-Q% MEUA7H0DP,:IX9](PG$*82:F(VIJH4@5FNF:K511'E/WG21$I>&<2=FFP](#; MMDHNZ9U<5O $3M7"B$M/O77LS>[:6!"UK*]UF#H61"7HG18VZ,PKIT,&@RB8 MT5KH_8J38I<9V*&7=\80&]@U2W3",)AB@;#/ELZJNE)R0IG>;D!+%[6LN^O+ M!KC-[66%( R*&-")=SFZ>RPGS(!>)YN"B+^'.#RF%UK@>.S_#Z'$I)OG- M4R(U==_>!"]DT;O$.+2)F-=).^MS,^2Z_]6B,+A@Q-?G!5% E0;80(M?<5Y$ MR:/&L]*1<+DQD4!K[T9:/WLGB!J3F+" 24SK!V$6Z?XY-4P"+0FWDX K3L) MU#][[U2.-J=QNJ-OILQO MM)X&J9@SBFA UL20R,"@@QJ8F(6<2Z+YC1.' MG!;**;-H-N7--J61C< M, ,4'-.E!J(J[J:)*_JZR')]AI]PG&[I%[73A5;<9?95$^AV^E65+ RJF %* M$K!2#=12<3*ME-_]N'GX9&1(6\@U+T2 ?38T$J X(,!2]3P5G+JW6<[Y&YYS M?I:$]Y?S"W6O:X2=];X1<,T"I20,-IC@]5G1EF=YHZC&Y/38LA0>&DIT!=S1 M0 :LZ?KVKT"Z6P))Z.)MF?0+U$'$;RPYF3XG84_&Y6&$%%[[.*(CX)T,.E1] M/I0RD\13M/D"6=%]!!CB^>J!FFZBV<85)4FNL%*S3MWAF-5/F?54I_L M:2N#S^HTS;9FEU5;RKG'2H0H.*P:$1CT4.)2NJNHY"133HZ7;Q[3IV]#'-'9 MYCOZ!\J'[UJ3#/FGOU[BQR#FL9Z2TVZIA LF:*!1%DA^]LX -28AM225J@-L M)WV:C)ZDD.W,79!IKC[)I-SM*)40FRVE(.*]L_6XA$UE*8CNW@1OLC?0[A75 M"2SNEC@)LBBU22?2E?621D0&5YH^I"WHG3HVZ(2E0RDR*"IM MM*1*TEUV(BW4)CF15,P[!!T?E*7&*8#!6D]Y9=N*?O MLX!L4W-,_>%)&J>/9/>JWS>:-!RF [*!WLH/I!.'01(KC&(&(:Z$VEJ'W72J M' TW]_.;3VE,=[D:%[94S)VK00VR\36(,C (H08F>!MN[JG-J&0GCXWYV&:; M?NNIEG47(V. V\3)* 1AT,& 3HB7^=BU"8?>F6I#+2]V"67B+ G//R_C71X] MX?[C'*;@RP%%. [''%RY7H"FM3X0WHT"K0CB+(MA1ZQU04AXB@68_^0BHNZ= M2P*59G$@U:*>_5F>XR(_>;D*_I9FIW&0ZY*T#BK!I:]E1-7:'I@!ZM[9/!ZS ML#]C)1RS(E!3!N*%H(<7Q(I!K!Q0B5_Y,)2OUQ0R+MDHA=?F6T< #*-DJ.0& M8U%*^Z=&_88A9=9N!*; M(ZD::O0FW]3=7IS=XAR3MEK/DZ5F6R<7=+>QTP%MMG8R*1C,T$$3MG=$%E7" M1V3"6;Z9F@B_X8<;PKG3-*%6BV4RBZDR93*F;Y[=I^5_Z4\KG-V]Y 66/VUQ MB *=$>L@%:\)N%=I,(AZB"H(H5?X =%"45DJ:HKE5H\5>%RDQ_Q/J"H;\<(G MGT2#8I<%\27!O",PV;V"5;#4G)>9-!P^9F8#O?6DF4X%0YIS!%[O;&5BUM_@F>A MY/*ND5T%VG>/]!HP2&8+4W(WB461\0KDB_XKGK"M/C;0) ]6BKHD MCPYLFS(R.3!$T8"3T(,E+6_$)[^\$#TF03R_T?H")$+NKB2H #:W#_H2,'I> M!4L(#&1R+.N!BWW_;%>DFY2^H:GN;U'&79IP!;PF*7A/ $9G*U )R9EK,1^1 M/\.B?D!$_ R(]H%$!R,^NRB?B3ER&B8Z*/R@*^I26@J@C4E 'L?-[T*IE& MSN7IIO8=,J60=UZ9D G'%0[?JR0[[WP7L^2CYL BC;"[@RL3X.;P2B7IG1!6 M\$165/(.$[BE]*V4R^#Y(LHV^AQN"DF'O-!!;9%")@:%$1IL(AVH,"+2B(J[ M>3X +W=95)"UTX!4D!9*#B_@6U:@=??>H &#.K8PQ1OWE9Z'])#S)"^B8D?] M8=)XLRP6UGBU,(PJ&.!4,P3UU)!M<[TLU&]?BISC^CN M3:B%'-,@!NOG$H2!CU,\ 0_77%,%(ZY!JI4IE^]%$7,)C:K58M2V.%JQ0"XM4I1 M2,+@APF>N"JIY,'>:#A-=S0>9DL?*KT.-EAS=4$NZM9OH@;;=9V(.]U$"5D+?0JRAS1C9\]JPZ(1=O=(HPEP\TJC2M([+:S@">\T MEO*(*Y1Q A//.[_B)-3N:WH"SF@@!59W?>=7&-TM@R0^E,1D)M^+T'<^XSB@ M>Z#%BFR!4GWDFE[>W8[$ G:S*=$(PR"$!4)A;FBIH'2%*J6I"?-+$N+L.8O( MO*1FB43(&364 &L^"!(P2*""U>_YEMSDCS:?G)UF.(RJ6[_Z5YO5PNY6!"; MS8I )0F##"9XPHK@Y QQA?IJM0-'^D6:%:3:HK-V1OXGQ.$L"6]Q3M.?A6K> MC"C$7<*IL15LRF3U78Y,ZU;1;% TY]]/+N M7&P6L!LOFT88!KLL$ J^-JKBY7#'XCS'WQ&.Z=0&Y$&-W=G,H4]C#N,PXZ\' MS(GA^HS#^W2>YSN=_WT7%RSWYN,:!9J?JTJ$VI#)M!YN-GG>RC0 K?RH" ME;JH2!'7_F..N/X1HB6 RNQQOMG&Z0O&[-"*5T ;"Z>1=TE%(^PV_Y3"8$AG M0MAG6B5?GC66Q)OZ)&E+W_--R!=LHN9TTN[.DHR0F\,DI:AWEMCA$XZ3&@5W MZY^S*,-+(KQ8M:ZAY3Q1%\\#=E=D9.6NNR0VO QW#H.1U6O\" ,+@,&]D:@% MKT-9#'5 M@LZ0G51;'=7%38U63]FNX>'W,*6*02=T4X+M.:65 H&@730^BSA MLNY,UBP)XI=ED&2=B8TF==B+?4J9P4)VF0E:YIG>=.)^_0C6>&W?+IJ85A$,8" MH>CMJU40TT%A#18RJ+J/!! M3UZ4-RV2*,W8W4(%+CA2+^_POH49=NO*A5K8.TML$8H7+Z@**G40 M54),:_H-2%1$04R_I=MU"$(.MQH*@*W]14\"!@M4L,2=!)-CW>TM_&U$L!N< MT+:A@6R06&('R! MIXW#+%-_#;(H>(CQ;5#HEJBBF,OEJ0ID>VG:E_'.% ,PX9).*8:H'*@H(+)8 M#FG0$UDO/P3)[^QN,@XIS,OYR>)6&Q%DJ>MXKV-?G=[FQZP(AG9#T$JV1R&+ M52N54:G-N?DU*^";R:+1)=-62GK:XTOP%4M\VM!&#PPH#,N]HF"8V+)HF M3S@KZ-NP^MY5"+K,2JL&VLY(*TK!Z'4=-$DFVDK6"0OFM[OD.=#$R?<$W!T* MR( U!P+M7V'TL@Q2OW+853(.+T0J(I5E IX)X,.E7"7STT(8C>5 M4Y,!3F_W;;0\I=7254&17TNFXITKPW":,FZU4ONYF#H643Q+PH]![0VY"5Y8 M-@:ZC34][#U V1G'!E>HIIJU)@STKF*TH1G\(-MN?$2FC<565I:!6,=._ M 48_,XJ!UJH.WPL;5)G6*V)6>C"X-PRL^.(8T_;*N7OR*SZ[#I*T5PDUUXPJ M[EZJL@/?/%>EEX?!*3N0?2Y].$-41>32Y+?&Z#543"SP@,,F"R6'=\HL*]"Z M8F;0@,$C6YCB!32FQ\YPW!_^]2!-3OX4\W](7+ MR6>6Y_1^G>YRPB/"P?/H<5U@+,^48B'O;DZQ@-U,*!IA&&RP0-BG!^G*']R2 MXSI*\!!R].4]D4,.6T&.KC!$X:00)&AZM@ MJ9Y'=^%YH=_*TB1::B=^F933_I9#['1X5P1.CTMQR;J<"1ZY6!R4YPOW61#2 M[0T-\32>VLB$79_@J 'W3W-$21B$,,%3G?(P!51J3'Y(3^R.D182(7>']2J MS8%]7P)&]ZM@"0?WU/([ZFUUP+3XLSN_@#SLN?\;C%ZU"%ZF$KZ.YBQ<0M:J MW@_I3.XA2ST8Q!D&=L"9G3.'$7>7)D&2CG)%#E)W[-@>5*F>D]M*%P8'AP-6 M.;_]NB[YG6@"_C]V] _T#KWFP$XM[/@:NP9P[PZ[1!(&@TSP%+?7*4VX!DMX M "R0Z33#[.VA,_T=1%',Z8.!"I"=QP)[,MXY8P#69\LMWJ99@B346L1"2PHM M[_^$*$LFCWTJ$:^CK'@91SFCJG.V659&()I!#Q;'[,"JZ/7AK1-ZW>$8)YB^ M]$WFVB6SN'7BR@CGVB?/['4=KIJ&5:>UB+)3A$&Q@6C%)1951QU]U"[@R,7S M:5\29Q390(>CPA$$#M'7(()&"01<=-/&H@)/S[/G*QUIT@NY, MBPYH8T=D4C!8H(,F6 @JBVKAR8\49IJ3A)GSKN[#:$=IR0R+HFA1)NGQ6"("A:J-"I>,'EW1"C=Q5:FWQ$+>OKZKDZ^8A* M$ 8Q#.B,=] =)!_Y)8F* 6>06G%G]+ 73-$(PN#)&: ?9Y0#0^'ACTV:_/4 MJ&5]V1!UGAJ5( QZ&- 9;<@A\]00X[_O"&//J0OX_D6;6U\I[?+L MT "Y?82H$/5.)CM\PCZGED9,'-X3Q[WZ2$V20=8CDT23I!6$RB+]7KG/H:D? M_HS3AR ^B8I?R<=VI.:MUTA/TVRKGK5L-=T]#3JH*LU;H59JWLDT'*OPFBA3 M1D0;5>KMMV<1+6#R@YL=68[AY?HF*+#V]3"%H+N#&QW0YN!&)@6#*CIHPL%- M*8M*87?)"9$% MRT)6"SL]AY<&[*O1NC%@5H+!F0%(Q;L"7!417<2544O[D/N>'"_?/*9/WX8X MHEN>[^@?*.6^:^UTR#_]E:.XQ8\119X4U\$&]VJM%G-!*1-(RB"5C'?"&(#U M^5%2HI%%5-@?+4X)5[,@IN_F?OY/_**LG"#GEA@*F%UF](0 44..3,&-4A@Q M:43$?;"CLF/49R.I5O=G5UR0@:HHT/X-1,]+ "DG"RKCLY=OR<+[8%7D1)&&4R*80&R7'.PV+"O2V'1H- M0&2R@*G:D#!-'IAZA+@R:FG[7+ER<\@72Q?DW_JA 99URM8)=S^*E80!,$D M$SKE:K:Y@89](9>$DP-L4ZLK 89$4EC"_OWN[OS^#A(5RNVB M%2,$6??$4, 5^=$3!$83.3K55CY@.C_!H,UID*]G24C_<_[W7?04Q#3T95:< M!EGV0A;YOP;QKN\-&JCK-&//D.ITTOC8*(*AW1"T @V)$@SNT0>VLVA9X' ? M%@XNQ24?1U:QS;>?)$4--E MI#*MV8 "7)O/817KVU [;:R.\5HE6;H(0A12',\DE_^]<,/WQ_]^/V?6?['^B\KEK]V6[ H1_3A[1'/ MC45ESDCQ_%_?L7_],PP.LR?3R3"\3(-D")$M]%RRV;H:;4H;E<#PVA:I- %[ M0VP8E+O)\#:(PO//VS)/[Z)8XZRSQ5,T@Y6F2]H-J$J;>!9J8*AGC[5/OE(3 M8:Z:,S.84FVT[.S1CRIS&T9Y:8RIA7U_].<__:@SJ?_ZX>C[]]\Q":#6U8;4 M'NEK)*H_2AI7DS8,+!>,';)!(L8UZ:(!GD29N'NZJ$&+S!%EP=@U T AW2FS M6Z!\BC=9NL59\7)#@+++%&1?M67/I&/U!*I3<3MSFL%WITRU/!A.68 4)TFN MPB8T7,G7,V*P7.XVNSB@CID0;\E2+N)94.D$^>[#AZ/W9 )D<^&[MS\X!;F(Z(70R^@)A_.D((U#4V24PU/)9).22R[;5:#-9KT&&#Y;P>PSNI'L M+^_:9 XV:59$_VB1^?W1#^\^'/WX[D\EG]\=?7C_X>C=#W]ZA91NK9&;&4;1 MR I9EP36PFWS5BH(AJXZ=/+Y/"'DL]J+?/_C]Y#W&1_3-'R.8E7#-#^[9%4? M5)M(U6]@N-,#)*2S*'^&T=V6EL6O4;&Q)UY-B>46TVA*^"XS;6T0(+%$6S,.J<]SRN6$R@LB_9#L#CJ'Y U60G]Q;J8(@Y'+/R7'];OC]-W04!+Z0^DH)!W9-='B4XST_3S4.4 M!#R_7E)$R2.I'OE3'I%)@/US5?L7/9/W*= EL?>O>)OGXTL#0_N]JR#8ZSC= MT4N$:'Z#<) E*-T5Z+CV>= W*0^<-VG\,#@KW^BXI>_/[;">XBIAE_35 VY3 M4RX)AG9:>&*H*!-".;VI6B\$#GHI>CR'RA<;G1# MC5K;8W"TL0XZ,NAX(I-=^)%6 8R-LT$IN/G2Y/&XP-D&(,D(-'J3HVVZ5367 MBCJEE 9LATD2.3@$4H.3SY(WBEF23Y+?'WU/9DC Y]PC]L?&4](]RP3N+]&? MO^Y5()A1<(A:V#A.8(R!WF;=R&^-O$=GB9Z72F&GG'O"V4.:8]WZT 3T53E/ M6$R4=$VB"[A2*#B/7],"%X+8I-)@+)H1HCR<+2;+ =19&P)AUA!2 >"3-97\ MLVC(#M8RDBD&O,-H )FKZXTS!J: Y8>>%="X,#C$"4I0T[ PIE<0N#0X5*FM M\$>RUUQ%RZ@ $D=RDY5+.@92EQ%'*NGX]K$*:N^V<5\,#'74V"2WB;DDRJDH MNL,9,47HY C]ZYNW;]^^0]L@0T^T@"/TI[='Y)_H__.%=HZ"7;%.L^@?./P) MO?OQ3T=_(@I1GM-8$'8KN3F30D'QRHX$6JF'M6G$!#&G*6\4(#N);7HR8%BJ M ":^\,PR.><\DW.?EC\3RFAX^3/Z_NC[[_]\1&C%R/;=T9\__'#T[MT/KX^0 MLS!D>3R#^":(PGER&FPCLH10A7JII)V&V.DA=\+IY*)@R*K')X3)U=*()FLX MCA*TY I N-3<&61[7#+&MAE>XR2/GO \6:8;?)GF]#KB8G4??%:UR=!2'(=W MCJEB+\1S2!%PN#H*MR34L[Y76N87:9>#(E80^CHF17T#@]:WN BB!(?G09:0 M14?>JD*Y'%:TF(VBV\R+MA7I)ELT:8&AJ#54'2M#+@F#>^)VS7I?YWNC;+=! MAN5@4>*3^UFN@BP@:\*D>C+W8Y;NMGQ-6>^8,2L&!INNHH0L8.DCK@4F[:>R M6Z*82R:I0+9YU)-!T;%^L.5>$]/7%_+RXLZ]*HZO*P%FR,D$O[!" 2AE22\%C21^:ABE4%#%9('29 M5F.IUG'A#"@!#S3&H!5>)-,WZOJS= MD)TTX^+;'S^\94R\FMW.;!(:GY51T;TJ#U=WP;^QE:+4&ZKKG74C 0NO(3:7 MPQ*TMB]0R;_%K7!]FW="L8@X*S-8L5\'J5HI7VSBQKB*J5"%V( MI(JHO1 %; MU[6J9;FHTVIX(IW-\8-.K>*658:FFDX=+,/,B3NCB8S9-902KLDF %R MFUL*43"TTN,3']QDUQM;H7^5 I# OS+IF2HZM/G9[<7%+JCN]43^&QA"] I MLLH!"5 Z37.6[KV,S\H-QD,M[G9ZTH/N3DUR63!T,0#LT^<A$ M'&HUP'#*"J80,M4+D]JR:\X\Z/89/^11 <0_=!D\I!E]M02S^*[22"J:0B7L M]+J=%G#GDIU4$@ROM/ D^RGZ,^<3)5'&M5 1?-[?A"GO$*0KG.(3G."5D,EC3 $.[Q&,J%CK)L$ ;>]T&PU9I&"2[V*:;QRM M,)1ILUVQ"ZS^\,0 33^4:,4#\^$@HG3'.S\)-E$1T MAU!$3U@_SQFU7++'L@IM,AE4P'#+#F>?:J46?^JTHP>$55M MM9UZK8=5J>/%ME,%P\%A>(5IE*?#@D;)Q98]+9,\5DXT1>4E"E6Q%!4^>726MI($]]EW7HDEO::IO6](+:42H4MHT8D")(P 4GE&I24-S MA2+:'&C)GI+:T7\L.46V>T"X1"^,\4K9G[>8E)P_W&.L@/!XCU(#S%QG!5/^ MB$^5K;8R6T RUE:7&]/N8-)O%TU*SKEFK(# -:4&+*Z98%IQ#0C5SEV&6C]R:B7XD?K+=1.H$6F? M71=IAJ/'A"R]N *HW-L?@RC)Z2( YXOD_#,=,;LH7_.-R1E^4$V<%GI.?1.V MU>BX*4Q*8*R:+5+Q?>2<9?6A&:0(_]IZ<.A'02Z2NR#&9%"5Z4R?<%Y0E$I_ MF%G/-?VLJM&GGU8)%/ULD*KHEQ,M>KQ-7R((DKUS=2O.(2G*17(11!F[CC$+ M_[;C\!:KZ@%;FK<^W4D/(8=H.SN!'%ZE^OC17M4[S<;A%0X>^>0:)6A%"N&7 M:U!0%T/Y-\4[Q@HRGL8!&2^KWX(L"T@=LMOH<5WPM>@B*U>CMWB9/B:2.S:C M2G!&RG%5JXDY3!T&.4=A[A.TU :ZSVBL.:^7(=#?.72[KG6&6 M ,5(=_YSR2! SUDI5'29#]LLV9Q@7IOM/ZL&)1GU63? [6*)N^HM)=M_JT#CVP[Y'_L#!. MEF6\',X'B1(^Y$@FS:$-'S9*NQ]!2L@B^P51> L-'4S%U4M"HII;P/8X-/HT MTH79M05*('56.4]7EH;48[3->O8:G;6 MLD,+@6;#QE9 QN7.V[DH:!6&BA3!?G.PTPXV;>61K$8BPK*#,F@R^BAXLRR3 M8-#L%^6+9S H4[WR6R6V.@GR:#E+PK,HWM&4\/K0*FMMIT$)PZK4B5"P4P7C M3AR&5[&8*RF[Y<^(US3]"3!!AS0' /)94PTVL10T8K_!)$LY#BPK64O[)$P/ MLHXRI2A8TG3QB7G:V:\PB=,SI"QXD":6)Z9REQDCCD>7YMU2V5=YP+2I*@HL M<8?A%\Z S^WLX_GZ'1Q=;6X1G>?9K?G=W_XEW=_?OOSXI?[ MN_O9]=G\^B.0>?8W3,^[R9KA"6?!([[>;1YPME@)6=YT\^_ ,ERR?53UVAP? M5(!39A- #VF.=;N7,> '3_-P=H[OP5@6.2[9QI$NPF%8 F;N:)81LE7%21X] MX:8*!.EB=1]\)I8R2D/R[QD.I8)A]\&J M(K^LL6R7S 8(D+E25>_R%@!_V6KY,#/@A^EAZ]K?QC_DI#!'M-P2?1("J%A MXJORHLRR_"HJF@_!&-R2EJJJ2?X6L^#B&YK2C;33^'.E@W_%<6KK*9JHEPW[ MD)^ =9@P3>5DB>*ZTR?X 3;-@'I5 VB" 0-G@-@?Z1ZF.D+8%"9KR-ZZLGO@ M6R=33.F[M,>RPU[PHVAXDX)A_T!FOQJS;FVBA9/CJR +BC59.97Y@#YFZ6Y[ M1$-NWL @(JDBO1A]DZ5/48C#DY=?)U99$:6E$]1$1F]YF,*1!>@2X"Q8]SZE5\&2 M913CCHOO/CW,6)C^LTX3@CMJQ$Y*\8F_"694.JJHD-:\^2R=IK+J8R@IG=EL M"47^3!&A;?D]]/""OMZ13Y+5U#>0Q_T9)A/S,F)^"47#=T53=$8M%IVQ:6X-MW) MA!/!1#EI')V?VWN#["';I:>))GLHHTP 4?'H1<9 4<;9&%?!J\=R7P *$W3@ M5$DXK$8GC&3>YY]+MW^5BEPQ$ :6 26QM[)ZMNF]A0*\SR7[H!8"\>LRJ(F* MZE+XZD5KJJ:<7/9]"\!M&)9%&)P!I[Y;'DME&,:DBE/%X6GK/2A%O57"+LV# M'G";37)), ->"Z]/(?92,GJ@TFSI48G#(!%]'3P@/;=8,9RS)"RGSOPBS:H7 MH1;9:1Q$&]5]PH%E.)V1QE2O,R,-*0 ,0<>@EO.6OP7/LD?DI=Y$R^;2DI+NH2V4G"VLK2M0K[2-&MX)-0BF$--,3\^IZ[Q^H M?NIKE9RUG9$5\]RN,$8Z.P&C!HQ,BF?I[J%8[>+9DMDG3>88C8KC7#)&\+WL M,DIY,.RU "D<0L9Q^DS7.FR-$I9**"BU8#"-YFZ?)WF1[39\3)&=:D&W]SS5 MTC(*8OZ/K.XX*':9*E/BN*+<'DV.KVSW"'-X.5!\E0>H@W#YKM:@"=]*%;3B M.A.MR;N!!:=BD.7>(0:R]::+KSK;%;AKPGI;,?TGH0PSM]65[&_@!@=7+R2Q M:* !SU9)Y'V\6*6$+7NL2A"&PD];H/++CTFU?VZ>-P"RGA$/T.M1JJ ?-B [ +&P22T$:HUI*.@L(.TF3,+])VU8=]X'XY;EON-^+D)9ZD'-HB5=1P^\-@B: MW/RBP@'NPFL+ D!VBXI:D%Y3"AC7V6CHIKOP454"O#NQ9&)B;NC[=+;\^RZB M[UEUX]U5!_MF/:?!$[;5Z$10F)2@+9YM 8M+"2*=1S3BAP;O;%G6D:G"/L^B M?)OF0;Q8\>PF4M>81,B9$TP)L'9W"1)0B*!%)R9CYW('[/*); ZQN&3Z+UYN M"/Z"K)'I5< M%;$=!YH"O%HA8\6TYDBI#86.HY$+'B@":DTV3(RJI>X1PI76 M4@F%<15XMZ+#ZBKPOU6@Z]B"Z3&K=P"R;<[LA4A:")?5)']^VYWM 4! M(+9%12T(KBD%^G;'#-VTW6EN@8#;[MSB;3E7+5;7:8$KQYRBB=3B+IEJ MWF MHTH6VI+!@%-8()3"-.U#0L4KKR@,6I$QM,0X9$]%-U?U3MG+:^S:G6KA9-9S M? 7!KAJ]>PAZ)3 &SQ:IU+[Q0!,R?>^VA(-1J4X7K)@E+D%?T\1H]*I_]1.[ M @?DZ5QYU:L[I(/:JU'R3\U^!&K?9M]I.X/&$0^7ZWPLEBLSC\OV26/6S*.%PEM#)K^ M@_R'^NF?@EAR:C>N"*=OWXZH7.?!VP'Z8&;@$:#[;.9%L(UL60C*2"EH6=X# MHL&6I" 8#);73/X>H:+)AA7A] V5$97K/*HR0!^621Z!7&:4PU*$WEV#Q5E- MO=US3,4=IYS8LLZ]*X*L,#%#YY8+"O2 'Z.$OO7-3H]9L9ZR:VH;UVWF3-X. MYXG^0:XV+GGS2@(X29-C>AQOT]@.DV?NMMN8)3\*8@K](DZ?Y\DJS38\.9+^ ML-):VVEZS6%5ZN3;M%,%LXX9AE?(;/C+S_W)ZC MQ04ZG=U]0A>7B]_^\"_O_OSV9_Z_\^N+Q>W5['Z^N-[[7%+A>6 [#'H?J_6R MJH*#%O+.O! VL&M?A$[8.[-L$4K-'KL.1]@'Y-2ZRGM"JT+6.8HQ)$BYO0HD MA=B]X],1\'**@XZMB"J"]:V ]*4 L M44#K$X6), LRX=3" ]%PJ#)ZS>].IXX^K,Y44?WHO4M5B*13053*T#WEAS-T M'20IC*%?9Q^J0A*3L'9ALM?B3/%Y]OI.?=)#J]5Q2=LJ>^?@6,0#EK[7B^MC MMOR=7_]Z?G<_O_Z(9M=GZ&)^/;L^97\[O9__.K^?G]]-M0J^Q4\XV6&67K_. M-3OG5[W#.4WM]K==LJ0K?)J0PW1&MT]ISLS@_E6NC>;XHKS3^S#X^V0O"T0Y M+;%Y"H@^]\W*9'Z_IE2>MX6>*DY\S%Q&Z\Q9:GVA8JT LRJZ0M9:(PIQ_<34 M\ KVWZ"R+P$&AUI8R%U#"W6& 7=JZ17NR0J\'(-ZX+A(GL, MDN@?5;+\/(VCD/L1D_"&-#]U,]*_+E;E6BN([\B_\-3YAF7S@O& 2-^ MJT3*^^I#, A>IF"B1P=DN"[-=QYU"BX):P;>)J9:&@P!C1 5V;-H5$"E TV9%OV0LU=JQPD M82P,FIZ(+U"9[*!>Q?-+95I;J),'0S\+D$(^XU(%M77 6<0*96O/>I.E%S0, MI!4-8KN7=B;I@'Z3K?-0ZO5V3G;*H-AX%#$TG?L2_T_ M(E["5+E,\4-1O8S.GVMC?RO?4J9;=.,";X]RW&5$W:.:3=+4$85XY^2^R(6< MJ^3+:5ET?/(NBBV4^D4!F3JWSWD^.\[ O'\R>*47BWN]@*7'G3WQI9*O)7H6,JT>UO$]2Z5>'*F&PM#*?GO1X-=%\6AYN]XYW7KBI M;:(W^+_R_]5.J_N5YVQV/42UZTEVG\*\$_10-1!.8FB1]/"O$_/#@X B,N-N M8\Q^[GP AL7\)<>+U7E>1)N@4"8[Z@NYM(UR@&V#V)7P3C(MK#YS?N$)\FLQ M1II9GN\V6T"G(8I<'EH+.5 70%(6M>4;I CM!;LAH&77Y6!0L'D^VI)W.@6W MF;Y-P+NYOE728.R:$:+RU'(E7=D&PI3I5:ES\:7KXSGEG,%5:GPVUJHPV#@8K^"/H04@7@*_Y\C+F"PE M0DRS9]\$6?%RGP5)'K ;EO:$&UB P\0'(RK6RG4P0!L&\\9 %N=K5@9BA:!V M*3!6BQ=!E/T:Q#OS H=!YD-"MGAE!W=+OFU]2C>T74;S3I_F>9D_T!VJZPD&.SK7P@@\WA4X$OZ M@*%VCK30\WEU0UD-W<4-00D,"VV1&B]MH&.R@P"4@$=S=ZKZ24O# ?I ;L+) MJV5Y"ZZK#.U,>"APU24X&-2<;[9DAT/W,8OL+,JW:1[$B]5EFCRR<8_%4<56JK#D+$R"H M;TC5]&ZJ424Y#4 ?7]5.:/KP8L"P>SQVZ67&XP=:%&J7-='ITV7T]UT4T@O M-,AO&Q5!?%NVC<'^#E=W=O(THE+UN=, 7>_L&PFX3[FZ!'[7BY>!ZD)@V--K M_-P*NL_2A/QQB5O'%W:KA>'%N'U_=UPENZ_P#BO#.XOW!"Z>H"YQ+WM:IRP8 M=+Y;KG&XB_%B-2,@0^H])-/#'5[N,O8^\/EGN@7 (7U)G4X#NRK5;-]1:;RD M-L&'G"XN)FNHSMKCX%\!,ZPFJYJP3&=VPT!"-Q4IRUFD_) _V'3\C\L#-)!^0!_H(P/%XV)KIAB-0+U %,=4U MQ<6NH&DV-FE6E'FBR[C0>WH7Q':L'>83/H;9(1M'-L(.43ZXP77 2NG&%2\) MM8N2#K\+"/\8JXY"_^VRXN#+%(5N_TRT_!B1>?G('G) M^2'A#8&_(HOK-->.J7%%.-OUCZQ8K4DI.$?\46FFRU^6!C=8I%YJ]J_Y;%>LTRSZ!PY_24@S MLFIR_S7S69^\G'_&V3+*\4T6+?$MK?& 4379AST-OXD;4C%.)_HJQ $];55U M+S"P\V7#F^9N&[0IDJOX&5)J\/+!(,H#I+$2I&Y3096F6O_7R*Z"HO3_ MT<%&EG?W.-N4B03IB7KU5XL-P=YENMLA'*CZS99ASP*]4_:0M;#8*%^13?EF MMZD26P4QV6"\@#R5X8!+O+,E)G.4?M=\X+(]>7KW M;PZ%=W=\P=X'SQ2U&3"(6"G0!I"P$:,)*+(/4.95$+.?-Y L7_4MK=$CIIS@;?0\+$OMJ218?9F7O ME!N+6&]'-B#M)T1\-!56D(:*4&A'I# ML JD,Q&-%H!8"5.Q[7JW>S#%0V#_0>O3W^$\ ]0H[RJ$T1$S3> K$YI72[.YJ>D M]CL:7+&A(UFQ-E+(NLXTJX3;SRPK"'IGG@TZ\2(KDT$/+XBJZ&@S8<-7.4>; ME*/7N"A3C\G:7R?_U_?0KF]:H56F8\S'NH: *-O,L!;H3=)IE2&,Q -R$4[QTP>4*I,D4JLPR>QGPWB6&5PY"' M[VB&OH4:/ LP!+0J.2-N)V=,V5W399F<,0 48G@9%=$CS^V+<\)*M440Y-Q: M @7,K@7H"0$:^7)DPIWD5B!%7.N@!YIQ<:H+;CAY+-:+U>PQP^P"B&Q]+!%R M=UE-!;"YDM:7\-[O6EB"F6=R=&\05))3I2#&&;W[LUA]S-(\O\G2)<:A=,.K MDG27/%@+M;PGN?Y#H<\S(-'>)0! M)ZUT=#I/NIV^\S.,(=423C)LE+W3<2QB,7G_9D.F(WZH$;%RIG(>2^.;9C2H M\)%9R).71J0\XIL]!UG(_N=7G!>\=G1,!8_X(LKR8I8D$3V5";)^)@$WGW3G MKG;3>(V?>]KO>1\^#BO9'W&E'B*C;D4UR&ZB5GD=0^\.$[J&;L>>Y)NO=? I MFV^JT2=\\(L5!29=)@4FU"_H&.JD/ MT7SDO\FJ9*/EC!KV5:BI8E:!01UKG(('LC8>4:F)UCB>:IM77=MO[3WI:6@5 MLRFKF5'%W9M!=N";AX+T\C"(8P=2;8"61!AM2VFT"4(@N4NJ"MRG9>J(JJ(X MO\9%&DI;TM M P3H9C7-T ->I83/_[%+,/KP]@@1SGT'PQ9+DO4TC4+^E$7/D6/:X5Y./1'/#]X=( &,CR2M,<7O ^L2:O5'W17P6=VOVB; MYCG+85,-NQ5:\1M(6U!WCFYQM'G893FKK#[N2R[J]IEB-=CNR\2B'!@::L") M%X5:HE6DUV0O:2[3)YR]5$?19SNL] [:*#A\*=,">.ME3(VT=XY80Q3V6)CR M@^O5T0$HW&&Z>LUQ')-]^U1NOM*>+586ML1*PYW[SPIZXPK4BL,@CQ5&Y5:' MS%*90YM3W:RH9N:SX"6?K0J<7:=%M,3S_&-$/B^KIJVF\_LT=E41[LKHU6!0 M:Q!6M1.HVD.CD.A3\T1 ;LE&96*.E2]ZZ2I6BSAG30^<0(_R=U@\Z(+2'#M M>DM-XQABD7C#_4FE&A"77J<2EFX\I@,NS-X.KQ"%%N1K&$RC2?1R'D_W3E'' MKHC3MQ(DX#KO(+1^]VYU-*#$"Q;I)LKSE*R"$R)]H#C$PQ""YOYIWOTNLP6] MG!'KJ*BO3L$E6I@&D3E%]RL9S! X:'6DSW"5MA=%"3\> MXQ\!.VX:%\MB]6M:\/4L8CG['%N9Y7 RHL&$<6)0$F??V\!7W?D M;&!,[&63+(=G8Z,1!6MU#M>8HC3W1L,(9&432^86^[UA.,'QBT<4='? CS@/!#MY M0NC8P;X 8TQ,52UAL<)^1(\T)3V4K>+Y9SH-D0EJS0*]62ID;<(=G8+3P'PC M\$XDOE+:.P6M(4JWBKBC-5546)SR=\ZW]+&YQ:ZXC(*'*"8C01I9I)%V%]]E MA-P$<2E%O7/##I_@F2P54+1%F*B@=%>@N%*:[%0_W"VIM9PG_8>]@S9')SG: M(0KV/A"FJ(V08XV4?5P53N]CEJ63N9@7CVB7H67W;=6P?%'5O'>?D#WSS3:( M,KZ^$)[;8R_QQ?0E/AD_+%7A9=$:"ES(=5CKTVX$:B5/8X)FL2K?NRI?TNH\ ML%/_6+^SI3HK'%F6TY2;^U2WDY)S3$%@K-P^Z/LT+^70BI =/='88[2E)=#; MN]QHP6#Z^6J%E]3RSA,:)GT??+X-"LS#JW?T6N&VW+6K BR&%.!T0SNX8IT- MKK4V&/8.ABQFH:5ZJ @^HP=V[[PXX%7SP["U/?G0EWG80[=\[OF$X_ BS7[) M58?REKHN.3JH.JK5@U(1##.'H-4O%V*B?*6+&UB=$)8Q6M31]@P6(@9K%K' KL@*TTO3-P%%Q)"KU:LLX1[&E3*G_!8%:DPV+*P4Y;,F5T'QTT!,.S)+S>WM/[M*=&\" MZG7 V U+H**ON%)CS)MH'?-;FOU.AL!IL(V*0#KW]B6C/BN]>N8"'Z#@H*, MJH==08,'Z!6E*K[$:+;RQ9-U2+0D1N6, MN[L5K36V,)>3P'X5;E-W7$G>32;\*NLD\@4L>":!Z_&5\: MO,W3 >HBHT$G0N:(3+]I5AP7.-N\'@)CK:M$!T5>Q)DX 0"_\!7&LS!TJEW.>"D &4\@'T!;R/MV;D*DS M T0MX:EZ'Q?\I3QBA,HD*)2D^M1&%DKN>&%;@88D)@T@C+&$*=NMQY5B_?PA MM"/FNX"]U$XO0K;OE]49E%GB%':%(6"QG@I3.[P8IR\DC:QDYZ&D@65X)^^> MP(7K)Z08=GN0W9F%1N-J&N>S$O1^MUW-$_)+CU2Z^C%;*X\F]BG1Z:'F MRG=?.AY?'AC:'Z 22N]34'J?=DR#6/D5/FK%=@+QN6IJ?IKFU.%,-S3A?7J+ M$_R\R,X_%SA1^:+&%N9R'.Q7X?8(&%<2&.[O!5^,D^O%+%=G/=$_O'FX9ILT M*Z)_E/'WNLLW=AKP]JZ6>(7;!2VU20+.#9O7]BUPEDWMMZA8GY,>33?1DH<0 MZW9E5NK.M[H#*B7L@"UTO9N-D8#5^^6@+@-64CV-7=0EU3.K 9GEE$GU3#K0 MK)\E7LU4-9O2VLV6R]UF%]/PN;;!I3?YZ_A=V1BSTW-FWX94HS9L-DHP+-H MI,(TVJBBSI3ZAV"S_1DU^I[6/YKQ<8VE)SAZ#1X[^-UKA49:_? M@)][V@PK V]O\2:(DI!.R!=1O@SB_\9!-KRQ[$L&,H,-;0I+BML6Z]UP';XN M_3%"Z?D:1P2MTOUS>I#VJLN"R_I>=+9?)YU6NY]&E M >=SN\I[,IH6]9HYW<(O8?6/KY75%Z1=#]9(O##8G&Y7>#]*TY)>,:-;\$5" MOW_[:@E-9 _71JPPX(1N57A/0A/9UTSH!KZ$T.]>(Z'94?]!6=TK$2ZUI54? MS^].<:^4Y+(Z2)C^GD6T%VN/'- V?HUB9G\%*U6EB MC &5Z>3%L-"#Y=@;@+A/Q?O4<+]PGP08019'."=8MA&/])4\=Z*5=)< 0PNU M28 A%?-NJR.6_K8-:]+Q."T?L:9/W>YZ*.>K\='LLOEK*HV=8M M55EM;+3+O ISM,@*+ M@(_2L/V6T46:W>'L*5H*;U",+<1I*/ZH"G8"\0>5 "VR911Z[;M5JS1#>2D/ MA,2M&PJ@- M[7/Y%D&1HBW!O0YR7-G;GAGVE;+6[_L3X.ZZ[5<-,6,V5RPW,@TA("T$9TE8 MU4BQ_KTAGV2/1O;E=:N4O8IUOG@\0",(R\H]R@1C( ]4$<4;+=6J\PBQTUK^ M6@N@H:&H[<@M4E\7P Y)7AW;W?RKV1])T:IW[_ V1*=I0B:OG%W 9G5LK\V5 MSU\9E)RN0:TJT%E0:#7 ,,X*IB216ZGTNOC&_[D83+FV'@#6B=6P(%ZC!)U[ M E(]_9:5N,6+CHY=0&S!K?-.E +.G3P=8()7A_T*AB4").EK[GR+,MFSV])= M%7].Z!YG&W%3)3MV'U6,PX>Z1U>R]8+WX#*\\VQ/X,I7IFBN6H!;9ND;13,* M\1'3:_@G+XU(F?5U1JH07@11QI:8,S+/;[;L.<"JKK^F,2F&YNF5/';F],O. M+:F;IA1,]+2?]3XFW==5V$W50H#>B*MK-4^VNR(_B_(E?1Y;,^BT&DZOF)BA M=ZZ0J,7!D-.,L4^J2N0@E!JR5MESC0)S;;+/FN35K44&K4'N02X]I/521P3; MJWD_C%3$!-OJ>*?=0*"J%\OAA0"/73[05_B*%YK8/MNQ5/4+>FGO?ATD"[Z6 M:#5*+_4M3R!#'WM+DR(+EL4NB.EX5#K;86%\%0OH*;OG($OM*0""L1(06\68 M7SJK"F II@&9IP=S0S[T&[)LKE]Q3ELH"6M'14K_:7@KJMSAD Z-TQ ZJVP M2B#0P3))D)JD;X_X=Y#I_:I7L#3B9S0W9308C2IG_WSHN4+YF5>Q0#$TTD'6 M&(IOP!J3AZ^8:F3M%:$(:-SEJF8I3=5''L>4\,B0GEGJ1/J-[9=#(@ U6@_? MM(,&\N$^_WK&^,'KK!C^![YII_"MCC9I54CV%5DMK.,7T[N$TWS'F;=VRF:J MW;I3?,3[N)JZ9NI(_PW7.>C[C <^])(Y+H%9;XYOJ(-LC]6? C)OI MZM8?:J4D&6M);?$A14N>;[9Q^H)Q>4%=WC#7--"3^6EH&^0LB5W[=_H>VW5: M_#R['X.3-UAZ)DWT,S'BCFXE%=>O=NJ M[P^>!$1BB=$)?HR2Y)\@<*+K\''>4?W/?QD#7]ZH;L9]]]M@YG+'%;88ZDQO M_PMRAW9-&NM[2@T4S1^A&+3N/P_?D3F^4??W;P[_MO=!ZZG"%H.V5OW2Y^7: M0^!M:I8@^#)F9V73NIF@A<]['^[^ZFPQXFO5+WW$\Y@G;\.]__DO8ZS+&]7- M0.]^^Y]@E$LK;#'$J[@"[1!_E?0#Y0%RFQR-^X#.DQ"&!TB54DWC SK_I[@Y M4S=4+]B';8_IBQ3U:;*_/K2 ]F5,5\,[P[$I,>+Z)_4SV[:+\EY,J5C/A8AG MO_TG]T?#LTF#\7T9AFEDM_AP><,R41!\XE,9IU?O01]J7@#A^I)\[H/,"1A0 MWLT(M)88:C[^V7SY-"X0WH)F&+@O8S4SID.<'@Y8(?-N@$ VQU K]$]ZO@#/ M$ W&]V78HI'=XN,(X_^W2&-;9*A1^BO'_.8MS M;\*()$FU-]?MCFX_I%^ Q^$07>7 ![$/3.]3,/RV,=JGNB1T&:TF.(-Q;J)* M1^W(S(C0P'T!AFADASBP/0.1?>GF9EQS#+0P1S8G*:]RM?]%YOT$]\@DS.89 M.\V^TFU N:D)'F+LYV*.%, 7,%=J&M;!?"CY^I<^YZFKK'QV$SU6T'A"C2H%!['V@&]-.KTAI_%G8]GL,Z)&7 MB$)6)"(# G&_VRL_%!*G\6DR/*B_\RH.:4S-=,@$2,)'OJB(64,EU='WI>)1 MXV6I%H1?QA#L1N1]S-+\X ]0Z+[TFH:AIJD..1 EG_$^ 4Y?-XL1>*"P3ACC M[OSS-LJ8SM09 *5?>DWC3M-4AQQWDL]\,>-.73>+<6<5#PF8/QXS2'XY+CF+ M2EI0"5I0&\WWSY^P;V_:6 OD[,>NZT&9)W),04Y-\.B*=D;(X%+@&-"QT"U( M_6J#HOQN+[^D<"5C)6UHQ/2^K-UERV4[J8-'\IW7M<)5---AU[>]CWQYXT]5 M1>/H0^>'.RB ,?+,+Y5-.B#M/_^:QNG01CWD\+7]]I+5,1$'>>WK4%]_3>-]8)-.M%X&\\*7^T.:$0]]&:+Z!Q[D^"3GE_,, MW>MS@TU0^<%$?5WG':86D[B@?3Q*.1@&J/EJHD8^J%T8B &.B]!/Q0>;A=>6 MGL+4;)(C!1^&83",5V481C;R00W#0 Q?CF$85_'!A@':X=K^]I37S_-Z81"( M5V441C7P@=<* Q!\.09A3+4'FX,OZ%@2JO/ERS["G&97^X4?B@%,QTY/KX=(H)Z9_XK-6#5=@7U&LR%H?I +>GM?]UWOND;BW,#X:6K!JKB% 6O3[*7N@[.>'/RJGR[I@],F MX9NO7@]YQN(V%83'YNYFA? Q+LM@%#[P=8 K,-BCS94[_14;?AN(K,^"LEK M6CKLT=2'7#J,@.'=7/BO^V!C,=#' 9BW@W=L3NE\.'1 @]-@MDB(DV9E=I@HOH'VS<7>/B%C_A9(>E^6>5HLZV-0:P]:Y#(>>=$A;@^G1H M2U,JD+^AK%2!:&&H,;4:"%S0GU5I U7;$RKEG39&:,(]H+3 J""_>UJ0G<9! MGM?)XA;9+9U".V[N)I-<^6LN73N-*NBO'YSV&&EG_2)GOTHH$CY6^1XQVK(7 M'+8X0SE=*D$T"B=!'N5WVPP'X2+Y-<@BNEFX#0JLVFK;J_LS(.9*JH ML3$"[M.4JJ,''&0Y6@;Y&D4)&2=D58PRHC316J8+>5Y^D:)<)#=!%,Z3_XR2 ML/IWV=P\M 1G*Y]Q5:L71,/4O7-P/.8^#>=MVB&RA-H2S>,H.?Z=Z-:D]#1- M\C3 5[A8IZ0>=,](:[IX3LB,LHZV-\3 D[^3/:?,H%@KP]OU#X?>[]83G.!5 MM(R".'Y!::5()\%279.15"+I+8:P#VJ0HEDG!&/TZ:.HE M426,P@/,,H=9"=7)DV?AWW8ET^OEGF* &'1&H.S3[$*6 MN!H&R;ISY2])L$FS(OH'#L^B?&GM[I/J^5M@:ZJA7EE+E,"0SA9IGW@M2126 MHA!Y=TJ&Q$N4/ [P,/=5_+%-#EY-M*X\4(Y)0?;I11U)*$D+G!^A1YJG&"2W MTC@FB AJ&]32@Q(XI%NKS9)GA M(,?SI/2OWQ7D[QOFQI M-_7RSI;M-K#KU;M.V#M7;!&*&W:N0O;FU3D'RID6 M>J!J,&S3993@Q>HTPV%$3_2BF.YG@\_19KR^O@!_$ZU- MQ=23KDX;#%D'0]9961>>>6+W=\N"9:.^P%AT;':"9I6R[L*G#7";\&:%H'>F MV*#KDZ(ECE883^]-O8H2:C OH[_O(F)V7VXQ^4.&.:=_22@ILXB&5-&UXRQA M_Z&^XZ<@QJ+S[#!%NHME.4SEFYB7_M MDOEQ99"4?\!-Z=.>*4@"9\2?79\?](-D^K_!8(T(2'5"8(J)<;<8.TV3)YP5 MT4.,Z6RN"AWI2[E<5BD@=N)SNB+>Z:#')8U1B.IU%$J;L&$8).D[6NI*\3_F M49JP^"&[,!JMOD_'F+%:.A^94AD,&8V%M6&5ZE[+L=,%8T8& I8$DA?K^.6PV_T#<[/VM*D?9I5(>F&<"%5* MKD8,'H\$;()#@$H>TS4SV@8O<)(8G>WP!>F5Q6I%#&V6+S)FK]=I')*_G>ZR M#*O/!ZU4G2Z&!E2FLPZRT /#N0%@-20,PB=Z+YU>L OH91A6& Q*WI#66@.?C M_MC5KS=M2W%W'"UQ M*_:9JR'GS].:_08J88". R-4<6%#?D41TX#BTY$_'D-FKPIV[,J-* L/D MO>#WF;@$(5:"<7=4M)-=@NX40Y0'12@I.3A67\> &4[8-MLJ/B MY0QOTSQ2V3A!RFD(BQQBQYW;%0'##SDNP;%>2J&0BTVTK[@E=NXC,6>83^"R M1:H@XFQ7H !7+_I[OWOO80VH?O?>ML^R'JDXXN\Z3=3/0^:X*.&&*\J7<9KO M,NG!_IX%.N/002I>,VZOTF#P\Q!54"]Z2@V4LGSB*'@*HMAC4OWN)N4J*+CE M5433JJ7AG?I98!6O=A?EE )FI:&NQ1G.EUFTU02A6>KZV_P;JF/'O):B=_LQ M!JV6A&1Q4\N#L! 3I<,%;CTLD$L=.$^E*,1P?'5V@;N"_$^HO+X_I@ 8>2)4 M%;/+$]'7!FIM+"!KT^>",#-[IFD#;DX4:(5%8YH\\I!X>B!OD;7-6?<<+&B:ET1ETR0@6LSH?T[&"9(0$F9X,EJM^%I+IE)Q%Q9 MYA]Y&R?XD:Y4=)99!U)FB]&2"Z$MM>#>MD^5K3#16R8';WK4HI0RGYD_%CYM MWQU^YL9RXQWA_!97)^^+57U0SQ\$#.FEGPLROP?Q?^,@LY@@QA7K:P[>IQ%4 M\_:8,J$2?\_Z](<(I>6K&PGSA-;H_CG=OZU:10%EO%#9D2RORWG%S.[70<+F M'SQ/LU;["+?3:D&G0=L>L)A,8=B+WF'8Q8XP!Y;4D[M= Y/#[MZ^-P]'386QQJR"8'.Y7=!R'JU)> M+X=[-9!P^-VKXO!^#0*2K7M0%);;81AH2,=:CEY4_N"VO\CW#_2>\@=%GRW< M/:%\_GFYIH'3]#H839O#]&^2]>VL&@.Q3IM(2$B#9 M,6BJ'KK),'WB_?SS%BG\_2;--$*.T MFMG0\F49XR,4K5"<$A9G;WR0E773-1'B?<0[3$E/K30L0MI -5.0L"*G?Z<= M^!#$C&/Y&A-*T@CX(_I34G^C8DN2%B@GPX%&K,8OK*R8K,(9486"O/2Z)%Y% MV><:65@];@:Z;W]7OY1A(DPRK@-AV?O%59IR%.ZPRA+T3(!G"R +FU&202<, MBPT62 ]!AVZG?TU['&WJDVHRXLE_@YA: <*'8%70[+HM.CS@EY1,.UI6?'-$ MIIUEO&.I^'J12EX8;D&..%3K62),T ; M%J?&0)=DN*O+X&^\E:60*8,5P]88I!CT=;E8^8:PB'8_H1-=VI!%1[1YV)$- M&<\01)<\^6Y+"5$5D?<63*Q\EN(U_1M9OI"U#GUGBK5/2-B:!/P2Z1$J\'*= M1,L265X$JU55MA>F?0RB9)%3M\28(P:4;*BBTZ^4L9908JF-H22@F^_U=;DJ4HH'9;?0D7PN=S7P.OJR](T17A@?[<4 M7U&GBZ@G[_FX^:2GC6I"W\ E,Q]->'%*/3MLX;791&P-)?:[40-6A]O"E?5T MM5!L+?:H0PKAG%ZM92[1LA"^T.3?:/O'J$N+>BLJ-QJ%\@;-J7Q[-4 *IA8VI9+S5^A;Y27+K:0O3P0CYJ*(9=7G&0)KHDDU"!-NS MP NSFH553OJ +>73F @]5A>.[U,ZN2;+*,;7N)QW+],\OT_ID\\W975/7GXA M-9TG]8'5;%E$3W*3-/TG87';67UE@R-X?,S8Q:V63[>A=-[C-&$L&1TY^2>R M>\J#[(4/IDWZA'GRU=6*;IQ8(7&,H@)O_L/0UV_D6Y3DI= M14E *EB-DE6G4!UH8VK+2F->23!*T/#_NI>IR1Z*ZEZ@1 M@]5M6HSJ7F+CC^R]J;6H_"]\( ;H.8N* M,GF%,RN[.7"+?!"WN-L'YDSL]. MG9ILLHYH/V,S>\B%O+-&85A=:(%4>)"9F4^ZI I*06\=PF,Q9(Z1UH_P&KR' M3./B"OA@B>J8D_9>QYR4<:JVO\5/.-EA]L!6M6U[F?.#0K*4(6NAO^V2)6T" M:KRU=FY\4;#Z=>]ZB"Q@!?+GKAHW)9WC6)EL0].4RNEY3'==X&96E.X\_ M^254NQ7^4CV;(Q!B< FP># 6?K_[RW*JY^MDG=T)"JH>$_+2ZU[3K%2?3Y"M/G-H4.U@G#ZDL+I$(*0:["-B9M)?07KO8_/KKG@BRP2 /E MU.J41D?1-TI)6!UC@MGOE4H>4054:GCM$G;OYXQLGM/+:$G=7.:^,:O ZB1K MO*)_@]Y!99JH5(73<72 9VD2+3D9_)_Y"8N!]$GO^(D3#.;/E%*PNH3$TSA_5HN#ZA+:)Z+Z@"& M>XK+0!^RI\3),L)YDT]=Z=T84PBLCMRC!L*;\M\&T#OR'G\N3F*R2=BK)^M2 M7F]7]JL@/74DFF2_'=9*+ *-9Y-<-A^I8]OJSWC9>+'LV(O5;,GB.:D'+XVC MY0MO@IS\.60-Q_^5_Z^:#?L4!HL4!ZA)GQNL2!9H5!>*N.9/J&$8.T%K!+9, M@#'HH=)O?CY"[7\O?7X,V!$_CZ+.;WKQ)..G=.5A6Q C=@+.>?@U+1Q_#C9; M>MOBESOT$2&I8>CNH#_'B1#+B' M,JB/Z%67#J0-<52>+=;.T>8C_ O>HK=/^&GM[0H]\@#-D6O.B*-\ MI$ZDTML@>:FD>+.1.3C) ^;](LCIK13)R3&_Y53V*ST?KMN^]9TNT4AEV8=+ M]QFK%?>HL?.HB@5>3CCH[S2ZF:*\C?+?2YID,^]B" M8!GU/6LAO!)A8;0S\I5^M'F#@0>;+B^T+RKFU4W%T_8U M,;O5P.B28+%FWVJ,H+EVL<[F*\6#6IH1>KNS5!564L)K1O)S V]?F>!0(CP6%J8\^*>FL0@#ZMG M[, *(<2E%JK4FK[RVE77P5,9FOPQ2W?;R\M311^I!&%UC@&E< )6BR,FCXB" MYW"G''5^6>\W!71$YDP5H0ZF3( REH75J<-!RX&2;$2 M$"D"\3(0*P35I:"R&+^]BZ.$?/O19 \58&5X6KM M7V&UN@R:L!#D,GZC-5Z28!,M9SS[6SZ_:6]X[X(L6IU$Z0:'-*6)HA>&%P&K MJT;C%W;ZO"!4E72$YC>H+HP9/58<:LKSN_Q;LEU#2"^3QC%>%KL@OLGH]42: MB%2^ C2JP.I;:[S".K!41&U-5*E"&K+JI:!*$%87&5":!YGOM6#+8/Q**DKV M\YH^T0G#ZA<+I,)+XVUS5RGY[Z">#5=WCDH05L<84 I1N[TIQW]_W+)$Q8EJ M5=?]&5;;2[$)U^I89C BY;65;X(7,ETM,0Z-?AVU**S6-^(44@4&+ZC2 +*C M8>2X?TYUY*]_AM7\4FQR\A,I *U,+_EHV[D1@-C2 CI%6[.[3%XO+-&8R76: M+%B>A5U"MTX&DV-6@=4CUGB%BTRE(FII C%%=SC&":9A[3N:LI16_9ZF+TWC M]#'2+6)M%6%UX4#4PCJ*J:../FH7X']A=86S1YP9AYY,"E97Z2"*-P6I+) A M588)D 99!ZU30>6Z2R,-JT=LH(JK+Q;D4"D!Z:(J!S#9WRH-G$0&5G>H 0JI M=$I)-+_Q;Z!N6,HE>KY*[RNJ1H5$"%;K:Q!*DI67HOPBLU='57F%X2Z(C:9) M(PNK+\Q !2]5=:F%J@ Q2E8@4IN_5,-U%+Q M;[1*4!\W#Y_T/=)(@.P' 9ZJ]:F@UQ9G66UN>%:;61+>7\XO%"VOE(35 R:8 MPE-^+7D6O$J[JA_2NPII= $YJ;RWC>C--;H">G:?)$+U8^Q/@F M*_.(LUQ>RJVXC1JL+AF$6=R&L]NR)ZBECFI]Q KPG";F,0GB^%4"J*[-\&;[(W?J![^TG.9-UE]RBH7@]4!6HQ"Y")_ MC+24]G[\VL&N/N^3BP'N!M/Y7Z\;?!\$7@6/R2Z?W^AV;X((K.97XA./FJ@@ M#3KTOH.[SX(G^N)Y^WQ$,__JQ6%UAQ56,=27*W4.C/Q/TJSHZ*EF_KO"/;2IH5DDJ05B=8$ IN,4_=D<"A(43/ZZZ MV"64'+,D/.>IFIYP_XZ?]C3/6A]8_XT"KSCQ*XMAGJNZ("1W%VBW-,Y-=JEXI4 M"E:OZ" *$Q61194P]YQX[83?\,,-(0/->4FW #0321P4*;T*>(;I-=G[M/PO M_6F%L[N7O, ;16?M51JL3CU$581G&? #HH6BLE34%,M')ROPN$B/0_8G5)6- M>.&>[RF3[5\07Y(*[4@=V%GK*EBJO!!Z<5A];855O+G,E%"EA6HUOU>_=D6Z M2>F%6T7'] 5@=84"G7")JQ8#X8,P^!\@-K04F]KO &!!URQ;B/E,,'V>\5.Z MP=QHJO:X W1A]<]PX*IU7U/$MW49B!92SC=^=\OEFS@R(I\5H:3+GDM]5XQ6_<%9O]%67BA5RX#I( U+2+>QZ=R,.SAT[ MP!4+L3^,..U;..B;ZJ"S@6UH"JHI 31E^G15IDN]B]L*VP5FHE(359R:8@N.BE@?B MYCM-:<:&R^#Y(LHVFH!_J1BTOM!@%#N""I-MYS.BXOZC:._PLDQ?:'L[QJ@! MJWMLX8H!;94>M)LR\R0OHF)'*QS$_$'A-%/-23IA6!UE@52\,M!20;6.9\M6 MO_-:/N2J/,%52<+J%Q-,T<2QATMXQ&>EX=>K5MRO\560_8Z+Q6J%Z2O:*O>: M2A)6EYA@"@ZWXI@H'',-5*EXGG>*(F:VU#S?*"1A]8D)ICB_5/) II6SE#Z. ME":?@NPAS9CC0M$C2DE8/6*"*:2P*N415RA]-P">T51T0^=76$TO@Z9Z(M/K M9$USE<4QJ\=B1180J<8;K1.&U?P62(59NZ5"TYI72EZ[YQ>:E?:9K,*527L% M"5@=H8+7;_V6G-\YX.3L-,-A5$4<:9(8JB1A=8 )IC 'G)PAKE!'2_G>H5RUNU 5S#ZT!%A].!:^F.6:ER/;SY=%L4".JC"_>Y9M M%L6V+AF=,*R^M$ J;%ZH"CP?C,GM MK38N=<@>!.N=O29&I6:=_5HK":WXA3 MV"HV"D#H?Q9E>$FX01]:KH^VSW$)<%,NAF21"_Y,HU0/M7 M6"TN@R;,\ES&\\'_SL1O40164ROQBL("J>"# M86_NM&*3(#RZ,R?[HBW='"7%21IDY19+N>Q5"\/J'@NDXH*X5D%,!W%QOU= M]&>,D \6K4X301P@LK-,?:HE40168ROQ"9L-=FX+(_52$J49B\.@&="R#:/B9G/], MH;,PC'BPBVXH2*5@M;P.HOCT9R4+@/-*7_10USO$7K$#.\2M[G6P"*<#M_@) M)SM\MPZRTDLS./CQ$(7"ZO0#UD@8N;)#E;)T5!;/'5Q@8RVO\7.Y E40HB\ MJW,5Z,3+9L]5I!ZD^4V=)4TE"*OU#2B-$YWO7&D]_.IL:2I!T-UARI@F=(?O MG&EDE&K6VIU?836\#)K,!'E?7[=RUVI:6BH%J\5U$"5W@^J$O=Y[8'Z[2YX# MU:EAYU=8+2Z#UF_IB,L BO)M@I U?#>KP.H*:[RF .!6B+;W@;&(8K(2_QC4 M2_ RD^>,KMJT*;*L-6'UXE#80O+X*$9_"#;;GQ$IH]E65 E06\5X3DM.,0SO M54L]6'TZ#+3@!>7:>[$)+1U^Q@U8/65+5PQ*("G@J0^&6".F$^:AQL^07VR0036;_%/-S2+H%^K M]9S>K]-=3CJ=)AB-'M<%QHG*9&F$8;6]!=)^9[Q_^^X'0%UQ'278NBNZPI"[ M0HI4TA4_^DZ21!,X:;9%@@2L1E?!4V6J\K[#H4"R-(F6:D,OBL!KHX G>=&K,(;2XRA=GVG!9ZL'JG6&@!W@?86S! MN <@(=OYX1OH ;JP^G0X<,$%$E)M!'AOS<,+2<7^8T?_<(8?U+E8%)*P.LT$ M4Q%?2;N&:R"J N#=T;-Q[XZ:U*#UU@#,BG='S\"^.TH#G[*(IFUN)=)2])Y& M%E:7F8&*KY)6&JB3( S W8G+*'B(XJAX$?JC+P"K$Q3H%#7GM]2S* MMVD>Q(L5?XPH%Y=\?0E8K:V")U[JY7+T4N^62WII\,6R2,G NG_&!,++1?2$ M6VZX.QJ$J?$M#E&&U4TCD LGQ[P(]/Y/Z/W;=]_[/?8OJ[..LN)E1 <:]&#V MG1UH8QR3[WB]N^4:A[L8+U;TM>UH%2V)&9XME^DNH9F8;](X6I*URSW=I(L+ MN0'*L'IQ!'+QPHWNW?*R2-24B:I"$=%#Q1JC#&_3C/U$]*,T]&*"M?6_C!(\ M+_!&G CMU(!U^A#,XK%S@E%$!6B_\G!4"0 $& !$'0K%40;UCP M!GH&U%'-% ]>MC(+9'*ZO#'#5*N%?).D]] 1/6TN@PAK^V73Y:<@>X:@&/^X M_D\A7H+(Z8@=CC0M'3UXO^P81RMO)I4CENVA'UCILJB:E+9J537*YKI5Q BA M0;D?(?_"JZ:]*-L=CY_RY^FRW*ZR3XJ:$+1$W\:>98DD' H@%RN.?P9@)@S2 M!$W!#[/XM_@^OGJ,_PE_?/V!*7LRD>+D;\%J'?$)0/WTVS_N?_KYZH?*I&6U ME0G,RC((?3Y>'*!&QL>*+^8)H!]H I=["059Q(?04T]'V0*5#MDBL6++'X M,7_C86%J4-?7WO>@YE\Y-+@XH9Y;#;YK16_KK5]-SR17Y%5]^AH#=\]B+1]" M!N[QE6O !+@G]8^Q%H:5N@_EU>8-J"89%6Z'*&*U"9QGJRG,2+8#*!/S" M-$=ZN&>0@-.?&G0-(39?4W32'2U&INR[H'GI:@AS$[ M.'J7(?A:(T/$ON LR*2,Y!<=_4QD4, %E2SR+,O M^&20W-507Q:6J'>B0DL!]NF":_)+#4B*?!DEK]:N(2I+3?+;.C%A,9=JDALR M@6Y.N?SX\UIG TVD15%\LV(-I/!K$H9%FG*0O*2,B\3BH_P:BA3& 8((W#3R MHG /L+;!HK8QT?15P:LUT)'=T %-2X&&L-IC/[:W#U +RLV#12$_>U[QC3F< M+A^X6,V+-).\Z/H\]AY/)S@M\0WBU3ITRNM;=<$*#S%*\V\F/V[RZ:4 OZ5U M\O O2=_K>8 Q<%?!)KM /_-+DHN0WV:?P?V,+:D.0Z,EW5$\M^_#+ !-N^*Q M1&0B8T^("O,WR.4DQO SWS /..6'W0'#*^?+3_3Z[;TF<9WFB+K3IVI65#1 M>@*\[9OYS+ Q5L;A7%2U@TS8*LU)JU$=3H*67'?FOV?Q-'NDR3P23^6;9+49 M.9&+**C#/=90#9\QHDJY?KY,:TD9JV5!Q*O%%L,NGLIS70 $<)/O\]-?)YCP M\W>O 1GT;RYBV0]\M%M N"C_\9@&<::26J]E+&F"V.PVRPI9OP__@N?1NG$YVZ@"8,M_W30L62X$Q4.$*R M(7_3?*!2A_4^E.DM9<@95KWU$W)&B>S6[?HZ2.-IT9%,VPY*2Y%Z^;02SS0" MNYTQ#BCH+'K.MGW@BR+$#M["?Q @/F%6W 6898?CT %+2S#]C-JKBL; F21* M' SAN2>GX?IMS3$+_B9)EUSD1=O)KWY5E"#!P M\*:SV6_V(P>>ER^0Z4T3W"_MV-OKQ2 FH8'LCM[CB\J'V_1F4%8#\CJGZO&8 MC)E_%?GS-6 G*Q&J$\S6J38 EYA\1S-^@+V(H"H8K+^_.=[OA!!W","%Q M 71P MZ*C?!* D!O\.&N[5?Q<0K<'OX-!*TI>@) 9?WZV6*9:?\*I1BVUO@:,E@FXF MR5^WU.RK+, !PK 24JCC4ORXJABJ>FR5B1B6N28L8+[I?9I6"\*+1$-YKAB9K(>15,B>-O2#+)LNM?9-4QDDF9T^?'BP_);ICW;8N ,-6H+= MO0,[AY'EAFB.CSN"5KR:AT_5N1 =9=A'"D[[DIUK;:SMBZ= MF9RWVNGU!&R6.=16:]>')&5%+/(?6:(:GJA,JE>>8O*K9H(M"OGP'YTR#<%5 9X/4KW\>F=SI^9%-\3RP%=J M&?U4+9^X/F>7_$G$L2NRH,GF]S*_#C!&O3,N-91LITH69K!F6U9;OLKERF-] M!T]'0$<3NC2>EDEM%?@)I^Q(SKZ76;K;L!QC8CXI3NJ.HG(/)_^?LT=5@>LW MGH8BP]Q3#_&9H_7O9>ZU=[TG1JOPU,54:\I@@KOM438"->54^CE!V38WI:== M;;9HNW0E>]:BE#M1H:5<^W1A3#Q2WV)J-;3^[-J\?WK-F]-K9S?SVGT.X8L1 M6@KI>13V=2RT9=,N1>U8Y3OT&!K/@4_C@4^;EX"T-+.'2_)'H[_ TCOTX90. M6%I"Z6>T*1?$H/842D.U0%.&S902D)90>K@D/U,^1\D\B"Y%_@UZ6< 0U4NZ M).FZ13C#T&B):A3/3<$I9 ;8S*"S&CY# GX?=X3U,1?_E;W_PDTE!GO7IP6. MEJBZF=SI-'A5(RDO$ICK WX>Z^#SO(I6S459O-TUC6>!6-S&_Q+QPOQN"7$< M.BW9[L2[PXZ6#FEY"QVOMTGWLOP%Y*YO6XG_>CJ_T;%E3_JH$XJ6W+I8;'L1 MAU<9I M?&:2W<9AR\']N8VU&ON;P[]5ED G;.G8!TQ+' $Z;4KDH*^X(C:R* M.DATEDE\-D<"?G8GP"3 C,:-DAO>5>:J#9"6@'JXM&IF5N!LR;GO2VWWL'"N MBM6= !=G(?+- Y>%%I3)_B5.J^?)ACUYL"<]6J(]3&>L*P^**HL,69B:)5V< MJ46-,K'W"[3!QSVFMK4-O]$2H\U8VSJ&>UY^;*+]Q&UY\U(6*M3UT:LR0??! MGPZ+N1,96M+:JP_=ASRJYF-9$ZFL1(IA ]" B;< P*QZ+MAST6S'N\>*=340 M+:6PAJ&1%WH[SY9!U?+4XM4%!\]'J+7]_>$BM9#("[2-8^O5P K.R)*8#.W= MV0'3<@@2+1F.X'C8E%1B-%5Z/0NQ[-7U6\Z!L873J7%"T1)3%XM6:%C5[M/ M_GP>2[WJ_.\THWH(T!+;CMSO-],(B/T!V/B)3Y[I MK"&=$:)JEZ0H@M+MQ!<6XR0WX9^??6OO8JLO=IY MJOF6Y'P6;&0*JKQY>HOU<_]=Q+* )M;-JATH6X(9A4U+9KNP;HD3DR76BH@I MY*N*]QHZK6^%W&,B+E:P]EG*W#"AJZ2UI%4XH6@)LXM%RP%N?:0VZDS?K M'.]::[O74;X(H2]%A&\H0928FL07+,$.GJ)(L9_VGL8 )%H2&<&QM>-1H;(Z MKCQ3J[ ]A<+E 6+E=;9,F [8/W[^(YI')Y/65F^V@^-^%NV(J!7GQ!(ILH]/ M0;#^ P]Q&P>YH&=?GT%U,-2[C?%%2LNI'H_]Q]^\2VT/IJU$+4"?,/P_JU%1 M:?N2T$=YGZ!&RI-X59G[3_(EN-PEP2T 0D)R\V69.PD%DE!P7@?Y"P#VC7,% M0VZH':RUC78%ZG7 VX>9W.#V#*FG830/E C>92%L*$+#V\&<5?ZS O5M,*ZX M>E!(YSAV6XY68$)BZ.>Q*0V#P30* :M24Y!NB3@!"4FCF[_.>4%)"#U#3W/ MAPRSIZ&5P89^25Q5%G"-L U%:* [F+,SCRO0'Y@"9A>YMAY X1?XW=QP3G9O5TO.L6S6$IDY;[7AT:HBL35C;!=!N6^FPW MPTP[_DTGQK.#9GL?#B$=&,QJA^65 ;H"]R2D\C@=RP+'F7N5LX (B:&=-RNS MT4 R ^I[S&%&)RM^EV3=HUZ!41QW!W?M(Z^ V0<$_]'3\%\OESS,ITN3/Z N M1>+FF4L*[="$A#& 22M[0J+@R6V91_$@2WK&\@BWB M OC31C2)LTN^3%*NX!Z#-YY=O^5ID& .6Y!N;G.^RH;[YD=LCI!JG**7]C2O MK74,A-X\M(S-($6F_S'*NOA$;=P91ECGF^[2&>7] +7:ALS:[[):.)$!+S[KSW M:@-QT3>J YIKL[*X8+V*(!:/"%UB'T6 D,AWX[NU,*(FPZK<8D6)3>O%#R4Q M7TDJR6J=\F=\(?E%NPR@K-,EK!"'VC(]7([JM6E17W-2D,DD+J-Q6"M)0 M'"KYJV-8=41HJM+6!X/](\B4E4D=&+IY26VJ5\ QYSX;2TI- "HB:>6KI8)/ M">@MCZE>]+!6!59%ZZ$((O5C!JO\#0_RQB7:?>@0LH=[L6\G1LTQ##/4)JQ& M#[SPDB*K2#)-T\N5C,6_"YWB_ 4+SEHK_&/R@$\1AR+B6Z'J8X+''K,T>1$+ MOKC<_)+A#;KRY.HBS,6+E09THB:IV(,3]M1*3*V:EGNCS.5437"!+CE@]@8" M?)9)\H83-M^P#\@,$_&/K#JFK!CR=42,3YV@ZPC<]I[-M (3LDG]/%J'QO*U M%XU"Z'"FX:1QIEF>@V'^FC+47F^.V)TOUQN5/3Y&\$Y4 MTI+NYGB@:*OU5E&A)E&S?N@:%Z#'\$M:\$5/BOYNE$C+>U0'QB[/FJB*S\=B$Y+X#TZXCU/,(>*IZPK)*#6;BY- 3W&5HM]V]2(2D.9S7 MIA!GM4+)&I=5R![W-:]$MDZR()HN=>49RVFV(*BXQ^V,6?M?34@J$P2F-+Z] MLYD!NSDL 7B-8-VL.#(>F_*4Z6=ZR-PQ5"9,TIF4ES D*5KKFZK8L.OZYL F M)-X=F!ZYOI6D_*]O#]P4'ITNL>YG>53IYF9,ZTP^&8%/2,8[L>TJZ"3]$KNFDZ+$'&&\1SFWR8^ J72RXQSO MWZ_X,BBBG-TAYJDK"O;H3Q*)EED(L9Z]MGGM.W&3@\.(=D.9G5(+%[A@D@1VY/,P&T2.;\3+]Q6 MV#:9]>$0DME@5ILR4X@?):9S&GJ46;,GX!E?O^E4?F,>W ="_7B$9#>*7<=5 M\Z;(,(#X4%(H#:DO[U$63E$%ZZ_D8RW*OU57?M3O-TGZE:LFX> W2A:FS9#)1,WE@_?@IPFA$F.9F8>FDU9G2^0@[L,,V/3 Q5'$WT[<'WJ^2- M2Y>?,?\>WXJ_"43Z+8@*YY8*!;Z^KZDQ?#A(S!KK$JYDF"''#%EFDN=SFU6Z MI[7[PT=8(MH:>0_ZWMNW(RAOJ9Y;U[[/TZSKOER_\304&9ZY'$\!K48H>;Q' MZ]LQ%;#6ZIDKX#=IYC%SXFW-\=F/QP1_.HEA'-KV.U+7T5T^IA8K9E2RBV8' M=^*^R7M3[\?&UGK2\+WT-.:S5(2']8['-?T^'8)!/3Z9FV#YL88?)ADZ4]VN M+42GUNV!3;\CXSVVQR?S0-ZG;O>OE:=6^?TX>DN"K0,0+K+!V([(PB'[C@=-AWYL M6OQ 6+V-AZ0GK"(^8=LIJV4#^$$W@;^K1ABV0E]W;F/D\_$UV5-?2CKGJ2,V M^P?0"[Q$AV09T/7]L, =Y@-F-P568;D7L5@5*Y-]<57PVQA81%:[GQT82H20 M#NS.>_N3!8K4A"EB3%,S*Q%\ ((H>R IY>_]58G>ON.KU@<0?TGF+!7 YOX M*H!$ST,);F#8]]>!DLHYJH#-_/X:@#3/1 '$RP&,0$GE+!7 8OX "H#E),] M ?:0^OF)>G_YHG@= JW_= =_@Y_-3_ _#%GAE_\!4$L#!!0 ( %4X=$L6 MZ"&WR% (H!0 5 ;6%R82TR,#$W,#DS,%]P&UL[7WK<^,XDN?W MB[C_05<3MSL3L=7UZ)KMQ\S.[=T]/3]\D[#%X8NGO MV3__#M^]&']_\Y^L]O1V<7U]\\ M3SDQ9T'.VXE?\V8?/O#_?'Q___[]CQ]^^/']]_\/^-$\R(ML\]'WS]^___#I M_?OW_UYV_VM,D]]_%/]Y"#(RXA EV8_/&?W;FQJI3]]^P]+9NX_OWW]X]W^_ M7-V%<[((WM)$0!62-^M>8I2N?A]^^.&'=_*WZZ:MEL\/:;S^QK?OUM/9C,Q_ M2S7M:S/)Z(^9G-X5"X-<2IKQ,R-E"_&OM^MF;\6/WG[X^/;;#]\\9]&;-?,E M!U,6DULR'8D_NL_SE"4123(2G02Q M8._=G) \,\U0W\OMW&Z"E/-F3G(:!G&_B78.,?BLQ:HD L=L,ITLA?+B^&4< M5*&P4C+GC>@CN>3J<4' =/09U"EEIT$VOXC9$UQFM+V'FNLDG04)_:=D#^?. M&B ,6<$503*[ M83$-*3'.W&Z4H>8^#O]1T(Q*B33-L*OM4/.X3/A.,:,/,1EG&4";J=H/AFG. MPM_G+([X\>2PPUIS/RD'.5L:"Y7(E2@4CAX,HPY/6W.- MVU*A[^].4\#F:>IW(*T!9*K-((<\#YR1/*!Q=AVDXECU:#R4[3/F8361+67[ MC7I8VMZ*JVI4Q(2?)OD9N,B#"H$@HZ& A<9%3J(KEF4W)+V;\[-_-?%AN+#_ M]UVL#2OE%M[5M:T$6QN.$"%-)E$-\$*YN-R-'G/'/CB@09.0PG=)]R90^RO]_ M^NOFNTQ)QOO*\\45_\%.%_+,]^2(1.N!Q*SW?B_B/Q:CO"__]V'T=K3N5?\K MWU%&Y1"C^AC5W->SCUFX,^%8/*6QU,0X\9[YFVZNXXW_@/_JMG,,M MF5'QZ207SZD=,^=-NULV)UJ7B7$:CEC*MSR.V'K,( UW)*']&EFU>+>43U1O MPSF--T(T3=G"EI45VYB!D#IW^10.#L$I)R0-XDN^9I[_@ZQT&+2: D'X@ \% M!=4^8%C3<<^'[>;^;@L@TS]B8GH7C3YY71YOSY-(^(#HF=YH"N3^MQBYWTFU M#QC&?#:1F-%%',RZV=]H F3[)TQL[Z32![M+LTQ^0;,PB/^+!*E6\-6M@2#\ M&1,()MK];;S2A>Z43V7&4NVVVV@(1.'?,:&@H=CCR8??L%@BK2#R;:!N%M(> M@[3]@/!\AP\>"#]\;MKE&BXWL0O^LTR_<7+\@XP_OJNTVCAT*)A\!'=L65\'+T=;=P"^=]YWXS%-.(_B4:;@4;5 M2*-RJ-$??TZ"(J*\S9]ZF3?J,C<-L@<)8)&]G07!4@C>=^](G&?KGTA#2$T" MJQ__MIGW9'I!$SX_RA<(*Y]2-=:0JCNL]]Y+JC]YY:N3F9!F.U^F$2N^[BXL M!27#*[A]T:B.DU!06LV]64ST'.Z"04$J#C2$][(PB_,_Q+/68Q!+0WE^&J3I MBI]79#R&&AU@=V^F%A 0K ])F$"\)9PB&O)=9$\XK0?R9L7I 6Q/+N& 6,RU M.=\DNINS-+\GZ>(R>225=XA^L4+'\&8GZKEB[7A3PY03-B7\*]%5R2_E].7< MWDS2O5 '$(_CG5[S7(BI/&* M!8DE7("NWDQ8/3 #BHL;G_+M6'QUH8/YQ;FRE*RQ+0KO[85+CX;U315HY@$.M"YH0G-R11])U.%D MKL;+U ^*F&.C"Q@Q&!]P8%;;3[?TJ:%2-(* QS:F\CK<#6\QG;O@(4'R=77+W>$2SY1,.[5F;-?B-3=<'BJ"S.[$U#$H4 M43_$K4V:-\%*F,4XJ?PG:<%52XL LX47- @466<79 TW69?"Q[A '>=2N&4 M+1ZX%A(/-3 M]('B? A;CMWKGY8).):D)4[[0?3M(6PN\%T4B,ZQ'VY!:,(Q/(359<^#ZTL! ML<_[U0 O5M\>PES3!^)C>:>Z60N;G+ A+J6S,10I9Z8;:VPT-., I1:Y;@K\ M:K6$PN',;&,-AXI:'%B,HTB^4HM\?#2Z3$Z#)9+M*%\C,F;+O+[WP;/VU=9N("B@S@PR]H#VXQ4.H&]%:L6$ M1.=!FM!DEM6(X5=5&E+-40/2%PJG0R<92SCA',&!H+H8#>1P"$?(F1EE@&/@ M2SGP?Z$)2V6:D9QPKK]T2BJ,S,XDUCBIJL:XKKLOC(I*U)5+)U3Q/Z4.1 M"_/[/1,V!);DG%]\*C,S@D.-#XYF1H/[L)P]]C5ONA.#S#>*GE#9. *;CI8W M@\H EEQ,W64P=Q(S?;MO8J;1'W>^\IJHR3UY]_IGZF8[TQ)N+0!'.KZWJWF3 MH'KL(P8\^/(EE_RO&CMY5UMDN.Q(E0J!VO3K7K 84#B-@RRKRHV,GRD$C':7 M8\2D344MO9=/Q: MV;^0Q0-)-4M%U\EW>BNU@#67BIET'#?&<1RS)W'0NF#I&2L>\FD1M[/YF -= M[(;!DLFQM8\VS:1]N+,OL(H2*8"4+Z*VK)A;!TYB"*L1?"=T-&-D31*J=5>W MT'+>\L.IX"S_>TRJXJ_U\H3*9!>@5XP]O^ [6R1\N0[,5!RBHDF;42.X3IA: M*/J,Y7O3!Q\!R;0_? M:1AA# <0[8C=77[]!G[KN_C.H0AC.(1L'-O'[AWD)D@GJ20QDCXVZ_KA4%\O M=7_?Z1/!VX0=0S""6%8Q&1?YG*7TGUNCO0F\=C_?"19[@J9B %ZP+K.LL 5J MW<=WXL2]0-HE'"] H,AR8T?O213WP@IM7'G-,]1^ P-U]IY+$0R[.;C+*#5Q=T&0JM>?+?MO#\V&7@=\N3?)0.TX=0_?#UMV M>)@HQX//9%K)CAZ46C/?[TI&WK:A:!&)@__U-XW)M/GXH7DC-/3S_?1CB1", M#3@@NPH>6"HRNA'Y*E51J(9*U=[W@Y E1'JRG;E.L"G),AG *$]BB9SB'4D? M:4BR:A(G)"'3SMBQTM/ :@S?ST906'J0AFD5U:=^073GL79+WP]-EBM'12H. M(#YSZ4BE^(RC!4VH("7G=P^C7C-V]/VN9 D3D!%(4*L*3EPNE@%-Y86<99I% MI&KO^QG)%B,MV3B@VBBN39#!_#]O&0)GB5C<*!9F6>2V9I( M-6X=3;V_*EE"I*3VV.,>-X1M4R0 @*PW]O[.U!?*-L5'#Z9P4BO)LC(MF?IY M?YVRLS#!V(!$C59^A6Q7*HV'3%,_[V]60! ZD#-R P=RY],I"?F.??X6 [(P\:S0KHZKU 62_2Y?+% M40^AH2L40F>&E]X0@GCBR(8IOC])+OC51[KZC*._%^6')]/3F,E$)"+[$RM4 M!DR; ;R7B;.#R)8\IT!5,:)5T99)*DNVE*1,THJ26Q*R6:+P@!*CV [BO2J< M/6#]^(1#06Z7?3EA<^8D=0_O9=]ZJ4,3![#@5,[*>$%H-?1>D:TG*IWT'O^A MLL>=;__KGKMB;;W M;GI':5!9FMBNN ,*PN&%)S8K6_;"9FRM'*>NP^>Q=LD MYQB'BR9!NI*.A+8I[9Q^U'NMN9Y:Q#D.+T-4.>E&WX$=GG9T\%[PSLY::"#\ M^'<:\J^/9X=S#K^A;U# M.E &$-3:VP/?E[+"UUG-U^%M)T%&0WZ<.:-Q(1)Z&%_LP -X+[9GA[8E8W#< MR3LG;8D=@D)ZMKP'((<;IXHP.%*;#MZ+X0V+58,1.-%JD"CO@2(_2T'M=O4%UJ(EQ.-#_E0CC.9?D1WY#GY'K0B2:G$Q;(9,&76LYC/?J>_MB MQ_:A?L^S%9K2IWW.Q;]]1%"8;UCT6_1A6M^0&DV<#91%_.YL M>X[MO?1?#Y>W0=B)6SPN6,IU6E(FA M7]VF09'SR929,^:]80K3V;1BG-.,K MZJQ(15D3R0!SM;2#?-Q[,<,!108FBPZPPR&L';2N)SILL:+!/^2];J,S(72$ MR;$;GC1L<2::PXJB6Q^Z XOBUV6OUC"BEV AJ&OI0VBJME9'+PS5@XZ]II82C-=:6A[P.-): M6B+VX3+A\E/(:[NVB%97VR-"H6OZ.,IF[<[L.E@04_$L=0\<@*C%2@M*G9 ] M*V@I@@.^D"@GX5P4JDGY%K^<,Y+09V5-+-%'W\5WAB:3[-0]_B'$.PK*N."7 M5\Z93*3KK[+U:YFN:>\[LX\-QXUD.V+W/?\M.4N"A%W14)PRH7R'=/2=$,8& M #@C'"$AUES*$AI"$=!U\)TIQ%;9Z EWQ/$[*HX"6;TPB);AFO;>DT78,-Q( MMR-^_\(OTBR%\UO3WGL: !M^&^EVI5$*D6,GG-_P,V^29WIETMW6>Q"WE2+1 MT>M*AYR77],KCD8C[T&[5MJBDT*GQY'K[2X,.(-TM/8>J6E_\E#2C.,M\)KD MPHQTD[)'&I'H9/5S)FKW;9(.C<.7+?SRO>9.7J3)T%&['%RI1S>,Q%ZGX0T)CN3OV>#K5?W7_:=7WPP^3D4 M2#A$LEZZ5V>"K+?R;08[&$)-\V6;53A ])R1WID?F">@#Y/97G%\;C[&7R9G MU0.Z<,I0 2JZ@GKZ-J@>&E(P8UJ@'MR3I8] 7-'@@<:2 WVD8J>[[Q3MZ$2C M@[DX]#V*E''.+!N>M'Z?G'-8=$25UVLML"N%+F@W\YU+WL>:5S'K^+T8==G: MSY\KU^)U/GZUCK FY3#>T_7[VBSZ<-N1A:&B^S1F(H9M7:)"%/^ELN*5ZB8)Z.?]3=_'>1+, M3QP+_Z3@TR19QB?X0!,)39EU<,:Y)J(6."O2"K%4Y,V7W#R5*?0OD_&"%=(A MO;O+YE#]0:TR#C8![V4+/"F; R.,0ZPEV\1RXPKUC!4/^;2(QV$H:-$G%]3T M\NXZXTF (+S$@?JNDP875'Z&SL4]K$R5&=(@+G\HJ2%!7J2:,*!^HWDOL>#M M/:P_[Q':T':Y>-J.=MV;GXISU2$^[-U=S2B)C5^>KHXOW M"AF>5**1B\]_HLR!<3 MH8_ZT&I8;^\50'J 8T)7S26$IY_V]$]8$F4W+./?^Y7F\U-6I!:N)XK>WHN! M],?9BD[_.+M:^SY_)XZSO>-YK>SC0#S:;<3/6CX>AOHBK M8PB$D\?_= T_K:NEQV8,[R5)AHR;<6[UP)5Q4$%QZ?(W3$"<=BSO!3#V#8D# M< K'%9;K/FD+NF?C\!\%%=74H#$2@*[>RV/L 0^S)=;_D4-Q@SVCV9)E03R9 M5L'CBKMJ1SOO-3/V!U!!F7^T'"U@SBJ^,>6KFSC@Q^$D$M[:2]'$8B5KQO!> M5\/=DC9R[OBE!\Z]T$/@!4V")!SF$*@=RWLUAWT/@0!. MX3@$WI)EI0LGTWHB'S6>ZA[>2R3L 08#TOA2=@/.HY"02-97WOKA"O],EDAO M7*U[F*FK]SH%@TD"F$\XEG/W=-=NU;:8;OMYS_;O&- FA_"A67,E$SYF,"A; MG;PGX'>"HX(W^$"$[;#J'E#X#FU4V0\^PPX[I#UD??&;) 8H1&M58R@*A[:, M6*"@(^^E'''@7!KB\F*1& :O6/2@^F5<>,^G4Q+FD^GY%'C:O=*%!Q.L23)?)E*6+DOWFREC0 : H.S,C@5&VY(FCVXT\M GOR5H) M5@TG /F<-,3KY-4 M+#B(X*3[X%E.M,;#17!#A54^6RZ+3S9H9"V3: L'=[48LO2 M]MPQB?8F_&[]9)U$F]N\W-< [[CP(<#Y5+WOV]9\<;0P;LDC20HBF,2C4\=$:D^* MZVBCE)K[*,*A+$E?F1K,: NC,(K$7 M@+T8U@'>X8M>3])9D%19SSG)9R0+4[HL'_J \U"I)H5!M,E+W>#.:#.@Q_H:+>H M%7"+;*&G=O4G8A++R/,J@^"HV/LL>85BP2F#X786W0_-1;?M M-JKZ^<_\SL\;36JV5U@W/LWSHRU'4"PDX4(N$Y67J1)EVO(JZ[/R#O?A0W-5B5'^;50; M1]I\=D<:,M";?VZ=8+U[WJ"M3$9,]QIJT*AUBQGH5I4M-0B65W\ VF;7O=B( M8BG>%0\9^4?!!SQ_W'$NW5E[']OVDW6W4=7/I[?4+@D0]RA5#Z].7[N3@FQF MZBZ^JYX;,&DY=QEH1[)6(!9(K27RP[?]+9&C/Z[_]J>OW2BIV-4J6W;C5/R_^:-K?]ACP:<^3^I [S'CR,C/Z6\XZ7 M@@!,("A"'XRK3A\YT7.%N2OL90N9%5N./S'B-@LU''I='W"&)"QXFQG@RA.4 M)2&GIRR?=$NSWRNW+2Y\GPF;I<%R3L-Q2@+81MA_.'#4IG?(]J,3D_*M)BW* M3O SY7;;!JT^8U>P]ZEW1.$T.5V+5<[M*M=VMDZV?5I/JVQS*MUC/"!V[JI& M6:W&O1GG"-#._/M6]PJ+ 8"0N2NB9'>-L&:-,X_O6*1)N G2?'6?!DD62&=( M*Y@LQ_!>U]X*J5X,PK&_700T_26("U)SA-L6A:LH4.]QP.[>2\S;[G-6;,&! M9)%M03-S =2FU@V\%%2W<-_B79;E$S4X\#H/$@33I/(,"'# M<\!0&3OZ+Z%NBQB0%SB :_K"$*])*R7BXN/N:_#KFUUG#'1U3 QA-8+_W,&Q.*_)4XW2E"7\KR&I65S "ME^).]U MJJV795]NH7 !V[INP9S![N7#;[5U9H)JCGGJL89OTF(Q[1MXI*:2=]*-0SVJ1<0)>@, M !R'QS5Y3$?>19$+1BU8FE?)02J/"*D0+$1KF*_X]I,=4JR&Y+NC:^/FJ"GV MPB!9966=S1L^JRG?<%EFE (QC/4HOEUK]T*Y%\6(SA#MP$[=V:&5"JO>_5^K M6&,,QX=C##K>[#_=P;;KPE:3]);.YK"XK?Y#'D50\KX2XM+&*.V*)ZOS9Y*&-",W*0W)K2CN82Q>WE27' M(*!0^X;(>-T>T,IQ!HB/WV]+>%&!\D/K##%UV]-Y=Z]C#Y0'$>GV +WY])<@ MKVQ,0J'P@^ ]21<5D>(] ADR ,Q5ULNWYY^?O";X>+8G$K M8(G7!?TN6#I9$A$CE,RN1.TF\Q6L;\UY[%)Y:RGF3_&9D&19QW+&HQTR]D\4!2-22PWCA@4@E: R@82=O; MVI WG$F8,S[\_1/AWUM=\!W__HG=SUF1\7/"G8A^SOEOE*"(,>R&\/TX8"-] M]Z,8[#*>_!,_B8<'$ZT8SW[?<#OEH<+J3+AP'ZNHMQ\CRW6:^DUT!6-Y% MEZL<5F(VDT2M(V0>IT8C[W%_&AYVS=<]!^^?F)F#M4;0=>_LJ@;A8(LHIQSD M30!2N-,,RD5GIB<0%]N$X5"?K42D)ZL3DH1SCM+OAN<.8\^7<9PSTUG;GU$A MN9[E&5L$M*N M9+"9D\=!ADJ MA4T[KHYX')KRGG]@,AT+I_*9M&_JU:.B^=%&LZ#VMG! MH*FT?:!0N$O$-X2R K#%$22724XXRW)QL84!HNT!=J]## > )3AN^JJ*%2>K M^F\,K]H68[P,FX -Q;6+&!*<33;2KK8XKOOVTJH!;B"+J$(I7@>/=";9\SEE MQ?+JZE2K$=7-?5\LU9)35W@F:1!/GA*2FHQBBN:^KYAF1/3S MQX3(>#JE,17DG'/MFZ^,=DI%>^_E3\"@Z"EV%:]/8BX+P@N9WY;"*GM;.$]8 MS&;"F#=O5]K8.K*EA^.8#F-69DW_\:$0&=+[Q<7&+,U5#J[GT<"SC/R M2&*VE [Z!OYJ>WB_D<#X#* :A]*_%_$!D^EE$M%'&A5!;'A>[&[^,JX2"N)J M!5\Q 27J3TIA%*?N.5W>LW(3,UTIK ?"<=_0"JH)2!.);NX=%USV^+CC)+I@ MZ8*DIW-*IN?/))09H2?\\!%J#K[R^<%F!-^WDYX2NO/<8L\Q1]O6?5IDN<$I ML-'&]UUD /YW4NWL')QR?7QRRI)'DN8B_>G-NA:6#,XSG()AG:%/\\[>Y@< MQ8Y1.(X5FVC,,CI6)#5DB33B:H\7AFXOXYAA(+*FIGW6VMR=F^E0H6B.X^@ M$L9F?;&TMG<]W:EE;"6K5A#L:O(@,TW:Q'C^B ! M70]P?+Q7?AO):+'\X 4L50E'EGKG2IEU8[<-]'#@.$DP )).XG#L]%6^:Y,2 M:C2#LMY9\*&-]NDD$0?WUUD198F0C$KV:4]8R@XOXVRE)*\668D,KK*X"S&= ML !=<9RV#"() *Q!EAOCS-DJ"18T'$>/01*:GUW4S;T_=X&%JKZCF,AW=*AJ M?/;RIEX7\RY(Z?2$L@6)^-*/;? #01%RMFF,P12%BQSY6.VG<$OG.8B-:\> M?1EL%W7CD[&R.93SSFS&O3AO(M_M2^;GQ<-/D/?+>COO MKY:]^*PDV%7.R#2?LYLY(PE]YKKM_NKR0G^=4[>',AS7IFQD (Y+A\+UKY=G MZDNZ?&A)K"3N>]^FP\XIVKBA=G3#\#Q#X5IAVDTP[&C=(A1-\/=[A@]LGQ9Z);D[:TPJ6=35NDRR/"W,26RZVKX,!=U%&9*Z/[M3NPX6 MQB<)=0\C\?+N@FAIDV.3U;J,Z/(MQ[%-BH(P032.8_8D1(K+V1DK'O)I$5>$9K7FBB2S?#Z9;I(9*>XH'>V\U9_8 M[ZZAI-A58C.2BFS2D^GGE&79.O.@ZH:N: SD]?!7]/UXK:<=QY8C(Q(NLZP@ MT5F1"LI(2EDD:_?5/2ZTD6;@(;P%RNRMF:SYY,I?37SP),AD1(G8"BO>;3*Y MG:RV36Z"E337/05I)/]3F;XKP0QFY(*F63Y.$BI*;@;I2K$PG7_57TC/?DO\ M0' .S_GPW4(F3$A <>T\9./2%Y',672:/?/:"'IG42X1S M;^E0[ST60_AS6=][\[%FE*O#7#,1J_(@U]$0RG],QB(5+4ZYO,%UG6[UE"4Y M)Y/WG)6_4W =TM%?@,!^*,"9X@B5#B]D8=^OE+ *$F,O*!Z8+#(@PC!M-.M9 MW;/*17(]>Y)=D[QZ3*N<)S4&-JM1_,6#[&]JZ\$N5ZD$F9PYGTTUJ9X0RH1] M_<:" HG-TK,7ZY"LVYWD/.5=N[R#:\W@RC[^ZG<,8?XVL ('9&O9XO>7!YI( MSFX%D?\MHYS%S5M-5E9ZG4Z*/&0+DOT2Q 7YB<[F:IB'_HX_#\^]1<,-RW&( MTRVABX22;HI$G16$.U%O$QSH^T#!0"; M-0;$"F<%8P4',<.P N5:S9\$J&T_Y)?2:Y30D ME]EGRJ>A0 3:&8H,-N.('7,<(U16"S+YF6Y:07F.S12B(!?'AJVY.\I7T%[7 MZZHG%#!,MA(P<2T0C]1U13BF5S>3#VJP=UOY*Z^P-[!=Y.)8B;MQ!5^"O$A% M;ERN--2PZ/KXB['=&R0S*W! UF%4+9]^UD;O2M(FJ?A3.JU6>P',-C+4^/YB M9@:[+ _#8K1BL[VG3*:_,,&@#7UF0W??\:!B@=B&TH^%CN^ '8>&<13)20;Q MV@M %5Q3OS_9#.0OS](P=T5[ICE^.-PUSVV- M&@?\CK_43\,\3@[.?/85Q$)+K@[!#^CD7) M\;X.*1J#X4.H4E*SP(<,-6WGRN6S*[$ M9E/N/C^16%2>_#G3/#< NX/S#N #T8I!CBY+(F1>E*#B'YL2*K+KWW8_ HG6 MJL;^"CSM=T72$X]C%8FD,J'( ]L=_E6E/-!>< M)-'6\K!#O( BG[-D.?N&WTK*97I7+/B/5X:$L&^WB6-W#%I\1Z AEYTS80/C MBD'DVZAL6VH(OVW-^_E_SZ^'[T=G=$LC)E(T7LIYK[VZ3EFZU!;4Z&KH^PC=JUBHFF(< M1V29W>V>?T6OIAK-< @]2#DU9EX[F/O(2<\V2 M8/N36NW.S%B.U'8@' AJI;&IEVU)=%3D2T:ZMQ(QZJM]Z?MXJUS2E[/M4PN( M*\Y"T\2W+PII7N3SEY[&&7TDZTH;%AA9C.(M?_C0J%ES;LB#:$;";V;L\5U$ MJ%";G\1?!,:?:MJ2_^BW*S(+XG-9FUBQ8_%6K48XM)Q^G^J:=ZUZS<$X7'Y? M>33D379;>.9M%]M:C-V=L9L-X4LA7-O#^5V0QEH-T]70F^IO,:>M'=2$.5+D M7X)94F27-Y\7#S_I.=G1T%L-% @GE80YXB17_R++.KGG\"4L9C-*,J,)Q=3) M6^43 (=A!+LZ@'RN?]:H!]3-O1TI !PV$8G#.K79:N_X 29(*=-?;Q7-C^'8 MH*>@5CO-)QK5G'Y.LB4)Z922R&AZ4G=!ADJ7A#7!41/CYBQR40BO\LH@-4GT M-:A5C<$A#JXX;)*:NEK24^Q(X>]\]/Z)P=E<:PQD\_!NFWNSN44Q#MU_2V+A ME7\3I/FJ?O\]6=5_H]\0;,9 IH]TNX0-6;6*C$C -.T976UQ@&,ODAK@'+^T MWMQ?WOS$8F$*4IN;Y0ME5TMOEP,-H]IJ3$,D$ATF#'@&%;5M@D/(81IH.^O: M3=PWITW/*CN-<'"[)2%=C![H"6083G^A"5T4"Q.O&\U\F]<[Y*/!Z4ZZ<*@1 M>!F&398D8TWO?<;T'-N@=G7L7;Y"Q;?C#X#HP8-KEH0.Q*<^K&]?+I'V['G,;>=\4X9RX)X.6V9WTX;*M+9 8/XEA7QK&[J7>CG=4ZZR+3 MD:V.2T'IS< U<%6D14B&L8X0H)]W"QZ,YU &X-!V=X$(J):5Y>I9KS02S?;>;;# -@>1==.%A>)J^6Z3*;1X.3U9?@[RR5B8SUNMUJ$!SZ M"*3]K>C"$4RIF?)VPI X2>N!<.#:0Y[AH'<3CF*WJJR[)M79:.;-L;POKQ5V MT@[:<:C7M7E60V@CM]3/&9D6\16=ZA+1[C7JL3Q8#L$['%*@H>"492+5G'@B MB^[9+4G(TR0]EV:G7KI9.Y[OPRD8^OT8A@-T='55/+Y#VE+D_RUK(/6_8&E. M_UDE3P64T%JK/D._HWG"A#$ \:.E&Y< )$^5 [L$&%A9+PLJO_LKS>?G(4O8 M@H9E 1P#FT$C',G+I3U34#YPU1)%*]Z^NI^\OC4_>>WF?58_B;T^A.$XRGY. MM2FAS3T]7TR&>"6#L@?ACC<.PV)1R$B#^JXMN+$YMBGT,ZRK[]O'7OC"R<1T M!]&(XS71Z"-3/]\W#L=+M<:;W@LU9WD0-Y8IJNVZ#'O4']"EF^$%2PF=):4S M>%C&>L4EU-'?BRR7GF[:S?Z3[69?SFU4GUSG&>#?1GR&LD,YQ]%ZDJ/:+$>U M:;X>&I"IH3K$576I6R)LO9$X'5]P.H+XOTB@,6D/,OC+/GK8,AG]YM5!D)C_ M_1,;2DXVPQWUJ64_TH]<&/CG-6\HO0=\X6/520N6#'81K(=S[1![D>+YMP)[DH>[=?H3R(,,*AA:*QJ"^3=.'EXQ.KN(0CXZ[ MKLP1*_)GK!FE>9P%]?8==#,$X#9\>G'6DG6Q3)$K/TA6694+FLOYE,64Z M?P:9/;:%,/,Y&54?^M=L5'YJM/W6J^W"!\&OD3^OD3^^_9 11_Z\^H\/[#_N M.;[HU7_\V/S'U;D!GECZNZAJ&N3!ER )9N9"$:9.OHVA>_J+0T@2YI"JD$4L.HO9D$<:DGM6_2E^Q<_/=ZN,JQDM9GN.Z=N<.0"D@W#5 ME?-;D!>IN-HDLX+/D9-(TFD0ZK,7FSKYMC@.L0Q!?'&7-T7H@.WBYZ*3D# G MT4^,3UK*BCY/J-4(O@V"PVE-&XZY*J1!(AH&\29A_TI?34/5VK,'87*LX>7MQ=LOIYP//+Y-0S\SNMMXNN1!^ZLASQ-*S51(L M:#B.'H.$']ROKDZU7%4WQUSCST2DJPM*51 /5.7/^Q71HL+?H:YWHB[CYY05 M90* C)9II@U:%-#/VY4/PF,HV8[8?D=G21!?WICT:T<[;_I M1NNZE-YO93UK4AY&4!E99.4*$7S0"VMW6V]7+XC ZLAS')_M)M0=1YCU82+= MSX,TY@LA/W]>TK(.PAG_KH*AJL:^W]A@C-63ZM#V&R0@[G8W]?W8!>.MCDQ7 MID;^":#<=C?U_20%XZR.3!3I%63:\SF+.;.R<[X+\+T"E$'\WYNNAO6!_N4/ MWW_\\-U?1N6 R%*)EY,R>PPVVV'P/#M*E\!NAK_Z_&$Q_.+W^3M-R49[ZAW[ MVBV/"('VY'&XZ)V1:5#$^05-@B2D0;PA)A,S-64 A?7& 9-*T!I P4AR8^:? MA#GCP]\_$?Z]E8ARN7]B]W-69$$2W8F2-#G_C?:::C>$[R.LC?35CUY]&.7H ML+N>RIR*TL5]X3+V]GTDWA29H+-XZ;=>B=_+K>1 KL M[-M=3BU$.]93*U:XLE#+29SM@X>YLV]G.AL\H*Q MI&4]V01C\D2L6D"-Y/N M;LB4&&A#Z::D=FKQB%)C;J9]1=$<&2HZB6N I" (12D*/JL%2_2Z;JU&VDU] M^Z)J):NYR:LH=>4)M?W>K\)VJROX(5V+U.VAKTS.GIE ?#80X939U<" >" M6FEL%IVP)=&1!SC_0A'G-)F-9RDQ!U]KVOL^%/64OMUMW, -9]?QL$AISN^A M-T4:SH.,P- ] .B\@-B5,#<<15-F-_/R9<@_5TDFIZ2E(N'/JQ0W1YZHG5F M;Q\ #B,[G"V2/(]+M0I<',KV4!B)&-_9,9 ='T7 M*!B8512$*8[PN&!ISCG6UHWCA73KXA3=DDR<+2,M2#W&@3X>.DL:, !RO=GG M:K-9IC2V.P7HNT!! )V1=!^CU'[.J,S/$$1*? MT^+A(8.!H&@+?2%T9N<:@/]:-CA+\E# ^-[5$,ITS&=>-0->$PH<**' GU\3 M"AQ!0@'&EB2]"IXN:+HP16RK&F..*=03Z"H2_N3L-"41S2^*1&0U,(;"J]O[ M.[)#@N%-=.)X=+@ELKS>32!<#VO;Q\FJ_AO]2X3-&,>@N'N057/_00*FR4.C MJRT.<.Q%4@.K]OELFF&:T[7O(N"A\ !FD[\6MLHF#8WNRL?G2:< M.S\%Z0-+9:H>_55!W=[[(YFUK.W<)4R,<+1-_"SJE3ZEE,]2R_B.=M"H.6<> M%'LQ7$DXCCWD5AC\#'>R;1,G31Y>.XUP<+LE(5V,'L@; M:QA.?^$:;E&H*R]4[1K-H&K&W=F^+2 -5G<2AD./? F>03S?;08.L_7(\R[" M@@D,:'$50S>R"&SG19@/;' M 9^-H%J"BBIZZGRQC-F*$!GP4L[,\,;M(I,TT X M(-2*HPE)$XF.3"LT)2%O/)G6DA]G5S0D228B!I+H+D^Y8!JJ_=@/XUT_]A36 M'7-,3^:Y\K),@GB5&=PJ=]MX]QT; (5.LEWYB<\IF6[K/DVF4PZVWB:F[^+= MCVP "!,$"8@N/\5HLPOYMS M[F3C(I^SE/YSF[A5F[J@W0E];FP($4@AN@G222HIC'X)XH+8?/@A6.#H=<1$+!FAD_3]5T]Z3(LSR0OKB*(R*DH^^\ M?+"T^W 6(%H_TE09G14B")L30%E4:N[RYQWJJP9 M5 -WN=:J5R73E/.7D^<+]H%E1+;U*QB!N!65.T'*23/OA^H>OG-ZP,$V$(UZ MSO\EJQH&"*(S#]1]5ZR>/:B1+97--7F2O^JKA6O]?3N[#Z-]6PQ! F)M M:X"J3G47\&7=/U8FNG' 4^7SK3+33=);.IOGZ^)IVR1!IT$8SO.[#W1)5PP\PP/$0L$.?/_"!/,R(%>?/+#04?+,7 /!P4?/\VGKWX]0(. MQC(=?A*M252<-':-*;7VAMU[KY&])P:SV]@'X"(.%:([T,][_(O%:PN$ ZC1JLHO] &LWA6*F7_K%)@/ M.&"3LY-'!,-=J&H#!0*!Y:A%F2N'F.[3UY*$'.Y[DB[:AR^5GTR?D:"(>#0# M]:8-W4HY"3(2B2SK),DJ#F\R3IVLMDUN@I7,-?@4I-%%0%.YSXZYWEY(1^)L M3?@O3'BUQ.)EJ+OH<5V877_<>W( N[5]&"QP"-]FWI?)LL@S46U9!'#JA4;; M">S X!UL .V'U.S[:_0]-?E'C]8F:YHP+:+.B>N?PG4&ECYOX1^1&HOPOH;W MU?2EOX7(SI,6,D/D))^+NJ)!4L;R9#62?R6"!R0:\R-Z,".W1+B5\I_S0[NL M4UX$L9!OG;T US2ATHC ZH2+<>A$_\',FHXC7D)*"2Y]\VZ@$;5]4#^JZA]9/\%ZZ(Y[$\ MOP1Q+&E77"'=?,I[3BK87=,EGW'H*YU%2FS1 /..LB<49/\>@E NX,"LMU16 M:HSOG%-"\T*\Y56ZS,%11?YT@ M+;MG7)O5?W_*LOR:Y?]%\EL2LEFB#VYS^$GO";' @N6<[QWB]==W+:;P:?Z^ M_FWG+W=&(\^YK%ZU_L8.Y\19)9^S9#G[)F2+TDFK'8+T]JY8\)8K&0VS#))5 MW5*R4^F:7S!/YV*99767D3.2!S3>__RQ^^__CAN[^,RGF(7Y8S&;'I*)^3436??\U&M1F5(XS6T)&_\D,F;MF85-MIY]9;J2KS3Y1:UVPY'SIENAK<< MH':GCB1?D%I=:;A?:XL# 5#BIJ[IUU\9,:#0**.>Z9-I&;H=(S;=E-3R#_@\ M*>EJW*OT:ZLY,E1T$M<\L703Y"8KUGK#U2:2:3;RG<="*R%UNT(W=3@N!.Z> MQ#:GV=(ZXN,YLS6%8\E6L=E+,N O#Q(",95=EO$FG$:R_S=)\9X$\Y='"6?!W;=F7"U$JC\Y7=,8FC2:/D M 9J7+I.E"XI/@6S.X'BR0AT8E)11TPN^/),H6"7:_W?OLK)LHU8CW%X\GDA8=GQVY:Z".Y M![I@#R>Q'OV'\/#JZSB&UQRM4"IEN_D=69(W!!S[.J1\]XJ-4M"MIW@\6>X0 M,>WK$/>7UL,@@R.>'A6,8K#4'/Z#WB!L^(3.:).ID^E@G>P3IZS"S[TAO MH'*MMS2 3=(#MZ!8S^\($OHAX]C7<7AYS?"!(2$B,L;M>:89(.GQP15^%1@M MW+^]^3-USN%(4A=Z0<;1L:*Q4#;'_6WNKFHSJ8=\J;R_^XUU!&D&]Z!.B1ZN MV+]:5?L^<7[?]XWS*Z/YJ@^_!O,Y#69Z#>;SQ?F68GD-YCL<"G+KO>=?T0?O M-9H=$>\;,\<1G-<_M\^6G"2ZB8/D.E@04VR?FZ_AD(%.^1TLDY*.?C>1A/6C MAC::L*NA]Y@:AV*]<\=0,NG(K33MN[HS-UWUIUY\D*&)RU^Y4V&GC]GGE&4N M#'ZZCWE79X>21 VK7X9".W]>TE3V.4 .K\Z/X8\'=$G]2Y*EH\D'=\2A?%;I MX(ZY$**J-F_]A+E.E:H3LQYC'4\(7F]&O0R%X_,T_G4$Q^FHQ^!6A4,.:^]? MKN6PXU- *3SB)W03FU]E$%),P;5HPF?P\@,J>X+R*L@Z=YBAJA8,-0'\P6.' MYLA79:7[6BMP'$.PF-,*',=ZK=Z7:1T&+$]2;3V3%Q0;Y@BE([$(F*CO,(QY MDE'KF;R@P"Y'*+T0&5W3YEM"+>A(I/.%7+]L0F$16.H/QY17 M2T*'O="/*(,G< 2A?X=FR:L8]RZ3>R#IWG=>7T'LWZ (OIBU\&#FY(/U/JB* ME?QH6 "'GLP1! OZ9,\P1VE=;.I!*3J7C56.XMZFO<[< ZN7(:S61R4/,CSD'*&BC>1A @G7G#S)'3ZR_8P\ MY)R9"YI+HZ0(8.>D/VXO 3@S[#\T8=C'JOXUJXY;Q MZ?61-S'IH\W@_:+3%0EBK'Y#88B>/JZX]?Z\5K@FOX:V MOX:V*U"X8LDLYYINJ]CC@T F6 13'P>,D MH2R](R'7G)$XQ%RSG!C"R+5=?$=@ZN5FYQ(/(-V1O>=4I(E-Q6 MM/5^]80S6DOM83@\2:R87&L.CKE"Q^<6S3@NXH*&R;1V/=-OLHKF.-0Z:)=5 M4% +'_:9S*?F>\+/U-=_R_A1FNHRBU0C60^$ T&M-#;S MF2Z&K+ MYCL6S?FEYZ9(PWF0D?$L)7(2AGW;V,_WYMU3&G=W=2!W'&T\%RS-.=4ZG4HM#R@HSAR% M!]G?#.QP!,.$QGS&GX.^*\>B/Q0F9YXH \!DS2Y'L/V&9 MMUUL:S%V=\9N[ %G)V>G*8EH?E%(;X6KJU.M-M&T]W;_;[&JK1V,9#I2VC_= M7":AEJ$[+?PI8@ /.VAQQ+4O),I3EM#0Q+RNAN#T53YXJ*8,AWU=O!-L2Z+H MC>M=;8]AR]),OV8(0P,")..ZN@<.0-1BI07%??KS2WZC=(F[#=3@G'%YJ2#@WP8NN$X9MMY4'=34LON[!&EQMQ,]Q]%7H'7) M3*U::C;R791 *R$[I4([J7-W=JF^9SJ^-)IY3^4'YJ>*1!SJ_9<@I4+YW?(U MI]?H[9;(U(5.B;+/PE8LEEDI/T(4A^ MGTRG)"61F.;5YL$-/E?,A7XKBM5V7= MK7&L)9 ZZR:@EC#?(Q2W9-ET*&A.UZ3I+(; 9I._!K06=#FR(1_6R1/P4IO MOM]M PU_R.(J+OMG*SJO]$K,YLQ<*P6D(JS M(:N2O^]]*[[MO,P:KMT6!SCV(JD!#M4ICY]C:$A2TVFNT0RJ^YR9RM5BU6!\ M)WTX]-Q)D=&$9-DXY+?F3#Z2Z)6:L@..10+28$H::A5AD&$B_LKW5Y/V G3% M@9-![@" -W93!(E8_K@&9@4.QR=16YN0E MC68X%@=(B35FCB6!3^_4_EMZDN@F#A+(==3-UW (0:< #U9(04>_(U7ZQ.[G MK,B"1":9DZGD2*+7H]HN4"7J+E.O0UG?T;L SCEZ!=K]]#7?,RQ!:W:!@N8N MLZT7T+HYAV.GW'6)N A",EX($XY:[:I[ .'UGBS31+,KSQG&Q8#^4[+CFN15 M5'C7\43ZGZA:^W;8A66'-A"+4?A%^BNHV)=MP?FG<$E\G5 <0)S&099-IM6# M_"2]%=M<67UW,MUF2S@-XIA$)ZNU+T354/>DM._ OOU#P! /Q$+$\K!3=V/S MRPT%FIS2/8?S[;N_'_90=M40MTO4G),41>74G(6_7V990:*S0B18*8O"R6-< M=DV>Y*^T+I&P_F#O5=_28,<0' M^=X/Z$N1"7:W..,70'7FWCV^GCIX[-\A \_,%%?1$3O3D Y"),O%ER?)34"C MR^0_:!*M?ZZX;]@. @3)8Z6D/E1A6G*E*^L7DL\9G^$CGY^@8?*4\'UW3I=< MJX>"X3.-BK08 HBGQZ)#]C3M>< 9H#B\WE5]6PU4A(Y?).F-LSO^]D/<*Q>% W\5[F#[LC "A M&\<"$61,IE4*KB"DL3B)!L]T42Q.6)JR)U$0+5CRW^0K]7*Q&P4*HG];1A_N MX,!5?4UF"%8V]YYD M UA>UT"OJT=JFHCU>D7Y+9LOX]4MD8Z!)?@_)P+\E(H"D:=!-A<%Z/@?XD;^ M&,2D^[HD7X/W'14*FN>:R -QSQ&VU9U.\EB(26E3S M/-EL".6\?]N!@D8< #0/\YNIEG_-.#?EXRCXT4([!!0T;-8# %]PP'G'E>1D M*E\WY?3XGBC?-#5/N\H>4+#\6P],5/NT;@_E-2"4U<%(&:35&J1.8LY M![/3(A7,T&Q]H-[>8]#ANYX%-W#@MPZTFCS$="8YJD:KJRT4&_]6!C6EKJP) M[0I":U])^8/H"TOR>;RJ0@"R>_8E^%UI:^@YF/<89J E8B]>'0[ :AKEG)1/ M%JKZ45V=H0!YMCK8\0*';BN]$4LO1>AI7MT%[*7M7=,9Z7X!Y_EN_U/I8M#? M'[?9'0JY?QN)%3\0.BMUJ)=)D6=Y($O0V"K:CJY0*#U:3N#$8%*R-RD+N?[/ MQ+E7B%F0B$@ &0S"95%KDP1T]9XW&WZ\A/+!T6&E766NJ#R9(( M%^UD)GY',B&2D^DI%\HT"#4GA;[C05'V:/W8DT)543VZHPL648URZO5$!R5[!T%!8V.SAZW?$:?^<(CI1I6'"U:K:#L M])Q/0T&=(U[::#R:E&N,9F',LJ+3@BI?W[6HYO/X M??W;SE_NC$:JD^;Z&SNL$6*0SUFRG'T3LD5I4!)GFU.V6% 9$23JF8N=C1- M^*F&9&_OPCF)"N&<(%J>D3R@\98E-!?#OY?_^_;]Z.UH2Z7X!^_Q;Z/:Z*,@ MB48[X_-6ZR^,V%3V&/VQ^LJ?W@P?UXK#+2[U&')IJA4.!J :FUQ9#*T*^95FW[=O13-I?=K+27] M 1,(KZ6D'6;JO",)%84EI6UUY+J*KRPKCMRG02225PM-""FWTM7>>W2_5=ET$]V.^"V A?"YHYWW MR%6K2L@J.@^C*DPUT]7-O?M0[*$Q#E4SO?%94\UT=7/OSX9[,/M0-=/=%Y=V M9YQ^0<6EO_;JHQ]?JX\><_51E5%;6S14&F][U 5U9F\VUP5M31F3#A&Y\B?3 MF@561$>&&"H^F#6J+=4FI[?)0'M[SZS04S1WS#9VK'*5AI4M:,(G^E.0/@@C M4CLH0P<8N+?WT.4! +-DE2/ )C3F\_\<]%UC%OV]A^(- )HUNQS!5E:B2X*$ M7=&0+WM9DJ?E66PNT0<< >IX@'F]]6 9CE.DI[SPWEVGK-+"'VF0<[,*Y.%$4!L&77L2H*\"(6='F^^/UA-X#4,9>I&_AJ&\AJ%@>,)_#4/!@,)K&,IK&$H5AL)UZ?\IQ%_$ MYP$Q*)WM?;\ V >@:,C&<;NJ7[>KEPJ^T]V2975$FDPWQZ9;(FB-1+;0"[X3 M!O%_D4#C7[3_R,?RQ#<4#U^69MEB.L()<)W]3$[#67X!Y#>3L#>!"&3BX>__D 3KKP MB!Q,A&J#>3MM>!.B%B>_(C&Z8$4ZE!35QO+FX>1+B%I\_)IDB#X.IHEJ8WES MN/(F0TT^?C4RM+?@>/38\B,M+^1Z?5<\9.0?!1_P_+%V5;X6 2(Y7P[==^9O MFW?F[3"CT&:K?_7>@)\@&F9HK\=KFHNR!X27UN)ZYC2Q]?W_I,LF9'A6,S^&;Y7_^CX+F*WZ.7;)$[I%ZI:;OAF0)66TUW93@2*O4F)M) MN2F:(T-%)W$-D!0$#:C:,A)^,V./[R)"!2R?Q%\$&I]J:/ ?_79%9D%\SJ]W M^4JQ0GBK5B-DG.]<#UWS'C(#$)3#Y?>5(LZ;[+;PS-LNMK48NSMC-VYGGV/V M$,0G-/^%SY9?CK-QR%=-1@4?3EFZU/J@03M[VX%;3-SEL0T-F+;?UU1C.XKF MTVNJL==48U9:[PM)9R2%Y8F:C27=K'*L$ MI.>Z":@]12""PG2=4+7' 8=.L R@X#*1K,7J- ZR;#*5M=>!M_!V%QS8V-W MVU34@O0](E.?EVFM=+5%AH5*OAJP=%&"8J&4QH O))^SZ#)Y))E\=YT\)23- MYG0)2=EC,<2QQ&184E[^:9*_ MTBI/6'_O1F>H!-@QQ%&&R_/G<"[.KJ*8\&+!$CDI[9(4W8R]?)_1814T@<1W ML%[M?U']1OSG(<@(_\G_!U!+ 0(4 Q0 ( %4X=$N[D0))&SL! +8E#@ 1 M " 0 !M87)A+3(P,3%2 0!M87)A+3(P,3&UL4$L! A0#% @ 53AT2T"Y#^O>AP HU0' !4 M ( !FZL! &UA

#M/$9K^,&[[_.S=8_!G&[0YJ#VY1<$ Y%6WTT+[MM( #;E?7 M$]$W'BVV)[N&24N6EI]9 M1=$WN3ZT*A=OG!OOF4W*L_SYN\,ERJD7T&TX.)5 M.;%3 ()A1&!T,GCSZB0(5-/#B3CY]XG%@D$VI& M=/GY]%#Y!Q7.:@ZT1'9@HF/32G**1W-:XA*G15'HF*,!XEFE>>E'TV7H+"[9 MZBYD-Y;,/5C2 V7G7#V)EU2NL5!G#VR0^FKIP+V$/_^L/-4A"_)U5/XPMR:D M#(]\R0^")[!LW?$G2%(^]>@[:I9V"WRN@3/P%?DUNWQLRB6R?>=>I_N'4>JJ MB'%V,V81'O6DCHKL=_5WG=\OVY/)**8F^'PV%\7") 1AGO :S0N*@VXD8,,1..9A3GE'C5[(5?](@EB39;W]*4JW MC==$A0\L3$K?]'[2E-S'N#/6BFRSBD(O@1;VG?F%?5R\)^A=AK&]HKTQYI#E M$O3:T?2('13#_C#N3Z;/\G<$\XPC";*B(;3B0!NI;=6FLN5,0EE&Q9'FL%-D MHYC!)$E*4]8LQ]L:2U)MBF)LXJ>0:BT+6T-E1R[B0+2]!6$[$\8!,L?-P-DU M\_NL AKDE;"Y$4O= 4_".GMM[CVA!-"E9XP-5+;N)=G65UBRTMLLCW'W(B[O MO/3*.T^IO%-8F4U^]A.4M7H2Z\\X\QWD']\C/;KIIE+7B"SQ].^9GJ9*_ MI&SP:RS)3V:\UDO)D2<=%EL M;^^(-^'^%*6$E,%"8C=)K*ITK$,[TPDJ$N0 M;.,@NH;4A%H\9P%R#K\L'W@.[ B*&F,<]6TM<;;LE4Q@-#G(Q;,AP M% M4?S406S4Y ^'S%,.>Y;>83ZZX4EJ?<)RJ\=H,-)\VH>N]#D;";1N"#JI\\OH(KE74T-RC3]\.+6."WY 7XI1.O#I MGI7XWU=KU MS(*Y;9"6+@LE;W'TKE$-W6;H 46*-C"X3PLXX!38]T?X3^UU M]%K GY>9%P0*'$C$-]4HV+%(*\_QZ.-V%P#KS[J-58=QZJO4=)5\UD&R"40- MDEOG3MZDFP=4]0?]GVA?AO"_LH+;$B$AUEH^Z;DBW+"S!*/ZM\S".4#7.100 MU?Y+(=*[ )%$S%ERIIOT9Q)/YGGD1N3S;^EB$;T#*4@18V;#$DE#/V) 4_^'Z%""7S9PS1"Q9+=8'$H3">AG> X@/VS^^07:.T MVXHZSH%:R5277!U.V;C'*-P#NCGN-1U5(NPWCU'G1U5[P[7'>R5H9M=([2YR[;*W>H(";S40S.??I6G&&+4,C?GV= MSN[>IOU'AG:])I5E#QI7!SSSY^@ 'NGP\8-^<#<'4"S-^8<=<,"-= MKYL2L(D/E&B#@VA-ES]+TS;+MR"K'KA.G].;OF^B[!%NS%;WS^ADKT"#6D1O ML@(U$P0T?VHW?\@\C9,N]0-U](.I&.TNWJ8,1#N&KY-5N4J7Y%'US#__T_%D M>OQ+PX6)].-\3X':I=0_Z#O)T;UH&1>ODM5-*(G_,8>)S5!JDJ$0ZZX&9-G\ M8+OTE"OQ4 @BAP4O(#CRT73,R3FLZK&CGE(@-A&J1%A?SU(,_J6%D:IJJ2A-_\VCM.J<34,:74D;&&.2H7;$N"N:F M>K/JMF2-C(2H+0M,J.!RDVV6+&U!4E0T3?'J!-%]+([ZFJVVJ]KI^]E7N)OU M=+1+$ 06$<*)TCD!(]S@Q4F7Q4/W30C8UF][)UHYI+T83W.8?]R-_TUWHXNP M&IK"_XIKP@+SM[T?=:'\W5>CZU9H,N?_I#LQZC_G1NQ-O:X&__#9%-PX\_^5 M#+[]_9" T5]$AC795-B'AQ),TQ+#"IB(HG'9E(I#T,9!!O.2+6J;X+7*MV*6RP%=0+ZQ!4R$%K5 M'?G&^"K*4W)JOW2.IGZ1%X.1'97B#8=N%GN,[G^;[7&DFT/']@21'@WBIK^% MB\P< =4G;T%<6A9 AO6S9MLRT?$/F6@S)<*O=][[UE$DH]N"?C'L'<*56BXI MH>,\I]R%>W8&P7*()@EKV;(98GIA4HD'.=+!2#B5/N!!30]#PTN:>]@&CZ;= M+6JQ%3ZY1[L\HPW;CC&AGNVEW#UFX*C$15' MGF2DD!JK.:)O';0,^U2[WA6X"5 !!E,ERJMTF>9)[/4RG=R:N!QI6L(GHO0^=O&VKBOQ5A1$#?MQ5U,CK M[$))-"SN4H/] EQUQH4YZ(K$)?G[BPQE,,7GDU(@%D$/>"C*7W$AY;:RQ4H< M>"&/7U$L*X%K1]K,J("1OY 2.@#F75'-1[))_&A3]5A18@M(TH<4JX>KZ'99 MW%!&FJO!E@E4DI_*;EQ2IN$O/7'9.^12V05!'W.U7YJ790,3&D_QBEQ:3\>F M&+.[FE)A"HUL,DP;0B]L$IPS(5[PYIU+!5#JSN_SN2,_TKC+[)824<*PH'R6 M[H%4DPD@0LT!+$1FA,B4 !K^5A\1+VG'8B-^Y[468,HC91;V[_86A>_&\^7" MKG ^+(HN(Z(K=@[\%P,GT4A+EUB^RQF )_JM3Q E2J)(@@>+*9 8C2+@4LD! M"46?D3*?#16K>7!!$AGGOG"GD4S_,OQH@4_6?IL;<&KP, MRUZ[7" 5KENE@EX6><"J#AX)LVR6#[38X5X$H,O^)N#82P&.1=JX_G#^SF=$ M_F?=8>N@[UUXO2@TIWMZ&2&2?2HV),I@AZJCQH@] M8=+F!I?O)UAM=^0BL6>C8J.PY2XA;&HMN-O%I.IZ]KE?C<&'B*F=A]/^ 9@- M#8.-2@.IKMC1!;J.FBUQF)0GXT.<*%I[Z?C@!!3_[2C<&H?H M6:,==,U,RF&G712]:*#T\\XC]I-V8M<7+;$']Z6+P^'Z],X9GG"#=O7+/&TT M^WVTA_I-Z2)E6?R$B_)(9T%9WD@?,F1')M:?QBF*XJAH[B4=X8K*<-*YYRIA M4FTF)]7HO97.S0XZ[PFVD/A\PLHY5&904 8\-;A7B=^'46Z5=U_HYCK+WSAF MRJH>F(3KC7*A]DG ?@T]2>'4(QDNCM;+;179.EV*\7/A-=R]=..G6)JZ,!%] MCB%8>2LHJ0I3R>@ISQM !//@A%=O/>Z$8W:?I*[&#W%A M9[^"\2[ 1]+S#-Y5O&SK#S0GF,#^E>KFV?X3W#]UED8O#\<_O?+5@M],W]+T M3B_5KH[UX)-E'%V^#^S(Z*J7],K>LM=P[>S*>Z,3M;XJT4]C,ID$U+*]T*E[ MEE&Z6B^+QY23D&$B\+0=0)IJ--W1P"P.$#%%&1E>V_H"V8TC%]_BEZ/-6W$F M3ZTRY"V+%-Y6ZZ_A##K%YE%LOJ+AIN3F'SZ<2$WM;UN[(-_/8,HEX67TK+(K M?[+2Q#D6J*"V)=&7OCKY1?Z'$M--7N1AQKD,+?^C\ZHU3Q4O0:65;T%#==YL M=^(A5>\@1WO0D8/IQI(?H.V207"8H=7'L^4%LZ2DR@3E!1S*(;&AA1I<.=ZQX9"B2XHC8?6N; G?AE54[9,1N <'1@VLN!(@:83T#38; MGI@E L-M\QAOTB5"P^LNB#\7(7.X_$G2L*GX5Y0;6VP=G!.QWSJHI,(DADIF M_8J?PRSOBQFMB'M075+ZFE[ P'T.=\6W>;#.YB&ONDC:T6D,Y&VHL0,,^K;8 MWD:GP#R3Y;(=@K(C=]6+*'*MM8<1I7+9P3L1Q2ZI-E(&M]_W0+-"4UY1L1/4 M64N;.%QH114/(",'J''.MT'PVAJ9,@P0HVXF;]KT& .%"$Y2LO$ZZ54?AS7Z4)PQ &W[%,3YP1#H.&46SS ^\W[;!B0 2,_)_XWX4C M*O$./?):R5V2;:ARFUUPZRWK4W8'#)5&9HA*8Y&W9-+-A?,@DI;)F@:[Z@E= M["9U?!9KT\DLSWD!5'6)'ASD :AL+*B"PEK]"/.6"$3L,L@*MZ$Q57!4G:(Z M.-%]>,)L>"2HEZ055E1QZ3;["T4UBAU+(9,62^2KC6%DM;R=N9\ET MZ>KIR9QOVWWL_&@^X'/1X.?HTPU*:NZKPR>@?M&_;0G9V]?=*JZMIRO&OQ=/ M+<%2SQQ%>!-#39A'&P:C\?L'O&(9&BMC\Z(Q(POZ#^9=6=P(>CX!O]' M=#UFM&!637%60#2*\#1G&I+]85(*B-3#?POAWE+JP&4Y3VT_+&(>84P:E<*N M3,6AI > A6ZB5=#25@MPE])80<1\R5!;WO+X-R)J\0+>)]D2QS:A!M!K;8SK MA70HH<56FQJJ)Q4:=$_5B*E2GE-5:A[[BQ!X)<:^H@9CEI-JP\;4PQ;E&M86 M;BGOM%REV-YNOR6/-1HQ6P8^3T'P;*6MT23P&UN(24)E*LFM_49I =-Q=%VF MMJZ]D-H"I'WFG5*\F3 8FV*?T4L[S\9X#AX.4Y'H0H_FDU ]/O(4YSQ-QX?Q M:#@@;Y/\.ZR:Y$OE)FFT'TF#V.M3;W0EC'[4S*DX=#H\"G!Z>@WX,VD*T$L3@"]1&L"7RD33XA1MI]@8\2 M"R"C/ZM^/5C@297JT+!=5O7NH[YG6;Z;5L>.2HA.;+,I>=BU0A5OE9&5P $A MBOQH?TV*NE_J66&$6WFT+)3+)DJ!#)D M/18S,GQ@ KI-MMJ_=55*!+DXQ*O&,EH0DHAA%3D!I^!42OPTKX5%A@ E]GR& M(Z=&4135R/2P?X!Q'YO;$="T/Z)V= G%>8SLUK9LH>0Z$I-,LL:W MBZ0/">Z$AQ],HKT-WE<\U:3E=WS&ZA3B7?81,?2;QG;";EII"G/@D+(Y"(RO MX&' YU,*#N$]2%<(QUH^"DPS_T&MGT#86>PI)D*: 3+1&G9U:%*?1)[9ZZ-V MVCP,K'5?+'@['BF;=-[H]NWK^2XOQ%BG24:.(ZH'7V:_I@2YFN3!#-PKRJ=XF)4&?)?A$1H3M",TO;*_1VI= M(#01^!6AA/6(&.L4I.#J9= M=)@R3D!2\AE[/FNW0C1I\@VX&)GMWEE#CXXV+1M*D^24VLJ_#KI40P:GZAAP ML^Y33\MV/<9(SW;R8D%.%>4NWJXXF%V_UTKH>4#HIUM%'(?K[)81>-+!?!1H MS_"NUISK34[2(-B0KWK7 G?IJR,FIOU65HX\8DW9_\V/!YAD(=KKZP M<$>S!(, E>%X%GSZD:TADAWA9F>.G0E&&YKQL O".RC^[ZT*=E-RG1&=VW)M MRH+CR$-;RPR'==76 42A6YZ$HO&3/;BU1YL"(9CEOJ9@2*:3XR*;<4%X!AP1 M_HB]XS]0-C^,>T76%/YJJ;_2F!S]!>'KM ?$W'0H_(P?.IST?X[.%/_NTG[< M0QS%9UP[0YZ:'=<-"*O?BN>3FAQ3GA;HF?2H4,Y#BH%GW!:$.KM-/916E[L3 MQNL]0!_/_:#-.LAM1R/;HJ.Y[%@NVV/<-&V\31%PZ%GT%P=C>LT=E.@:$]?I MNNG%PNT?'8=!#-0#'2.$D$=H3 %+:'A__2-#X\ MFL9'QX>=KWD%DX:[H,^\$DH*GG&2/PP_'=>SJ?QO\26W?]JG)+,QEH$5QN/^ MH&L(_]!;X<)B/SA%@)IXUVPPL8,B6L[,A&=&<7-"$<[#PZ.F*#.+SU&/\"FM M"==UJ34D8%3YMX:LG1WRWAM[UW6>X>7ZV;P3#?2:6.9'=K6==;C:GO7TQ#Y] M@4:]/+SCHSL?FQAD22)A7N(J7C7PMD\]/J5M\UY$+R?Q9(I4/(Y>\8_#Z6%\ M"$8)_3@8PI\.X^/A(?\\C(>303P^'$:OS-LT+TA %:7Y2_V6^ERQ8O<&F,E- M[HKC]>/A\7$$Y ^?GAY-(J#0"")PGQM/=(^)Z^KU M)[+"WF0J:^OI*ON]":[_W+EA!83O0)JZ5O[?Q,:TV%[RA&U?X[57KUQ^%V$$ MI5MBN^BY#S"#0H0ITB#K7R5MP0J[(/:"N'Q>(C-:F]QJ^,E)!-]DLR(KFZ$> MY?Z5M=PJNPWD;0P \\Q&,/*TM-9OKD1=MX)62TWGM\ (N\8?ZI%CW$$+Z)K: MAL\V%,I8UQMNG+9@?%YIL42 K]A7D7.]R-SAKGT,.A@DPC;;>M0<&^2"S N* M3Z6EQ)4+@14-!9#=8&\NW,F#9 MKX#\Z &"\IAE/^_]CKDP2,,&6>38,%W08 MY534L\P6J23Y6!5CXW)5'/ZQUH=\^^(F;7$9X!Z@'8Z.1I(('(^'8V RH]B$ M$8[WVG7+_@.3!%HI)=F8,,9+R+ 44V_IU].A]8TPK9EC]NP>XQ=HR(I-:LTZ M1+!,ID>?"(UMEVUMJ59#1UH4U0+]="*U%5"=-Q%<&),2QQ+&G;>,LD?&*L]7 MNY49?X-LC*\&3HE&NH]%CS;HW^ KV8;K9%.GGE/>"_?H>GMP<\<(;CH=<5]) V)<]5VSITVP>V-GZE6 [S.YY@?\V3:G(57L2>[?!](C MT[_1]68?A_./JQNQ]'IF=J1[[(64K#>+T=D<3U$7LC':S,)4@XLA_NNN MBG?@G(.UR"3;PW[].>J/V:'^\%5B[6=3UWNB=[8_6EM'24Y7S#"&A%U+Q+3D MOI]@O-S>&U M88 ]U-8U/KZR+IZ\TD)%!9<@>Z>J*GL[?^9H&RP[G(>Z'=R!(31",QVJ:KO[ M58VN^.KW.O)@49-QE\KU"?3&;DW$6H$Z4[C+$JIBGRV_FSUW(]<_FVQS^;M@RH(D$'.J#:VTK MK-(_A2",'[(WA(5@N%3N7-/HD2L,UP/#((X+QKUP6X4@C:/+92(%0&=P3]=> MT5U(%-P\F11] QN9$34+!\6W.RU(NF_,VIXT)JOVU70P6?-9?W"]FO@%IB3N MRIK/.5<:M5T-DI%VS#IG5KGP5-VT+18N)UKVT&4!US;(F]'J#LD W9QRK.]^W_= MSF^Y&*$*V\_;UJK>%C>_:TZ4X-&&3]KZ:=_C!T.<=F*CE*KS^]>;/_S^=97] MX??XG\T?_/2M^M\T52D*4I7^\^2FHEY>_U5__N+3]5DTLIE.)Z?__N7\ZOSZ M_-/%E4M^Y'JE'P9(X1?3VC&:)>1JD8?3"+!;9K4>S\F>$"TVG*/?MH/B5^JH M#'O"Q=2_:POL;&1;9?*/HLDC(WF,[A176#=4G (N; MP!J52'3>ECNM5S:(-;>X4R3FCC>1.+]-%',8>%S*:26/Y[9\.G_;^ FO7%&S M3PKWM^1O)ZV*@R$!KCD,SF/!^H3T!/OMDKE-H*A47C8W6XS=*WU^1G?[>7C0 M&GP +T;#>#*:1B]5UY&,BE?BY#L:Q(/I&%W_6AX0/, 3>R)Z[&7M=\TK:LP+ M!CX>];OF-8@/L1L7S8?H7E%]OR]EN1J+IQPN.0)R-**$=*6G+ 0VSXR\L33:(DF)Q;<@'R MR;A'*KL+?O05?A/RKJL,1ZC,R:^;+$4]+%TN*WAVL>F*HB (F>XBI^'A"'\Y M.'W[\81AQ*\^1C/XS':9E$$S7E3V"$$P$>@\;IO%T%)&;#';U(BDRAV(R3AZ M)VV&@G8^ ICU)WAN7JQL$"/ T>K!^CRY39EB]B!$"&H_&.,*D>?I;*FN_)O4 M-CH%[4?JS6Q0RR)(G5VZ#;<<]VR+VG*"T&'+=.:#B57NHQ:.RI+BV?75N2_T M7HL>?R(A!/']?D[F((S.V9S5EL5O;.:V2XOX?/[&?LY+G$0K F8&]^OL7G+9 M[!0^7)^YB_!%$&N6TO^[E,O!Q"R KDAT^W>"AEE0%F[?I+=.L!N\K31&A64/JGQ?W(V?< MTUT+'%(U((RG2H8P^3RIG!6C[PFXQ$HLQ(SKU"79O6[QHN>)999!Q^RV"AP4 MXF;PG$FVE[*-2(*DMNU]'WV0 J^SB[P41R"ZYVA8Y<8R:)@%?@8$9W*;$U8$060YD4F_#@4F2+*QE9<*Y=E\48!)?$4Z<1W+ M6/=/%9[@>X6D@H1TBTC3+B)#\7B4#,0EZ2)2O8U&G!0Z%ZQ(W=RY^G:RYULW MSNL&IF67IEM\>V,Y"7XNR(T'Q>+@^H[S0LX_7;_R1+C?+Y>7HS:1#SQ V9A@ M>5/_\DK@.HB7/J"\ VZ\.+C##&'$#)=NWM7 M&+QBQV)6(8/CU#G.7:;YFAB6=Y121K"H-Z:/Y MYV'0&,(?N$N6"Q]RB:SY?XC8_WX1:['-6FUA99K&9Z<*42]2#I%.WKR-&[6: M[RAEP('+*=)+0R(Q0-6?@_DI%!@X8Y,")=,Y('#ROX]<#_B& ="EH36 M'.X1A781!S"=4\EE\9#6P2!E[WO8GA2-AC1$@PK1E?097__0HEV5FJW?,;N_ M@YI(B*=<=T9^MRYB=N@B'=9ZJ(H,AC4GXN4U\M@_ C]BV:L>R\MK9PYY4M $ M(MWNDI/G-R2!U2ZTG4Z7CV*$HUPIX+!/JBS)V\UGA2;9BYWK%!P[QR6!362[ MBGP;,Z_UNW@>,]=)_8.3_R_CY):@]^7ENSAP)P>-E(.:'\5![;SWY*&1\%#3 MQD,[P0*5.5R^-]FW:![)TT:*)S\E6X(7.H/W$B^@[.>?0@X*\<$V:_H8\R3/HC M&4RD9J"^%8NPGT1X-Y9>:@A5@. EDU6]HVX1:33NZ^I#BZ3;K1FUN#7-][LU MKW?P(VG8;-&UE0(HWL.NQ@K$UY_/S^3KM4X^#OEKA5+0MD/%"+. R&!XU-)\ MO?>IEYBG(V=YB(!F7!W;$[(%#AE)F,A/:1$\LCKZ: M_8SR'G&N*U1(DX?:?<";4:THR @G>OMD"S %6%V&CMZD(Q_M7405F M'$)'_Z22B8IX+%?7YD__D'+_3Z7<]&F/8(Y.?!4P%,\N\D6FB18=F-;VC3#" M $P:W="VS6V#L?,#^I)I\UU(Z0P ML(<.NCNQ 6,!#:J]+JPEU4(KG!))>OVNU2%Z]>2/1CIL_8$@T[69//LVJY#1 MX?!/9)@22'N*_@)["WXS@"K$TUC$3$)CA?1-!X? M][%*$/X-[X\&A_%D>-2R:$[D68%4JGCA:GT2>;N$+;] S97K!#C=A.(_F' 9 M/3).N)'K93+C4Q*4ZY!W,GE+:1S]12OH3+/>BU2P30US,9@7):#B34!'Z0&" M35%!:V5!ITG[>$Z6_+1>!!9H0LDZVP@01B)MXKQ<>-)*%)BK1LS"D;IF99XH M\OJ668WB\=CK2#B)#YT/MCE+0[/$K+R*><*VE'BY]H*QTM5S4*>WA&)&F32V M2T PH:HM)17EL:N/;!RBH4/T\IP<$^9)],(KY*5O99:?:8Z5RUV7]!_."E)( MD!:@CR[D40_<9D/KH M:*);T(<#'AQ/ZG4])^31V[$-V2TJKH8 D%).C0.#"C1#2="?"4:T0$HF\[^" M>2Y6XSM6K9+:S6Z0=KS/IXWW:>KS52D2V<^&MOY%=-C'S3[$'X_ 0!L#[Q\. MCO''8_CQ\' :3R9]^''8CS#'Y#">3J;XXR!"\Q'D:Y_^.E1UM4P9208V$XYO M,!F9:^+%OG ^ZFT6KQCOK754 MB4N_+K=8P4.P-S0X7I@#@N!9%L6O!S?)[%$*6[WMQDO8Y&""$( MEMBJ&0#9_2'_RERY&,J%9=*JWI_I$9^YI;S%I7SD3:S_^@,OO/[K*TDT^,B) M!K5\^.$X&KX>O8:K>OQZT'\-MW#\>G@,_X](1-0VDQ2LL.^E.?W\[JWM$QE3 MPDK/_W*0^)S5 M8-X^Y@G>O)/Y/ $* MM'')/>-Q-'@]/'H-? 9>FN)[@R&\/QK8A7^TZWU]:C,@_H@9$&\YINH>!@))$O <;7>#]6*;Q_J3_-L=S@K_4__2_I'HZVKYSG&T4%T=?WI]$]__/3A[1GGF-)D_OW+^?5_!#HYR@Q!@_L[%1F0 M@0*+! 'N6I]WX$%)@S!-\(>=0 =-#.)X.-W&%( MN Q.QF[K#BG">-KDMO&'"M#-J-R.N#Y%@@LLMZ\J)D&@M@.0?O"?+?-;_+.C M4/WSY@$HE/N#Q5X7&_XH'.E-K:Z4YOJFP$PU+(#07E.QQC# U..2LC)E)$3_ M9HW]F]6V%W8MZ/)\.7A%<4=:P; G& $;,FTATBZ+G_"6F17*6Z"* H4F=*SMC]W6%"7='@@,<^FEV@7O>R\%.PYD'V/=-^-W??>?OAPU_4(5=M;IOX6 M U6B5D67G73PG^$P"<)V#O+K;XBO2]O+KU*,X\]\[3XS$^;O$R"RC/GVR9FZ MF!YM7MM[C;EF+BSN:NR#'7=C^IV?,U\V2F=GV\JYS8CAF(/Q-G'W@O!BR."2 MFM]")@W\O[SPN&C76(U-8.PM?]V]SJ/?/>L??/3!^H %4(/;UNJL6BXZNJD0 M\CEO]%/GEP@?_T/R@)D5JS 3G?^XJV R$ >V=((( X1F390]=6P=#2PQ+MW5 MP5(Z+."O9!P):G/O);.K;^9M287LF^C%I'?4]QE&&;T8C"8X>^*VUJ5_O,=V M5RY?\(DRVV8"61CG4SLZD^@]6^,94$1%M?1Z1ZF;-]RGH"\\K.]HVH_'3QY MR$>Q351;3_E)K]^O*S)M,)_F<#2.AX?'75"I8K8V!P"NS3Q;OAKS*4SC_N"X M=SPF,QK])+WHPFMR^! T*'$A*$%A> "CK1NW:_ MF0))$5E8$[JU(D34G,'1M'8(P7[X-PJ#Q)L#8#8''YEJ;2'7]4?7B-*15X$X M29FB2[=2BW'4@B>;6]!)_V2/)_[)/F8I:X:U9&I.B!CU!_'Q<,2%YYRS,-35 MU]9BU8TP]:?(I1'D1$&.>)<=6KAW7>IO6CES+.V/_08*E@\A@"6F)2 /^6-2 MWA1EO>T[R2T@B>&X\V2H:V+PD>]B3Z:-/>ULZ^O84[]W-*JSISYAX/KGQ*",L*JJSJ.,&C.]3+*J30PV!AX==?#S^9)-FH_&T/N)>7Q_U M1L.:G<4[-#S<@P;X7V8Q; MO7B$:KY?CNY)J.$N$:'"_AP=3WV@BK86J;IAP[WH(=BS>G[HS*E,!?4"KWUP MM^YF1!%IX&ITS#?\O JIO28.\R4#4/'N-I9&*/):4KTQ2:&-:Y=.)J0[.^SF.]DQW_'H,)X.?N"$7QP.I_%T,A*PHP&==+4$'[>\E'#S2UKJZLRNXT*=7K81 M_<[&PV3RK14HAR.,77?BVC>GQA9PRS"Z1^S31.&5EK,,K(! O0P$)V([2F@Q MEASL5!W8N&@%D8[^+#O'<'4^/T; \RO-\MD M]NO!U0RN4BIH>(J70Z2^*;-?NR<9UWH;EQB"QXQ_S,!\,46;$?W@1[WQT 3& MHP=TAC@4\.51#TB24L3BR&L0&7QQ=/03?F]T_%.MS[-:-=Z+K-B!&*6\;<[: MP8NJV6+^7]G:8] AL0]K"(083-[>++/JSKEFWTG?FL]2B11,==##_DB8^-8; M3WX*4G^,GPQM:5Z)RKMEDN#)).38$8<8PR1MGYX1N._PB-.YJ&DB5J+7/FW: M/^V:(B>N9:-R0J(L93YV;B?/[HS7WT$'*U]CE MZNRTZR:!@9 1W">5@EMH7_YUJDD]E;L?<8LWH$R]1="A^!W)T2%-D22.F6/P@=,(/#:.=4$![!#9\;_JO8;XWD$EP"CD(^U>?_S+\4^N$]SS;GOTU&U_[F4W>MEA0+C9P_!F1[_]S39/W>R.3Z]2!;&F M+$T?/36XZ7PGV'S&2^1PZ$YL0I"Y3++Y 4BA4PX+-BMY]M"0.G7 NIZTR[OQ M6VI)@\.:=Z@IWI^A$06NA/Z1)^=-H!%19FQ;%F37?GVC:L2?^V$*4M.K\ALH M2'4?C/^!]E;5SU!U3$/5"<^IG6L->VU*"S.M9^HHYK?C6E' M2;]GSK)5\_A M&\1#N[X8GMF3JI^I[>+1MVMZW[2+9N]=G/ZFO-]\DU;7\>DNK4[UGSKW[FA( MWW#C:\5QFP>4;#M$4).B2\RCV)D/2 M:8S'?CJ^8IN\2:\2Z@O?RI@2:E0&$T[*98$H0EOQ]NZ\6L:?C].QM&N47JPQ M&"'M[ F!PVHW*PAP=Y" !'VQ,S>YHMTWQ5NL!=<$3";A2?CWP3QY])_.5I0X M2^5!KA&=!A,\C/!=3,[LO)YJ=#UU0H+%]PU'9)[F?C_XB#Q06SH#SNOFC@'? M)1*.CY[#S((M-=]OEW8^\Z.M$=\G<6*;CATLVS^A.J8 C1Z; M[DBU0&7<&XVUV,VF5&O-=5C[W*AW]6972>J+M[N*F-_H,8K_S*5^I):2[?*P M[<;:#H0GLH8S97:7Q%SLWS_ BLP;*:*%TVPB6@X&6 ?3QVK"<6\P)5%NWN,P M\/HT/CXQZVLL7D4+Z)^KW]L[0 ' M5/(AQ21E3MW!^/<^R3MY6\J.(SF5G5U%!G[&%I4YBPSV(NF"&H^7 2]]E7J< MS+EQ-U1>:5,S_.XS-ZD5EJ[TR-XKO _QT:B[Z6L]Y+DF3 Q:;X+HLWAQ5#!@ M)A/Y@3@Y2M.K<4 .!>B]JJ^;VE;[^!6D2NK)Q$WF_4#%?]@<;F[8F3F8(*<6 MG06N%@\V>(7>S7XM>6CX2JS@5:I9%/;/_/TD[/-#0+7>%F6;4&4Q4N"AB!7( MU&-JC>>9 WW= M.J1D[W?-;()F9MG'LN=_QW ;/Q9:X?;9!6N.+&Z(WX\A%D 9"^DFG82(+##2 MZM&- \8/>]>YY#8.=]>FAR6U:;6>9Z0J6<_#(9UW36\&R)SZI?Q MQ;1W&%BF]]+#C%1NSGJFS.+AX2MIK8;Y&:/9(.Y=S70<]Z8=!OCA]*K]TOV.TD3Y:/U>89MR1J MW!+W_>=>$$,79$>V3.U^>&KW<2U9T;\?=UD)]X,*8E^.)KONA]GS?M2W^T=> M#=-^->H+;/.J3#HMBV=?C?\VU]31T4]>"8M>#9;\?]WF+NW.["F.WB;W&>JQ M6X>- __>5_S@LT^+'7-Z_2ENN*VY_T1K;%]U1QWB6T3'R,\C,WO?C,&@-YA\ M_]5H$QVFY6H$F_W;B@S3NKS?^&(\(Z[\?1=CV/\IJ/L9C+J31@PC/PBLV>G\/NWL^Y .^Y-#I^,4JIQ <\LET2>EMAXBQ_2 MY3V6\H"2+8@&,^K_-Q,D-?3E!YF)_PVJ2FUEIHWLQEVA@L/)_U1-93CXB83_ M!E$+>.>PUJ[:+A 7$$G+RWML88P23,QR1'5%1KT&&[YBL!C*NJ5SVE D_U;B M^,@43\OB*Y[^PCH'$FT%1/F/G%6+^:QM-!S0["X/4"#!.("W8BD$L5 M*:2E$M^7"U5G\Z@GG$1L?J9H0MMZ),\_I#;A#W0/'4V/X_Z(G#+3WM%AA D" MUCW$#A_G$#H\BL>'PYI7:(AP&\='$9C?TT'@'^+7=[N%)H2/)>/W#S')8&)T MG6=/.H7&QX/XZ'" KX\P!7_8.Q[8U_U6C<2FAH-X-#XD;*_>:!1->\/14^XD M/=!=WJ2#1JO!MY1P@EPW$^02 11$28Z,,&U@QKT]>W,-KWSZ^/'\^N/9Q?55 M='+Q%GZ^N#Z_>']V<7I^=K5_1?7$XL8U/FL:GXUPMHJA9D6(!Z'V$>$-D$V< M*\1?>!(^51E"@/B,_T4'1/!J5VF.8I92#93?8GEB%1T?@")Y,.Q''\[??/H< M_7_1,9J+/Y&W,CXZ&L2'QR/^80),8SH^-A_2JOJ976669[X"7!+1>,?N'$M\HS]Q L,D@V.QXCYYGX8'P^_?_5^WB\YT@?] M ] 2#A"L9D!K1>_L6'!,[7 ?"$KCB:'>I?Y(V>=M_I 0? [! #(B*I7'K9 M![WQ3R0$22S+P .X0I/CZ?>OD]:F@XX&!_^6Y ?PMXL3NB(P4'\4KO";R4EZ M48SZ!_!F.$8\F0[CX^'A]X]2*RT"&N13\T=C[]#WC_4I6PI\X/ND\@Z,1G)8 MN2^BX\-#8+:3WX8H/R:/2)1$%/'1=(+P\+C2KCMW-,9&A0.XM M%PTOY_"8/OSCEP%T)\M@-D+HB_'Q:-B]D"%ZOV&M1\]=R&@"Y#8\_#$K4607 M/@Q=A"6U'S#"Z&UTD>2%A>Y&WM%Z39D1[06XB'<[T?'8!BTM:%I-Y5#/-*3^&;F455-X0S MHYX/^+O77#!*0(E?9F(HV616^8!T]:4\.J_2.\@18!F+5L'/AF&WQY:7%&5V MFQ%V6+V^QA^,]]*O.CS/,RI[PK_H9'\Q@M=-81\.5!$@;V@5Z&[;@E6*VP2( M\-Q1@B&S':IO#1G9GX[M!P/S358RH3AB #?ZP'I3?Y_\$-Y.+';,@=&%O=(N M,L6"[>'E,UZYS2:VC_S%Y3TZ^^>Y"3&-=.(AZ$F3)RWU7XC(":9\-(HGH-F$ M0YZC-Z)L'S%HC:.+H:9YKIU:6&(];+ME%DK&AZM[$6R^T)B%K,.>O&@&%4(Z MG(2"'PT/^Y7F%SJ"Q-YF!+A=B(<2KC[! O:\Y%@9L*/RR:ZUY1+SUR,P@<2O MP62FV1<\GVU.'5;LM?+P-S?UZ:Z76W98MF\.07B\])@,;.CE^9^L!"#XP'FZ M8'P<8 BS!-TP ME&08DL(W]855\MB,\=,18* 5TZ/P!X)G$C@=:UA;WU7;3+!%H/88R18QMVC0 M46(_J/\@>0;2CF+)K4<\R*?#WO'Q3_NG_C6KU/ ]32'/*F6 BL"H?_%L]P>Z M&K76YR]&@R/0'8ZC+7KM_JXDT^I8)#H4O?D^[-[\]@VVM_/GJRC7X,AT*& /]U;6H *<"WDF\N94Z MMT B[3L_PUC4==4T$+>?5#7;)PJ&>IV]N X>Y<70(=6QRH5],HORT8@Y4RA( M[ O/TY*%"6Y=7DSMSY('31_:KK;5HTC5$WHPT@1$VSNTH=3LIR/YP!#,.>38 M^<0J_\!8T.K>FK!*@EDN,4[<4,X-6J8MFF,2O3B,Q]I+VFZKR&KO%"_2AT!) MCFP_-8Q_9'FU+35ETV,=K7O1J#\+ #'J@]9*9IK9X[)'L;%T8YLRT)&R!C9W M#31(W7+*O5YK>[BWU'IVT]34-W=EL;V]:W1]PMP7!J@T#F77]B_V'Y8+YNF< M_BGK7"O)N@OFRY!]6-TZB(=,3N';#)3-'L9G MZL.Z"W6M.'J65OR+$HO4?9 J5&L$,2/WOB4;Q$N^%Z/Q;;I(,*_QI3<_X9B^ M/2"0U7:*I5-\E=(QI3XTIH;>-#UMO&A^WNZ%H9U^4L&? 0?,YXFZBT,O0(N. M[NC<4Y%5TBF]N"F:0*5O,QNB_QZSP728#9[VM-MLB 4Y,^,,%,U>Y6;4>.7: MYV:[,YW_R>@3'M?V"-LM8T/E&ZIPIOY]<1>%3YN W!#G?UNNBRH-^GVX6S"; M@?F^-*I)PYG/M,"EX#Y>:^?_@'^N,B2S:X_)T^E1)HOM[[C@UHS#7O^GQK1( MXI.]P"U%\2&#+]"=HN/UF"\.4.>GTN#/@SUK#-#VFMI)6S61$'/;P\XU;J.< M4$J")-7;LGA 3"U/K^?N8RP!E[:9;6IW/10YR"- =%8N87I;84=UT,NDI@9= MS,PM% P=@Z MIE-0])2[,^7R#QSB'AG#ILV8]?2/*C1D20'DK#$5+Z%MR[\>#G^X;6O\[_U& M)NT.3UJ;_D7J%_=^X,[O3@61FT8(K6F);9#I*F"SANW27G*US#[=+*6;9]4F M7,04>6PMW@;#]KZP35K8'R4:9QDJ-,W/N'KLFK6D!!K:>I0'*/83&-?H( FG MP"S8C9ZT39TS9:1[2_/O<7 7ULMT?MO9(%;Y'R7&J%G28J:2-;[8EG3)7:.. MSNV-F\YBVM@GSHG]R.AOT1@YP6MS;2+I7CC*,DM9Z5"J"G0*@_V.BN/ZKO7"WO!=#@H3."B"AN5U4'U'K'KPKL'4KD#0#^Y4[[D&]/7? MHE.]=7_@^5-"CVA27L]X)\X*CUQKYZ_:.[!TI2.U)Z/0M^&06MA0H;;+8GXO M'\-M9?W*U/TN13.(UV2G+=MA.K8C]N P-YC3A&CG2XHUP.^U7_*.<-/;%%LQ MT#+/+^WFLIEYDWJ=&@K.@2M98'!/^YGH;HIW)BH"[@331,!S+\^5 ERF(I%DH08L0=#Y3\RRBPQ;D] M2>E4U!,R3%HVTK1N)!$--0Y$>]';KNC;MLLJQ1;6&R]H97TA17Y@@@/KR=2# M!M$T*TJ\\PHH@M>D-64P1CM-2",=&:87?4$-QWA(>)%%S;,*-Y4UJP?^&9W3 MPRBH]XS7+1RVQS]!\]F&-^O*,^ZI M&P-^*-6FX<:C/:8+!$XEO?GDEI;+^]I!=S5D.M8>V0GKK3[D\AZ)5&O,<,-: M"=6U;)YH&YH+J-C!/5 =&2/CY7ZO4ZP?5H!99CO&Z%E MB9^>[$($T@D9+:8<5UPP+XJ;X'!0GTHV./T$YF>RAU[T%YUED\.8O3Y1JWB3 M$N"YF"GU/F//Z:1D?FPGI=:V&*SD.$<&B:JZLN.I.=J-J:NQ7Q!],V'TS8^9 M2$=K*6/P@RL<KIQB+\"K4? NMWM5;Q,EBW@')@HQMU\EC[3OC*8( MAI8=#SRO9VQ3,OX&FO &(=JLLU2=G[)6ZB<:&RP0B[FE*"V&"G(.V(OK\A.\ MFV0];E3N(6Y_]@$[=&/\FT-L47?:#-O3!5:K]6G8U6GRO+ Q4863RW!7E7H]7XQZ->@ 6S/)[C2 MY ?GF!=\!>_V/'FL'"!*Q;HL!5CR.?86S%!KM5UPD!8#5,B&*;V10^.&W.HL M]K:>8S=(5<((Z,O[=5- MQ^%-V2YV-H=BKP_X6T<&.6KZ9;IYW-6KB/=$)TM9#I+=H!GU.VMQ6O(I0K:L M.?7^SKN))N04*MH1WWWQ3?T=Q:''%\7KD5(G8469Y\33.Q"R7+N@?. !*Z-J M"J&MZS;H5M=9<_59MO+:18$^8]L0A'F#UOE8S>[2^9;Z]*JG"K:Y$(5HT^I> MGADE3,\R0$8V17M*/QQWT1A&)M IX8UBX$&#_MRE9IN:R@7-( MPSX:)*-TDW;W3.+H:>X0L9CSZEYA+R7Y#H7$@9'EAGOHZ+!RRFZI*F7]#E9[ MZ1VUK!\GMT/Z-ZQJ<&%'G:!)M[@42O*INI[P;.G.)*S+2:$-6K1[ \2*D!&(3$SM1%;15@TD21@;0$%21DL'FT,N%.0\%:ID M':+%OW*!-6$ST>2,3#NQ4=9T]&Q$QY9>35*H#<*"E:R71Z^[+#%AUIF*''/CS=8WRZK>56';8BV%D-2<)S MQ7+K-T#RKX]C,E7X7AXV^4:+9,,E=0F9] M^W8S5IN'\J:K4,&F#G A#&?ZOW 5AT2C4G18HU'C.O;:#?$KKC7Q#'U"]:2Q M%F_'I]UHM?4V:2@:GFJ0U@&1VMX?#=5.3 PFHE.\6\Y@(.6EUB9-D@+'?E(@ MZ*AJ"/O>DUJ2:!CFZ72F:(AG+P^'[0#"K.6Z3(8X1 M="0>CH:]2*MH&^)+_U 374NIMJ6$GJ88(Q[TQTOLX]VS'M8_NM"R)^;H/*QT MV\(WLX4==797<.J:?0H?LAY+W X+624?C,TN@R06%(&*.HE77JY;>^C<9P+6 MH__HQ8K;A:]Y4OCJ!N)?W8>9(0,1^L+XA=0N1YQO8N,TDD1-TG8&KO] M%F/7*,JH2MYV8O8ZQEK"]4TZCZPQ90$]17-)V<.C$L3EO]QE"! A(Z#?"&M2 MF+?1EKIEN&ART-R'K(:@WHII(%9$:OOQM**;@\. 610[:@DVR/BTDSF7NN6- M\(]CFQ%(9 &?A,6K4RU02Z4_.7Z'LH)[45#;_RG@O;NUG-R'U* =QT^519[- MXI!EV-\[_2$@3[KJ]O*%FE]= LIT76E&O-OC2(F\=@**UD14I[4(.!+B7U.F MO:*%!;AUI*UR5-&+KAMU,=DX;)83)@"Y4.V8?ANK!E.8>G9DQIN/9\KP?[M= M&@BQ:8^V:#0_MD;]H&3%OL6Y& [BX_$HG@['T2=R@D8?Z$#/_; _0O_MNM3IYD#( ''!8;** MPSQ6<+2F,7H]>0!5)"EU2R1W ^Z20Q0N! M')ZLI>?P MU>!0>HZC1X.[.>JU6=0JK?-*1B(_J#( !AW6R&O M<-( H>:6&=X"8S63Y@S$PL!*HI1EG:3MDR7!^>B;^EX'RB]F3Q=Y>D!A'Z?U M<2FTP/D9'DL$P.%0C[UVHGH%Q;4<4(3+]<*<>HZOM /YZ2[EH!'P)A$5FM9; M^/(:8]A/!GPAIX?Q^+!O2!Q/IV"K#@V6PT=P:4>C"?Y[$ VQ M4._0W=CC*?QMU(!HN]K>5'"D>(I4IM4 9&L\$/WGR0VV/)QM_JO^+(&N32WH MVM67-U=G__[E[.(Z.OLS8;G](RWH?WE:D'^ TR!F!2+RV%B>!M2JNQ1D+&8<$/N0]B]:X4V(6_4,.G\,"_7CU*;$U?-R6D[M M=>%)P$E0?W+]@HQ^UU)A3_FEK+3B>$B1$>RLG"KB M3\9#&OI M"^+9W%;TXN9UA+3BZ/VR@(V-WH#,_#-\@"!MO'8)"OZ41!?I?3)/;-D9^J0L MQOR;/Y^<.FN ^SW)FJ1^S6:EM(S']D7[&)$W1LU?:42763Z*+Y0)8(WM."I0 MDV^Y< X3?:*;)0P/]Q,+V^ ,0%,A35CRO0G+@D MT6CL$-IA<= ET"+:]ET2\JN&$[A%X'.(:S"YC\MNLA=2CDB@#4XV@2R05U>TJ#BBHY:,UAOY]5RC]6+*P#,-UU=]4SP_ M"$(58VGT5VSG*QYC;YAHQ@(?GLGE;WF?W+++D[EPWY^X55N*];"E/ M:A%\7H&7YM'+YW@I7M"YHRO]E=>5OM<4^1;2]PIX: ;:.#4(XAQW'/82^,F, M2C7T7Z_J'WE#L /PB4L&\DULUK@8,DMME)!7\(TY_?U;/F+J'^$,BIGLNFR= M_)EC$G-4C.=FD6%>>T;D)9V;Q;=\@W%$*O@M&SGG;!Y@8EP"9[!I-&"&"[RT M6O>M%!';6^-*GTC&GNDE(9#HIP[#3QQ![MV9R.UO(B=3QVQ79D>.K@I6TUPG5#G M*H%&HI=?>E>]Z/W)R>4K;Q_MAE.MJI3:Z:9A@@+%!5IWC:Y,E78<8/M*RW2! M7EE2(AP&')"J0/MR 'U)Y,W[9TH\%*Y.ZZJ+-<=[L2S UA+%9$/G M(+8K@KHB$!4B5<)+$L V-T\R *VQPFV>B(+%;B/0;*TQ7J ]4,^6M!6RA%E1 M.9QL,(8VS$)N;QGA6Y/3]MA XVT@67G)O*V;!7-?_UNM1Z#\D^-\Z"U/,6?" MH]&V8-JJ(#N1A,))GF\)Y!VU%[3GW\%)(3CKGYB+RLY%X<[IWI *EZWL'B6" M!Z_GE-&-F0/)$E:!E/[J-SEH:V.XUKA%YQ"AGM>YU!^.]$^K$&YMFHF2^DY[JT\&+$T!4 M6I^'AT?"+Q%S(W( +8)C-GK>W!UNGF&3,E6?J+F81_/H390*6K#$^1FHZN?V2_ MA9CM<71;%'-6[>#B9:46:J..:>D,2Q<.EF2#Z"3FFIX,B\.4*O(?Q02.P.JI M@=]8SL9C6R 5>.,&W2U<0*5RIG&%3I'?77ML3G-)*N+C=]DMN>((JL%P@\ < MS7)''QR4\[*$.5[*#[!#3Y&#B=30NR).*KC@&'DF]W[NP,-B[3M?QWLP_D35 M,55U D2XU+F$D] =C>,BL@TG#6GI($%BI8U^%V_%>7BNB%G&RW>(%.#+PZJ( MV>F FG@U*XN'AIZR5Q_=( Y0^,DIQN6VP_"\_;M71C7S^R[/3^<($OZMO!!R M$N<*\1+>/ATXEO24A&\@14$$W8/E]K?,Q1I][]Z>6[NR9SI#\C6O)/9RR7]U M)($P/ZDM@<1O1@X3C:9-*>?K(.5@2 M:#%(0I)7%!=Q)3=XLW^Z66ZD"G-#2:B5^KF;AL6)GMAG\G-@C&:/1P*^P'[= M-5H==)&YX0.6&Z"<_ML6^6N1<_1'/V5[UI"G!ET[RL.M%68#Q&!.W7#Y">,C M@CCC",^_OP[LU#\@'%V7U98Z,SJ:QL<"U:H_U,-^)TW28 3X]J8O]?D: MGB\/RIO]8C )"3(RU FUC?H0<;R.4; MWS7XKOV;#0+7?12"C.@7F7LEV.$)AR:I>DRI.^1C$ W5/)JJ9HXD&_>6%,#Q M-XV:N<[,R$JW@S925,SLJMGU2\.DSL%<-G^'%GF.7!.TJCE8QK-L62MN0X)[ MT8]\E$G<+\/0$(K=S4JC71E.WE:E!YH.)Z)TT-*^3T^8T^EVJ7VTWT"H!FQ M30']6%E?0EVI_&/>N/PF]#U4E*!GN7S':MK=H:8J%7/&].RU.^9CO-^2I@< YN@?Z52FR88:BE&%"L,Q:Z$ MVQRY&$3_MJN&VC!:482P^9!P'^+.>6?$9IPMTX[JU(9TKJ-N/J,%4=N M.R9.EIC/6^$P^$>._= ^V51!UV#"^AZL#TX(MO*6CH2\EW )SU0]X7@C@7U%Y9SV<*=W9A/DE+K\L]0@_!BSX)E MU @9UN]+Y;)S']=R4T344D66\3T":EC8)FL6=MK..JES"YCN.J6YVY183@-N MG7;4,FU3=^A+VQ9%DSP +G*P*0Y N"I-D)LJJ]!%GPAH%%(.)W756.'N#19O MC'&[0Z!+=E%P0#EEIS<1OGR#/>"/S=27O+!P?5X>*=UFT5V,?-1N-#MLO:VV M$B-V.)O!UD@:7Q5[=H; &N(U"9!6,8GVZYI0MC';"U. L*S+S:UH3\*D9&D_ M_P?>WJYO*2>;]T15A9@!FN7Z<%2\VJ[9@5Q2"#4CZ(3W*A\X7=X3,[7+%^[- MM^Q&Y?D-_9VQ@)L,IJ3J3.+R4TXJ$AI\LC:X3V"OE2B_L(>IP%24;=S3(%W$D8FUT@)UX-(3,+,R0_=[XG'<5;H)A:G"N8J/SU.; MC$-1M]D5KB)47,BNV-.>'69FYBD71.']=#*+\[- -*$P.A@Z>?0113!LXL&9 M?/S$X\0BF8R <7EPG91**;H&+9'=K^B6M:H(0;)2UB>"P:0,RJJ]7-DO3//2 MCZ;+T-5=LLE?&$74Y5H&T@TH+801J.Y3Y0U"G9HAX*^6#ASCQ*#1H<'OGY6G M;&1!HQ"5/\RMTWE(ON2$P1-8MN[X$R0IGWKT_4I+NP4^U\ 9^*K_.I&$7[G? MV\KAU,C]0S@^3'%W*<$>]:1:5VRI*-7?=7]?:D[JG&F5_!6E"NEG2ZM-AJQ8 M@G.5<&S,R=9E&B%8J^O!T=QB<9RXFFSX(XQQA==(T28D6N7W<'#J/MH 0J[Z M1Q+$J/60L]#M3U&Z;;RV?8?SPAE[>"6?-#[W,0>-M3O;[*B=+HI+R=@^\S-< M/Q$_.A7;Z(1B%\]_T?"+D3X9)-$RRQ/SRSB 6<3/B8^F7"/Q8M@?QOW)=$^G M3XK/EGI;98K2V@ZF]\4",5Q650V5>ZT )6H011=SPDG;<5? MTM130X59&VMCP'/O4X2J?FRD;HM5[>=/(\YG@IK\#._D1LJ,X,!NL/K*B[?C M=%JK_LQS')=PC8-2!%KWVELWOL#3US&;]N12 #Y1H[WV(-GV?Y)^E;G:5^>D M];-Y;7%WIK4Z]%(,6CB($\RK0S4RUY]<0J$/H$IY 17PS@/8@+$.K0S8TAY MQ-\*Z!;ELEF@SJ9C0)>WUK5P:$LOE.U%0%FEM12.F/B[GT.RHJ-S,&0*L6,6 MR0HT,@D-[_XJI[@%'_:8ELZ35M(&[H-DB-8'-ZU?TZG)\L'T0ZSYW-=FR:A; M@-JC0M8;%5UTM@IAK9EBBHE T^',4!]#R8.!LDA_^#K/VZQ(_;DA9G7/5AZ) M(DS*$.0B72^\P'P.@P9Z6J0T8/'M$_K:P-HH MY@CDSRC?LSRQHR+_1)^[TNL84\:MPX4?L%F<:$CP MZ9Z5^-]7:]1GI>E"VP6@ 8"J)->X9HY=5KGUQZUT)@^FFA6UD'T?N00(+KNJAD*JO M2/W'3YPMEHR(K"J,>]K2U5VZ@YA!+<4.\GT)_HT,IHMI^*;5(ZTF$_I+<>F/KR%Z_%=?7Z9%Z5?$$M>-: M?A&( O8QP!X**\.1%&(@#>DD\0J4 6R@%8I@AP5GZ9!VE[JF<-E[JTQ/R3YT"QB2G,85);X0!)WF;K1QA\RV6&/QNX#3TC6:^9DF(3)[KT3"B](0G-\E"]50\@ MJ$A0V;=-E"S9WFQE_Q*9[)F2H*[3-[,2))-+0"K?L)O/,L_$O"[U S7TPXAR M =.T_P8"K"E=)RUR+4TL3=5._N/_3$?CZ<^>Z17H)X+0(-1O9Y;$%\WCVHE& M2.7UQ+!,=M4A2[_#\.O)5P+ 22R01E)6$7.88J!(U#,@#U#,@K,-Q*HBXN.C MQC/@8F/@8RZN0ME$DN2OJ9 >F'CC M VG:W4NG8RCVMR$]A:%7WS1!KTILL;PF#L(EK%WF1 G#78:*(]@PD465>AO- MTW')B(E:LT @90AF6$ M'LSO>S_JC_(W7XW8K9"8V;_3G>AW=KD16U/O47&QI$)+@YTIV#OS'Y+!A[]W M"1CL1:A8HTZEY"VL5<<9G;FI-P?!BQR3B=F"I%'K4+;;&:2]BY(AQ>#$0+V7 M!HHW?A$C%AN!9=9LC1<-"KV>4B#)ZT;?O_K>^6)>F"MI90T8IL*CK1; M\HZH'2"[[M^DCRS@=GQ&VU@EB$W6J?T< M'4WL(B\(VM7 8 [,++88W>Z;]'&@FX%A>Y?KVS6[,GU["V4&&@*J3Q[O9F0! MJ%CO--O 1(?/,E$_E,/!\=KVUJ'G)*Y!O^BU!^I*S><8B'*\P)B+>S(&,8@& M(5)I-B,)3/8@!FLLPD@H8\'A0;Z%P;.2 O >A&* M_C10I-RDM/!9OL9P(U- MTYAEU-/MP#12[FZE;![3,53"H@B=3=&U72FZXOAU"MNF:)<5(!BAR:-N2#4^ MVH324RP: _AX@5G5MA<]L7KE*>/W1_]:V*QH5^X%4GE5NM"%B6Y9#[0N+:-F M?149&U13*:@%O/:QIG][W[#Q_W/.-AOJ(^$^&/%#'QY'TJ 8*]&PAQ C6=XQ MK,?)01K[%DD218#N6(CRK)@7"TJU5MM)H8N)@Z]2LVJ8N$;W]U9IN6T-'8YQ MQ+9Z)%'K3%9W-!#.0=W(&UJ5@QKC>@RHN4E9J#.$I'11"V 6(KE5S1LPAVKQC M3K0R5=+//AXW81M6M6Z=(B'3D &X<&'9A !\3&D+@S6W"$1GK7(P^\&\I."= MXU.B/"JZ9U7=TGT;V%[U="7\=&7&@/^B:UXTE-(%J$_'**@6G6 +I$0.<,GK MV-,2N^(^?0GG1JTP)]#"V._;0'(PB-$%W(/%;XE:3)4H)^2-!QY9X/+"NXS/ M)'&PETE16Q2U+'R+K[?]/9=L2UO;T,BV-:W#4?A,7W IN*MGLZ_:^%'=SF9J M7!@T)D0KCE 8CIWQ^62G(X_5P6B]E7 MI(WSD^,CFQ'9W9K#ED$!ZPOEM-#Q6EYH%]49CH.B9@L-PJ?^(9V^Z.KK4-/. MK;^4;KDT4T\!:Z6]G.ZE]2)IC\F5@'V@+$S]\B,+Q>RIX-ZP"404[B-@_U)Y MH[!C/"SL\>(2YYSA,R[GA7?\U-SQ]]$[+L69ZT08J$[ORN!8 *BT2ID[T+[J M&]VC93;0C2\4XR-L?0I3T$2]R@F:@*C1!!H,X]"&B7''(IJ#7&NIOO;H!'0U M%)%CRT9%2F'@+J4"2VYH-\:DZG+VL9U%0H<((:F#<:>EU 9/85L21OS,#IC MHEN8(PH[I'C=9ZUYOQ@-!UC3C.!;)1^SPFS=%"-,_0\M2 CT_T92U(8NR%V_ M@:Z)21FTP/=E.^UJ-$*+V,/5BO6'FMB=^Q+C<%@-G.]<$BX%KGNF:8/:;V-L MU&]*C)1Y\:,:B*\7/D1 &*9N6FG!2)?^7N(1WF+Z4'%EF4J(5/W@I!J]!^D\ M:2R6>"[OY;*H824BHAX\E Y/=>Y5 &#;OB]X4@GO- Q7>!(E M0&R;E\*(1QK/^VZ^KE*=W(P^?LI65W>O6-DAG4G],6%Y[G*>SVXK*)2JUIE LQ22@^V%L"W2.@,055J*4L0J"J' PQ4XMGK_FMZ4FF27 M2>B>@8=V;'8SNVRF-0\*L+768TXX(_-)8;+Y2N*Y*EEM!S2DT+;JNTU%$$GB$@0 MGUHNJUK&LD'ZM%%;:F)_:.T,Z7^IIKP4.%A^3_A/^C4QA@5,'0Y$"&.OHY_Y M'Q@(GRS*A208DTV=A^9_R+S>,.#I&0">5F(EJ"1C;U78^!;75/ \;"5J($=] MT*E R!"TA*+M)4$/61CQUG@Z+0+PXA]=J/@9 ;X_2DJV\](PT\N7\YG:"N)I MZLK1CO5ZZ%T2\ TM=\WF4)=E453AR0@T+*3E$1[>')*="=S8@)ZS ^.BN,S7 M5.9#QS%>%&HZ]WH75KK@+J=MPDL]Q?"U:"E#2^>!_*"'1;3.@HWXVC],L&(%X V7ZYOT0#'/?#[/ M@A]&8E=I"(+5 LIEO"&>7#=OP55YJKRE%<.YC*UZTL=.%Q*)A@- MH.&'21#0@'425[DTV"L)X?"(FV)%& M[#DV61Q/^,19_6V1$_JD,Q/--MF<8<""T !8+EK6;\)P<(J,UJ2NVOVJ0U[" M+7RDW4*#RVR%.>MDQ+M;DT2F]S#!I- 9@ %IQ#2>M+UUZ9$9A ,[258A8[^4 M.=&<&O+X4;%?,' O)HS-R)G$%5X1:XKM!@#/!WX/I9P@$*21:+1S340D$<@P M Y"E)YHPJ2XY2#90XTN2ULGBR,)59I@2*L4 )\"%8A'M:&T SO7$]2REBH)@ M#Z!!(+3[ZBJ_3DZ@7=I]G7ZX@+<^IYIE> )B60W4DZP(50 O*?V>;;U7L*!+ M0Q'6Q$"6IM%ZSFCT?8M6S$-#3O"B]&9$:(:8ZK%V'QKI$*%%$UWH12>Z('XA=NL M39J)5C9UYY)Z3 D@6E!8$B::M3SZC4'USN_SV1QKTK@RA&.+Q<1MU-6,,1%# M8G2>;8*9M$R#IE6-F"KA.54E"K:]"$:U(L@QL&L83FH5Y-&0LI2]&^"6_$W@ M*F7Z=FO0"AMM$^)M5/?H1I_=LJM(W..9A@9%,*PE&L;?""U 0(^L*ZFM:RM( M/2MG65Y33EO-"37/+@36?#:)92(B1Q<^76 3W0AK9 -^2;VE0=;O==%>Q?_N MYGG2I3*33+@3G]CK4PVI M.\6213"!@BQ%ZT!I"$H:F-TR4'6J!%"ECT"3T/L$^;KW)31%%H!F@UGUI74- M)R6U)87YF+L/$J-F^69:D1UE)Y\45./")A1$![V)J0U.LQ(FJ%\!YXS-&+R\"/DIF MON-&H4@R)SBBK,'ODITR9\\=%=NKM9>^04'XHQ:5ACP9V6;4EV/@-Z\Q-ZR> M ,GJ %<&PK_=K&< G[ H"/F;0_IF87/[I#,D';_W<_J&IPI:I>#O5"[R)$G M)58X-9N-]U C) 17)>2S8&-\Y2TC@"J%K*Y<(-@,5?-17=-:Z+%A9,NVS6H8 MK*ERFW@1@3A+>+>7J&Y8T1ND*"<\N)&A;B!-#PY H@8]4CTF].-S0#]N^IOK M]!5)BD(;#'YR4K]9&'M0L4(*AS<>=%K@GM(A* [YVR.RQ:D38:,CJJ"@ M2!@4=O)5PR=P;EB1ZI(=DL4M@/,N'QG#F_Y@5X/WQ&FF5YP!<.H:L+FK^>^G MEG9N([*:ZL80!7%-V_&(0:]ZWZPU&F7"A*\DVK8S0_L6IJW/9U\*!.#-,7K3 M/*I.S[3_;FTVVR@F)&AS#YO(\ X80K/S[VNT]FDAMBY#=0"8P,$'?V"C8'R*#XJBC: H!(+.CPE6*R"Z-Z5^I!RU&N8+RD_%:0P]CDI(;%/8"B - METW]>NY!9R@0'[!R\3W8%Q[ZYP)W9$ZUX=5K>#HZYBJ FL]_8[6 )42N:8'B M24($;709C:V7V1%6'HE6*^LP5RZ)ZGF*C3)^AEGBVN04NRCG&J9*L1)%SFP2 M6.FJU02 A=AB",+61F*L4Y @[_.M!*>(1!^QJHODD>COO&XP% B4:*0/1;\M M6G(+Z!=POQ*;JVD7 8[,IILK42_G 'X,YF=#0L!W^(C%M(V7!&\'!(3R!H., M@9*5W&W:10/98]Y2C)$C VWM5K"XC@8(X\KC\2NOHM@JL*$X28K\K>SK($M- M4*L5<82JBQI1GDNRB#!OWHMKM-P(=[%VQ4 HVW5\ZE76X'EC_/G'Q%J&8_!7 M.BICK;IWM>8#\#F)1[ N7[6N!>S25T-,1/M!5@X\X@Z3%/S.'<@W%\QO944Y MQ+8OL;>/IGK-@/88NK@B/ QYQH5;UQU3-889X+G'&#:)U5G(%L #]8P(;9L MZ@G1XPZZ#Q? 1+>;ZOJ15"Y\.]S-GAEVQA!X8"M0N\"\ \,4K%6IW>20;$!> MUUP;@_7(01*J?&.@Q$+5901A9B/4CAV30F5C0@($X=$GOJ3@(QGE%=23AC3V MF6*0JNU[1?XG$.MRJJ:!M;QV^.9.OL%?S>57XGW$OP# H-08N4HBZ@4AO/9& MG=?I6T$HU!.R,6&AC8XX3FEJ>EPSH-K -5MHKV;J)<*(-"6J8E,FOH<"7.RP MLP!&=U-8R+LF2LF-3+ PCRPSB12#0?,BCJS3JZYXQQ:\/8F9IO8L"M8/M@6[ MMC.F52U$Z-:;N$S73"_C!^/1,"E J6W)&&Z% : S*?$"<8!B2QEU^UEW.K2V MPX7@T#5B[(_&V6 RSB;30?0S*S4T>8]UG2ZM9%%T$U(Z@QI>RIV'^R(^H?^T M3?*I-U:B5I@-.]W8$/:A1\KQ6FXXA#R%ZZK=IA&*")Q9XIX91@@@,O3"/3PL MNG.ID4CJODRA-6;<)H@(WRC1'[3:K&<'[/M"WW69IWNY7B='+,3:1873MQ&3 MX$ZM1[KU>S A<..&3AN;C1)@2?Q(O815['D8Z@<6G^(*ANF+]"64J00J'J9[ M]&-O/,@&2J_!'[L]]:=!-NT-Z.=>UAMUL^&@E^XEA\6BQ#>N7"9_U&^IS14K M7=G8YZXP7B?K3:>I(G_5]7@R2H=0XSL;C(;PN[YJT>TGFE'RZNJ<][77(CXF MK*O=&?$*VZ,QKZTMJ^RT1VK]OK%"6X\9[;"5GE($_PY-TV//"*WQS[B%KJ2$ MQ@;YK8Z!0QRE8HT,&WP3#JZ2B\*%XFN]5Q15]$OK>)< *]$*]@95]S;=:A). MGZ33S):^,TO>C4JKC97>!K2G.B"&R8IQ"R7]V"[[U4X_U8J ^>9]AH@V%67$ M)Q/_G='$DK@:_A8L2+V70$W ,R7RM&DRX=JIEEX75+JX>%8ML@$/J+8"3(U'^G.=<&SD D?[ MFH )47&F^4I9O<3>(.W4K &!@L' +CL ^O!_JUYF*THM+HRJ@*%"5 MJDW'0 M3*'B8T*[TS5_:#GHL,AW9$ )+]MJJ-0:R@T=0T< 9>S!ZE8/94O1T)U-/W#$ MG(P;^2M4$U'_SY>P"AQ>Z$;IXTSP.)F7Z+/$NCCE%SG38R_:Q0O6P&[$[N'3 M1>9L!^H%LOL)]Q[VYC:,8*83<71SW!-!Z#?-'C=![XV>J94TO\WD_ [LV?K3 MX,3_?&'?!Q1(B__&ZTWV%F.K%Y/FTJH-&XEOV0H46VX6,7W#4\2<;4U+]6*V M914Z&>)I%GM6:UB"9<%GR.U49-P&%NY7#1H[IZPW8A%X=82@G:.\WCRHF6;B MEBKR1H6,NXVC^M7-&!IB0E 1S>C=A+?M299;-HME%JG'I-4WWC+S796TS(.F M\;[%9U;#Y4&N;2Z81284JG8]XZ 8W?LN,E32($/1!201:E47GM(C7;TO5"&5 MXD)GX 6#LC:LV5)96Z4[W=Q0BK)94,)F,1'85Y_=&BS=/:=R!>;6\*W"7;>+ M#V@/G:F-Q(4X_NEX[@PD,%O7?DY>]MQQK'U#J[NZNV39L0,817 W$8/P:\S M*&Y,>6SI@# PP*/VJL"G&,JD97Q##:D7!AD'_,I3)5+*VQ@_%JMTH(*DT(CA-*YLHV MB5OM^H+T]P+!YE?&]48U5&<+"!7#T'#:-H[$U] >M^55,7\R5X^5-MB9VY,# MWU.(_ %AV&=F$+.80:[H7D\C,%ECH#>0:BV5!C)*R#-[-K"+$%^/>H(KQ:D MV"P]G>>1^M8%OD ML0D8$2.WU_!IFH^ILB.IB>AZ(%ZG2\UF6IZU+1$/R]D*,'"N('89G@"9AUV- MW+''8!BZC<>A7<[M]*T;,JSC\8V_2'?%-10@RB2?P>^8P2V-'_+B4?,'#+:N M;9&U(VTP.!.N&L65:\[QS_75#>6,V%5WK87:;,KO-]D7@@J&J->>KZN!UZ\":+$>W ZU#)B]"=11[V MA*YF5Y9KLL;>$[&3D)LK<)&>;L\)"T/ )0&??AU8'1E%C)*HJ:EA\(' M@4="UDF0".XA1FGKS M[/29Y]X3Y[01$K]U1=4ZZJHXMB?/?HR6I 2V&]=CA*,'K+9I<^][#!)6,[I6 M_) D*\YB3PR[XS<-:L2BEKN4EQ5$_PI#LZX=/D]E,3&N;L6;2T8XXE_V<*2Z MB[,,HG\MEO4T:8GKW.EH/ST:"7D0SM_MM\EB[[U)+^V MA/("4PMS!LUZ7498XSB?U%82Y&-]""[N"*'6C&R#F)#FM;<7H>= KJO*1!O5 MPG.T65OTPN!6.(PSPBT].QPB#WF/NP%EA=,XR.]F*XQ(JLKU\M(/T-[0'/+C M@S$"[,NW01R2%YVV@5)25+9>V#G\@DR&_V+%@63JWK6G]G>AK_):=P!:1WC% M-.,KK/:!F5+.I*#L7+MOT#_?V#OM74BN8&?G M,RL=MZ'Q/&R\FU!TK&)<2H4 \K*J02N-9GVQ8HQ8$4[KBQ0-CY@"<2QCW,( M1ZPU3M6[EPOT,T"5=BK!B$&E5".'ZIV&=U\,6]H8<3GG/$L,L1;#%1O;'PH. M!">@G-<:W!GU)!O"!G89&9I &8:6:$[@9QWDGJ6?RP%2A(X E<(/F0HD;]0F5:-55-Y : QX01?A"F.=2AD"%L$5K-2EVB.)&!1.A1-PR>E7I8> 8*@BC->/3X^N19VY7!" M/9 ))_ H+1@1AF/A&=_P4>S!63(?-:5NPU8H%M+>YG>E2M*0I=$ M;D%7LL)T;2TE,V-*QO:[?/EQ!H[XK A):$=69LGILER4,&X0E&)3>_ #(0J:T1Z.]L_>2-[B_MDG_$NK MV\T2%K9",:HZA'4O/20> ?< ACNQLY%@B]Z2&LR?#";PB1*][HDGX,[_6ES= MP+?<9M(=[F521YK+G%Y=+8V+Z1)K;WT5>Z&;=2,WT%P;6P/'VXX&N"44]4NO M"\0M5=?QT/\EA@#I'TI3UXM4^Y:Z_U]0?C?]OP1'B)*&KC LDC]E1'XF'+X9 M(*M\$>@,25: @ MC_8/BUQ($ ^TX0URHGS:V!*42SJ>MJ_A:.Z*392XQ+;@B M;1[)W6PB)B@ZJ/\$;V@L)5>"?P[#[C '1($GR5FO\#"1$:KW;_$*]*PL,7Z. ?1T'#_"(ZK)- M:(L /0FX'ZT%.KX%A$01PV1!9E16OP#&$:^H-H>9@;Z;0(+-^)\/X^;.Y'JV E-'E)937!8V,/8PMB6ILR4'GLAQP*\&?O&1 MD"TK5JC5;T[%7&+N^<":Q_\2$0R0F4BJ$B&4 _X<)-Q3\MR!VC1U%,@1*ZIC M2(:A+'VY?W:PQU:B46?$ &_J[Z(ZVS;Z2B;%*A/T!5"/%-^F<]6!FJS@YL1) MP7^@T"FH'&H&<0Q $GF\U'6FYPQ?!;J2KCG R7?Z.]T9#J?6P_9A)J^$ %MN MT:L&@3XH66J;..HMO$ML6V2#$3]^*-N*4&-7*])U9-&2231-!DWQC!8,49[X M?@!X@[S)M%U2'T:?$OQK"V@P?/JI>_JODT/,.2$W-O3Y5K^=APC )8@CDK#U MV7Y>;8.#32&:*F!)\LK&GM*$G](1 N#5WM=QUOS *E&!DG$9O]#X]'2) '>Z M0$J*/]FQ50IB&)H;4)9-HR8ZNN$KQO49!9(KZP2ES6 M B]&!W%193\K,;.=N1@.J-GLG<[0/[;KFD5?!_UJ=GHZCBX]*1 >082!06\/ M^ \$ <#_D:/W&F6W++'39P3AFP(<^H2->KE4FQ>4AS),'JE M@,%*,8!L*2G.PEB /N&!DNBM&:MA;(M);*<9VAER@PG2G(WE;V(620IEB#5V M_7NNY?7M+1=V.;,"W6RM5A'>)=9&.T?CJ)>M6GA>_D=^ M>_>SK8H!A4PX)W=/_=3-^JJ?+I!3XBTBPT30%^DX&TX[<*SJW]7W?27%C'J3 MM&D;C\B:XDPFM+L9IGW#!TJ&5$R)K2V7K&LPH-F^L5YN=1P\>EX;W8M:S#!( MC3RY./JEC+ZR1K=LIQAL4PF*S6M46M6F##K=;-(9)&AW4/=-24>][A1^G*H? M!X-Q-AIUU(^]COJQ.QRHJS.&'[OJQTY'[68'_]J39+EE09)8+^NHF]4=]9-S M](O:1]' W:U'Y#\K3I%4O%WRN[;:PGV(W0IT:/+%L-O$2ANK['ZF!,7ZKT_R5:CU&6-#O%/<4XE)&I:0L,A[ MP[3WJO]*G^DIBO%!;@1QT@?LLE(,Q.JKW O2$UJILT;\9<%ZJ%98$ M:ZVGO;3;?36B <B3O-TK@AY#<.BR>Q:'5[R+K]9(*A].ARF MW5>]R2M%4.JC,7S7[:GO^UV]\'=ZO:\.J."!8AV_PG-TB-.L$BER]PMBD=DU MYVAS!T,Z#?6=ZGP"NSQYA9O[C@H &V_-8P+R!H XG_)^]E1;F& ']I'W&:>O!/.$_ZN=]/3V:M8S6]-T@+CZ]^54\< M.-?S2U#SWH).N"R5(IRR>?K!0 LB^^(=M"C[@,.)#$ZEXBOK/TZXS M>+V,-:F.=6\C%A"(A&N6YKEX"!;D .82LBX[,#Q +TM+(?LLA;S]6BPOP2][ M"O9[(Z6==-CN=),#Z M1_UOP'Y#;(&I'_RQ3N4J'8\*/Z+?[/?4':QJ!=]Q 5ZB9 MM$$X:O>'B5YQ0;T23'"P@Q$\T-.!+Z&Y$2KZ.&YXC?Y1O$@[[OT@(;9RD,-UX;@]&:2C M]J2CB8G(PY#/8(+RM4M#/9 IDH6&+7'78>:Z/-F(B+0%!Z_,U"4UQDELLZW M&TEH.%72R* +G_?;DW[::T^[^O-Z[*:::M8?#E"X;"LF.F[W^IN(3PZTB?9: M'N$=%A@ 31$W2NC:5N^$?K8B1VCHU *IB>'O!.K[6!"ZW,VT M"2-!<>,C_!_N,8KH9\5BAK; 2\R=0*!OA )/IZW?UO.6XDLLE$R833/OTP4C+]>#A-3HJJ>DVEPG1*T:T$6S M>XU>-+B<2AJ%CI]_&8KN>!G$1E"#SZ9*(HDN1,D1_8%:ZV37A?1'BMQZ@^=9 MB:@1=!BR"$UJSS "5YI2[_HEQO4"[PA>4V)$6QE?1-U6#'HXZ2F5?82/,42J M9\..<&O)T10LRY=6 &^)>;^8Y>%;0I08 MSL\;&4,4(U&,J]?OZ2U5\L9TV,_&2BG=895H^=]MA?(I!_;,"[N*(:61)^B\ MH;]$@-DD+P'C?+%6'@:@A-?_TC8E@VFR.\DZDRYMQ7B@!,4.&87&BI3&/;(( MJ>WJ]T=D#NJ-U?$/S%Y-Q^IOOJWGP_(F7]BEP \1[53[I'0$Q,O# N([*W5# MEDOT7^TAI;UB2V^]8R6UM&'2N'@_"H[T<9+JJ[OY#+.>9Z4W/:D).I%==*S8 MY;5DZ<%O*(WZ-O]G:95=<2#S[LN5'77NJJP4>8Z9?.CEK$^PKN!V!Z.?=4$! MS)VP1G)@$S$5%M<'G8 KT^0FEHNBI2A#_6^]Y))2*PLS5_Z\>E"T1B46,ZL0 M&'5*#F<7#0>F2K$'(.A*N3Y,B()@]*J<4[KGLD!?FK?Q$O Q),;V7^^0G/__ M5O?%JL[8&]J)4*%MU?L"P T0#W!'?CY6"/8NRH[(F<3G1Q;9^ZI=)YIW$5 M]H3#U5@0NA7'E;?0X8H^5G2Y/C/)9I#\PVH:5+OH=+H6 MJ"F"&\2/ZYOQM=W+4U!?.X M4.YNMEH':X_8[4>1K=S49WB6^)744HF_$KCK4MHEWDR)5;I9=)X;*.N_3L"/ M>@PBB'?_C0W(C4J6-:9_IDW;N!\J0Z;DLWJ[4T@%F%D%IDS&G5LNTR-GZYI: MJ/%8Z:S>5GLN9G>!6E#^2VR5DO*\6O76;'VTC3@4'VUXPY\-,L&Q0>D6E'A3 MS+;>> ALYZ=F= \O^[[>_&TDQ[3>CI)PO=]B$JJWP:&\3Z]1+%_./P G6\[; M<3=1SB,,MI_%'K9]!ZK7Y [5H(&;88'_C!RG4$-L\*T0D*,SOP88='P_.614 M6JKYA#U=5H-]@5,";HO%9"&?5A!9XG+ Z06?58W1T/M \")1Q>=(&T:+H*' M;A4@OX)[$5$Y_G%JI>,R#)15@,DH>DA1O"Y_JR%03%>JEZQ7K/)Q48!/6LG1 MBOTQ'Q\$.!.?"C__4N*61(48!;S+OY+.)XD_)MV6=:6[R*)W/-[CT]2DNNX# M3@;$;:=O9HJ?D(OPVP_?')^&#]?EOND%P(=[IY4X\_Y==;1>/A^U-HY*W+ZUT8]*5)OQ+(]*Q="7T;+'L9F<%(L;J'AR M;8ZIWF1**K97&;B849WYX-3?X-.$,@#R _MOY\MUM5)ZN?4K.\3>AFJ/3?O MJ8;>?+]^YUSX\H_%[/8"DAUQKAS-[/,U)21\5COY 9.) 3'S<=<5>NRE6$D&Y*,N M(II>4>@L%& N?$(U+$FG2UWECYS=6MVI0_9/"EMX"U+4#KM?5N?\>A8'V84H!L$*W1 MT5F8=F CY^L>::L%7 ?$4U5FP6O_;OP5?[V]=["8>MM/6G]F<#3&R37A, MC-$9BWT^C\S_77$%1 E11<6\O",,ZB?3QV 8XFAH;@40:Y:CRHLYOV+>(DD^ M$K]U;%UXM,572< -O5'/M'1I\\OMQ:]/O#*:_<-E_J[G]&&IN.OIY[)8S+ZB MEG1^ M'VSZ'%;ZMY&G^/P)5@O#X?F1JC?L!:6!P-I^" $!V!_F9IT_E-&]^?$7A^ZD MZ/+8P?6WI,O Y'ZPO6\@+&KQ85'\<,L+K\1>ZX^ZDD&0OX7NT8^Z0FUR0@?J M%@K1#AZ<5OH-J5W:_P/.Y8BA_TD)3Y[MLA[C*7(OR74M?Z:>:;F6=;3%)TYM M]RT\7>A$Z73#/G1TG71=GTA$[\*FG?XV3=%MWQL[3<'UD<_G2#%-GW6&VXP0 M\B>%]M9Q6X!!4BGB&*"X16/T"X3:;J4IO0-]'T38LW;>7K;GT6MTX*2$@VLG MKAS/K$UD=Y+\&!)I401'12INE?FVQ<#C3#9: >ZU7Z'O/5;3F[C=6#I'Q=%X MGM17.#\$DE,DE_<&6RB M/ZQSJDO+B>:RD6"^P\S@0&IBVE\Z^.Z4_)?,HXG*G0RS!H722SW=\MVHL=C- ME1 EW90\C8#)X;TCF[(@PWL=ORJ&/5J0AQO-B)LHS#]=A3V(H2*2#;F_VXCW&R=?[OQ((,1")OF_-V2;O,U?A\G,L3H M>Z>#6:^>7XV28#T;6C"UU@OLH,Q9_]9>J&-"29S27\_=]-=#G?Y*_Z8AI-(S M3']U%A](O(UM :?C!I8X#OR:DW6]?>1DVA-)ICV69-KMPQ8\OD-IN_[$QH$) M4%)OC%8VYNB&):OHS"@EV)\99@A[K2EA.'0+0)O53ZJC%V_*&8Y-C1.) W.8 M!.B8THQ]=4DRAQTW62WQ.#8#3D<.$$Z8GD:!G=PR_WBS#!N;)"<^!WX]#&P( MIT5[U/5JW]D@*QD:0GH;Z!KSHSVS"Z9+^X2-V=-!)Q/K]IQKK-.EMQ20_.C$ MAE!&CK@<-S3IC#8W&38UL4-0FYIT&ILX@?<-D9=W2S78P)$1-^T$?N-WW=2X MM], 1\5%6^)FM_WFMWRA0WTW3@H#27G_1EL.0+'$;#W9.!LTA- *1K:2O^E# M0A9\VGK MS^42JT_$_+>QN+@M/M5)XQ0A:V7:!\Q(&BCW>LO(._<;!O?='++Y:6&5W'!J M6?R9OO!6( 6%[.Q^F^,?+ZZ*.TAX4-(:I6/0WZ*L__<2- .$V0Y%X0Y&(@T"M5H&[(R-)6)$.9-2 MI5&WRCATNMUVO]<027O+$1D[F$]E%Z>17?QEN;ZXB/AJ-N[&/L*=QF.>N^W) MQ%O.:,.YGLS63YP.^5(M$7J3,U7=%_\,8C$_!U0<"$XX'%)4@I])*3T/Z=%L M>=NLSCAA0=PZ5[]+H@25<,P'H>++?S,!,HW6XZMK!#0#1: M@P%%.S?KVPY/V8[GGS9O@>F;'YIOX6;1,+!5Z_QST7I'A_*!L>WC#%\?2VV% M.QR%E+ (GT =A( 4QKC')D+I!,)B&;SNR[I>_+MZZ9K.UNE;X_1$C91\1G8& M7C31HF[0I+)5E UT[1M8F-T,I(S0*!@3VCQ?).Y-Y/R$+K;P%#RQUPVA61M[ MW?K2?X*(%B@6V\!GGV^T75F,'HS1:KD0&F5KA:0\6R)I$E/[3%8](:M^.-;X MKUOZ%K1$407X>'CKF83ED>&&!_*[+VD#(?>GD7F/=I^WDBA7H#2%9AW,9;8Y M[YO#]$"I1C/C3&MZ__MAP5O-VY?_SC>0XC#ZVQ_ZDGV7T MS?>[MT&8[+9'/G7(:W.$620':;>IAZ@O!;GBQ(X18;Z!G M4VY/IUY7G%AX^*3$P@;+88,#Z:F0BH[/;Z-0X!A--MDT C"( @;W1N/PQT2* MP,<"2[?#)P:[;H>/C!:[PT<&]FZ'CV0[WFXI7H7Q_H*[&C>L;NK-;//3^[#W M_>F]V ?Q]%[LDWEZ+]Y1[=#51RT- R"C?UP[=I#)$<7EZI#8L^VTW@;Y7!#7 M7"?3V2GX7-\,N?(GH.A9L_#4;/G8:G9\_#4 M (5\0U]AXGF&#@-T]63>'Z"MF"U6K,-I=_(4=E[?W*BRW'M:[X'MCBD"W8XL MI??$I<2.HM[1N&X!Z/6# VZ%S[O92T\1[KNYJ!&<:4-T.?@_Q8W9T*3FA_9& MLOW.C8!1!%@U=0"K) -C*Y]K[=OM'-8C!WUJJV\ZTYV^"8!_8:\Q4. ) M(%2;?8(15+38:G0P6C+H6VZ#!#$(VN:"U M6-+RP0JOXP2>;VGOBX=T(P@90Z%[M+,/W]7BIKV#EX\,$ 35NXREMNWFJ[3: M-]*?':7]*"$0,3@Q*S2BA@<6]HVP2W:7YTU[=>-.;(_-6_;3\&Q[C06*L2K%7G3) MR.0N4&E _+K&5W<:6JDZIB7*'H1/&?^Z%_**;;7$Y^)( 5&CL+-H%H7.K_;M M+7#_0Z^AD4-U4D5(/A0]@>1#+_K\*&0@_%_=+/1UJ7[4"]G(^P:]B$1*F_<.AOOJ!_[5SW399?,ZO<:EI_N2DV)\'\9R?;DB-\1UT903_>/L2E-2\X^SBJ:4Z+_M*D#1:'RE MO"H[L88"3!]YM0!Q.AZ]$9(/4,*"Z.CEFB#KXK$44L5,$@=V$?D=U%*NGK73 MY[7]J2$>?5*B0-,I14RXD5T,8OMID!Y$O 8M!8U)$)O*]!92Z;VUIQ'T_";ZH$Y&]9 \#D<9-D335DKG G CGE#5KMYH.D M^S#DD_1R IU)JRGHVC1>/U(1S'/$U&HZ;= -8P;LR/Q0"(U*W2<"0\.;%]3" M A6WGJ:H87W 1D7L7C%'=-PU*E)B03W'6W[*Y>JBM@FXS9L:-5[_H-4TRB&# MV%Q>_\U8?EA/*-+_[A=^8Q4M-_J!SA(Z_6V-_XI'$YNLN>+//E&W$%830(-7 MC\HCT/5%I21/N$AO[YW>W')1]78-5'5OD*\BWJ<8I''<>K:]N>KM5ZHBZWT5 M%R1_F9<7ZM#?J(=,@-Z]O/4X&VPTN[ZJJM4__@=02P,$% @ 53AT2Q86 MJ!9 @ )0L T !X;"]S='EL97,N>&ULU5;;:MM $/V595-* B62[-HE MC21H X%"&P+Q0]_"6AI)"WM15RM7SM=W+[)DN_3F-L7V@W?FS,Z9LQ"A M"HXTPT":ZTKM\&09-5P$ES*6L0)E)(Q8DVKBJ#IE9 \L8F<19,PG > M<$(%3F/1\ENN&Y3)5N@$3P<(^?P;F4."'\]??FFEOGZ!_'CVZNPL?+RXWL?/ M7> "(\_Q(4]P-'^-@]\GO0S-[X?,+KI'/_M#^I^1[U'/+770;U$:%U+L[I0% M3&W" :T(2_ -872IJ,TJ"*=L[>&)!3+)I$+:')'1%EFD>?+AR'OV]'H>3H54 MKK:OX/^7_?2]P,:S BEC@\ )]D :UT1K4.+6.&ZR [\+H=Y>K&NCL%1D'4UF M>$QP@RFRE"H'-92)\ 9*8P:%E:-H6=E1RSJP0:TE-T9.22D%<1HV&;UA:#-@ M[,%>[<_%#G=7(#_''DF(D56Q,W,\M=!)WF;SW-NTA_&BFJZD?M^:Y0CG MV[L#]PH*VCF_*P8!AIW4-5N_8[04'/QB?EDP.K!@&I--'51)19\,G[TJF0% M8;0"I6FVC7Q5I%Y IS?7J2L.U3PY0I]+$* (VQ9M[OXQ[_)_5CQ]\_>2 MW5=E7_!Q[>IS2[2]] 1$SDY!Y/SX14ZOGEECT#?&K>Z[TWL'%"U;RC05O=J* MYCEX/?;QD^ [^^YB.QUP;,&&7I.E>;/N\)O<' K2,GUOE^B""1[MCU9X-!]F M+0:*!(_V)\AIRZ]&PO=V]R:V)O;VLN>&ULQ9A;3]LP%(#_BI67,6E;:J?E)HK$* ^5)D#J MM%?D)FYKD=C%=F#LU^\D7>$PV-%>#GV*;[$_I3W^?'SRX,/MW/M;\;.I71QG MJY36QWD>RY5I=/SBU\9!S\*'1B>HAF4>U\'H*JZ,24V=J\%@/V^T==GIR7:N MZY"?GG2%']8\Q.?VKBITF>R]^:[GXVR0P;@<#>PGW3XW1,?A?YC\8F%+,_%E MVQB7-E#!U#I9[^+*KF,FG&[,.-L.$=I5XL(EFQ[%U&VF@K&9Z)>>5N-,0CGI M!._J5@$IE7(325UUK5QJ!(!4!J78) M62#(@H L=@(YZW#@500Y)""'NX0<(<@1 3GBA;P*2^WLK[ZC#YZ)B66PZ[[N M%PARGX#(->D#M MT ->MHF9IT\0K$UC4S8@Q*:E(9JO0L7.$,2G)2&[+4)AJ@ _; ME' 4LW#PJ4'L34S2MH[B4H>@NWP*8U+"46,GPJP8D\Q=F/7S&O.SF,&\ M50LM+TZSBM*/8M8/B:FP?A2E'_7N^@',Y[#"F)2#U#LZZ.;)04]_3XQ)64AQ M)S%O83Y_4(Q)64@Q6XC$5-A"BK*08K80Z72%+:0H"REF"Y&8!;9005FHV&7: M4TB,25FH8+80C:DP)F6A@CT)^BL[^Z>M15O7Y]!VY;YYW5]W=G-L;VI/?P-02P,$% @ 53AT M2VM_$;U^ 0 V!0 !H !X;"]?I, M=C:Y59RF"^7&,Y+=9CQS- ,'C2/!\WA M08MXT (>M(P'+>%!JWC0"AZTC@>MX4&4"C*F^"0):[S6)'!->*]) )OP8I- M-N'-)@%MPJM- MN$=YL$N DO-PET$]YN$O FO-XLZ,UXO5G0FU]PUI8.VWB] M6=";\7JSH#?C]69!;\;KS8+>C->;!;T9KS<+>C->;Q;T9KS>6M!;X_76@MX: MK[<6]-8ON"N1+DOP>NN1WKXPSAX_@BN;W#^[Y&;XPYH1W#Y<*_O\C&'JP_TC MI4._Q:KA^?0_[S#U-T+=7&3N?@!02P,$% @ 53AT2\P5_4B3 0 ;Q4 M !, !;0V]N=&5N=%]4>7!E&ULS9C?;L(@%(=?Q?1VL0C=W)^H-]MN M-Y/M!5A[:HDM$$"G;S]:= MN73A138Q,=O4[,>$]'(<85M3/T 7.6?E$*\%]97J KLG/ZG@X3;DQM'0NAAU M0?5L+R+-8]2S=N(YMTCMU2FH.*IX3'VY#_MIW+)[[SOP[Z!G77/:J9^/0X!P M9" Q ./D(!03$J1U$J1W$J1Y$J1[$J1]$J1_$J M1Q$K1S&K0#&K0#&K0#&K0#&K0#&K0#&K0#&K0#&K0#&K0#%KAF+6#,6L&8I9 MLPN:M6O31BK]%\F',D !D;V-0&UL4$L! A0#% @ 53AT2Y=/O\/N *P( !$ M ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% @ 53AT2YE\[%8" "N!P & @ 'W" M>&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2[#P#9OH M! J1< !@ ( !@PL 'AL+W=O$P >&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2_S)Q0@/!P >"< !@ M ( ! AL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ 53AT2\_;[>6T 0 T@, !@ ( !&"8 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2YY?0E&T 0 T@, !D M ( !QBT 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 53AT2]QII7C. 0 G 0 !D ( !BC0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2W_/ M>Q3N 0 P04 !D ( !DCH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2R5*L9IA P M@\ !D M ( !5T@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 53AT2P X[_ . @ V 4 !D ( ! M"%$ 'AL+W=O#W\F4# #X$@ &0 @ %-4P >&PO=V]R:W-H965TE6 !X;"]W;W)K&UL4$L! A0#% M @ 53AT2V8Q 9ZU @ %@H !D ( !OV 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2ZX'L[4S M!0 &QX !D ( !G6\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 53AT2X=;3D?$ 0 :00 !D M ( !*WD 'AL+W=OP >&PO&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !5.'1+S!7] M2),! !O%0 $P @ %0+ $ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 *@ J %@+ 4+@$ ! end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 251 328 1 false 143 0 false 9 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://marathonpg.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) Sheet http://marathonpg.com/role/CondensedBalanceSheets Consolidated Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://marathonpg.com/role/CondensedBalanceSheetsParenthetical Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Income (Unaudited) Sheet http://marathonpg.com/role/CondensedStatementsOfOperationsAndComprehensiveIncome Consolidated Condensed Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited) Sheet http://marathonpg.com/role/CondensedStatementsOfCashFlows Consolidated Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Description of Business Sheet http://marathonpg.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://marathonpg.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Acquisitions Sheet http://marathonpg.com/role/Acquisitions Acquisitions Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://marathonpg.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Stockholders??? Equity Sheet http://marathonpg.com/role/StockholdersEquity Stockholders??? Equity Notes 10 false false R11.htm 00000011 - Disclosure - Debt, Commitments and Contingencies Sheet http://marathonpg.com/role/DebtCommitmentsAndContingencies Debt, Commitments and Contingencies Notes 11 false false R12.htm 00000012 - Disclosure - Subsequent Events Sheet http://marathonpg.com/role/SubsequentEvents Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://marathonpg.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://marathonpg.com/role/SummaryOfSignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://marathonpg.com/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - Intangible Assets (Tables) Sheet http://marathonpg.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://marathonpg.com/role/IntangibleAssets 15 false false R16.htm 00000016 - Disclosure - Stockholders' Equity (Tables) Sheet http://marathonpg.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables 16 false false R17.htm 00000017 - Disclosure - Debt, Commitments and Contingencies (Tables) Sheet http://marathonpg.com/role/DebtCommitmentsAndContingenciesTables Debt, Commitments and Contingencies (Tables) Tables http://marathonpg.com/role/DebtCommitmentsAndContingencies 17 false false R18.htm 00000018 - Disclosure - Organization and Description of Business (Details Narrative) Sheet http://marathonpg.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative Organization and Description of Business (Details Narrative) Details http://marathonpg.com/role/OrganizationAndDescriptionOfBusiness 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://marathonpg.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Loss Per Share (Details) Sheet http://marathonpg.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Loss Per Share (Details) Details 20 false false R21.htm 00000021 - Disclosure - Acquisitions (Details Narrative) Sheet http://marathonpg.com/role/AcquisitionsDetailsNarrative Acquisitions (Details Narrative) Details http://marathonpg.com/role/Acquisitions 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Details Narrative) Sheet http://marathonpg.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://marathonpg.com/role/DisclosureIntangibleAssetsTables 22 false false R23.htm 00000023 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://marathonpg.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 23 false false R24.htm 00000024 - Disclosure - Intangible Assets - Schedule of Future Amortization of Intangible Assets, Net of Foreign Currency Translation Adjustments (Details) Sheet http://marathonpg.com/role/IntangibleAssets-ScheduleOfFutureAmortizationOfIntangibleAssetsNetOfForeignCurrencyTranslationAdjustmentsDetails Intangible Assets - Schedule of Future Amortization of Intangible Assets, Net of Foreign Currency Translation Adjustments (Details) Details 24 false false R25.htm 00000025 - Disclosure - Intangible Assets - Summary of the Company's Patent Portfolios (Details) Sheet http://marathonpg.com/role/IntangibleAssets-SummaryOfCompanysPatentPortfoliosDetails Intangible Assets - Summary of the Company's Patent Portfolios (Details) Details 25 false false R26.htm 00000026 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://marathonpg.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://marathonpg.com/role/StockholdersEquity 26 false false R27.htm 00000027 - Disclosure - Stockholders??? Equity - Summary of the Company's Outstanding Stock Warrants and Changes During the Period (Details) Sheet http://marathonpg.com/role/StockholdersEquity-SummaryOfCompanysOutstandingStockWarrantsAndChangesDuringPeriodDetails Stockholders??? Equity - Summary of the Company's Outstanding Stock Warrants and Changes During the Period (Details) Details 27 false false R28.htm 00000028 - Disclosure - Stockholders??? Equity - Summary of Stock Options and Changes During the Period (Details) Sheet http://marathonpg.com/role/StockholdersEquity-SummaryOfStockOptionsAndChangesDuringPeriodDetails Stockholders??? Equity - Summary of Stock Options and Changes During the Period (Details) Details 28 false false R29.htm 00000029 - Disclosure - Debt, Commitments and Contingencies (Details Narrative) Sheet http://marathonpg.com/role/DebtCommitmentsAndContingenciesDetailsNarrative Debt, Commitments and Contingencies (Details Narrative) Details http://marathonpg.com/role/DebtCommitmentsAndContingenciesTables 29 false false R30.htm 00000030 - Disclosure - Debt, Commitments and Contingencies - Schedule of Debt (Details) Sheet http://marathonpg.com/role/DebtCommitmentsAndContingencies-ScheduleOfDebtDetails Debt, Commitments and Contingencies - Schedule of Debt (Details) Details 30 false false R31.htm 00000031 - Disclosure - Debt, Commitments and Contingencies - Schedule of Future Minimum Principal Payments (Details) Sheet http://marathonpg.com/role/DebtCommitmentsAndContingencies-ScheduleOfFutureMinimumPrincipalPaymentsDetails Debt, Commitments and Contingencies - Schedule of Future Minimum Principal Payments (Details) Details 31 false false R32.htm 00000032 - Disclosure - Debt, Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) Sheet http://marathonpg.com/role/DebtCommitmentsAndContingencies-ScheduleOfFutureMinimumLeasePaymentsDetails Debt, Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) Details 32 false false R33.htm 00000033 - Disclosure - Subsequent Events (Details Narrative) Sheet http://marathonpg.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://marathonpg.com/role/SubsequentEvents 33 false false All Reports Book All Reports mara-20170930.xml mara-20170930.xsd mara-20170930_cal.xml mara-20170930_def.xml mara-20170930_lab.xml mara-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 51 0001493152-17-013526-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-013526-xbrl.zip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